Title,Brand Name,Generic Name,PDF Links,Therapeutic Area,Recommendation,Status,Submission Date,Recommendation Date,Project Number
regorafenib,N/A,regorafenib,https://cda-amc.ca/sites/default/files/DRR/2025/PX0374-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PX0374-Supplemental_Material.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PX0374_consolidated_input.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0374%20consolidated%20feedback.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0374-Regorafenib_Recommendation.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0374_Regorafenib_DPI_Table.pdf,Metastatic osteosarcoma,Reimburse with clinical criteria and/or conditions,Complete,"Oct 7, 2024","May 27, 2025",PX0374-000
dabrafenib trametinib,N/A,Dabrafenib trametinib,https://cda-amc.ca/sites/default/files/DRR/2025/PX0373-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PX0373-Supplemental_Material.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0373-Dabrafanib-Trametinib_DPI_Table.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0373_Dabrafenib_consolidated_feedback.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0373_Dabrafeninb_FINAL_Rec.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0373_Patient_Clinician_Group_Input.pdf,Head and neck cancer,Reimburse with clinical criteria and/or conditions,Complete,"Oct 7, 2024","May 16, 2025",PX0373-000
myelofibrosis,N/A,N/A,https://cda-amc.ca/sites/default/files/DRR/2025/PH0069-Rapid_Algorithm_Report_for_Myelofibrosis.pdf,Myelofibrosis,N/A,Complete,N/A,"Apr 4, 2025",PH0069-000
non small cell lung cancer nsclc,N/A,N/A,https://cda-amc.ca/sites/default/files/DRR/2025//PH0071-NSCLC-EGFR.pdf,Non-Small Cell Lung Cancer (NSCLC) with Activating Epidermal Growth Factor Receptor (EGFR) Mutations,N/A,Complete,N/A,"Apr 4, 2025",PH0071-000
trametinib,N/A,trametinib,https://cda-amc.ca/sites/default/files/DRR/2025/PX0372_trametinib_Combined_Report.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PX0372_trametinib_Stakeholder_Input.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0372%20Trametinib_FMEC_Nonsponsored_Review_Final_Recommendation.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0372-Trametinib_FMEC_Nonsponsored_Review_DPI_Table.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0372_consolidated_feedback_on_draft_recs.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0372_trametinib_Supplemental_Material.pdf,Gynecological cancers,Reimburse with clinical criteria and/or conditions,Complete,"Aug 28, 2024","Apr 2, 2025",PX0372-000
urothelial carcinoma,N/A,N/A,https://cda-amc.ca/sites/default/files/DRR/2025/PH0070-MUC_Rapid_Algorithm_Report.pdf,Urothelial carcinoma,N/A,Complete,N/A,"Apr 1, 2025",PH0070-000
large b cell lymphoma,N/A,N/A,https://cda-amc.ca/sites/default/files/DRR/2025/PH0064-Rapid_Algorithm_Report_LBCL.pdf,Large B cell lymphoma/  Lymphome B à grandes cellules,N/A,Complete,N/A,"Feb 11, 2025",PH0064-000
colorectal cancer,N/A,N/A,https://cda-amc.ca/sites/default/files/DRR/2025/PH0062-mCRC_Rapid_Algorithm_Report.pdf,Colorectal cancer,N/A,Complete,N/A,"Feb 6, 2025",PH0062-000
blinatumomab,N/A,blinatumomab,https://cda-amc.ca/sites/default/files/DRR/2025/PX0367-Blinatumomab_Supplemental.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PX0367-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PX0367-DPI_Table.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PX0367-FMEC_Recommendation.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PX0367-Feedback_DRAFT_REC.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PX0367_consolidated_input.pdf,"Acute lymphoblastic leukemia, pediatrics",Reimburse with clinical criteria and/or conditions,Complete,"Jun 11, 2024","Feb 4, 2025",PX0367-000
dimethyl fumarate,N/A,dimethyl fumarate,https://cda-amc.ca/sites/default/files/DRR/2025/SX0751-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SX0751-Supplemental_Material.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SX0751_Dimethyl-DPI_Table.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SX0751_Dimethyl_FMEC_Recommendation.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SX0751_Feedback_%20DRAFT_REC.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SX0751_Feedback_Input.pdf,Multiple Sclerosis (MS),Reimburse with clinical criteria and/or conditions,Complete,"Jun 21, 2024","Feb 4, 2025",SX0751-000
teriflunomide,N/A,teriflunomide,https://cda-amc.ca/sites/default/files/DRR/2025/SX0752-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SX0752-DPI_Table.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SX0752-Supplemental_Material.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SX0752_Feedback_%20DRAFT_REC.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SX0752_Feedback_input.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SX0752_Teriflunomide_FMEC_Recommendation.pdf,Multiple Sclerosis (MS),Reimburse with clinical criteria and/or conditions,Complete,"Jun 21, 2024","Feb 4, 2025",SX0752-000
nivolumab ipilimumab,N/A,nivolumab ipilimumab,https://cda-amc.ca/sites/default/files/DRR/2025/PX0371-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PX0371-DPI_table.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PX0371-Supplemental_Material.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PX0371_FMEC_Recommendation.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PX0371_Feedback_%20DRAFT_REC.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PX0371_input.pdf,Melanoma,Reimburse with clinical criteria and/or conditions,Complete,"Jun 25, 2024","Feb 4, 2025",PX0371-000
chronic lymphocytic leukemia cll,N/A,N/A,https://www.cda-amc.ca/sites/default/files/DRR/2025/PH0063-CLL_Rapid_Algorithm_Report.pdf,Chronic lymphocytic leukemia (CLL),N/A,Complete,N/A,"Jan 31, 2025",PH0063-000
pembrolizumab,Keytruda,pembrolizumab,https://cda-amc.ca/sites/default/files/DRR/2025/PC0377-Keytruda_Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PC0377-Keytruda_Feedback.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PC0377_Keytruda_FINAL_Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0377_Patient_and_Clinician_Group_Input.pdf,Unresectable or metastatic MSI-H or dMMR solid tumors,Reimburse with clinical criteria and/or conditions,Complete,"Jul 16, 2024","Jan 31, 2025",PC0377-000
pembrolizumab,Keytruda,pembrolizumab,https://cda-amc.ca/sites/default/files/DRR/2025/PC0369-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PC0369-Feedback_Draft_Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2025/PC0369_Combined_Patient_Clinician_Group_Input.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0369-Keytruda-NSCLC_FINAL_REC.pdf,Non-small cell lung cancer (NSCLC),Reimburse with clinical criteria and/or conditions,Complete,"Jul 15, 2024","Jan 30, 2025",PC0369-000
zolbetuximab,Vyloy,zolbetuximab,https://cadth.ca/sites/default/files/DRR/2024/PC0338_zolbetuximab-Patient_Clinician_Input.pdf; https://cadth.ca/sites/default/files/DRR/2025/PC0338-Vyloy_Combined_Review.pdf; https://cadth.ca/sites/default/files/DRR/2025/PC0338-Vyloy_Stakeholder_Feedback.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0338_Vyloy_Final_Recommendation.pdf,Gastric or gastroesophageal junction (GEJ) adenocarcinoma,Reimburse with clinical criteria and/or conditions,Complete,"Jun 28, 2024","Jan 29, 2025",PC0338-000
prostate cancer,N/A,N/A,https://cda-amc.ca/sites/default/files/DRR/2025/PH0057-Prostate_Cancer_Rapid_Algorithm.pdf,Prostate cancer,N/A,Complete,N/A,"Jan 22, 2025",PH0057-000
anaplastic lymphoma kinase alk positive non small cell lung cancer nsclc,N/A,N/A,https://cda-amc.ca/sites/default/files/DRR/2025/PH0058-ALK_Positive_NSCLC.pdf,Anaplastic Lymphoma Kinase (ALK) -Positive Non-small Cell Lung Cancer (NSCLC),N/A,Complete,N/A,"Jan 21, 2025",PH0058-000
amivantamab,Rybrevant,amivantamab,https://cda-amc.ca/sites/default/files/DRR/2025/PC0376_Rybrevant_FINAL_Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0376_Patient_and_Clinician_Input.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0376-Combined_Review.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0376-Rybrevant_Draft_Rec_Feedback.pdf,Locally advanced or metastatic non-small cell lung cancer (NSCLC),Reimburse with clinical criteria and/or conditions,Complete,"Jun 21, 2024","Jan 10, 2025",PC0376-000
erdafitinib,Balversa,erdafitinib,https://cda-amc.ca/sites/default/files/DRR/2025/PC0375-Balversa_Final_Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0375_Combined_Patient_and_Clinician_Group_Input.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0375-Balversa_Combined_Review.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0375-Balversa_Stakeholder_Feedback.pdf,locally advanced unresectable or metastatic urothelial carcinoma (UC),Reimburse with clinical criteria and/or conditions,Complete,"Jun 14, 2024","Jan 9, 2025",PC0375-000
momelotinib,Ojjaara,momelotinib,https://www.cadth.ca/sites/default/files/DRR/2024/PC0355_Patient_and_Clinician_Group_Input.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0355-Ojjaara_Combined_Review.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0355-Ojjaara_Stakeholder_Feedback.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0355_Ojjaara_FINAL_REC.pdf,Myelofibrosis,Reimburse with clinical criteria and/or conditions,Complete,"Jun 19, 2024","Jan 8, 2025",PC0355-000
ravulizumab,Ultomiris,ravulizumab,https://www.cadth.ca/sites/default/files/DRR/2024/SR0855_Patient_and_Clinician_Group_Input.pdf; https://www.cadth.ca/sites/default/files/DRR/2025/SR0855_Ultomiris-Combined_Review.pdf; https://www.cadth.ca/sites/default/files/DRR/2025/SR0855_Ultomiris_Feedback_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0855_Ultomiris_FINAL_Recommendation.pdf,Generalized Myasthenia Gravis,Reimburse with clinical criteria and/or conditions,Complete,"Jun 4, 2024","Dec 17, 2024",SR0855-000
spesolimab,Spevigo,spesolimab,https://www.cadth.ca/sites/default/files/DRR/2024/SR0844_Patient_and_Clinician_Group_Input.pdf; https://www.cadth.ca/sites/default/files/DRR/2025/SR0844-Spevigo-Combined_Review.pdf; https://www.cadth.ca/sites/default/files/DRR/2025/SR0844-Spevigo-Stakeholder_Feedback.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0844_Spevigo_Final_Recommendation.pdf,generalized pustular psoriasis (GPP),Reimburse with clinical criteria and/or conditions,Complete,"Jun 4, 2024","Dec 12, 2024",SR0844-000
exagamglogene autotemcel,Casgevy,exagamglogene autotemcel,https://cda-amc.ca/sites/default/files/DRR/2025/SG0830-Casgevy-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SG0830-Casgevy-Feedback.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SG0830-exa-cel-SCD_Patient_Clinician_Group_Input_Revised.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/SG0830_Casgevy_FINAL_Recommendation.pdf,Sickle cell disease (SCD),Reimburse with clinical criteria and/or conditions,Complete,"May 27, 2024","Dec 11, 2024",SG0830-000
ferric carboxymaltose,Ferinject,ferric carboxymaltose,https://cda-amc.ca/sites/default/files/DRR/2025/SR0842-Ferinject-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SR0842-Ferinject-Feedback.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SR0842-Ferinject-IDA_FINAL_REC.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0842%20ferric%20carboxymaltose%20IDA%20consolidated%20Patient%20and%20Clinician%20Group%20Input.pdf,Iron deficiency anemia,Reimburse with clinical criteria and/or conditions,Complete,"May 10, 2024","Dec 11, 2024",SR0842-000
hr positive her2 negative breast cancer,N/A,N/A,https://www.cda-amc.ca/sites/default/files/DRR/2024/PH0053-HRPositive-HER2-Breast-Cancer.pdf,"HR positive, HER2 negative breast cancer",N/A,Complete,N/A,"Dec 10, 2024",PH0053-000
non small cell lung cancer nsclc activating epidermal growth factor receptor egfr mutation,N/A,N/A,https://cda-amc.ca/sites/default/files/DRR/2024/PH0054-FINAL_NSCLC_EGFR.pdf,Non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation,N/A,Complete,N/A,"Dec 5, 2024",PH0054-000
advanced or metastatic gastric gastroesophageal junction or esophageal cancer,N/A,N/A,https://www.cda-amc.ca/sites/default/files/DRR/2024/PH0051-Rapid_Algorithm_Report.pdf,Gastric Cancer,N/A,Complete,N/A,"Dec 3, 2024",PH0051-000
everolimus,N/A,everolimus,https://cda-amc.ca/sites/default/files/DRR/2024/SX0836-Patient_Clinician_Industry_Group_Input.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SX0836-DPI_Table.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SX0836-Everolimus-SEGA_FINAL_REC.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SX0836_Reimbursement_Review.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SX0836_consolidated_FEEDBACK_DRAFT_REC.pdf,Tuberous Sclerosis Complex (TSC),Reimburse with clinical criteria and/or conditions,Complete,"Dec 13, 2023","Dec 3, 2024",SX0836-000
enfortumab vedotin,Padcev,enfortumab vedotin,https://cda-amc.ca/sites/default/files/DRR/2024/PC0353_Padcev-Patient_and_Clinician_Group_Input.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PC0353-Padcev_Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PC0353-Padcev_Stakeholder_Feedback.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0353-Padcev_FINAL_Rec.pdf,Metastatic urothelial cancer,Reimburse with clinical criteria and/or conditions,Complete,"May 22, 2024","Nov 29, 2024",PC0353-000
venetoclax,Venclexta,venetoclax,https://cda-amc.ca/sites/default/files/DRR/2024/PC0362-Venclexta_Reassessment.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0362_Patient_and_Clinician_Group_Input.pdf; https://www.cadth.ca/sites/default/files/DRR/2025/PC0362_Venclexta-Combined_Review.pdf; https://www.cadth.ca/sites/default/files/DRR/2025/PC0362_Venclexta-Stakeholder_Feedback.pdf,Chronic lymphocytic leukemia (CLL),Reimburse with clinical criteria and/or conditions,Complete,"May 22, 2024","Nov 28, 2024",PC0362-000
fruquintinib,Fruzaqla,fruquintinib,https://www.cadth.ca/sites/default/files/DRR/2024/PC0352%20fruquintinib%20Patient%20and%20Clinician%20Group%20Input.pdf; https://www.cadth.ca/sites/default/files/DRR/2025/PC0352_fruquintinib-Combined_Review.pdf; https://www.cadth.ca/sites/default/files/DRR/2025/PC0352_fruquintinib-Stakeholder_Feedback.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0352_Fruzaqla_FINAL_Recommendation.pdf,Metastatic colorectal cancer (mCRC),Reimburse with clinical criteria and/or conditions,Complete,"May 22, 2024","Nov 27, 2024",PC0352-000
lisocabtagene maraleucel,Breyanzi,lisocabtagene maraleucel,https://cda-amc.ca/sites/default/files/DRR/2024/PG0358-Breyanz_FINAL_REC.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PG0358-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PG0358-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PG0358%20Breyanzi%20-%20Patient%20and%20Clinician%20Group%20Input.pdf,Relapsed or refractory large B-cell lymphoma,Reimburse with clinical criteria and/or conditions,Complete,"May 8, 2024","Nov 27, 2024",PG0358-000
enzalutamide,N/A,Enzalutamide,https://cda-amc.ca/sites/default/files/DRR/2024/PX0366-Enzalutamide-nmCSPC.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/PX0366-Patient_Clinician_input.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/PX0366_Enzalutamide_DPI_Table.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/PX0366_Enzalutamide_FINAL_Recommendation.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/PX0366_Enzalutamide_consolidated_SF_Redacted.pdf,Genito-urinary cancer (prostate cancer),Reimburse with clinical criteria and/or conditions,Complete,"Apr 30, 2024","Nov 26, 2024",PX0366-000
mepolizumab,N/A,Mepolizumab,https://cda-amc.ca/sites/default/files/DRR/2024/SX0839-DPI-Table_FINAL.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SX0839-FINAL_REC.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SX0839_Feedback_DRAFT_REC.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SX0839_Clinical_and_Pharmacoeconomic_Combined_Report.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SX0839_stakeholder_input.pdf,Eosinophilic Granulomatosis with Polyangiitis,Reimburse with clinical criteria and/or conditions,Complete,"Dec 19, 2023","Nov 25, 2024",SX0839-000
adult classical hodgkin lymphoma,N/A,N/A,https://cda-amc.ca/sites/default/files/DRR/2024/PH0052-Adult_Classical_Hodgkin_Lymphoma.pdf,Adult Classical Hodgkin Lymphoma,N/A,Complete,N/A,"Nov 15, 2024",PH0052-000
ciltacabtagene autoleucel,Carvykti,ciltacabtagene autoleucel,https://cda-amc.ca/sites/default/files/DRR/2025/PG0361-Carvykti_Feedback.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PG0361-Combined_Review.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PG0361REC_Carvykti_Final.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PG0361_Carvykt_Patient_Clinician_Group_Input.pdf,Relapsed or refractory multiple myeloma,Reimburse with clinical criteria and/or conditions,Complete,"Apr 18, 2024","Nov 1, 2024",PG0361-000
avapritinib,Ayvakyt,avapritinib,https://www.cadth.ca/sites/default/files/DRR/2024/PC0335%20avapritinib%20-%20Patient%20and%20Clinicain%20input.pdf; https://www.cadth.ca/sites/default/files/DRR/2025/PC0335-Ayvakyt-Stakeholder_Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2025/PC0335_Ayvakyt-Combined_Review.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0335-Ayvakyt_FINAL_Rec.pdf,Advanced Systemic Mastocytosis,Reimburse with clinical criteria and/or conditions,Complete,"Apr 19, 2024","Oct 31, 2024",PC0335-000
alectinib,Alecensaro,alectinib,https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0350-Alecensaro_Patient_Clinician_Group_Input.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0350_FINAL_Recommendation.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0350-Alecensaro_Combined_Review.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0350-Alecensaro_Stakeholder_Feedback.pdf,ALK-positive NSCLC,Reimburse with clinical criteria and/or conditions,Complete,"Apr 18, 2024","Oct 30, 2024",PC0350-000
sotatercept,Winrevair,sotatercept,https://cda-amc.ca/sites/default/files/DRR/2024/SR0828_Patient_Clinician_Group_Input.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SR0828-Winrevair_Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SR0828_Winrevair_Stakeholder_Feedback.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0828REC-Winrevair.pdf,Pulmonary arterial hypertension (WHO group 1),Reimburse with clinical criteria and/or conditions,Complete,"Apr 8, 2024","Oct 21, 2024",SR0828-000
eplontersen,Wainua,eplontersen,https://cadth.ca/sites/default/files/DRR/2024/SR0826_Patient_Clinician_Group_Input.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SR0826-Wainua_Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SR0826-Wainua_Stakeholder_Feedback.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0826REC-Wainua_FINAL.pdf,Polyneuropathy in hereditary transthyretin-mediated amyloidosis,Reimburse with clinical criteria and/or conditions,Complete,"Apr 9, 2024","Oct 21, 2024",SR0826-000
clindamycin plus benzoyl peroxide and adapalene,Cabtreo,clindamycin plus benzoyl peroxide and adapalene,https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0794_Cabtreo_Patient_and_Clinician_Input.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0794_Recommendation.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0794-Combined_Review.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0794_Cabtreo_Stakeholder_Feedback.pdf,acne vulgaris,Reimburse with clinical criteria and/or conditions,Complete,"Mar 8, 2024","Oct 18, 2024",SR0794-000
danicopan,Voydeya,danicopan,https://cda-amc.ca/sites/default/files/DRR/2024/SR0815-Voydeya_Patient_Clinician_Group_Input.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SR0815_Voydeya_Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SR0815_Voydeya_Stakeholder_Feedback.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0815_Voydeya_Recommendation.pdf,Paroxysmal nocturnal hemoglobinuria (PNH),Reimburse with clinical criteria and/or conditions,Complete,"Apr 4, 2024","Oct 18, 2024",SR0815-000
elexacaftortezacaftorivacaftor and ivacaftor,Trikafta,elexacaftor/tezacaftor/ivacaftor and ivacaftor,https://cda-amc.ca/sites/default/files/DRR/2025/SR0837-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SR0837-Trikafta%20_Feedback.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0837_Trikaft_Patient_and_Clinician_Input.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0837_Trikafta_%20Final_Recommendation.pdf,"Cystic fibrosis, F508del or responsive CFTR mutation,  2 years and older",Reimburse with clinical criteria and/or conditions,Complete,"Mar 5, 2024","Oct 17, 2024",SR0837-000
burosumab,Crysvita,burosumab,https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0818_Crysvita_Patient_Clinician_Group_Input.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0818_Reassessment_Final_Recommendation.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0818-Crysvita_Combined_Review.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0818-Crysvita_Stakeholder_Feedback.pdf,Treatment of X-Linked Hypophosphatemia,Reimburse with clinical criteria and/or conditions,Complete,"Jan 2, 2024","Oct 10, 2024",SR0818-000
lebrikizumab,Ebglyss,lebrikizumab,https://cda-amc.ca/sites/default/files/DRR/2024/SR0819_Ebglyss_FINAL_REC.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0819_Ebglyss_Patient_Clinician_Input.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SR0819-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SR0819-Feedback.pdf,atopic dermatitis,Do not reimburse,Complete,"Nov 1, 2023","Oct 9, 2024",SR0819-000
ivosidenib,Tibsovo,ivosidenib,https://cda-amc.ca/sites/default/files/DRR/2024/PC0349-Tibsovo_Patient_Clinician_Group_Input.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PC0349_Tibsovo_Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PC0349_Tibsovo_Stakeholder_Feedback.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0349_Final_Recommendation.pdf,Acute myeloid leukemia (AML),Reimburse with clinical criteria and/or conditions,Complete,"Mar 19, 2024","Oct 4, 2024",PC0349-000
pembrolizumab,Keytruda,pembrolizumab,https://cda-amc.ca/sites/default/files/DRR/2025/PC0356-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PC0356-Keytruda-Gastric_Feedback.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0356-Keytruda-Gastric_Patient_Clinician_Group.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0356_Final_Recommendation.pdf,Gastric or gastroesophageal junction (GEJ) adenocarcinoma,Reimburse with clinical criteria and/or conditions,Complete,"Mar 13, 2024","Oct 4, 2024",PC0356-000
abemaciclib,Verzenio,abemaciclib,https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0345_Final_Recommendation.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0345_Verzenio_Patient_and_Clinician_Group_Input.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0345-Verzenio-Combined_Review.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0345-Verzenio-Stakeholder_Feedback.pdf,"Adjuvant treatment of HR-positive, HER2-negative early breast cancer",Reimburse with clinical criteria and/or conditions,Complete,"Feb 9, 2024","Oct 3, 2024",PC0345-000
osimertinib,Tagrisso,osimertinib,https://cda-amc.ca/sites/default/files/DRR/2024/PC0336-Tagrisso_Patient_Clinician_Group_Input.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PC0336-Tagrisso_Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PC0336-Tagrisso_Stakeholder_Feedback.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0336_Final_Recommendation.pdf,Non-small cell lung cancer,Reimburse with clinical criteria and/or conditions,Complete,"Dec 11, 2023","Oct 3, 2024",PC0336-000
baricitinib,Olumiant,baricitinib,https://cda-amc.ca/sites/default//files/DRR/2025/SR0843-Olumiant-Stakeholder-Feedback.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0843REC-Olumiant.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0843_Patient_and_Clinician_Group_Input.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SR0843-Olumiant-Combined_Review.pdf,"Alopecia areata, severe",Reimburse with clinical criteria and/or conditions,Complete,"Mar 4, 2024","Sep 13, 2024",SR0843-000
secukinumab,Cosentyx,secukinumab,https://cda-amc.ca/sites/default/files/DRR/2024/SR0781REC-Cosentyx-HS.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0781_Patient_Group_and_Clinician_Group_Input.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SR0781-Cosentyx_Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SR0781_Cosentyx_Stakeholder_Feedback.pdf,Hidradenitis suppurativa,Reimburse with clinical criteria and/or conditions,Complete,"May 10, 2023","Sep 12, 2024",SR0781-000
capivasertib,Truqap,capivasertib,https://cda-amc.ca/sites/default/files/DRR/2025/PC0341-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PC0341-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0341-Truqap_Patient_Clinician_Group_Input.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0341_Truqap-Final_Rec.pdf,"HR-positive, HER2-negative locally advanced or metastatic breast cancer",Reimburse with clinical criteria and/or conditions,Complete,"Feb 14, 2024","Aug 30, 2024",PC0341-000
brentuximab vedotin,Adcetris,Brentuximab vedotin,https://cda-amc.ca/sites/default/files/DRR/2024/PC0371-Adcetris-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/PC0371-Adcetris_Feedback.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/PC0371-Adcetris_Patient_Clinician_Input.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0371REC-Adectris.pdf,Hodgkin lymphoma,Reimburse with clinical criteria and/or conditions,Complete,"Apr 18, 2024","Aug 29, 2024",PC0371-000
remdesivir,Veklury,remdesivir,https://cadth.ca/sites/default/files/DRR/2024/SR0833_Final_Recommendation.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0833-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0833-Veklury_Feedback.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0833-Veklury_Patient_Clinician_Group_Input.pdf,COVID-19 in hospitalized patients,Reimburse with clinical criteria and/or conditions,Complete,"Mar 1, 2024","Aug 16, 2024",SR0833-000
remdesivir,Veklury,remdesivir,https://cda-amc.ca/sites/default/files/DRR/2024/SR0834-Veklury_Patient_Clinician_Group_Input.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0834_Final_Recommendation.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0834_Veklury_Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0834_Veklury_Stakeholder_Feedback.pdf,COVID-19 in non-hospitalized patients,Reimburse with clinical criteria and/or conditions,Complete,"Mar 1, 2024","Aug 16, 2024",SR0834-000
inclisiran,Leqvio,inclisiran,https://cadth.ca/sites/default/files/DRR/2024/SR0791-000REC-Leqvio_HeFH.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0791-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0791_Feedback.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0791_Patient_Clinician_Group_Input.pdf,Primary hypercholesterolemia,Reimburse with clinical criteria and/or conditions,Complete,"Sep 19, 2023","Aug 15, 2024",SR0791-000
cariprazine,Vraylar,cariprazine,https://cda-amc.ca/sites/default/files/DRR/2024/SR0827-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0827-Feedback.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0827-Vraylar-Resub_Patient_Clinician_Group_Input.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0827_Final_Recommendation.pdf,Schizophrenia,Reimburse with clinical criteria and/or conditions,Complete,"Dec 20, 2023","Aug 15, 2024",SR0827-000
etrasimod,Velsipity,etrasimod,https://cda-amc.ca/sites/default/files/DRR/2024/SR0795-Velsipity_Patient_Clinician_Group_Input.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0795_Final_Recommendation.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0795_Velsipity_Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0795_Velsipity_Stakeholder_Feedback.pdf,Ulcerative colitis,Reimburse with clinical criteria and/or conditions,Complete,"Feb 5, 2024","Aug 14, 2024",SR0795-000
cabotegravir,Apretude,cabotegravir,https://cadth.ca/sites/default/files/DRR/2024/SR0825_Final_Recommendation.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0825-Apretude_Patient_Clinician_Group_Input.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0825_Apretude_Combined_Review.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/SR0825_Apretude_Stakeholder_Feedback.pdf,"HIV-1 infection, pre-exposure prophylaxis",Reimburse with clinical criteria and/or conditions,Complete,"Feb 1, 2024","Aug 14, 2024",SR0825-000
evolocumab,Repatha,evolocumab,https://cadth.ca/sites/default/files/DRR/2024/SR0821-Repatha-Patient_Clinicia_%20Group_Input.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0821_Final_Recommendation.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0821-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0821-Feedback.pdf,Primary hyperlipidemia,Reimburse with clinical criteria and/or conditions,Complete,"Nov 29, 2023","Aug 8, 2024",SR0821-000
multiple myeloma,N/A,N/A,https://www.cadth.ca/sites/default/files/DRR/2024/PH0047_Multiple_Myeloma.pdf,Multiple Myeloma,N/A,Complete,N/A,"Aug 1, 2024",PH0047-000
large b cell lymphoma,N/A,N/A,https://www.cadth.ca/sites/default/files/DRR/2024/PH0048_Rapid_Algorithm_Report_LBCL_Final.pdf,Large B cell lymphoma,N/A,Complete,N/A,"Aug 1, 2024",PH0048-000
cutaneous melanoma,N/A,N/A,https://www.cadth.ca/sites/default/files/DRR/2024/PH0049_Rapid_Algorithm_Report_Melanoma_Final.pdf,Cutaneous Melanoma,N/A,Complete,N/A,"Aug 1, 2024",PH0049-000
pembrolizumab,N/A,Pembrolizumab,https://www.cadth.ca/sites/default/files/DRR/2024/PX0346_%20Clinical_and_Pharmacoeconomic_Combined_Report.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PX0346_Final_Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PX0346_Report_DPI.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PX0346_stakeholder_input.pdf,Melanoma (Skin),Reimburse with clinical criteria and/or conditions,Complete,"Oct 16, 2023","Aug 1, 2024",PX0346-000
nivolumab and ipilimumab,N/A,Nivolumab and Ipilimumab,https://www.cadth.ca/sites/default/files/DRR/2024/PX0347_Combine_Report.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PX0347_DPI_table.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PX0347_Final_Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PX0347_Stakeholder_consolidated_input.pdf,Melanoma (Skin),Reimburse with clinical criteria and/or conditions,Complete,"Oct 16, 2023","Aug 1, 2024",PX0347-000
nab paclitaxel,N/A,Nab-paclitaxel,https://cadth.ca/sites/default/files/DRR/2024/PX0348_Nab-Paclitaxel_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PX0348_DPI_Table.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PX0348_Final_Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PX0348_consolidated_input_Redacted.pdf,Solid tumours,Reimburse with clinical criteria and/or conditions,Complete,"Oct 16, 2023","Jul 24, 2024",PX0348-000
relugolix,Orgovyx,relugolix,https://cda-amc.ca/sites/default/files/DRR/2024/PC0342-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/PC0342-Orgovyx_Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0342_Final_Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0342_Patient_and_Clinician_Group_Input.pdf,Advanced prostate cancer,Reimburse with clinical criteria and/or conditions,Complete,"Nov 14, 2023","Jul 22, 2024",PC0342-000
atogepant,Qulipta,atogepant,http://www.cda-amc.ca/sites/default/files/DRR/2024/SR0817_Patient_and_Clinician_Group_Input.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0817-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0817-Feedback.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0817_Final_Recommendation.pdf,"Migraine, prevention",Reimburse with clinical criteria and/or conditions,Complete,"Dec 21, 2023","Jul 15, 2024",SR0817-000
pembrolizumab,Keytruda,pembrolizumab,https://cda-amc.ca/sites/default/files/DRR/2024/PC0344-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/PC0344_Feedback.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0344_Final_Recommendation.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0344_Patient_and_Clinician_Group_Input.pdf,Biliary tract carcinoma,Reimburse with clinical criteria and/or conditions,Complete,"Dec 7, 2023","Jul 11, 2024",PC0344-000
endometrial cancer,N/A,N/A,https://cadth.ca/sites/default/files/DRR/2024/PH0045-Endometrial-Cancer_Final.pdf,Endometrial Cancer,N/A,Complete,N/A,"Jun 27, 2024",PH0045-000
nsclc without actionable oncogenic alteration,N/A,N/A,https://cadth.ca/sites/default/files/DRR/2024/PH0046_Final_Report_NSCLC.pdf,NSCLC without actionable oncogenic alteration,N/A,Complete,N/A,"Jun 27, 2024",PH0046-000
pembrolizumab,Keytruda,pembrolizumab,https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0343-Combined_Report.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0343_%20Patient_and_Clinician_Group_Input.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0343_Final_Recommendation.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0343_Stakeholder_Feedback.pdf,Gastric or gastroesophageal junction adenocarcinoma,Reimburse with clinical criteria and/or conditions,Complete,"Nov 22, 2023","Jun 26, 2024",PC0343-000
aflibercept 8mg007ml,Eylea HD,aflibercept 8mg/0.07mL,https://cda-amc.ca/sites/default/files/DRR/2024/SR0813_Eylea_Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0813_Eylea_HD_DME-Final_Rec.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0813_Eylea_Stakeholder_Feedback.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/SR0813_Eylea_HD_Patient_Clinician.pdf,diabetic macular edema,Reimburse with clinical criteria and/or conditions,Complete,"Aug 18, 2023","Jun 5, 2024",SR0813-000
aflibercept 8mg007ml,Eylea HD,aflibercept 8mg/0.07mL,https://cda-amc.ca/sites/default/files/DRR/2024/SR0812-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0812_Eylea_HD_nAMD-Final_Rec.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0812_Patient_and_Clinician_Input.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0812_Stakeholder_Feedback.pdf,"macular degeneration, age related",Reimburse with clinical criteria and/or conditions,Complete,"Aug 18, 2023","Jun 5, 2024",SR0812-000
cutaneous melanoma,N/A,N/A,https://cadth.ca/sites/default/files/DRR/2024/PH0042%20Algorithm%20Panel%20Scope_Melanoma_final.pdf; https://cadth.ca/sites/default/files/DRR/2024/PH0042-Cutaneous-Melanoma.pdf,Cutaneous Melanoma,N/A,Complete,N/A,"Jun 4, 2024",PH0042-000
elranatamab,Elrexfio,elranatamab,https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0315-Combined_Report.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0315-Stakeholder_Feedback.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0315_Final_Recommendation.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0315_Patient_and_Clinician_Input.pdf,Relapsed or refractory multiple myeloma,Reimburse with clinical criteria and/or conditions,Complete,"Nov 9, 2023","May 31, 2024",PC0315-000
epcoritamab,Epkinly,epcoritamab,https://cda-amc.ca/sites/default/files/DRR/2024/PC0334%20Epkinly-Feedback.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/PC0334-Combined_Review.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0334_Epkinly-Final_Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0334_Patient_and_Clinician_Group_Input.pdf,Relapsed or refractory diffuse large B-cell lymphoma,Time-limited reimbursement recommendation,Complete,"Nov 14, 2023","May 31, 2024",PC0334-000
nivolumab,Opdivo,nivolumab,https://cadth.ca/sites/default/files/DRR/2024/PC0339_Final_Recommendation.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/PC0339-Opdivo-Melanoma-Combined-Report.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/PC0339-Opdivo-Melanoma-DRAFT_REC.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0339_Patient_and_clinician_input.pdf,"Stage IIB or IIC melanoma, adjuvant",Reimburse with clinical criteria and/or conditions,Complete,"Nov 6, 2023","May 29, 2024",PC0339-000
colorectal cancer,N/A,N/A,https://cadth.ca/sites/default//files/DRR/2024/PH0044-Metastatic_Colorectal_Cancer.pdf,Colorectal cancer,N/A,Complete,N/A,"May 22, 2024",PH0044-000
insulin icodec,Awiqli,insulin icodec,https://cda-amc.ca/sites/default/files/DRR/2024/SR0790-Awiqli-combined.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0790-Awiqli_Feedback_DRAFT_REC.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0790REC-Awiqli.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0790_Patient_and_Clinician_Group_Input.pdf,"Diabetes mellitus, type 2",Reimburse with clinical criteria and/or conditions,Complete,"Oct 18, 2023","May 17, 2024",SR0790-000
bimekizumab,Bimzelx,bimekizumab,https://cadth.ca/sites/default/files/DRR/2024/SR0809REC-Bimzelx.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0809_Patient_Clinician_Group_Input.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0809-Bimzelx_Feedback.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0809-Combined_Report.pdf,Ankylosing spondylitis,Reimburse with clinical criteria and/or conditions,Complete,"Oct 19, 2023","May 16, 2024",SR0809-000
bimekizumab,Bimzelx,bimekizumab,https://www.cadth.ca/sites/default/files/DRR/2024/SR0803%20Bimzelx%20PsA%20-%20Patient%20and%20Clinician%20Group%20Input.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0803%20Bimzelx%20PsA_Rec_final.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0803-Bimzelx-PsA-Combined-Report.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0803-Bimzelx-PsA-Stakeholder-Feedback.pdf,Psoriatic arthritis,Reimburse with clinical criteria and/or conditions,Complete,"Oct 5, 2023","May 15, 2024",SR0803-000
metreleptin,Myalepta,metreleptin,https://cadth.ca/sites/default/files/DRR/2024/SR0784REC-Myalepta.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0784_Patient_and_Clinician_Group_Input.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0784-Combined.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0784-Myalepta-Feedback.pdf,Leptin deficiency in lipodystrophy,Reimburse with clinical criteria and/or conditions,Complete,"Jul 25, 2023","May 9, 2024",SR0784-000
tralokinumab,Adtralza,tralokinumab,https://cadth.ca/sites/default/files/DRR/2024/SR0787REC-Adtralza.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0787%20Adtralza%20-%20Patient%20and%20Clinician%20Group%20Input.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0787-Adtralza-Combined-Report.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0787-Adtralza-Stakeholder-Feedback.pdf,atopic dermatitis (AD),Do not reimburse,Complete,"Jun 5, 2023","May 8, 2024",SR0787-000
avatrombopag,Doptelet,avatrombopag,https://cadth.ca/sites/default/files/DRR/2024/SR0721%20Doptelet_Rec_final.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0721_Patient_and_Clinician_Group_Input.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0721-Doptelet-Combined-Report.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0721-Doptelet-Feedback.pdf,Chronic immune thrombocytopenia (ITP),Do not reimburse,Complete,"Feb 3, 2022","May 8, 2024",SR0721-000
dostarlimab,Jemperli,dostarlimab,https://www.cadth.ca/sites/default/files/DRR/2024/PC0325%20Jemperli%20-%20Patient%20and%20Clinician%20Input.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0325%20Jemperli_Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0325_Combined_Report.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0325_Stakeholder_Feedback.pdf,Endometrial cancer,Reimburse with clinical criteria and/or conditions,Complete,"Oct 18, 2023","May 3, 2024",PC0325-000
cemiplimab,Libtayo,cemiplimab,https://www.cadth.ca/sites/default/files/DRR/2024/PC0331%20Libtayo%20-%20Patient%20and%20Clinician%20Input.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0331-Libtayo_Rec.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0331-Libtayo-combined.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PC0331-Libtayo_%20Feedback.pdf,Locally advanced or metastatic NSCLC (first line),Reimburse with clinical criteria and/or conditions,Complete,"Sep 27, 2023","May 2, 2024",PC0331-000
infliximab,Remsima,infliximab,https://cadth.ca/sites/default/files/DRR/2024/SR0816-000%20%26%20SR0816-001%20Remsima%20SC%20-%20Patient%20and%20Clinician%20Group%20Input.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0816-000%20Remsima%20SC%20(CD)%20-%20Final%20Rec.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0816-000_Clinical_and_Pharmacoeconomic_Combined_Report.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0816-000_Stakeholder_Feedback.pdf,Crohn’s disease,Reimburse with clinical criteria and/or conditions,Complete,"Oct 4, 2023","Apr 22, 2024",SR0816-000
inclisiran,Leqvio,inclisiran,https://cadth.ca/sites/default/files/DRR/2024/SR0791-001_Resubmission_Final_Recommendation.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0791-Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0791_Feedback.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0791_Patient_Clinician_Group_Input.pdf,Primary hypercholesterolemia,Do not reimburse,Complete,"Sep 19, 2023","Apr 22, 2024",SR0791-001
infliximab,Remsima,infliximab,https://www.cadth.ca/sites/default/files/DRR/2024/SR0816-000%20&%20SR0816-001%20Remsima%20SC%20-%20Patient%20and%20Clinician%20Group%20Input.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0816-001%20Remsima%20SC%20(UC)%20-%20Final%20Rec.pdf,Ulcerative Colitis,Reimburse with clinical criteria and/or conditions,Complete,"Oct 4, 2023","Apr 22, 2024",SR0816-001
maralixibat,Livmarli,maralixibat,https://cadth.ca/sites/default/files/DRR/2024/SR0780-Livmarli_Rec.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0780-Livmarli-Combined-Report.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SR0780-Livmarli-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0780%20Livmarli%20-%20Patient%20and%20Clinician%20input.pdf,Alagille syndrome,Reimburse with clinical criteria and/or conditions,Complete,"May 5, 2023","Apr 22, 2024",SR0780-000
etranacogene dezaparvovec,Hemgenix,etranacogene dezaparvovec,https://cadth.ca/sites/default/files/DRR/2024/SG0805%20Hemgenix%20-%20Final%20Rec.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SG0805-Hemgenix-Feedback_DRAFT_REC.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SG0805-Hemgenix_combined.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SG0805_Patient_Clinician_Group_Input.pdf,Hemophilia B,Reimburse with clinical criteria and/or conditions,Complete,"Oct 4, 2023","Apr 19, 2024",SG0805-000
everolimus,N/A,everolimus,https://cadth.ca/sites/default/files/DRR/2024/SX0814%20DPI%20Table.pdf; https://cadth.ca/sites/default/files/DRR/2024/SX0814%20Everolimus%20Recommendation_Final.pdf; https://cadth.ca/sites/default/files/DRR/2024/SX0814-Everolimus_combined.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/SX0814-Stakeholder-Input.pdf,Renal angiomyolipoma associated with tuberous sclerosis,Reimburse with clinical criteria and/or conditions,Complete,"Jul 6, 2023","Apr 18, 2024",SX0814-000
panitumumab,N/A,panitumumab,https://cadth.ca/sites/default/files/DRR/2024/PX0333-DPI-table.pdf; https://cadth.ca/sites/default/files/DRR/2024/PX0333REC-Panitumumab.pdf; https://cadth.ca/sites/default/files/DRR/2024/PX0333_Combine_Report.pdf; https://cadth.ca/sites/default/files/DRR/2024/PX0333_Stakeholder_Input.pdf,Left-sided metastatic colorectal cancer (mCRC),Reimburse with clinical criteria and/or conditions,Complete,"May 19, 2023","Apr 18, 2024",PX0333-000
cannabidiol,Epidiolex,cannabidiol,https://cadth.ca/sites/default/files/DRR/2024/SR0800%20Epidiolex%20LGS%20-%20Final%20Rec.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0800%20Epidiolex%20LGS%20-%20Patient%20and%20Clinician%20Group%20Input.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0800-Epidiolex-LGS-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0800CL-Epidiolex-LGS-Combined-Report.pdf,Lennox-Gastaut Syndrome (LGS),Reimburse with clinical criteria and/or conditions,Complete,"Sep 20, 2023","Apr 18, 2024",SR0800-000
cannabidiol,Epidiolex,cannabidiol,https://cadth.ca/sites/default/files/DRR/2024/SR0799%20Epidiolex%20DS%20-%20Final%20Rec.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0799%20Epidiolex%20DS%20-%20Patient%20and%20Clinician%20Group%20Input.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0799_Combine_Report.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0799_Stakeholder_Feedback.pdf,Dravet Syndrome (DS),Reimburse with clinical criteria and/or conditions,Complete,"Sep 25, 2023","Apr 18, 2024",SR0799-000
cannabidiol,Epidiolex,cannabidiol,https://cadth.ca/sites/default/files/DRR/2024/SR0798%20Epidiolex%20TSC%20-%20Final%20Rec.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0798%20Epidiolex%20TSC%20-%20Patient%20and%20Clinician%20Group%20Input.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0798-Epidiolex-TSC-Combined-Report.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0798-Epidiolex-TSC-Stakeholder-Feedback.pdf,Seizures associated with Tuberous Sclerosis Complex (TSC),Reimburse with clinical criteria and/or conditions,Complete,"Sep 29, 2023","Apr 18, 2024",SR0798-000
nirmatrelvirritonavir,Paxlovid,nirmatrelvir/ritonavir,https://cadth.ca/sites/default/files/DRR/2024/SR0808%20Paxlovid%20-%20Final%20Rec.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0808%20Paxlovid%20-%20Patient%20and%20Clinician%20Group%20Input.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0808_Combine_Report.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0808_Stakeholder_Feedback.pdf,"Mild-to-moderate COVID-19, treatment",Reimburse with clinical criteria and/or conditions,Complete,"Sep 15, 2023","Apr 11, 2024",SR0808-000
hr positive her2 negative breast cancer,N/A,N/A,https://www.cadth.ca/sites/default/files/DRR/2024/PH0041-HR%2BHER2-Breast-Cancer.pdf,"HR positive, HER2 negative breast cancer",N/A,Complete,N/A,"Apr 10, 2024",PH0041-000
large b cell lymphoma,N/A,N/A,https://www.cadth.ca/sites/default/files/DRR/2024/PH0040%20LBCL.pdf,Large B cell lymphoma,N/A,Complete,N/A,"Apr 9, 2024",PH0040-000
teclistamab,Tecvayli,teclistamab,https://cadth.ca/sites/default/files/DRR/2024/PC0332%20Tecvayli%20-%20Final_Rec.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/PC0332-Tecvayli-Combined-Report-meta.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/PC0332-Tecvayli-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0332%20Tecvayli%20-%20Patient%20and%20Clinican%20input.pdf,Relapsed or refractory multiple myeloma,Reimburse with clinical criteria and/or conditions,Complete,"Aug 31, 2023","Apr 8, 2024",PC0332-000
prostate cancer,N/A,N/A,https://www.cadth.ca/sites/default/files/DRR/2024/PH0039-Prostate-Cancer-Rapid-Algorithm-Report.pdf,Prostate Cancer,N/A,Complete,N/A,"Mar 28, 2024",PH0039-000
chronic lymphocytic leukemia,N/A,N/A,https://cadth.ca/sites/default/files/DRR/2024/PH0038-Chronic%20Lymphocytic%20Leukemia_Rapid%20Algorithm%20Report_final.pdf,Chronic Lymphocytic Leukemia,N/A,Complete,N/A,"Mar 21, 2024",PH0038-000
drospirenone,Slynd,drospirenone,https://cadth.ca/sites/default/files/DRR/2024/SR0806-Slynd-Combined-Report.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0806-Slynd-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0806REC-Slynd.pdf,"Contraceptive, oral",Reimburse with clinical criteria and/or conditions,Complete,"Aug 14, 2023","Mar 18, 2024",SR0806-000
ravulizumab,Ultomiris,ravulizumab,https://www.cadth.ca/sites/default/files/DRR/2024/SR0785%20Ultomiris%20NMOSD%20-%20Confidential%20Final%20CADTH%20Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0785%20Ultomiris%20NMOSD%20-%20Patient%20and%20Clinician%20Group.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0785_Combined_Report.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0785_Stakeholder_Feedback.pdf,Neuromyelitis optica spectrum disorder (NMOSD),Reimburse with clinical criteria and/or conditions,Complete,"Aug 29, 2023","Mar 13, 2024",SR0785-000
inebilizumab,Uplizna,inebilizumab,https://cadth.ca/sites/default/files/DRR/2024/SR0793-Uplizna-Combined-Report.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0793-Uplizna-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0793_Uplizna-Final_Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0793%20Uplizna%20-%20Patient%20and%20Clinician%20Input%20(with%20Redactions).pdf,Neuromyelitis optica spectrum disorders (NMOSD),Reimburse with clinical criteria and/or conditions,Complete,"Aug 18, 2023","Mar 13, 2024",SR0793-000
trifluridine and tipiracil,Lonsurf,trifluridine and tipiracil,https://www.cadth.ca/sites/default/files/DRR/2024/PC0330%20Lonsurf%20-%20Confidential%20CADTH%20Final%20Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0330_Combined_Report.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0330_Stakeholder_Feedback.pdf,Metastatic colorectal cancer,Reimburse with clinical criteria and/or conditions,Complete,"Aug 15, 2023","Feb 29, 2024",PC0330-000
sotorasib,Lumakras,sotorasib,https://cadth.ca/sites/default/files/DRR/2024/PC0300-Lumakras-Combined-Report.pdf; https://cadth.ca/sites/default/files/DRR/2024/PC0300-Lumakras-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0300%20Lumakras%20-%20CADTH%20Final%20Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0300%20Lumakras%20-%20Patient%20and%20Clinician%20Input.pdf,KRAS G12C-mutated advanced NSCLC,Do not reimburse,Complete,"Aug 19, 2022","Feb 29, 2024",PC0300-000
treosulfan,Trecondyv,treosulfan,https://www.cadth.ca/sites/default/files/DRR/2024/PC0324-Trecondyv-Combined-Report.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0324-Trecondyv-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0324REC-Trecondyv.pdf,Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS),Reimburse with clinical criteria and/or conditions,Complete,"Jul 14, 2023","Feb 28, 2024",PC0324-000
renal cell carcinoma,N/A,N/A,https://cadth.ca/sites/default/files/DRR/2024/PH0037-Renal-Cell-Carcinoma.pdf,Renal cell carcinoma,N/A,Complete,N/A,"Feb 21, 2024",PH0037-000
fidanacogene elaparvovec,Beqvez,fidanacogene elaparvovec,https://www.cadth.ca/sites/default/files/DRR/2024/SG0802%20Beqvez%20Final%20CADTH%20Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SG0802-Beqvez-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SG0802-Beqvez.pdf,Hemophilia B,Reimburse with clinical criteria and/or conditions,Complete,"Aug 1, 2023","Feb 16, 2024",SG0802-000
belumosudil,Rezurock,belumosudil,https://cadth.ca/sites/default/files/DRR/2024/SR0789%20Rezurock%20-%20Stakeholder%20Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0789-Rezurock_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0789%20Rezurock%20-%20Confidential%20Final.pdf,Graft-versus-host disease,Reimburse with clinical criteria and/or conditions,Complete,"Jul 26, 2023","Feb 15, 2024",SR0789-000
odevixibat,Bylvay,odevixibat,https://www.cadth.ca/sites/default/files/DRR/2024/SR0788%20Bylvay%20-%20Confidential%20Final%20CADTH%20Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0788-Bylvay-Combined-Report.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0788-Bylvay-Stakeholder-Feedback.pdf,Progressive familial intrahepatic cholestasis (PFIC),Reimburse with clinical criteria and/or conditions,Complete,"Jun 23, 2023","Feb 13, 2024",SR0788-000
nivolumab and relatlimab,Opdualag,nivolumab and relatlimab,https://cadth.ca/sites/default/files/DRR/2024/PC0329%20Opdualag%20-%20Stakeholder%20Feedback%20February%202%2C%202024.pdf; https://cadth.ca/sites/default/files/DRR/2024/PC0329-Opdualag_combined.pdf; https://cadth.ca/sites/default/files/DRR/2024/PC0329REC-Opdaulag.pdf,unresectable or metastatic melanoma,Reimburse with clinical criteria and/or conditions,Complete,"Jul 10, 2023","Feb 2, 2024",PC0329-000
glofitamab,Columvi,glofitamab,https://cadth.ca/sites/default/files/DRR/2024/PC0320-Columvi-Combined-Report.pdf; https://cadth.ca/sites/default/files/DRR/2024/PC0320-Columvi-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2024/PC0320REC-Columvi.pdf,Relapsed or refractory diffuse large B-cell lymphoma,Reimburse with clinical criteria and/or conditions,Complete,"Jul 18, 2023","Feb 2, 2024",PC0320-000
sacituzumab govitecan,Trodelvy,sacituzumab govitecan,https://cadth.ca/sites/default/files/DRR/2024/PC0323REC-Trodelvy-HR.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0323%20Trodelvy%20HR%2B%20-%20Stakeholder%20Feedback%20February%201%2C%202024.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0323-Trodelvy%20HR%2B.pdf,"HR+, HER2− advanced or metastatic breast cancer",Reimburse with clinical criteria and/or conditions,Complete,"Jul 18, 2023","Feb 1, 2024",PC0323-000
niraparib abiraterone acetate,Akeega,niraparib abiraterone acetate,https://cadth.ca/sites/default/files/DRR/2024/PC0326%20Akeega%20Final%20Recommendation.pdf; https://cadth.ca/sites/default/files/DRR/2024/PC0326-AKeega-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2024/PC0326-Akeega-Combined-Report.pdf,Metastatic castration-resistant prostate cancer (mCRPC),Reimburse with clinical criteria and/or conditions,Complete,"Jun 14, 2023","Feb 1, 2024",PC0326-000
olaparib,Lynparza,olaparib,https://cadth.ca/sites/default/files/DRR/2024/PC0319-Lynparza-PC-Combined-Report.pdf; https://cadth.ca/sites/default/files/DRR/2024/PC0319-Lynparza-PC-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2024/PC0319REC-Lynparza.pdf,Metastatic castration-resistant prostate cancer (mCRPC),Reimburse with clinical criteria and/or conditions,Complete,"May 19, 2023","Jan 31, 2024",PC0319-000
vutrisiran,Amvuttra,vutrisiran,https://cadth.ca/sites/default/files/DRR/2024/SR0801%20Amvuttra%20-%20Stakeholder%20Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0801-Amvuttra-combined.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0801REC-Amvuttra%20Final.pdf,Hereditary transthyretin mediated amyloidosis (hATTR amyloidosis),Reimburse with clinical criteria and/or conditions,Complete,"Jul 4, 2023","Jan 29, 2024",SR0801-000
unresectable hepatocellular carcinoma,N/A,N/A,https://www.cadth.ca/sites/default/files/DRR/2024/PH0036-Hepatocellular-Carcinoma.pdf,Unresectable Hepatocellular Carcinoma,N/A,Complete,N/A,"Jan 24, 2024",PH0036-000
evinacumab,Evkeeza,evinacumab,https://www.cadth.ca/sites/default/files/DRR/2024/SR0778-Evkeeza-Combined-Report.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0778-Evkeeza-Stakeholder-Feedback.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0778%20Evkeeza%20-%20Final%20CADTH%20Recommendation%20-%20Revised%20version%20-%20KH-meta.pdf,Homozygous familial hypercholesterolemia (HoFH),Reimburse with clinical criteria and/or conditions,Complete,"May 10, 2023","Jan 12, 2024",SR0778-000
eltrombopag,N/A,eltrombopag,https://cadth.ca/sites/default/files/DRR/2023/SX0777CL-Eltrombopag_combined.pdf; https://cadth.ca/sites/default/files/DRR/2023/SX0777eltrombopag%20%20-%20Clinician%20and%20Patient%20Input.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SX0777%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20FOR%20POSTING.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SX0777/SX0777-Eltrombopag-DPI-Table.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SX0777/SX0777REC-Eltrombopag-for-SAA.pdf,Severe Aplastic Anemia (SAA),Reimburse with clinical criteria and/or conditions,Complete,"Mar 3, 2023","Jan 10, 2024",SX0777-000
ibrutinib,Imbruvica,ibrutinib,https://cadth.ca/sites/default/files/DRR/2024/PC0328%20Imbruvica%20WM%20-%20Final%20CADTH%20Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0328%20Imbruvica-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PC0328-Imbruvica-Combined-Report.pdf,Waldenström’s Macroglobulinemia,Reimburse with clinical criteria and/or conditions,Complete,"Jun 20, 2023","Jan 5, 2024",PC0328-000
calaspargase pegol,Asparlas,calaspargase pegol,https://cadth.ca/sites/default/files/DRR/2024/PC0321-Asparlas-Combined-Report.pdf; https://cadth.ca/sites/default/files/DRR/2024/PC0321-Asparlas-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2024/PC0321REC-Asparlas.pdf,Acute lymphoblastic leukemia (ALL),Reimburse with clinical criteria and/or conditions,Complete,"May 12, 2023","Jan 4, 2024",PC0321-000
bevacizumab and lomustine,N/A,bevacizumab and lomustine,https://www.cadth.ca/sites/default/files/DRR/2023/PX0318/PX0318-FMEC-DPI-Table.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PX0318/PX0318-Stakeholder-Input-Clinicians.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PX0318/PX0318-Stakeholder-Input-Industry.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PX0318/PX0318CL-Bevacizumab-and-Lomustine.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PX0318/PX318-FMEC-REC.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PX0318%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20FOR%20POSTING.pdf,Recurrent glioblastoma multiform,Reimburse with clinical criteria and/or conditions,Complete,"Feb 17, 2023","Dec 20, 2023",PX0318-000
polatuzumab vedotin,Polivy,polatuzumab vedotin,https://cadth.ca/sites/default/files/DRR/2024/PC0313%20Polivy%20-%20CADTH%20Final%20Rec.pdf; https://cadth.ca/sites/default/files/DRR/2024/PC0313%20Polivy%20-%20Stakeholder%20Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2024/PC0313-Polivy.pdf,Large B-cell lymphoma,Do not reimburse,Complete,"Mar 1, 2023","Dec 20, 2023",PC0313-000
upadacitinib,Rinvoq,upadacitinib,https://www.cadth.ca/sites/default/files/DRR/2024/SR0775-Rinvoq-Crohn-Combined-Report.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0775-Rinvoq-Crohn-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0775REC-Rinvoq-(Crohn's)-meta.pdf,Crohns disease,Reimburse with clinical criteria and/or conditions,Complete,"Jun 5, 2023","Dec 14, 2023",SR0775-000
efgartigimod alfa,Vyvgart,efgartigimod alfa,https://www.cadth.ca/sites/default/files/DRR/2024/SR0782%20Vyvgart%20-%20Stakeholder%20Feedback%20December%2014%2C%202023.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0782-Vyvgart.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0782REC-Vyvgart-meta.pdf,Generalized myasthenia gravis (gMG),Reimburse with clinical criteria and/or conditions,Complete,"May 9, 2023","Dec 14, 2023",SR0782-000
hr her2 breast cancer and triple negative breast cancer inclusion her2 low breast cancer,N/A,N/A,https://cadth.ca/sites/default/files/DRR/2023/PH0033-HRplus-HER2-BC-and-TNBC-with-HER2-Low-Inclusion.pdf,"HR+ HER2- Breast Cancer and Triple Negative Breast Cancer, with inclusion of HER2 Low Breast Cancer",N/A,Complete,N/A,"Dec 7, 2023",PH0033-000
andexanet alfa,Ondexxya,andexanet alfa,https://cadth.ca/sites/default/files/DRR/2023/ST0772%20Ondexxya%20-%20Confidential%20Final%20CADTH%20Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/ST0772-Ondexxya-Combined-Report.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/ST0772-Ondexxya-Stakeholder-Feedback.pdf,Reversal of FXa inhibitor anticoagulant effects,Do not reimburse,Complete,"Mar 2, 2023","Dec 5, 2023",ST0772-000
nsclc without actionable oncogenic alterations,N/A,N/A,https://www.cadth.ca/sites/default/files/pdf/PH0015%20Rapid%20Algorithm%20Report%20for%20NSCLC%20without%20actionable%20oncogenic%20alterations_%20Final%20Report%20for%20CAPCA%20Endorsement.pdf,Non-Small Cell Lung Cancer,N/A,Complete,N/A,"Dec 1, 2023",PH0015-000
elexacaftortezacaftorivacaftor and ivacaftor,Trikafta,elexacaftor/tezacaftor/ivacaftor and ivacaftor,https://cadth.ca/sites/default/files/DRR/2024/SR0776-Trikafta-Combined-Report.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0776-Trikafta-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0776%20Trikafta%20-%20Final%20CADTH%20Recommendation.pdf,"Cystic fibrosis, F508del CFTR mutation, 2 years and older",Reimburse with clinical criteria and/or conditions,Complete,"May 10, 2023","Nov 24, 2023",SR0776-000
somapacitan,Sogroya,somapacitan,https://cadth.ca/sites/default/files/DRR/2024/SR0779-Sogroya-Combined-Report.pdf; https://cadth.ca/sites/default/files/DRR/2024/SR0779-Sogroya-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0779REC-Sogroya-meta.pdf,Growth Hormone Deficiency (GHD),Reimburse with clinical criteria and/or conditions,Complete,"Apr 27, 2023","Nov 17, 2023",SR0779-000
mirikizumab,Omvoh,mirikizumab,https://www.cda-amc.ca/sites/default/files/DRR/2023/SR0773REC-Omvoh.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0773-Omvoh-Combined-Report.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/SR0773-Omvoh-Stakeholder-Feedback.pdf,Ulcerative colitis,Reimburse with clinical criteria and/or conditions,Complete,"Mar 7, 2023","Nov 16, 2023",SR0773-000
cabozantinib,Cabometyx,cabozantinib,https://cadth.ca/sites/default/files/DRR/2024/PC0312-Cabometyx-RCC-Combined-Report.pdf; https://cadth.ca/sites/default/files/DRR/2024/PC0312-Cabometyx-RCC-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0312%20Cabometyx%20-%20Final%20CADTH%20Revised.pdf,Advanced or metastatic renal cell carcinoma,Reimburse with clinical criteria and/or conditions,Complete,"Feb 17, 2023","Nov 3, 2023",PC0312-000
durvalumab and tremelimumab,Imfinzi and Imjudo,durvalumab and tremelimumab,https://cda-amc.ca/sites/default/files/DRR/2023/PC0308%20Imjudo%20and%20Imfinzi%20-%20Final%20CADTH%20Recommendation.pdf; https://cda-amc.ca/sites/default/files/DRR/2023/PC0308-Imfinzi-and-Imjudo-Combined-Report.pdf; https://cda-amc.ca/sites/default/files/DRR/2023/PC0308-Imfinzi-and-Imjudo-Stakeholder-Feedback.pdf,unresectable hepatocellular carcinoma,Reimburse with clinical criteria and/or conditions,Complete,"Dec 15, 2022","Nov 3, 2023",PC0308-000
ibrutinib,Imbruvica,ibrutinib,https://cda-amc.ca/sites/default/files/DRR/2023/PC0317REC-Imbruvica-Final-Recommendation-meta.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/PC0317%20Imbruvica%20Stakeholder%20Feedback.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/PC0317-Imbruvica_combined.pdf,Chronic lymphocytic leukemia (CLL),Reimburse with clinical criteria and/or conditions,Complete,"Apr 21, 2023","Nov 2, 2023",PC0317-000
rivaroxaban,N/A,rivaroxaban,https://www.cadth.ca/sites/default/files/DRR/2023/SX0750/SR0750CL-Rivaroxaban-rev-njcover.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SX0750/SX0750-DPI-Table.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SX0750/SX0750-Rivaroxaban_final.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0750%20Stakeholder%20Feedback%20on%20Draft%20Recommendations%20FOR%20POSTING.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/SR0750%20Stakeholder%20Input%20FOR%20POSTING.pdf,Venous thromboembolic events (VTE),Reimburse with clinical criteria and/or conditions,Complete,"Jun 29, 2022","Nov 2, 2023",SX0750-000 - SR0750-000
axicabtagene ciloleucel,Yescarta,axicabtagene ciloleucel,https://cadth.ca/sites/default/files/DRR/2023/PG0314%20Yescarta%20-%20Final%20CADTH%20Recommendation.pdf; https://cadth.ca/sites/default/files/DRR/2024/PG0314%20Yescarta%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20November%202%2C%202023.pdf; https://cadth.ca/sites/default/files/DRR/2024/PG0314-Yescarta.pdf,Relapsed or refractory follicular lymphoma,Reimburse with clinical criteria and/or conditions,Complete,"Apr 13, 2023","Nov 2, 2023",PG0314-000
prostate cancer,N/A,N/A,https://cadth.ca/sites/default/files/DRR/2023/PH0034%20Rapid%20Algorithm%20Report%20Prostate%20Cancer_final.pdf,Prostate Cancer,N/A,Complete,N/A,"Oct 27, 2023",PH0034-000
chronic lymphocytic leukemia,N/A,N/A,https://www.cadth.ca/sites/default/files/DRR/2023/PH0035-Rapid-Algorithm-Report-for-CLL3.pdf,Chronic Lymphocytic Leukemia,N/A,Complete,N/A,"Oct 27, 2023",PH0035-000
setmelanotide,Imcivree,setmelanotide,https://cadth.ca/sites/default/files/DRR/2023/SR0769-Imcivree-Combined-Report.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0769-Imcivree-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0769%20Imcivree%20%E2%80%93%20CADTH%20Final%20Recommendation.pdf,Bardet-Biedl syndrome,Reimburse with clinical criteria and/or conditions,Complete,"Mar 7, 2023","Oct 16, 2023",SR0769-000
dupilumab,Dupixent,dupilumab,https://www.cadth.ca/sites/default/files/DRR/2023/SR0774%20Dupixent%20Peds%20%E2%80%93%20CADTH%20Final%20Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0774%20Dupixent%20Peds%20-%20Stakeholder%20Feedback%20October%2013%2C%202023.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0774-Dupixent-Peds.pdf,"Atopic dermatitis, pediatrics",Reimburse with clinical criteria and/or conditions,Complete,"Mar 29, 2023","Oct 13, 2023",SR0774-000
nelarabine,Atriance,nelarabine,https://cadth.ca/sites/default/files/DRR/2023/PC0307-Atriance-Combined-Report.pdf; https://cadth.ca/sites/default/files/DRR/2023/PC0307-Atriance-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0307%20Atriance%20-%20Final%20CADTH%20Recommendation.pdf,T-cell acute lymphoblastic leukemia,Reimburse with clinical criteria and/or conditions,Complete,"Mar 6, 2023","Sep 29, 2023",PC0307-000
abiraterone acetate and prednisolone,n/a,abiraterone acetate and prednisolone,https://www.cadth.ca/sites/default/files/DRR/2023/PX0291/Clinical and Pharmacoeconomic Combined Report.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PX0291/Recommendation%20and%20Reasons.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PX0291/Responses to Questions From the Drug Programs.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PX0291/Stakeholder Feedback on Draft Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PX0291/Stakeholder Input.pdf,High-risk non-metastatic prostate cancer,Reimburse with clinical criteria and/or conditions,Complete,"Mar 23, 2022","Sep 8, 2023",PX0291-000 - PC0291-000
abiraterone prednisone docetaxel,N/A,"abiraterone, prednisone, docetaxel",https://www.cadth.ca/sites/default/files/DRR/2023/PX0298/Clinical and Pharmacoeconomic Combined Report.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PX0298/Recommendation%20and%20Reasons.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PX0298/Responses to Questions From the Drug Programs.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PX0298/Stakeholder Feedback on Draft Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PX0298/Stakeholder Input.pdf,Metastatic castration sensitive prostate cancer (mCSPC),Reimburse,Complete,"Jun 13, 2022","Sep 8, 2023",PX0298-000 - PC0298-000
upadacitinib,Rinvoq,upadacitinib,https://cadth.ca/sites/default/files/DRR/2023/SR0730%20Rinvoq%20UC%20-%20Final%20CADTH%20Recommendation%20Final-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0730-Rinvoq-UC-Combined-Report.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0730Rinvoq-Stakeholder-Feedback.pdf,Ulcerative colitis,Reimburse with clinical criteria and/or conditions,Complete,"Apr 18, 2022","Sep 1, 2023",SR0730-000
tisagenlecleucel,Kymriah,tisagenlecleucel,https://cadth.ca/sites/default/files/DRR/2023/PG0306%20Kymriah%20-%20Stakeholder%20Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2023/PG0306-Kymriah_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PG0306%20Kymriah%20-%20Final%20CADTH%20Recommendation.pdf,Relapsed or refractory follicular lymphoma,Reimburse with clinical criteria and/or conditions,Complete,"Feb 1, 2023","Sep 1, 2023",PG0306-000
zanubrutinib,Brukinsa,zanubrutinib,https://cadth.ca/sites/default/files/DRR/2023/PC0310%20Brukinsa%20-%20Stakeholder%20Feedback%20September%201%2C%202023.pdf; https://cadth.ca/sites/default/files/DRR/2023/PC0310-Brukinsa_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0310REC-Brukinsa_KT%20-%20MFJ_KT-meta.pdf,Chronic lymphocytic leukemia /small lymphocytic lymphoma.,Reimburse with clinical criteria and/or conditions,Complete,"Jan 20, 2023","Sep 1, 2023",PC0310-000
belzutifan,Welireg,belzutifan,https://cadth.ca/sites/default/files/DRR/2023/PC0309%20Welireg%20-%20CADTH%20Final%20Recommendation%20Final.pdf; https://cadth.ca/sites/default/files/DRR/2023/PC0309-Welireg-Combined-Report.pdf; https://cadth.ca/sites/default/files/DRR/2023/PC0309-Welireg-Stakeholder-Feedback.pdf,von Hippel-Lindau disease-associated tumours,Reimburse with clinical criteria and/or conditions,Complete,"Jan 23, 2023","Sep 1, 2023",PC0309-000
cenobamate,Xcopri,cenobamate,https://cadth.ca/sites/default/files/DRR/2023/SR0770-Xcopri%20-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0770%20Xcopri%20-%20Final%20CADTH%20Recommendation%20Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0770-Xcopri.pdf,"Epilepsy, partial-onset seizures",Reimburse with clinical criteria and/or conditions,Complete,"Feb 7, 2023","Aug 29, 2023",SR0770-000
dapagliflozin,N/A,dapagliflozin,https://www.cadth.ca/sites/default/files/DRR/2023/SX0749/Clinical%20and%20Pharmacoeconomic%20Combined%20Report.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SX0749/Recommendation%20and%20Reasons.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SX0749/Responses%20to%20Questions%20From%20the%20Drug%20Programs.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SX0749/Stakeholder%20Feedback%20on%20Draft%20Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SX0749/Stakeholder%20Input.pdf,Chronic kidney disease,Reimburse with clinical criteria and/or conditions,Complete,"Jun 17, 2022","Aug 23, 2023",SX0749-000 - SR0749-000
roflumilast,Zoryve,roflumilast,https://cadth.ca/sites/default/files/DRR/2023/SR0771-Zoryve-Combined-Report.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0771-Zoryve-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0771REC-Zoryve.pdf,Plaque psoriasis,Reimburse with clinical criteria and/or conditions,Complete,"Feb 2, 2023","Aug 16, 2023",SR0771-000
non small cell lung cancer without actionable oncogenic alterations,N/A,N/A,https://cadth.ca/sites/default/files/DRR/2023/PH0029-Algorithm_secured.pdf,Non-Small Cell Lung Cancer without actionable oncogenic alterations,N/A,Complete,N/A,"Aug 10, 2023",PH0029-000
avacopan,Tavneos,avacopan,https://cadth.ca/sites/default/files/DRR/2023/SR0732-Tavneos-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0732-Tavneos_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0732REC-Tavneos-KH_BF-KH-meta.pdf,Antineutrophil cytoplasmic antibody-associated vasculitis,Do not reimburse,Complete,"Oct 14, 2022","Aug 10, 2023",SR0732-000
cariprazine,Vraylar,cariprazine,https://cadth.ca/sites/default/files/DRR/2022/SR0708-Response-to-Procedural-Review-Panel-Report.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0708_Memorandum%2C%20Panel%20Report%20%E2%80%93%20cariprazine_Vraylar%20-%20Procedural%20Review.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0708%20vraylar%20-%20Stakeholder%20Feedback%20on%20draft%20recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0708-Cariprazine.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0708REC-Cariprazine.pdf,Schizophrenia,Do not reimburse,Complete,"Oct 29, 2021","Aug 10, 2023",SR0708-000
ravulizumab,Ultomiris,ravulizumab,https://cadth.ca/sites/default/files/DRR/2023/SR0765Ultomiris%20-%20Confidential%20Final%20CADTH%20Recommendation%20August%2024%2C%202023%20revised.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0765_Ultomiris_Combined_Report.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0765_Ultomiris_Stakeholder_Feedback.pdf,AChR antibody-positive generalized Myasthenia Gravis,Do not reimburse,Complete,"Oct 25, 2022","Aug 8, 2023",SR0765-000
deucravacitinib,Sotyktu,deucravacitinib,https://cadth.ca/sites/default//files/DRR/2023/SR0756%20Sotyktu%20-%20CADTH%20Final%20Recommendation%20-%20KH%20-%20MFJ%20-%20KH-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0756%20Sotyktu%20-%20Stakeholder%20Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0756-Sotyktu.pdf,"Psoriasis, moderate to severe plaque",Do not reimburse,Complete,"Sep 27, 2022","Aug 8, 2023",SR0756-000
multiple myeloma,N/A,N/A,https://www.cadth.ca/sites/default/files/DRR/2023/PH0031%20Multiple%20Myeloma_Algorithm-Secured.pdf,Multiple myeloma,N/A,Complete,N/A,"Jul 27, 2023",PH0031-000
difelikefalin,Korsuva,difelikefalin,https://cadth.ca/sites/default//files/DRR/2023/SR0752%20Korsuva%20-%20CADTH%20Final%20Recommendation%20(with%20correction%20notice.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0752%20Korsuva%20-%20Stakeholder%20Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0752-Korsuva.pdf,Chronic kidney disease,Do not reimburse,Complete,"Sep 22, 2022","Jul 13, 2023",SR0752-000
trastuzumab deruxtecan,Enhertu,trastuzumab deruxtecan,https://www.cadth.ca/sites/default/files/DRR/2023/PC0305%20Enhertu%20-%20Final%20CADTH%20Recommendation%20(with%20redactions)%20June%2029%2C%202023%20-%20KH_KAS%20-%20KH-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0305-Enhertu-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0305-Enhertu.pdf,unresectable or metastatic HER2-low breast cancer,Reimburse with clinical criteria and/or conditions,Complete,"Dec 13, 2022","Jun 29, 2023",PC0305-000
adult b cell precursor acute lymphoblastic leukemia philadelphia chromosome negative and positive,N/A,N/A,https://www.cadth.ca/sites/default/files/DRR/2023/PH0030%20Rapid%20Algorithm%20Report-Adult%20B-Cell%20Precursor%20Acute%20Lymphoblastic%20Leukemia%20Philadelphia%20Chromosome%20Negative%20and%20Positive_SECURED.pdf,"Adult B-Cell Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative and Positive",N/A,Complete,N/A,"Jun 28, 2023",PH0030-000
foslevodopa foscarbidopa,Vyalev,foslevodopa foscarbidopa,https://cadth.ca/sites/default/files/DRR/2023/SR0768%20Vyalev%20-%20Confidential%20CADTH%20Final%20Recommendation%20Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0768-Vyalev-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0768-Vyalev.pdf,Parkinson’s disease,Reimburse with clinical criteria and/or conditions,Complete,"Nov 23, 2022","Jun 16, 2023",SR0768-000
triple negative breast cancer,N/A,N/A,https://www.cadth.ca/sites/default/files/DRR/2023/PH0024-Rapid%20Algorithm%20Report%20for%20Triple%20Negative%20Breast%20Cancer_FINAL.pdf,Triple Negative Breast Cancer,N/A,Complete,N/A,"Jun 14, 2023",PH0024-000
atogepant,Qulipta,atogepant,https://cadth.ca/sites/default//files/DRR/2023/SR0724-Qulipta-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default//files/DRR/2023/SR0724-Qulipta_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0724%20Qulipta%20-%20Final%20CADTH%20Recommendation%20June%202023%20Final.pdf,"Migraine, prevention",Reimburse with clinical criteria and/or conditions,Complete,"Feb 23, 2022","Jun 14, 2023",SR0724-000
vericiguat,Verquvo,vericiguat,https://www.cadth.ca/sites/default/files/DRR/2023/SR0758%20Verquvo%20-%20Final%20CADTH%20Recommendation%20(with%20redactions)%20Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0758-Verquvo-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0758-Verquvo.pdf,Heart failure,Reimburse with clinical criteria and/or conditions,Complete,"Oct 14, 2022","Jun 14, 2023",SR0758-000
ret fusion positive non small cell lung cancer,N/A,N/A,https://cadth.ca/sites/default/files/DRR/2023/PH0026-Implementation-Advice-Report-Algorithm-RET-Positive-NSCLC.pdf,RET fusion-positive non-small cell lung cancer,N/A,Complete,N/A,"Jun 1, 2023",PH0026-000
non small cell lung cancer nsclc activating epidermal growth factor receptor egfr mutations,N/A,N/A,https://cadth.ca/sites/default/files/DRR/2023/PH0028-NSCLC-EGFR.pdf,Non-Small Cell Lung Cancer (NSCLC) with Activating Epidermal Growth Factor Receptor (EGFR) Mutations,N/A,Complete,N/A,"Jun 1, 2023",PH0028-000
risankizumab,Skyrizi,risankizumab,https://cadth.ca/sites/default//files/DRR/2023/SR0767%20Skyrizi%20Stakeholder%20Feedback.pdf; https://cadth.ca/sites/default//files/DRR/2023/SR0767-Skyriz_combined.pdf; https://cadth.ca/sites/default//files/DRR/2023/SR0767REC-Skyrizi_August%2022%2C2023-meta.pdf,Crohn's disease,Reimburse with clinical criteria and/or conditions,Complete,"Oct 28, 2022","May 12, 2023",SR0767-000
upadacitinib,Rinvoq,upadacitinib,https://www.cadth.ca/sites/default/files/DRR/2023/SR0759%20Rinvoq%20-%20Stakeholder%20Feedback%20June%202023.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0759%20Rinvoq%20AS.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0759REC-Rinvoq_KT.CY_MFJ_KT_KT-meta.pdf,ankylosing spondylitis,Reimburse with clinical criteria and/or conditions,Complete,"Oct 17, 2022","May 11, 2023",SR0759-000
palovarotene,Sohonos,palovarotene,https://cadth.ca/sites/default/files/DRR/2023/SR0761%20Sohonos%20-%20Stakeholder%20Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0761-Sohonos_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0761%20Sohonos%20-%20CADTH%20Final%20Recommendation.pdf,Fibrodysplasia Ossificans Progressiva,Reimburse with clinical criteria and/or conditions,Complete,"Oct 21, 2022","May 11, 2023",SR0761-000
selumetinib,Koselugo,selumetinib,https://www.cadth.ca/sites/default/files/DRR/2023/SR0764-Koselugo-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0764-Koselugo.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0764REC-Koselugo.pdf,Neurofibromatosis type 1,Reimburse with clinical criteria and/or conditions,Complete,"Oct 28, 2022","May 10, 2023",SR0764-000
fostemsavir,Rukobia,fostemsavir,https://www.cadth.ca/sites/default/files/DRR/2023/SR0760%20Rubokia%20Stakeholder%20Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0760-Rukobia.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0760REC-Rukobia.pdf,Human immunodeficiency virus type 1 (HIV-1),Reimburse with clinical criteria and/or conditions,Complete,"Oct 28, 2022","May 10, 2023",SR0760-000
prostate cancer,N/A,N/A,https://www.cadth.ca/sites/default/files/DRR/2023/PH0023-000-Prostate-Cancer.pdf,Prostate Cancer,N/A,Complete,N/A,"May 3, 2023",PH0023-000
ciltacabtagene autoleucel,Carvykti,ciltacabtagene autoleucel,https://cadth.ca/sites/default/files/DRR/2023/PG0302-Carvykti-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2023/PG0302-Carvykti.pdf; https://cadth.ca/sites/default/files/DRR/2023/PG0302-Carvykti_combined.pdf,Relapsed or refractory multiple myeloma,Reimburse with clinical criteria and/or conditions,Complete,"Sep 23, 2022","May 1, 2023",PG0302-000
crisantaspase recombinant,Rylaze,crisantaspase recombinant,https://www.cadth.ca/sites/default/files/DRR/2023/PC0301%20Rylaze%20-%20CADTH%20Consolidated%20Stakeholder%20Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0301%20Rylaze%20-%20CADTH%20Final%20Recommendation%20Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0301-Rylaze.pdf,Acute lymphoblastic leukemia,Reimburse with clinical criteria and/or conditions,Complete,"Aug 18, 2022","Apr 26, 2023",PC0301-000
mavacamten,Camzyos,mavacamten,https://cadth.ca/sites/default/files/DRR/2023/SR0755-Camzyos-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0755-Camzyos.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0755_Camzyos-FinalCADTHRecommendation-meta.pdf,Obstructive hypertrophic cardiomyopathy,Reimburse with clinical criteria and/or conditions,Complete,"Sep 22, 2022","Apr 14, 2023",SR0755-000
large b cell lymphoma,N/A,N/A,https://www.cadth.ca/sites/default/files/DRR/2023/PH0027-LBCL.pdf,Large B-Cell Lymphoma,N/A,Complete,N/A,"Apr 11, 2023",PH0027-000
caplacizumab,Cablivi,caplacizumab,https://cadth.ca/sites/default/files/DRR/2023/SR0736%20Cablivi%20Resubmission%20-%20Final%20CADTH%20Recommendation%20Final.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0736%20Cablivi%20Resubmission%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation_Redacted.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0736-Cablivi%20Resubmission_combined.pdf,Acquired thrombotic thrombocytopenic purpura (aTTP),Do not reimburse,Complete,"Jun 7, 2022","Apr 5, 2023",SR0736-000
nivolumab,Opdivo,nivolumab,https://cadth.ca/sites/default/files/DRR/2023/PC0303%20Opdivo%20NSCLC%20-%20Final%20CADTH%20Recommendation.pdf; https://cadth.ca/sites/default/files/DRR/2023/PC0303-Opdivo-NSCLC-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2023/PC0303-Opdivo-NSCLC.pdf,Resectable Non-Small Cell Lung Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Sep 13, 2022","Mar 30, 2023",PC0303-000
brexucabtagene autoleucel,Tecartus,brexucabtagene autoleucel,https://www.cadth.ca/sites/default/files//DRR/2023/PG0304-Tecartus-ALL-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PG0304%20Tecartus%20ALL%20%E2%80%93%20CADTH%20Final%20Recommendation%20Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PG0304-Tecartus-ALL.pdf,Acute lymphoblastic leukemia,Reimburse with clinical criteria and/or conditions,Complete,"Sep 16, 2022","Mar 29, 2023",PG0304-000
pegcetacoplan,Empaveli,pegcetacoplan,https://cadth.ca/sites/default/files/DRR/2023/SR0748-Empaveli-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0748-Empaveli_combined.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0748REC-Empaveli_KT-meta.pdf,Paroxysmal nocturnal hemoglobinuria,Reimburse with clinical criteria and/or conditions,Complete,"Aug 26, 2022","Mar 20, 2023",SR0748-000
finerenone,Kerendia,finerenone,https://www.cadth.ca/sites/default/files/DRR/2023/SR0737%20Kerendia%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20March%208%2C%202023.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0737-Kerendia.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0737REC-Kerendia.pdf,Chronic kidney disease,Reimburse with clinical criteria and/or conditions,Complete,"May 20, 2022","Mar 8, 2023",SR0737-000
hormone receptor hr positive human epidermal growth factor receptor 2 her2 negative breast cancer,N/A,N/A,https://cadth.ca/sites/default/files/DRR/2023/PH0018%20HRplus_HER2neg_Implementation%20Advice%20Report%20Algorithm.pdf,"Hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer",N/A,Complete,N/A,"Mar 8, 2023",PH0018-000
lutetium vipivotide tetraxetan,Pluvicto,lutetium vipivotide tetraxetan,https://cadth.ca/sites/default/files/DRR/2023/PC0297%20Pluvicto%20-%20Final%20CADTH%20Recommendation%20(with%20redactions)%20March%203%2C%202023_For%20publishing_JH_BMc-meta.pdf; https://cadth.ca/sites/default/files/DRR/2023/PC0297-Pluvicto-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2023/PC0297-Pluvicto_combined.pdf,Metastatic castration-resistant prostate cancer,Reimburse with clinical criteria and/or conditions,Complete,"Jul 21, 2022","Mar 3, 2023",PC0297-000
amivantamab,Rybrevant,amivantamab,https://www.cadth.ca/sites/default/files/DRR/2023/PC0289%20Rybrevant%20-%20Confidential%20CADTH%20Final%20Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0289%20Rybrevant%20-%20Final%20Stakeholder%20Feedback%20May%2011%2C%202023.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0289-Rybrevant_combined.pdf,Non-small cell lung cancer,Reimburse with clinical criteria and/or conditions,Complete,"Apr 21, 2022","Mar 1, 2023",PC0289-000
olaparib,Lynparza,olaparib,https://www.cadth.ca/sites/default/files/DRR/2023/PC0299%20Lynparza%20%E2%80%93%20CADTH%20Final%20Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0299-Lynparza-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0299-Lynparza_combined.pdf,"gBRCAm, HER2-negative high-risk early breast cancer",Reimburse with clinical criteria and/or conditions,Complete,"Aug 3, 2022","Mar 1, 2023",PC0299-000
ravulizumab,Ultomiris,ravulizumab,https://cadth.ca/sites/default/files/DRR/2023/SR0740-Ultomiris-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0740-Ultomiris_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0740%20Ultomiris%20-%20CADTH%20Final%20Recommendation%20Final.pdf,Atypical hemolytic uremic syndrome,Reimburse with clinical criteria and/or conditions,Complete,"Jun 8, 2022","Feb 27, 2023",SR0740-000
berotralstat,Orladeyo,berotralstat,https://www.cadth.ca/sites/default/files/DRR/2023/SR0723%20Orladeyo%20-%20Final%20CADTH%20Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0723-Orladeyo-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0723-Orladeyo.pdf,hereditary angioedema (HAE),Reimburse with clinical criteria and/or conditions,Complete,"Feb 22, 2022","Feb 17, 2023",SR0723-000
lumasiran,Oxlumo,lumasiran,https://www.cadth.ca/sites/default/files/DRR/2023/SR0734%20Oxlumo%20-%20Final%20CADTH%20Recommendation%20(with%20redactions)%20Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0734-Oxlumo-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0734-Oxlumo.pdf,Primary hyperoxaluria type 1,Reimburse with clinical criteria and/or conditions,Complete,"May 10, 2022","Feb 8, 2023",SR0734-000
melanoma,N/A,N/A,https://cadth.ca/sites/default/files/DRR/2023/PH0022%20Rapid%20Algorithm%20Report%20for%20Melanoma_with%20CAPCA%20Endorsement_FINAL.pdf,Melanoma,N/A,Complete,N/A,"Feb 6, 2023",PH0022-000
differentiated thyroid carcinoma,N/A,N/A,https://cadth.ca/sites/default/files/DRR/2023/PH0021%20Differentiated%20Thyroid%20Carcinoma%20Rapid%20Algorithm_for%20CAPCA%20Endorsement.pdf,Differentiated Thyroid Carcinoma,N/A,Complete,N/A,"Feb 6, 2023",PH0021-000
axicabtagene ciloleucel,Yescarta,axicabtagene ciloleucel,https://www.cadth.ca/sites/default/files/DRR/2023/PG0293%20Yescarta%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20February%203%2C%202023.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PG0293-Yescarta.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PG0293REC-Yescarta-meta.pdf,Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL),Reimburse with clinical criteria and/or conditions,Complete,"Jun 9, 2022","Feb 3, 2023",PG0293-000
durvalumab,Imfinzi,durvalumab,https://cadth.ca/sites/default/files/DRR/2023/PC0296-Imfinzi-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2023/PC0296-Imfinzi_combined.pdf; https://cadth.ca/sites/default/files/DRR/2023/PC0296REC-Imfinzi_JH_GP1_KAS.pdf,Biliary tract cancer,Reimburse with clinical criteria and/or conditions,Complete,"Jul 14, 2022","Feb 3, 2023",PC0296-000
pembrolizumab,Keytruda,pembrolizumab,https://cadth.ca/sites/default/files/DRR/2023/PC0280-Keytruda-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2023/PC0280-Keytruda_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0280%20Keytruda%20-%20Final%20CADTH%20Recommendation.pdf,Advanced endometrial cancer,Reimburse with clinical criteria and/or conditions,Complete,"Dec 15, 2021","Feb 3, 2023",PC0280-000
dupilumab,Dupixent,dupilumab,http://www.cadth.ca/sites/default/files/DRR/2023/SR0745-Dupixent-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0745%20Dupixent%20-%20CADTH%20Final%20Recommendation%20Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0745-Dupixent.pdf,Asthma,Reimburse with clinical criteria and/or conditions,Complete,"Jun 28, 2022","Jan 20, 2023",SR0745-000
anifrolumab,Saphnelo,anifrolumab,https://cadth.ca/sites/default/files/DRR/2023/SR0717%20Saphnelo%20-%20CADTH%20Final%20Rec_JH_BF.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0717%20Saphnelo%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0717-Saphnelo_combined.pdf,Systemic lupus erythematosus,Reimburse with clinical criteria and/or conditions,Complete,"Jan 28, 2022","Jan 20, 2023",SR0717-000
deferiprone,Ferriprox,deferiprone,https://cadth.ca/sites/default/files/DRR/2023/SR0741%20Ferriprox%20-%20Final%20CADTH%20Recommendation%20Final-meta.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0741%20Ferriprox%20-%20Stakeholder%20Feedback%20January%2019%2C%202023.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0741-Ferriprox_combined.pdf,Transfusional iron overload,Reimburse with clinical criteria and/or conditions,Complete,"Jun 8, 2022","Jan 19, 2023",SR0741-000
belimumab,Benlysta,belimumab,https://cadth.ca/sites/default/files/DRR/2023/SR0746%20Benlysta-%20CADTH%20Final%20Recommendation%20February%207%2C%202023_For%20Publishing_KT_NA_BF_KT_BF-meta.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0746-Benlysta-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0746-Benlysta_combined.pdf,Lupus nephritis,Reimburse with clinical criteria and/or conditions,Complete,"Jul 7, 2022","Jan 19, 2023",SR0746-000
brolucizumab,Beovu,brolucizumab,https://cadth.ca/sites/default/files/DRR/2023/SR0747%20Beovu%20-%20CADTH%20%20Final%20Recommendation%20KH_SC%20-%20KH-meta.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0747%20Beovu%20-%20Stakeholder%20feedback.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0747-Beovu_combined.pdf,Diabetic macular edema,Reimburse with clinical criteria and/or conditions,Complete,"Jun 30, 2022","Jan 18, 2023",SR0747-000
dupilumab,Dupixent,dupilumab,https://cadth.ca/sites/default/files/DRR/2023/SF0754%20Dupixent%20RfA%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20January%2018%2C%202023.pdf; https://cadth.ca/sites/default/files/DRR/2023/SF0754-Dupixent-RfA_combined.pdf; https://cadth.ca/sites/default/files/DRR/2023/SF0754REC-Dupixent-RfA.pdf,atopic dermatitis,Reimburse with clinical criteria and/or conditions,Complete,"Jul 15, 2022","Jan 18, 2023",SF0754-000
her2 positive metastatic breast cancer,N/A,N/A,https://www.cadth.ca/sites/default/files/pdf/PH0016-HER2-mBC-CAPCA-Endorsement_FINAL.pdf,HER2 Positive Metastatic Breast Cancer,N/A,Complete,N/A,"Jan 13, 2023",PH0016-000
renal cell carcinoma,N/A,N/A,https://cadth.ca/sites/default/files/pdf/PH0019-Adjuvant%20RCC-CAPCA%20Endorsement.pdf,Renal Cell Carcinoma,N/A,Complete,N/A,"Jan 11, 2023",PH0019-000
metastatic urothelial carcinoma,N/A,N/A,https://cadth.ca/sites/default/files/pdf/PH0017-mUC-CAPCA-Endorsement.pdf,Metastatic Urothelial Carcinoma,N/A,Complete,N/A,"Jan 11, 2023",PH0017-000
lemborexant,Dayvigo,lemborexant,https://www.cadth.ca/sites/default/files/DRR/2023/SR0716%20Dayvigo%20-%20Confidential%20Final%20CADTH%20Rec%20DM%20-%20KH-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0716-Dayvigo-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0716-Dayvigo.pdf,Insomnia,Do not reimburse,Complete,"Feb 28, 2022","Jan 10, 2023",SR0716-000
pembrolizumab,Keytruda,pembrolizumab,https://cadth.ca/sites/default/files/DRR/2023/PC0295%20Keytruda%20mTNBC%20-%20Final%20CADTH%20Recommendation_for%20Publishing-KH%20-%20KW%20-%20KH-meta.pdf; https://cadth.ca/sites/default/files/DRR/2023/PC0295-Keytruda-mTNBC-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2023/PC0295-Keytruda-mTNBC_combined.pdf,Triple-negative breast cancer,Reimburse with clinical criteria and/or conditions,Complete,"Jun 20, 2022","Jan 6, 2023",PC0295-000
darolutamide,Nubeqa,darolutamide,https://www.cadth.ca/sites/default/files/DRR/2023/PC0294%20Nubeqa%20-%20CADTH%20Final%20Recommendation_KT_DM_KT-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0294-Nubeqa-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0294-Nubeqa.pdf,Metastatic castration-sensitive prostate cancer,Reimburse with clinical criteria and/or conditions,Complete,"Jun 16, 2022","Jan 5, 2023",PC0294-000
tebentafusp,Kimmtrak,tebentafusp,https://www.cadth.ca/sites/default/files/DRR/2023/PC0290%20Kimmtrak%20-%20CADTH%20Final%20Recommendation%20January%204%2C%202023_JH_KAS%20(clean)-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0290-Kimmtrak-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0290-Kimmtrak.pdf,unresectable or metastatic uveal melanoma,Reimburse with clinical criteria and/or conditions,Complete,"Apr 21, 2022","Jan 4, 2023",PC0290-000
edaravone,Radicava,edaravone,https://cadth.ca/sites/default/files/DRR/2022/SR0727-Radicava-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0727-Radicava_combined.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0727%20Radicava%20-%20CADTH%20Final%20Recommendation_for%20posting.pdf,Amyotrophic lateral sclerosis,Reimburse with clinical criteria and/or conditions,Complete,"Mar 10, 2022","Dec 22, 2022",SR0727-000
lurbinectedin,Zepzelca,lurbinectedin,https://cadth.ca/sites/default/files/DRR/2023/PC0281%20Zepzelca%20-%20Stakholder%20Feedback%20January%2030%2C%202023.pdf; https://cadth.ca/sites/default/files/DRR/2023/PC0281-Zepzelca_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0281%20Zepzelca%20-%20Confidental%20Final%20CADTH%20Recommendation%20(Redacted)-KH_SC%20-%20KH-meta.pdf,metastatic small cell lung cancer (SCLC),Do not reimburse,Complete,"Feb 24, 2022","Dec 19, 2022",PC0281-000
eptinezumab,Vyepti,eptinezumab,https://www.cadth.ca/sites/default/files/DRR/2023/SR0743%20Vyepti%20-%20Final%20CADTH%20Recommendation%20(with%20redactions)%20final%20-%20KH%20-%20DM%20-%20KH2-meta%20(1).pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0743-Vyepti-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0743-Vyepti-meta.pdf,Migraine,Reimburse with clinical criteria and/or conditions,Complete,"Jun 8, 2022","Dec 15, 2022",SR0743-000
dexamethasone intravitreal implant,Ozurdex,dexamethasone intravitreal implant,https://www.cadth.ca/sites/default/files/DRR/2023/SR0739%20Ozurdex%20-%20Final%20CADTH%20Recommendation_RW_SC_RW_RW-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0739-Ozurdex-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0739-Ozurdex.pdf,Diabetic macular edema,Do not reimburse,Complete,"Jun 8, 2022","Dec 13, 2022",SR0739-000
pitolisant hydrochloride,Wakix,pitolisant hydrochloride,https://cadth.ca/sites/default/files/DRR/2022/SR0715%20Wakix%20-%20Final%20CADTH%20Recommendation%20for%20publishing-KH_BMc%20-%20KH-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0715-Wakix-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0715-Wakix.pdf,Narcolepsy,Do not reimburse,Complete,"Dec 8, 2021","Dec 6, 2022",SR0715-000
pembrolizumab,Keytruda,pembrolizumab,https://cadth.ca/sites/default/files/DRR/2022/PC0292%20Keytruda%20Cervical%20-%20Final%20CADTH%20Recommendation%20(With%20Redactions)_Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0292-Keytruda-Cervical-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0292-Keytruda-Cervical.pdf,"recurrent, or metastatic cervical cancer",Reimburse with clinical criteria and/or conditions,Complete,"May 20, 2022","Dec 1, 2022",PC0292-000
guselkumab,Tremfya,guselkumab,https://www.cadth.ca/sites/default/files/DRR/2022/SR0733%20Tremfya%20PsA%20-%20CADTH%20Final%20Recommendation_KAS-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0733%20Tremfya%20PsA%20-%20Stakeholder%20Feedback%20December%202022.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0733-Tremfya.pdf,Psoriatic arthritis,Reimburse with clinical criteria and/or conditions,Complete,"May 2, 2022","Nov 17, 2022",SR0733-000
ozanimod,Zeposia,ozanimod,https://www.cadth.ca/sites/default/files/DRR/2022/SR0714%20Zeposia%20-%20Final%20CADTH%20Recommendation%20SC%20-%20KH-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0714-Zeposia-UC-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0714-Zeposia-meta.pdf,Ulcerative colitis,Reimburse with clinical criteria and/or conditions,Complete,"Jan 5, 2022","Nov 17, 2022",SR0714-000
tezepelumab,Tezspire,tezepelumab,https://cadth.ca/sites/default/files/DRR/2023/SR0731-Tezspire-Stakeholder-Feedback-on-Draft-Rec.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0731-Tezspire.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0731%20Tezspire%20-%20Confidential%20CADTH%20Final%20Recommendation%20(with%20redactions)_RW_DM_RW-meta.pdf,Asthma,Reimburse with clinical criteria and/or conditions,Complete,"Apr 14, 2022","Nov 16, 2022",SR0731-000
dalbavancin,Xydalba,dalbavancin,https://cadth.ca/sites/default/files/DRR/2022/SR0728%20Xydalba%20-%20Stakeholder%20Feedback%20November%2016%2C%202022.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0728-Xydalba_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0728%20Xydalba%20-%20CADTH%20Final%20Recommendation%20JH_SC_ready%20for%20formatting-meta.pdf,Acute bacterial skin and skin structure infections,Reimburse with clinical criteria and/or conditions,Complete,"Apr 11, 2022","Nov 16, 2022",SR0728-000
mepolizumab,Nucala,mepolizumab,https://cadth.ca/sites/default/files/DRR/2023/SR0735%20Nucala%20-%20Stakeholder%20feedback%20on%20Draft%20Recommendation.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0735-Nucala_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0735%20Nucala%20-%20CADTH%20Final%20Recommendation%20(with%20corrections)_Final.pdf,Severe chronic rhinosinusitis with nasal polyps,Reimburse with clinical criteria and/or conditions,Complete,"May 11, 2022","Nov 16, 2022",SR0735-000
multiple myeloma mm,N/A,N/A,https://www.cadth.ca/sites/default/files/pdf/PH0014%20Rapid%20Algorithm%20Report%20Multiple%20Myeloma.pdf,Multiple Myeloma (MM),N/A,Complete,N/A,"Nov 15, 2022",PH0014-000
cariprazine,Vraylar,cariprazine,https://cadth.ca/sites/default/files/DRR/2022/SR0718-Vraylar-BPD-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0718-Vraylar-BPD.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0718%20Vraylar%20BPD%20-%20CADTH%20Final%20Recommendation%20(with%20redactions)_RW_DM_RW-meta.pdf,Bipolar Disorder,Do not reimburse,Complete,"Jan 28, 2022","Nov 9, 2022",SR0718-000
pegvaliase,Palynziq,pegvaliase,https://cadth.ca/sites/default/files/DRR/2022/SR0712%20Palynziq%20-%20Stakeholder%20Feedback%20.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0712-Palynziq_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0712%20Palynziq%20-%20CADTH%20Final%20Recommendation%20Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0712%20Palynziq%20Procedural%20Review%20Panel%20report.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0712-Response-to-Procedural-Review-Panel.pdf,Phenylketonuria,Reimburse with clinical criteria and/or conditions,Complete,"Dec 22, 2021","Nov 9, 2022",SR0712-000
pembrolizumab,Keytruda,pembrolizumab,https://cadth.ca/sites/default/files/DRR/2023/PC0286-Keytruda-Melanoma-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2023/PC0286-Keytruda-Melanoma_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0286%20Keytruda%20Melanoma%20-%20CADTH%20Final%20Rec%20Revised%20Jan.%2031.pdf,Melanoma Adjuvant Treatment,Reimburse with clinical criteria and/or conditions,Complete,"Apr 26, 2022","Nov 4, 2022",PC0286-000
maribavir,Livtencity,maribavir,https://www.cadth.ca/sites/default/files/DRR/2022/SR0720%20Livtencity%20%E2%80%93%20CADTH%20Final%20Recommendation%20(with%20redactions)%20KH2_SY%20-%20KH-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0720-Livtencity-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/SR0720-Livtencity.pdf,Post-transplant cytomegalovirus infection,Reimburse with clinical criteria and/or conditions,Complete,"Mar 31, 2022","Nov 4, 2022",SR0720-000
entrectinib,Rozlytrek,entrectinib,https://cadth.ca/sites/default/files/DRR/2023/PC0278-Rozlytrek-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2023/PC0278-Rozlytrek.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0278%20Rozlytrek%20-%20CADTH%20Final%20Recommendation%20for%20Posting.pdf,Extracranial solid tumours with NTRK gene fusion,Reimburse with clinical criteria and/or conditions,Complete,"Jan 25, 2022","Nov 3, 2022",PC0278-000
cabozantinib,Cabometyx,cabozantinib,https://cadth.ca/sites/default/files/DRR/2022/PC0287-Cabometyx-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0287-Cabometyx_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0287%20Cabometyx%20-%20CADTH%20Final%20Recommendation%20for%20formatting-meta.pdf,Differentiated thyroid carcinoma,Reimburse with clinical criteria and/or conditions,Complete,"Apr 27, 2022","Nov 2, 2022",PC0287-000
empagliflozin,Jardiance,empagliflozin,https://cadth.ca/sites/default/files/DRR/2022/SR0726%20Jardiance%20-%20Stakeholder%20Feedback%20October%2014%2C%202022.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0726-Jardiance_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0726%20Jardiance%20-%20Final%20CADTH%20Recommendation.pdf,Heart failure,Reimburse with clinical criteria and/or conditions,Complete,"Apr 6, 2022","Oct 14, 2022",SR0726-000
faricimab,Vabysmo,faricimab,https://cadth.ca/sites/default/files/DRR/2022/SR0729-Vabysmo-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0729-Vabysmo_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0729%20Vabysmo%20-%20Confidential%20Final%20CADTH%20Recommendation-KH_BF%20-%20KH-meta.pdf,Diabetic Macular Edema,Reimburse with clinical criteria and/or conditions,Complete,"Mar 24, 2022","Oct 14, 2022",SR0729-000
pembrolizumab,Keytruda,pembrolizumab,https://cadth.ca/sites/default/files/DRR/2022/PC0273%20Keytruda%20RCC%20-%20CADTH%20Final%20Recommendation_Final.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0273-Keytruda-RCC-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0273-Keytruda-RCC_combined.pdf,"Renal cell carcinoma, adjuvant",Reimburse with clinical criteria and/or conditions,Complete,"Mar 3, 2022","Sep 29, 2022",PC0273-000
pralsetinib,Gavreto,pralsetinib,https://cadth.ca/sites/default/files/DRR/2022/PC0283%20Gavreto%20-%20CADTH%20Final%20Recommendation%20Final.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0283-Gavreto-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0283-Gavreto_combined.pdf,RET fusion-positive non-small cell lung cancer,Reimburse with clinical criteria and/or conditions,Complete,"Mar 9, 2022","Sep 29, 2022",PC0283-000
abemaciclib,Verzenio,abemaciclib,https://www.cadth.ca/sites/default/files/DRR/2022/PC0282%20Verzenio%20-%20CADTH%20Final%20Recommendation%20(With%20Redactions)_Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0282-Verzenio-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0282-Verzenio.pdf,"Adjuvant treatment of HR-positive, HER2-negative early breast cancer",Reimburse with clinical criteria and/or conditions,Complete,"Mar 23, 2022","Sep 29, 2022",PC0282-000
tafasitamab,Minjuvi,tafasitamab,https://cadth.ca/sites/default/files/DRR/2022/PC0266-Minjuvi-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0266-Minjuvi_combined.pdf; https://cadth.ca/sites/default/files/DRR/2023/PC0266%20Minjuvi%20Procedural%20Review%20Panel%20report_Redacted.pdf; https://cadth.ca/sites/default/files/DRR/2023/PC0266%20Response%20to%20the%20Procedural%20Review%20Panel.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0266%20Minjuvi%20-%20CADTH%20Final%20Recommendation-Final.pdf,Diffuse large B-cell lymphoma (DLBCL),Do not reimburse,Complete,"Nov 19, 2021","Sep 29, 2022",PC0266-000
nivolumab,Opdivo,nivolumab,https://cadth.ca/sites/default/files/DRR/2022/PC0272-Opdivo-UC-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0272-Opdivo-combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0272%20Opdivo%20UC%20-%20CADTH%20Final%20Recommendation%20Final.pdf,Urothelial carcinoma,Reimburse with clinical criteria and/or conditions,Complete,"Feb 22, 2022","Sep 28, 2022",PC0272-000
lutetium oxodotreotide,Lutathera,lutetium oxodotreotide,https://cadth.ca/sites/default/files/DRR/2023/PC0284%20Lutathera%20-%20Stakeholder%20Feedback%20.pdf; https://cadth.ca/sites/default/files/DRR/2023/PC0284-Lutathera_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0284%20Lutathera%20-CADTH%20Final%20Recommendation%20Final.pdf,Gastroenteropancreatic neuroendocrine tumours (GEP-NETs),Reimburse with clinical criteria and/or conditions,Complete,"Mar 23, 2022","Sep 28, 2022",PC0284-000
trastuzumab deruxtecan,Enhertu,trastuzumab deruxtecan,https://www.cadth.ca/sites/default/files/DRR/2022/PC0285%20Enhertu%20-%20Confidential%20Final%20CADTH%20Recommendation-KH%20-%20Validated-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0285-Enhertu-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/PC0285-Enhertu.pdf,Metastatic HER2 positive breast cancer,Reimburse with clinical criteria and/or conditions,Complete,"Mar 23, 2022","Sep 28, 2022",PC0285-000
selpercatinib,Retevmo,selpercatinib,https://cadth.ca/sites/default/files/DRR/2022/PC0264-Retevmo-MTC-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0264-Retevmo-MTC-combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0264%20Retevmo%20MTC%20-%20Final%20CADTH%20Recommendation%20for%20Posting%20Final.pdf,Thyroid cancer,Reimburse with clinical criteria and/or conditions,Complete,"Oct 29, 2021","Sep 26, 2022",PC0264-000
semaglutide,Wegovy,semaglutide,https://www.cadth.ca/sites/default/files/DRR/2022/SR0725%20Wegovy%20-%20CADTH%20Final%20Recommendation-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0725%20Wegovy%20-%20Stakeholder%20Feedback%20October%202022.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0725-Wegovy_combined.pdf,Weight management,Do not reimburse,Complete,"Mar 10, 2022","Sep 16, 2022",SR0725-000
ruxolitinib,Jakavi,ruxolitinib,https://cadth.ca/sites/default/files/DRR/2022/SR0688%20Jakavi%20(acute)%20-%20CADTH%20Final%20Recommendation-meta.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0688%20Jakavi%20(acute).pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0688%20Jakavi(acute)%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation.pdf,Graft versus host disease,Reimburse with clinical criteria and/or conditions,Complete,"Aug 10, 2021","Sep 15, 2022",SR0688-000
pembrolizumab and lenvatinib,Keytruda and Lenvima,pembrolizumab and lenvatinib,https://www.cadth.ca/sites/default/files/DRR/2022/PC0288%20Keytruda%20and%20Lenvima%20-%20Final%20CADTH%20Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0288%20Keytruda%20and%20Lenvima%20-%20Stakeholder%20Feedback%20Sep%201%2C%202022.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0288-Keytruda-Lenvima.pdf,Advanced endometrial cancer,Reimburse with clinical criteria and/or conditions,Complete,"Mar 7, 2022","Sep 9, 2022",PC0288-000
renal cell carcinoma rcc,N/A,N/A,https://www.cadth.ca/sites/default/files/pdf/PH0013%20RCC_final.pdf,Renal Cell Carcinoma (RCC),N/A,Complete,N/A,"Sep 6, 2022",PH0013-000
atezolizumab,Tecentriq,atezolizumab,https://www.cadth.ca/sites/default/files/DRR/2022/PC0277%20Tecentriq%20SCLC%20-%20Final%20CADTH%20Recommendation%20(With%20Redactions)%20Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0277%20Tecentriq%20SCLC%20-%20Stakeholder%20Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0277-Tecentriq-SCLC_combined.pdf,Small Cell Lung Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Jan 24, 2022","Sep 1, 2022",PC0277-000
atezolizumab,Tecentriq,atezolizumab,https://cadth.ca/sites/default/files/DRR/2022/PC0269%20Tecentriq%20NSCLC%20-%20Stakeholder%20Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0269-Tecentriq%20NSCLC_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0269%20Tecentriq%20for%20NSCLC%20-%20CADTH%20Final%20Recommendation-Final-meta.pdf,Non-small cell lung cancer,Reimburse with clinical criteria and/or conditions,Complete,"Feb 24, 2022","Sep 1, 2022",PC0269-000
pembrolizumab,Keytruda,pembrolizumab,https://www.cadth.ca/sites/default/files/DRR/2022/PC0279%20Keytruda%20TNBC%20-%20Final%20CADTH%20Recommendation%20Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0279%20Keytruda%20TNBC%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20August%2031%2C%202022.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0279-Keytruda%20TNBC.pdf,Triple-negative breast cancer,Reimburse with clinical criteria and/or conditions,Complete,"Feb 17, 2022","Aug 31, 2022",PC0279-000
tepotinib,Tepmetko,tepotinib,https://cadth.ca/sites/default/files/DRR/2022/PC0255%20Tepmetko%20-%20CADTH%20Final%20Recommendation%20Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0255%20Tepmetko%20-%20Stakeholder%20Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0255-Tepmetko_combined.pdf,Locally advanced or metastatic non-small cell lung cancer,Do not reimburse,Complete,"Aug 30, 2021","Aug 24, 2022",PC0255-000
dostarlimab,Jemperli,dostarlimab,https://www.cadth.ca/sites/default/files/DRR/2022/Jemperli%20-%20Stakeholder%20Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0263%20Jemperli%20-%20CADTH%20Final%20Recommendation_JH_SC-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0263-Jemperli-combined.pdf,Endometrial cancer,Do not reimburse,Complete,"Oct 7, 2021","Aug 24, 2022",PC0263-000
abrocitinib,Cibinqo,abrocitinib,https://cadth.ca/sites/default/files/DRR/2022/SR0686%20Cibingo%20-%20Stakeholder%20Feedback%20August%2019%2C%202022%20for%20posting.pdf; https://cadth.ca/sites/default/files/DRR/2023/SR0686-Cibinqo.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0686REC-Cibinqo_Final.pdf,"Atopic dermatitis, moderate to severe",Reimburse with clinical criteria and/or conditions,Complete,"Apr 26, 2021","Aug 19, 2022",SR0686-000
faricimab,Vabysmo,faricimab,https://www.cadth.ca/sites/default/files/DRR/2022/SR0719-Vabysmo-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0719-Vabysmo_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0719REC-Vabysmo.pdf,"Macular degeneration, age-related",Reimburse with clinical criteria and/or conditions,Complete,"Jan 31, 2022","Aug 12, 2022",SR0719-000
mogamulizumab,Poteligeo,mogamulizumab,https://www.cadth.ca/sites/default/files/DRR/2022/PC0244%20Poteligeo%20-%20Stakeholder%20Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0244-Poteligeo_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0244REC-Poteligeo.pdf,"mycosis fungoides (MF), Sézary syndrome (SS)",Reimburse with clinical criteria and/or conditions,Complete,"Sep 13, 2021","Aug 12, 2022",PC0244-000
nusinersen,Spinraza,nusinersen,https://www.cadth.ca/sites/default/files/DRR/2022/SR0713-Spinraza-Reassessment-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0713-Spinraza-Reassessment-combined-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0713-Spinraza-Reassessment.pdf,Spinal Muscular Atrophy,Do not reimburse,Complete,"Dec 2, 2021","Aug 11, 2022",SR0713-000
asciminib,Scemblix,asciminib,https://www.cadth.ca/sites/default/files/DRR/2022/PC0275%20Scemblix%20-%20CADTH%20Final%20Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0275%20Scemblix%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20August%205%2C%202022.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0275-Scemblix.pdf,Philadelphia chromosome-positive chronic myeloid leukemia,Reimburse with clinical criteria and/or conditions,Complete,"Jan 20, 2022","Aug 5, 2022",PC0275-000
nsclc without actionable oncogenic alterations,N/A,N/A,https://cadth.ca/sites/default//files/pdf/PH0012-NSCLC-Rapid%20Algorithm-for-CAPCA-Review.pdf,Unmutated Non-small cell lung cancer,N/A,Complete,N/A,"Aug 5, 2022",PH0012-000
selinexor,Xpovio,selinexor,https://www.cadth.ca/sites/default/files/DRR/2022/PC0276%20Xpovio%20-%20Final%20CADTH%20Recommendation_KT_KAS_KT_GP-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0276-Xpovio-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0276-Xpovio.pdf,Multiple myeloma,Reimburse with clinical criteria and/or conditions,Complete,"Jan 14, 2022","Jul 29, 2022",PC0276-000
zanubrutinib,Brukinsa,zanubrutinib,https://www.cadth.ca/sites/default/files/DRR/2022/PC0267%20Brukinsa%20MCL%20-%20Final%20CADTH%20Recommendation%20Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0267-Brukinsa-MCL-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0267-Brukinsa.pdf,Mantle cell lymphoma (MCL),Do not reimburse,Complete,"Sep 30, 2021","Jul 27, 2022",PC0267-000
sodium phenylbutyrate and ursodoxicoltaurine,Albrioza,sodium phenylbutyrate and ursodoxicoltaurine,https://www.cadth.ca/sites/default/files/DRR/2022/SR0711-Albrioza-Stakeholder-Feedback-July21-2022.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0711-Albrioza.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0711REC-Albrioza.pdf,Amyotrophic lateral sclerosis (ALS),Reimburse with clinical criteria and/or conditions,Complete,"Nov 24, 2021","Jul 21, 2022",SR0711-000
ruxolitinib,Jakavi,ruxolitinib,https://cadth.ca/sites/default/files/DRR/2022/SR0706REC-Jakavi-(Chronic).pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0706-Jakavi-(chronic)-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0706-Jakavi-Report.pdf,Graft versus host disease,Reimburse with clinical criteria and/or conditions,Complete,"Aug 10, 2021","Jul 15, 2022",SR0706-000
avalglucosidase alfa,Nexviazyme,avalglucosidase alfa,https://cadth.ca/sites/default/files/DRR/2022/SR0703%20Nexviazyme%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0703%20Nexviazyme%20combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0703%20Nexviazyme%20-%20CADTH%20Final%20Rec-meta.pdf,Pompe disease,Reimburse with clinical criteria and/or conditions,Complete,"Sep 30, 2021","Jul 5, 2022",SR0703-000
lisocabtagene maraleucel,Breyanzi,lisocabtagene maraleucel,https://www.cadth.ca/sites/default/files/DRR/2022/PG0258%20Breyanzi%20-%20Final%20CADTH%20Rec-Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PG0258-Breyanzi-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PG0258-Breyanzi.pdf,Relapsed or refractory large B-cell lymphoma,Reimburse with clinical criteria and/or conditions,Complete,"Aug 9, 2021","Jun 29, 2022",PG0258-000
selpercatinib,Retevmo,selpercatinib,https://cadth.ca/sites/default/files/DRR/2022/PC0274%20Retevmo%20DTC%20-%20CADTH%20Final.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0274%20Retevmo%20DTC%20-%20Consolidated%20Feedback%20June%2029%2C%202022.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0274-Retevmo%20DTC.pdf,Thyroid cancer,Reimburse with clinical criteria and/or conditions,Complete,"Oct 29, 2021","Jun 29, 2022",PC0274-000
lenvatinib and pembrolizumab,Lenvima and Keytruda,lenvatinib and pembrolizumab,https://cadth.ca/sites/default/files/DRR/2022/PC0268%20Lenvima%20and%20Keytruda%20-%20Final%20CADTH%20Rec_KT-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0268-Lenvima-Keytruda-Stakeholder-Feedback-on-Draft-Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0268-Lenvima-Keytruda.pdf,advanced or metastatic renal cell carcinoma,Reimburse with clinical criteria and/or conditions,Complete,"Nov 15, 2021","Jun 23, 2022",PC0268-000
cenegermin,Oxervate,cenegermin,https://cadth.ca/sites/default/files/DRR/2022/SR0704%20Oxervate%20-%20CADTH%20Final%20Rec-meta.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0704%20Oxervate%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20June%2023%2C%202022.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0704-Oxervate%20combined.pdf,Neurotrophic keratitis,Reimburse with clinical criteria and/or conditions,Complete,"Oct 29, 2021","Jun 23, 2022",SR0704-000
human epidermal growth factor receptor 2 her2 negative gastric gastroesophageal junction gej or,N/A,N/A,https://www.cadth.ca/sites/default/files/pdf/PH0010-EC%20GEJC%20GC-Final-Report.pdf,Esophageal or Gastroesophageal Junction Cancer,N/A,Complete,N/A,"Jun 21, 2022",PH0010-000
tafamidis,Vyndaqel,tafamidis,https://www.cadth.ca/sites/default/files/DRR/2022/SF0722%20Vyndaqel%20RfA%20-%20Final%20CADTH%20Rec-revised.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SF0722-Vyndaqel-RfA-Stakeholders-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SF0722CL-Vyndaqel.pdf,Transthyretin-mediated amyloidosis,Reimburse with clinical criteria and/or conditions,Complete,"Dec 14, 2021","Jun 17, 2022",SF0722-000
elexacaftortezacaftorivacaftor and ivacaftor,Trikafta,elexacaftor/tezacaftor/ivacaftor and ivacaftor,https://www.cadth.ca/sites/default/files/DRR/2022/SR0710%20Trikafta%20-%20CADTH%20Final%20Rec-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0710-Trikafta-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0710-Trikafta_combined.pdf,"Cystic fibrosis, F508del CFTR mutation, 6 years and older",Reimburse with clinical criteria and/or conditions,Complete,"Nov 5, 2021","Jun 17, 2022",SR0710-000
amifampridine phosphate,Firdapse,amifampridine phosphate,https://www.cadth.ca/sites/default/files/DRR/2022/SR0664%20Firdapse%20-%20Final%20CADTH%20Recommendation%20(With%20Redactions)%20KH_LdL-Clean-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0664-Firdapse-Stakeholder-Feedback-Draft-Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0664-Firdapse.pdf,"Lambert-Eaton Myasthenic Syndrome, adults",Reimburse with clinical criteria and/or conditions,Complete,"Nov 15, 2021","Jun 16, 2022",SR0664-000
immune globulin human and recombinant human hyaluronidase,HyQvia,immune globulin human and recombinant human hyaluronidase,https://cadth.ca/sites/default/files/DRR/2022/ST0695%20immune%20globulin%20human%20and%20recombinant%20human%20hyaluronidase%20-%20Patient%20Group%20Input%20_Redacted.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/ST0695%20HyQvia%20-%20Final%20CADTH%20Recommendation%20July%204_KT_BF_KT_KT-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/ST0695-HyQvia-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/ST0695-HyQvia-meta.pdf,Humoral immunodeficiency,Reimburse with clinical criteria and/or conditions,Complete,"Jun 24, 2021","Jun 15, 2022",ST0695-000
upadacitinib,Rinvoq,upadacitinib,https://www.cadth.ca/sites/default/files/DRR/2022/SR0685-Rinvoq-AD-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0685-Rinvoq-AD.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0685REC-Rinvoq%20AD-KH_BF-KH-meta.pdf,atopic dermatitis,Reimburse with clinical criteria and/or conditions,Complete,"Apr 13, 2021","Jun 8, 2022",SR0685-000
cemiplimab,Libtayo,cemiplimab,https://cadth.ca/sites/default/files/DRR/2022/PC0262%20Libtayo%20NSCLC%20%20%E2%80%93%20CADTH%20Final%20Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0262%20Libtayo%20NSCLC%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20May%2019%2C%202022.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0262-Libtayo-combined.pdf,Non-small cell lung cancer,Reimburse with clinical criteria and/or conditions,Complete,"Oct 13, 2021","Jun 2, 2022",PC0262-000
multiple myeloma,N/A,N/A,https://www.cadth.ca/sites/default/files/pdf/PH0011-MM-Implementation-Advice-Report.pdf,Multiple myeloma,N/A,Complete,N/A,"May 25, 2022",PH0011-000
anaplastic lymphoma kinase positive non small cell lung cancer,N/A,N/A,https://www.cadth.ca/sites/default/files/pdf/PH0009-ALK%2BNSCLC-Algorithm.pdf,ALK-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer,N/A,Complete,N/A,"May 24, 2022",PH0009-000
ospemifene,Osphena,ospemifene,https://cadth.ca/sites/default/files/DRR/2022/SR0709%20Osphena%20-%20Final%20CADTH%20Rec%20Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0709-Osphena-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0709-Osphena-meta.pdf,"Dyspareunia, vaginal dryness",Reimburse with clinical criteria and/or conditions,Complete,"Oct 26, 2021","May 13, 2022",SR0709-000
selpercatinib,Retevmo,selpercatinib,https://cadth.ca/sites/default/files/DRR/2022/PC0261%20Retevmo%20-%20CADTH%20Final%20Rec-meta.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0261-Retevmo-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0261-Retevmo_combined.pdf,RET fusion-positive non-small cell lung cancer,Reimburse with clinical criteria and/or conditions,Complete,"Aug 17, 2021","Apr 28, 2022",PC0261-000
ripretinib,Qinlock,ripretinib,https://cadth.ca/sites/default/files/DRR/2022/PC0265%20Qinlock%20-%20Confidential%20Final%20CADTH%20Rec-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0265-Qinlock-Stakeholder-Feedback-Draft-Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0265-Qinlock.pdf,Gastrointestinal stromal tumours,Reimburse with clinical criteria and/or conditions,Complete,"Oct 15, 2021","Apr 28, 2022",PC0265-000
prasterone,Intrarosa,prasterone,https://www.cadth.ca/sites/default/files/DRR/2022/SR0707%20Intrarosa%20-%20CADTH%20Final%20Rec-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0707-Intrarosa-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0707-Intrarosa.pdf,Postmenopausal vulvovaginal atrophy,Reimburse with clinical criteria and/or conditions,Complete,"Oct 1, 2021","Apr 14, 2022",SR0707-000
alpha1 proteinase inhibitor human,Zemaira,Alpha1-proteinase inhibitor (Human),https://cadth.ca/sites/default/files/DRR/2022/ST0702-Zemaira-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2022/ST0702-ZemairaCombined.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/ST0702%20Zemaira%20-%20CADTH%20Final%20Rec%20Final.pdf,Severe Alpha1-proteinase inhibitor deficiency,Reimburse with clinical criteria and/or conditions,Complete,"Oct 1, 2021","Apr 13, 2022",ST0702-000
her2 positive metastatic breast cancer,N/A,N/A,https://cadth.ca/sites/default/files/pdf/PH0006-HER2MBC-Algorithm%20Panel%20Scope.pdf,HER2-Positive Metastatic Breast Cancer,N/A,Complete,N/A,"Apr 12, 2022",PH0006-000
fostamatinib,Tavalisse,fostamatinib,https://cadth.ca/sites/default/files/DRR/2022/SR0701%20Tavalisse%20-%20Stakeholder%20Feedback%20January%2027%2C%202022.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0701-Tavalisse-combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0701%20Tavalisse%20-%20Patient%20Group%20Input_Redacted.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0701%20Tavalisse%20-%20CADTH%20Final%20Rec-meta.pdf,Chronic immune thrombocytopenia,Do not reimburse,Complete,"Jul 22, 2021","Apr 5, 2022",SR0701-000
bimekizumab,Bimzelx,bimekizumab,https://www.cadth.ca/sites/default/files/DRR/2022/SR0698%20Bimzelx%20-%20CADTH%20Final%20Rec%20Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0698-Bimzelx-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0698-Bimzelx.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/TSDrugClas/TS0001/TS0001-PsO-Updated-Streamlined-Rec.pdf,"Psoriasis, moderate to severe plaque",Reimburse with clinical criteria and/or conditions,Complete,"Aug 17, 2021","Mar 30, 2022",SR0698-000
metastatic urothelial carcinoma muc,N/A,N/A,https://cadth.ca/sites/default/files/pdf/PH0008%20mUC%20Algorithm%20Report-Final.pdf,Metastatic Urothelial Carcinoma,N/A,Complete,N/A,"Mar 28, 2022",PH0008-000
pemigatinib,Pemazyre,pemigatinib,https://cadth.ca/sites/default/files/DRR/2022/PC0252%20Pemazyre%20-%20CADTH%20Final%20Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/PC0252%20pemigatinib%20-%20Patient%20Group%20Input_Redacted.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0252-Pemazyre-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0252-Pemazyre.pdf,Cholangiocarcinoma,Do not reimburse,Complete,"Jun 23, 2021","Mar 23, 2022",PC0252-000
lorlatinib,Lorbrena,lorlatinib,https://cadth.ca/sites/default/files/DRR/2022/PC0249%20Lorbrena%20-%20CADTH%20Final%20Rec.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0249-Lorbrena-Stakeholder-Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0249-Lorbrena.pdf; https://www.cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2021/PC0249%20Lorbrena%20-%20Patient%20Group%20Input_For%20Posting.pdf,ALK-positive locally advanced or metastatic non-small cell lung,Reimburse with clinical criteria and/or conditions,Complete,"Jun 18, 2021","Mar 17, 2022",PC0249-000
colchicine,Myinfla,colchicine,https://www.cadth.ca/sites/default/files/DRR/2022/SR0691%20Myinfla%20-%20CADTH%20Final%20Rec-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0691%20Myinfla%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20-%20For%20posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0691-Myinfla-meta.pdf,Atherothrombotic events in coronary artery disease,Do not reimburse,Complete,"May 28, 2021","Mar 8, 2022",SR0691-000
somatrogon,Ngenla,somatrogon,https://cadth.ca/sites/default/files/DRR/2022/SR0683-Ngenla-CombinedReport.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0683-Ngenla-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0683%20Ngenla%20-%20CADTH%20Final%20Rec.pdf,Growth hormone deficiency,Reimburse with clinical criteria and/or conditions,Complete,"Jun 3, 2021","Mar 8, 2022",SR0683-000
tralokinumab,Adtralza,tralokinumab,https://www.cadth.ca/sites/default/files/DRR/2022/SR0689%20Adtralza%20-%20Confidential%20Final%20CADTH%20Rec-Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0689%20Adtralza%20-%20Stakeholder%20Feedback%20March%207%2C%202022.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0689%20tralokinumab%20(TBC)%20-%20Clinician%20Input.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0689-Adtralza_combined.pdf,atopic dermatitis,Do not reimburse,Complete,"Apr 27, 2021","Mar 7, 2022",SR0689-000
nivolumab,Opdivo,nivolumab,https://cadth.ca/sites/default/files/DRR/2022/PC0259-Opdivo-Stakeholder-Feedback-Draft-Rec.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0259-Opdivo-combinedReport.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0259%20Opdivo%20-%20Final%20CADTH%20Rec.pdf,"Gastric, gastroesophageal junction, or esophageal adenocarcinoma",Reimburse with clinical criteria and/or conditions,Complete,"Aug 18, 2021","Mar 4, 2022",PC0259-000
cemiplimab,Libtayo,cemiplimab,https://cadth.ca/sites/default/files/DRR/2022/PC0260REC-Libtayo_Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0260-Libtayo-Report.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0260-Libtayo-Stakeholder-Feedback.pdf,Basal cell carcinoma,Reimburse with clinical criteria and/or conditions,Complete,"Aug 19, 2021","Mar 4, 2022",PC0260-000
ravulizumab,Ultomiris,ravulizumab,https://cadth.ca/sites/default/files/DRR/2021/SR0700%20Ultomiris%20-%20Patient%20Group%20Input.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0700%20Ultomiris-Stakeholder-Feedback-on-Draft-Recommendation.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0700CL-Ultomiri_combined.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0700%20Ultomiris%20-%20Final%20CADTH%20Rec.pdf,Paroxysmal nocturnal hemoglobinuria,Reimburse with clinical criteria and/or conditions,Complete,"Jul 22, 2021","Feb 11, 2022",SR0700-000
estradiol and progesterone,Bijuva,estradiol and progesterone,https://www.cadth.ca/sites/default/files/DRR/2022/SR0697%20Bijuva%20-%20CADTH%20Final%20Rec-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0697-Bijuva-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0697-BijuvaCombined.pdf,Vasomotor symptoms associated with menopause,Reimburse with clinical criteria and/or conditions,Complete,"Jun 30, 2021","Feb 10, 2022",SR0697-000
trientine hydrochloride,Waymade-Trientine,trientine hydrochloride,https://cadth.ca/sites/default/files/DRR/2022/SR0696%20Waymade-Trientine%20-%20CADTH%20Final%20Rec-meta.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0696%20Waymade-Trientine%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20February%208%2C%202022.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0696-Waymade-Trientine-combinedReport.pdf; https://www.cadth.ca/sites/default/files/attachments/2021-07/SR0696%20Waymade-Trientine%20Patient%20Input%20for%20posting.pdf,Wilson's Disease,Reimburse with clinical criteria and/or conditions,Complete,"Jul 21, 2021","Feb 8, 2022",SR0696-000
inclisiran,Leqvio,inclisiran,https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0681%20inclisiran%20-%20Patient%20Input%20for%20Posting%20April%2022%2C%202021.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0681%20Leqvio%20-%20Confidential%20Final%20CADTH%20Rec%20Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0681%20Leqvio%20-%20Consolidated%20Clinician%20Input%20for%20Posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0681%20Leqvio%20-%20Stakeholder%20Feedback%20Februray%207%2C%202022.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0681-Leqvio.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0681-Response-to-Procedural-Review-Panel-Report.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0681_Memorandum%2C%20Panel%20Report%20%E2%80%93%20Inclisiran_Leqvio%E2%84%A2%20-%20Procedural%20Review.pdf,Primary hypercholesterolemia,Do not reimburse,Complete,"Mar 17, 2021","Feb 7, 2022",SR0681-000
adult classical hodgkin lymphoma,N/A,N/A,https://www.cadth.ca/sites/default/files/pdf/PH0007-cHL-Algorithm-Report-Final.pdf,Adult Classical Hodgkin Lymphoma,N/A,Complete,N/A,"Feb 2, 2022",PH0007-000
isatuximab,Sarclisa,isatuximab,https://cadth.ca/sites/default/files/DRR/2022/PC0256%20Sarclisa%20-%20CADTH%20Final%20Rec%20revised.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0256-Sarclisa-CombinedReport.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0256-Sarclisa-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2021/PC0256%20Sarclisa%20-%20Patient%20Group%20Input_Redacted.pdf,Multiple myeloma,Reimburse with clinical criteria and/or conditions,Complete,"Jul 15, 2021","Jan 28, 2022",PC0256-000
daratumumab,Darzalex,daratumumab,https://cadth.ca/sites/default/files/DRR/2022/PC0257%20Darzalex%20-%20Consolidated%20Clinician%20Group%20Input%20for%20Posting.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0257-Darzalex-Stakeholder%20Feedback%20January%2028%2C%202022.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0257-Darzalex-combinedReport.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/PC0257 Darzalex - Consolidated Patient Input for Posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0257%20Darzalex%20-%20CADTH%20Final%20Rec%20Final.pdf,Light chain (AL) amyloidosis,Reimburse with clinical criteria and/or conditions,Complete,"Jul 15, 2021","Jan 28, 2022",PC0257-000
sacituzumab govitecan,Trodelvy,sacituzumab govitecan,https://www.cadth.ca/sites/default/files/DRR/2022/PC0254%20Trodelvy%20-%20CADTH%20Final%20Rec-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0254-Trodelvy-CombinedReport.pdf; https://www.cadth.ca/sites/default/files/attachments/2021-08/Sacituzumab%20govitecan%20-%20Patient%20Group%20Input%20-%20For%20posting.pdf,Locally advanced or metastatic triple-negative breast cancer,Reimburse with clinical criteria and/or conditions,Complete,"Jun 30, 2021","Jan 27, 2022",PC0254-000
nivolumab,Opdivo,nivolumab,https://cadth.ca/sites/default/files/DRR/2022/PC0253%20Opdivo%20-%20CADTH%20Final%20Rec%20Final.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0253-Opdivo_combined.pdf,Esophageal or gastroesophageal junction cancer,Reimburse with clinical criteria and/or conditions,Complete,"Jul 7, 2021","Jan 26, 2022",PC0253-000
alpelisib,Piqray,alpelisib,https://cadth.ca/sites/default/files/DRR/2022/PC0247%20Piqray%20-%20Final%20CADTH%20Rec-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0247%20Piqray%20-%20Clinician%20Input%20for%20posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0247%20Piqray%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20January%2026%2C%202022.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0247-Piqray.pdf; https://www.cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2021/PC0247%20Piqray%20-%20Patient%20Group%20Input_for%20posting.pdf,Advanced or Metastatic Breast Cancer,Do not reimburse,Complete,"Apr 21, 2021","Jan 26, 2022",PC0247-000
pertuzumab,Perjeta,pertuzumab,https://www.cadth.ca/sites/default/files/DRR/2021/PC0241%20Perjeta%20PI%20for%20redactions_Redacted.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0241%20Perjeta%20-%20Final%20CADTH%20Rec_Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0241%20Perjeta%20-%20Stakeholder%20Feedback%20January%2025%2C%202022.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0241%20Perjeta%20Clinician%20Input.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0241-Perjeta.pdf,Early stage breast cancer,Do not reimburse,Complete,"Apr 14, 2021","Jan 25, 2022",PC0241-000
mecasermin,Increlex,mecasermin,https://cadth.ca/sites/default/files/DRR/2022/SR0692-Increlex-Stakeholder-Feedback-Jan21-2022.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0692-combined_Increlex.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0692REC-Increlex_JH_BF-meta.pdf; https://www.cadth.ca/sites/default/files/attachments/2021-07/SR0692%20Increlex%20Patient%20Group%20Input_For%20Posting.pdf,Severe primary insulin-like growth factor-1 deficiency,Reimburse with clinical criteria and/or conditions,Complete,"Jun 14, 2021","Jan 21, 2022",SR0692-000
triheptanoin,Dojolvi,triheptanoin,https://cadth.ca/sites/default/files/DRR/2021/SR0684%20Dojolvi%20Patient%20Input%20for%20Posting.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0684-Dojolvi-Clinician-Input-Redacted.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0684-Dojolvi-CombinedReport.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0684-Dojolvi-Stakeholder-Feedback-Sep23-2021-Jan7-2022.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0684%20Dojolvi%20-%20CADTH%20Final%20Rec-meta.pdf,Long-chain fatty acid oxidation disorders,Reimburse with clinical criteria and/or conditions,Complete,"Mar 31, 2021","Jan 21, 2022",SR0684-000
estradiol,Imvexxy,estradiol,https://www.cadth.ca/sites/default/files/DRR/2022/SR0694%20Imvexxy%20-%20CADTH%20Final%20Rec%20KH.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0694%20Imvexxy%20-%20Clinical%20and%20Economic%20Review%20Report%20_Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0694%20Imvexxy%20-%20Stakeholder%20Feedback%20January%2020%2C%202022.pdf,Dyspareunia,Reimburse with clinical criteria and/or conditions,Complete,"Jun 23, 2021","Jan 20, 2022",SR0694-000
osimertinib,Tagrisso,osimertinib,https://cadth.ca/sites/default/files/DRR/2021/PC0246_Tagrisso_PI%20Submission_for%20posting.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0246-Tagrisso-Clincian-Input-April-2021.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0246-Tagrisso-rec%20Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0246%20Tagrisso%20-%20Draft%20Recommendation%20Stakeholder%20Feedback%20February%203%2C%202022.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0246-Tagrisso.pdf,Non-small cell lung cancer,Reimburse with clinical criteria and/or conditions,Complete,"Mar 24, 2021","Jan 10, 2022",PC0246-000
enfortumab vedotin,Padcev,enfortumab vedotin,https://www.cadth.ca/sites/default/files/DRR/2021/PC0251 Enfortumab vedotin - Patient Group Input - For posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0251-Padcev-Stakeholder-Feedback-on-Draft-Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0251-Padcev.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0251REC-Padcev%20Final-meta.pdf,Locally advanced or metastatic urothelial carcinoma,Reimburse with clinical criteria and/or conditions,Complete,"Jun 23, 2021","Jan 6, 2022",PC0251-000
zanubrutinib,Brukinsa,zanubrutinib,https://www.cadth.ca/sites/default/files/DRR/2021/PC0248%20Brukinsa%20%E2%80%93%20CADTH%20Final%20Recommendation%20Final-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/PC0248%20Brukinsa%20-%20Patient%20Group%20Input_Redacted_0.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0248-Brukinsa-Clinician-Group-Input.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0248-Brukinsa-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0248-Brukinsa.pdf,Waldenström’s macroglobulinemia,Reimburse with clinical criteria and/or conditions,Complete,"May 21, 2021","Dec 21, 2021",PC0248-000
pembrolizumab,Keytruda,pembrolizumab,https://cadth.ca/sites/default/files/DRR/2021/PC0250%20Keytruda%20EC%20GEJ%20Patient%20Input_Redacted.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/PC0250%20Keytruda%20-%20CADTH%20Final%20Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0246-Tagrisso-Clincian-Input-April-2021.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0250-Keytruda-Final-Stakeholder-Feedback-Jan5-2022.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0250CL-Keytruda.pdf,"Esophageal carcinoma, gastroesophageal junction adenocarcinoma",Reimburse with clinical criteria and/or conditions,Complete,"May 26, 2021","Dec 20, 2021",PC0250-000
galcanezumab,Emgality,galcanezumab,https://www.cadth.ca/sites/default/files/DRR/2021/SR0693%20Emgality%20-%20CADTH%20Final%20Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0693-Emgality-Stakeholder-Feedback-on-Draft-Rec-jan18-2022.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0693-Emgality.pdf; https://www.cadth.ca/sites/default/files/attachments/2021-07/SR0693%20Emgality%20-%20Patient%20Group%20Input%20-%20Migraine%20Canada%20and%20Migraine%20Quebec_For%20Posting.pdf,Prevention of migraine,Reimburse with clinical criteria and/or conditions,Complete,"Jun 3, 2021","Dec 15, 2021",SR0693-000
macitentan and tadalafil,Opsynvi,macitentan and tadalafil,https://cadth.ca/sites/default/files/DRR/2021/SR0690%20Opsynvi-Rec%20Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0690-Opsynvi-Stakeholder-Feedback-on-Draft-Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0690-Opsynvi_combined.pdf,Pulmonary arterial hypertension,Reimburse with clinical criteria and/or conditions,Complete,"May 20, 2021","Dec 14, 2021",SR0690-000
luspatercept,Reblozyl,luspatercept,https://cadth.ca/sites/default/files/DRR/2022/SR0670-Reblozyl-Clinician-Input-for-Posting.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0670-Reblozyl-Stakeholder-Feedback-Dec7-2021.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0670-Reblozyl-combinedReport.pdf; https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0670%20Reblozyl%20-%20Patient%20Input%20for%20Posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0670%20Reblozyl%20-%20CADTH%20Final%20Rec.pdf,Myelodysplastic syndromes-associated anemia,Reimburse with clinical criteria and/or conditions,Complete,"Jan 28, 2021","Dec 7, 2021",SR0670-000
chlormethine hydrochloride,Ledaga,chlormethine hydrochloride,https://www.cadth.ca/sites/default/files/DRR/2021/PC0242%20Ledaga%20-%20CADTH%20Final%20Rec-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0242-Ledaga-clinician-group-input.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0242-Ledaga-report.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PC0242-Ledaga-stakeholder-feedback-on-draft-rec.pdf; https://www.cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2021/Ledaga%20-%20Patient%20Group%20Input%20-%20For%20Posting.pdf,T-cell lymphoma,Do not reimburse,Complete,"Dec 21, 2020","Nov 24, 2021",PC0242-000
tucatinib,Tukysa,tucatinib,https://cadth.ca/sites/default/files/DRR/2021/PC0243%20Tukysa%20-%20CADTH%20Final%20Rec_Final.pdf; https://cadth.ca/sites/default/files/DRR/2021/PC0243%20Tukysa%20-%20Patient%20Group%20Input_redacted.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0243%20Tukysa%20-%20Clinician%20Group%20Input.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0243%20Tukysa%20-%20Stakeholder%20Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0243-Tukysa-combined.pdf,Advanced or Metastatic Breast Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Mar 26, 2021","Nov 17, 2021",PC0243-000
idecabtagene vicleucel,Abecma,idecabtagene vicleucel,https://www.cadth.ca/sites/default/files/DRR/2021/PG0240%20Abecma%20-%20CADTH%20Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PG0240-Abecma-Clinician-Input-Dec1-2021.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PG0240-Abecma-Stakeholder-Feedback-(with%20redactions)-Nov22-2021.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/PG0240-Abecma.pdf; https://www.cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2021/Idecabtagene%20vicleucel%20-%20Consolidated%20Patient%20Group%20for%20Posting.pdf,Multiple myeloma,Do not reimburse,Complete,"Dec 16, 2020","Nov 12, 2021",PG0240-000
colorectal cancer,N/A,N/A,https://www.cadth.ca/sites/default/files/attachments/2021-11/PH0005-000_CRC-FINAL-report-Nov11_0.pdf,Colorectal Cancer,N/A,Complete,N/A,"Nov 12, 2021",PH0005-000
trientine hydrochloride,MAR-Trientine,Trientine Hydrochloride,https://www.cadth.ca/sites/default/files/DRR/2021/SR0680%20MAR-Trientine%20-%20CADTH%20Final%20Rec-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0680-MAR-Trientine-Stakeholder-Feedback-on-Draft-Recommendation-for-posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2022/SR0680-MAR-Trientine.pdf,Wilson's Disease,Reimburse with clinical criteria and/or conditions,Complete,"Apr 19, 2021","Nov 11, 2021",SR0680-000
romosozumab,Evenity,romosozumab,https://cadth.ca/sites/default/files/DRR/2022/SR0676%20Evenity-Stakeholder%20Feedback%20on%20Draft%20Recommendation.pdf; https://cadth.ca/sites/default/files/DRR/2022/SR0676-Evenity-combined-report.pdf; https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0676%20Evenity%20-%20Patient%20Group%20Input_For%20Posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0676%20Evenity%20-%20CADTH%20Final%20Rec_Final.pdf,"Osteoporosis, postmenopausal women",Reimburse with clinical criteria and/or conditions,Complete,"Feb 1, 2021","Nov 11, 2021",SR0676-000
pembrolizumab,Keytruda,pembrolizumab,https://www.cadth.ca/sites/default/files/DRR/2021/PC0236%20Keytruda%20-%20CADTH%20Final%20Rec%20Final.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/PC0236%20Keytruda%20-%20Clinician%20Input.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/PC0236%20Keytruda%20-%20Stakeholder%20Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/PC0236%20Keytruda-combined-report.pdf; https://www.cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2021/Keytruda%20-%20Patient%20Input%20Group%20-%20For%20posting.pdf,Classical Hodgkin lymphoma,Reimburse with clinical criteria and/or conditions,Complete,"Jan 29, 2021","Nov 1, 2021",PC0236-000
azacitidine,Onureg,azacitidine,https://cadth.ca/sites/default/files/DRR/2021/PC0245%20Onureg%20-%20CADTH%20Final%20Rec.pdf; https://cadth.ca/sites/default/files/DRR/2021/PC0245-Onureg%20-%20Consolidated%20PI%20for%20Posting%20April%2022%2C%202021_Final.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0245%20Onureg-Stakeholder%20Feedback%20on%20Draft%20Recommendation.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0245-Onureg-Clinician-Group-Input.pdf; https://cadth.ca/sites/default/files/DRR/2022/PC0245-Onureg-combined-Final.pdf,Acute myeloid leukemia,Reimburse with clinical criteria and/or conditions,Complete,"Mar 1, 2021","Oct 20, 2021",PC0245-000
decitabine cedazuridine inqovi mds,Inqovi,Decitabine-Cedazuridine,https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/10228Decitabine-CedazuridineMDS_Clinician Feedback_Post22Sep2021_final.pdf; https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/10228Decitabine-CedazuridineMDS_ClinicianCOI_Post22Sep2021_final_Redacted.pdf; https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/10228Decitabine-CedazuridineMDS_FnRec_REDACT_Post22Sep2021_final.pdf; https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/10228Decitabine-CedazuridineMDS_PAG_Post22Sep2021_final.pdf; https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/10228Decitabine-CedazuridineMDS_Patient Feedback_Post22Sep2021_final.pdf; https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/10228Decitabine-CedazuridineMDS_PatientCOI_Post22Sep2021_final.pdf; https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/10228Decitabine-CedazuridineMDS_Sponsor Feedback_Post22Sep2021_final.pdf; https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/10228Decitabine-CedazuridineMDS_fnCGR_REDACT_Post22Sep2021_final.pdf; https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/10228Decitabine-CedazuridineMDS_fnEGR_REDACT-ABBREV_Post22Sep2021_final.pdf; https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/10228Decitabine-CedazuridineMDS_inRec_REDACT_Post02Sep2021_final.pdf,Myelodysplastic Syndromes (MDS),Reimburse with clinical criteria and/or conditions,Complete,"Oct 9, 2020","Sep 22, 2021",PC0228-000
elexacaftor tezacaftor ivacaftor and ivacaftor,Trikafta,elexacaftor / tezacaftor / ivacaftor and ivacaftor,https://cadth.ca/sites/default/files/DRR/2021/SR0673%20Trikafta%20-%20CADTH%20Final%20Rec%20Revised.pdf; https://cadth.ca/sites/default/files/cdr/relatedinfo/elexacaftor%20tezacaftor%20ivacaftor%20and%20ivacaftor%20-%20Patient%20Group%20Input%20-%20For%20posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0673-Trikafta%20-%20Clinician%20Group%20Input%20-%20Consolidated_For%20posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0673-Trikafta%20-%20Stakeholder%20Feedback%20-%20For%20posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0673-combined-report.pdf,"Cystic fibrosis, F508del CFTR mutation",Reimburse with clinical criteria and/or conditions,Complete,"Jan 22, 2021","Sep 16, 2021",SR0673-000
budesonide glycopyrronium formoterol fumarate,Breztri Aerosphere,budesonide/ glycopyrronium /formoterol fumarate,https://cadth.ca/sites/default/files/DRR/2021/SR0675%20Breztri%20Aerosphere%20-%20CADTH%20Final%20Rec.pdf; https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0675_budesonide-glycopyrronium-formoterol%20fumarate_PI%20Submission.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0675-Breztri%20Aerosphere%20-%20Clinician%20Group%20Input%20September%202021.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0675-Breztri%20Aerosphere%20-%20Stakeholder%20Feedback%20Septebmer%202021.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0675-combined-report.pdf,chronic obstructive pulmonary disease (COPD),Reimburse with clinical criteria and/or conditions,Complete,"Jan 28, 2021","Sep 14, 2021",SR0675-000
larotrectinib,Vitrakvi,larotrectinib,https://cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2020/Vitrakvi%20-%20Patient%20Group%20Input%20-%20For%20posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/PC0221%20Vitrakvi%20-%20CADTH%20Final%20Rec%20KG_NA_Corrected-meta.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/PC0221-Vitrakvi%20-%20Clinician%20Group%20Input%20-%20Consolidated_For%20posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/PC0221-Vitrakvi%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20-%20Consolidated_For%20posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/PC0221-Vitrakvi-combined-report-meta.pdf,Solid tumours with NTRK gene fusion,Reimburse with clinical criteria and/or conditions,Complete,"Nov 16, 2020","Sep 13, 2021",PC0221-000
incobotulinumtoxina,Xeomin,incobotulinumtoxinA,https://www.cadth.ca/sites/default/files/DRR/2021/SR0678%20Xeomin%20-%20CADTH%20Final%20Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0678%20Xeomin%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0678-combined-report.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0678_Xeomin_PI Submission_Redacted.pdf,Chronic sialorrhea associated with neurological disorders,Reimburse with clinical criteria and/or conditions,Complete,"Feb 26, 2021","Sep 9, 2021",SR0678-000
risperidone,Perseris,risperidone,https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0671%20Perseris%20-%20Patient%20Group%20Input%20Submission_Redacted.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0671%20Perseris%20-%20CADTH%20Final%20Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0671-Perseris%20-%20Stakeholder%20Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0671-Perseris-Combine.pdf,"Schizophrenia, adults",Reimburse with clinical criteria and/or conditions,Complete,"Jan 29, 2021","Sep 8, 2021",SR0671-000
givosiran,Givlaari,givosiran,https://cadth.ca/sites/default/files/DRR/2021/SR0679%20Givlaari%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation.pdf; https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0679%20Givlaari%20-%20Patient%20Input%20for%20Posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0679%20Givlaari%20-%20CADTH%20Final%20Rec-pw.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0679-Givlaari%20combined-meta.pdf,Acute hepatic porphyria (AHP) in adults,Reimburse with clinical criteria and/or conditions,Complete,"Feb 23, 2021","Sep 8, 2021",SR0679-000
liraglutide,Saxenda,liraglutide,https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0668%20Saxenda%20-%20PI%20Submission.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0668 Saxenda - CADTH Final Rec KT_BF_KT-pw.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0668%20Saxenda-combined-report.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0668%20Saxenda-stakeholder-feedback.pdf,Chronic weight management in adults,Do not reimburse,Complete,"Dec 23, 2020","Sep 1, 2021",SR0668-000
risdiplam,Evrysdi,risdiplam,https://cadth.ca/sites/default/files/DRR/2021/SR0661%20Evrysdi%20Recommendation%20Final.pdf; https://cadth.ca/sites/default/files/cdr/relatedinfo/risdiplam%20-%20Consolidated%20Patient%20Input%20for%20Posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0661%20Evrysdi%20-%20Clinician%20Input.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0661%20Evrysdi%20-%20Stakeholder%20Feedback%20August%205%2C%202021.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0661-combined-report-final.pdf,Spinal muscular atrophy,Reimburse with clinical criteria and/or conditions,Complete,"Nov 19, 2020","Aug 26, 2021",SR0661-000
brexucabtagene autoleucel,Tecartus,brexucabtagene autoleucel,https://cadth.ca/sites/default/files/DRR/2021/PG0219%20Tecartus%20-%20CADTH%20Final%20Rec.pdf; https://cadth.ca/sites/default/files/DRR/2021/PG0219%20Tecartus%20-%20Clinician%20Group%20Input_For%20Posting.pdf; https://cadth.ca/sites/default/files/DRR/2021/PG0219%20Tecartus%20-%20Stakeholder%20Feedback_For%20Posting.pdf; https://cadth.ca/sites/default/files/DRR/2021/PG0219%20brexucabtagene%20autoleucel%20-%20Patient%20Group%20Input.pdf; https://cadth.ca/sites/default/files/DRR/2021/PG0219-tecartus-combined-report-meta.pdf,Mantle cell lymphoma,Reimburse with clinical criteria and/or conditions,Complete,"Dec 18, 2020","Aug 24, 2021",PG0219-000
daunorubicin and cytarabine,Vyxeos,daunorubicin and cytarabine,https://cadth.ca/sites/default/files/DRR/2021/PC0237%20Vyxeos%20-%20CADTH%20Final%20Rec.pdf; https://cadth.ca/sites/default/files/DRR/2021/PC0237%20Vyxeos%20-%20Patient%20Group%20Input_For%20Posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/PC0237-combined-report-final.pdf; https://www.cadth.ca/sites/default/files/pdf/htis/2021/PC0237%20Vyxeos%20-%20Clinician%20Input_For%20Posting.pdf; https://www.cadth.ca/sites/default/files/pdf/htis/2021/PC0237%20Vyxeos%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation.pdf,Acute myeloid leukemia,Reimburse with clinical criteria and/or conditions,Complete,"Jan 22, 2021","Aug 24, 2021",PC0237-000
venetoclax,Venclexta,venetoclax,https://cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2021/PC0239%20Venclexta%20%28LDAC%29%20%E2%80%93%20Patient%20Group%20Input%20Submission_Redacted.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/PC0239 Venclexta  - CADTH Final Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/PC0239%20Venclexta%20(LDAC)%20-%20Clinician%20Input.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/PC0239%20Venclexta%20(LDAC)%20-%20Stakeholder%20Feedback.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/PC0239-combined-report.pdf,Acute myeloid leukemia,Do not reimburse,Complete,"Jan 22, 2021","Aug 23, 2021",PC0239-000
human insulin,Entuzity KwikPen,human insulin,https://cadth.ca/sites/default/files/DRR/2021/SR0672%20Entuzity%20KwikPen%20-%20CADTH%20Final%20Rec.pdf; https://cadth.ca/sites/default/files/DRR/2021/SR0672%20Entuzity%20KwikPen%20-%20Patient%20Group%20Input_for%20Posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0672%20Entuzity%20KwikPen%20-%20Clinician%20Group%20Input%20-%20For%20posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0672%20Entuzity%20KwikPen%20-%20Feedback%20on%20Draft%20Recommendation%20-%20For%20posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0672-Entuzity-KwikPen%20Final.pdf,Diabetes mellitus,Reimburse with clinical criteria and/or conditions,Complete,"Jan 27, 2021","Aug 23, 2021",SR0672-000
budesonide,Jorveza,budesonide,https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0666%20Jorveza%20-%20Patient%20Input%20Submission.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0666 Jorveza - CADTH Final Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0666-Jorveza-Stakeholder-Feedback-on-Draft-Recommendation.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0666-combined-report.pdf,Maintenance of Eosinophilic esophagitis in adults,Reimburse with clinical criteria and/or conditions,Complete,"Nov 5, 2020","Aug 23, 2021",SR0666-000
upadacitinib,Rinvoq,upadacitinib,https://cadth.ca/sites/default/files/DRR/2021/SR0658%20Rinvoq%20-%20Final%20CADTH%20Rec.pdf; https://cadth.ca/sites/default/files/DRR/2021/SR0658%20Rinvoq%20-%20Patient%20Input%20for%20Posting%20Consolidated.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0658%20Rinvoq%20-%20Stakeholder%20Feedback%20for%20Posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SR0658-combined-report.pdf,"Psoriatic Arthritis, adults",Reimburse with clinical criteria and/or conditions,Complete,"Jan 4, 2021","Aug 20, 2021",SR0658-000
venetoclax,Venclexta,venetoclax,https://cadth.ca/sites/default/files/DRR/2021/PC0238%20Venclexta%20(AZA)%20-%20Clinician%20Input.pdf; https://cadth.ca/sites/default/files/DRR/2021/PC0238%20Venclexta%20(AZA)%20-%20Final%20Rec.pdf; https://cadth.ca/sites/default/files/DRR/2021/PC0238%20Venclexta%20(AZA)%20-%20Stakeholder%20Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2021/PC0238-combined-report-FINAL.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/PC0238%20Venclexta%20-%20Consolidated%20PI%20for%20Posting%20February%2023%2C%202021%20(1).pdf,Acute myeloid leukemia,Reimburse with clinical criteria and/or conditions,Complete,"Jan 8, 2021","Aug 20, 2021",PC0238-000
nivolumab ipilimumab,Opdivo-Yervoy,nivolumab-ipilimumab,https://cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2020/Opdivo-Yervoy%20-%20Patient%20Group%20Input%20-%20For%20posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/PC0229%20Opdivo-Yervoy%20-%20Clinician%20Group%20Input_For%20Posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/PC0229%20Opdivo-Yervoy%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation_For%20Posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/PC0229-Opdivo-Yervoy-combined.pdf; https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/PC0229%20Opdivo-Yervoy%20%20Final%20Rec.pdf,Malignant Pleural Mesothelioma (MPM),Reimburse with clinical criteria and/or conditions,Complete,"Oct 9, 2020","Aug 4, 2021",PC0229-000
pembrolizumab,Keytruda,pembrolizumab,https://cadth.ca/sites/default/files/DRR/2021/PC0235%20Keytruda%20-%20Clinician%20Group%20Input_For%20Posting.pdf; https://cadth.ca/sites/default/files/DRR/2021/PC0235%20Keytruda%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation_For%20Posting.pdf; https://cadth.ca/sites/default/files/DRR/2021/PC0235-Keytruda-Combined.pdf; https://cadth.ca/sites/default/files/attachments/2021-07/PC0235%20Keytruda%20-%20CADTH%20Final%20Rec%20revised_1.pdf; https://cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2020/PC0235%20Keytruda%20-%20Patient%20Input_For%20posting.pdf,Colorectal cancer,Reimburse with clinical criteria and/or conditions,Complete,"Nov 30, 2020","Jul 27, 2021",PC0235-000
durvalumab,Imfinzi,durvalumab,https://cadth.ca/sites/default/files/DRR/2021/PC0234%20Imfinzi%20-%20CADTH%20Final%20Rec.pdf; https://cadth.ca/sites/default/files/DRR/2021/PC0234%20Imfinzi%20-%20Clinician%20Group%20Input%20-%20For%20posting.pdf; https://cadth.ca/sites/default/files/DRR/2021/PC0234%20Imfinzi%20-%20Patient%20Group%20Input%20-%20For%20posting.pdf; https://cadth.ca/sites/default/files/DRR/2021/PC0234%20Imfinzi%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20-%20For%20posting.pdf; https://cadth.ca/sites/default/files/DRR/2021/PC0234-combined-final.pdf,Extensive-stage small cell lung cancer,Reimburse with clinical criteria and/or conditions,Complete,"Dec 1, 2020","Jul 27, 2021",PC0234-000
encorafenib,Braftovi,encorafenib,https://cadth.ca/sites/default/files/DRR/2021/PC0233%20Braftovi%20-%20CADTH%20Final%20Rec.pdf; https://cadth.ca/sites/default/files/DRR/2021/PC0233%20Braftovi%20-%20Patient%20Input%20Group%20-%20For%20posting.pdf; https://cadth.ca/sites/default/files/pcodr/Reviews2021/PC0233 Braftovi - Clinician Input Group_For Posting.pdf; https://cadth.ca/sites/default/files/pcodr/Reviews2021/PC0233 Braftovi - Stakeholder Feedback on Draft Recommendation_For Posting.pdf; https://cadth.ca/sites/default/files/pcodr/Reviews2021/PC0233-braftovi-combined-revised.pdf,Metastatic colorectal cancer,Reimburse with clinical criteria and/or conditions,Complete,"Dec 16, 2020","Jul 26, 2021",PC0233-000
encorafenib and binimetinib,Braftovi and Mektovi,encorafenib and binimetinib,http://cadth.ca/sites/default/files/DRR/2021/PC0232-combined.pdf; https://cadth.ca/sites/default/files/DRR/2021/PC0232%20Braftovi%20and%20Mektovi%20-%20Clinician%20Input.pdf; https://cadth.ca/sites/default/files/DRR/2021/PC0232%20Braftovi%20and%20Mektovi%20-%20Stakeholder%20Feedback.pdf; https://www.cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2020/PC0232%20Braftovi%20and%20Mektovi%20-%20Patient%20Group%20Input%20Submission_Redacted%20for%20Posting.pdf; https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/PC0232%20Braftovi%20and%20Mektovi%20Final.pdf,Advanced Melanoma,Reimburse with clinical criteria and/or conditions,Complete,"Dec 16, 2020","Jul 26, 2021",PC0232-000
dinutuximab,Unituxin,dinutuximab,https://cadth.ca/sites/default/files/pcodr/Reviews2021/PC0222%20Unituxin%20-%20CADTH%20Final%20Rec%20v4.pdf; https://cadth.ca/sites/default/files/pcodr/Reviews2021/PC0222%20Unituxin%20-%20Clinician%20Group%20Input%20-%20For%20posting.pdf; https://cadth.ca/sites/default/files/pcodr/Reviews2021/PC0222%20Unituxin%20-%20Patient%20Group%20Input%20-%20For%20posting.pdf; https://cadth.ca/sites/default/files/pcodr/Reviews2021/PC0222%20Unitxuin%20-%20Stakeholder%20Feedback%20-%20For%20posting.pdf; https://cadth.ca/sites/default/files/pcodr/Reviews2021/PC0222-combined%20report%20for%20posting.pdf,Neuroblastoma,Reimburse with clinical criteria and/or conditions,Complete,"Nov 23, 2020","Jul 23, 2021",PC0222-000
ozanimod,Zeposia,ozanimod,https://cadth.ca/sites/default/files/cdr/clinical/SR0652%20Zeposia%20-%20Final%20Clinical%20Review%20Report%20(with%20redactions).pdf; https://cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0652%20Zeposia%20-%20Final%20Pharmacoeconomic%20Review%20Report.pdf; https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0652_ozanimod_PI%20Submission.pdf; https://www.cda-amc.ca/sites/default/files/attachments/2021-06/SR0652%20Zeposia%20-%20CDEC%20Final%20Recommendation%20June%2029%2C%202021_for%20posting.pdf,"Multiple Sclerosis, relapsing - remitting",Do not reimburse,Complete,"Aug 25, 2020","Jun 23, 2021",SR0652-000
tildrakizumab,Ilumya,tildrakizumab,https://cadth.ca/sites/default/files/cdr/clinical/sr0624-ilumya-clinical-review-report.pdf; https://cadth.ca/sites/default/files/cdr/complete/SR0624%20Ilumya%20-%20CDEC%20Final%20Recommendation%20June%2023%2C%202021_for%20posting%20(1).pdf; https://cadth.ca/sites/default/files/cdr/pharmacoeconomic/sr0624-ilumya-pharmacoeconomic-review-report.pdf; https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0624_Ilumya_PI%20Submission.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/TSDrugClas/TS0001/TS0001-PsO-Updated-Streamlined-Rec.pdf,"Psoriasis, moderate to severe plaque",Reimburse with clinical criteria and/or conditions,Complete,"Jul 15, 2019","Jun 21, 2021",SR0624-000
fedratinib,Inrebic,fedratinib,https://www.cadth.ca/sites/default/files/attachments/2021-06/CADTH_reimbursement_recommendation_fedratinib_%28inrebic%29_comp.pdf; https://www.cadth.ca/sites/default/files/pcodr/CRR_PCproject_Patient%20Group%20Input/2020/Inrebic%20-%20Patient%20Group%20Input%20-%20For%20posting.pdf; https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/PC0205-Inrebic%20-%20Clinician%20Group%20Input%20-%20For%20posting.pdf; https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/PC0205-Inrebic%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20-%20For%20Posting.pdf; https://www.cadth.ca/sites/default/files/pcodr/Reviews2021/PC0205-combined.pdf,Myelofibrosis,Reimburse with clinical criteria and/or conditions,Complete,"Nov 5, 2020","Jun 21, 2021",PC0205-000
semaglutide,Rybelsus,semaglutide,https://cadth.ca/sites/default/files/DRR/2021/SR0637%20Rybelsus%20-%20Stakeholder%20Feedback.pdf; https://cadth.ca/sites/default/files/DRR/2021/SR0637-combined.pdf; https://cadth.ca/sites/default/files/attachments/2021-06/CADTH_reimbursement_recommendation_semaglutide_%28rybelsus%29.pdf; https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0637%20Rybelsus%20-%20Patient%20Group%20Input%20Submission_redacted%20for%20posting.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf,"diabetes mellitus, type 2",Reimburse with clinical criteria and/or conditions,Complete,"Nov 26, 2020","Jun 8, 2021",SR0637-000
luspatercept,Reblozyl,luspatercept,https://cadth.ca/sites/default/files/cdr/complete/SR0669%20Reblozyl%20-%20Steakholder%20Feedback%20July%202021.pdf; https://cadth.ca/sites/default/files/cdr/complete/SR0669%20Reblozyl-combined-final.pdf; https://www.cda-amc.ca/sites/default/files/attachments/2021-06/CADTH_reimbursement_recommendation_luspatercept_%28reblozyl%29.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/Reblozyl%20-%20Patient%20Group%20Input%20for%20Posting.pdf,beta-thalassemia associated anemia,Reimburse with clinical criteria and/or conditions,Complete,"Nov 26, 2020","Jun 8, 2021",SR0669-000
dupilumab,Dupixent,dupilumab,https://cadth.ca/sites/default/files/cdr/complete/SR0667%20Dupixent%20-%20Clinician%20Group%20Input_for%20posting.pdf; https://cadth.ca/sites/default/files/cdr/complete/SR0667%20Dupixent%20-%20Stakeholder%20Feedback%20on%20Draft%20Recommendation%20-%20For%20Posting.pdf; https://cadth.ca/sites/default/files/cdr/complete/SR0667-combined%20clinical%20and%20PE%20report.pdf; https://www.cda-amc.ca/sites/default/files/attachments/2021-06/CADTH_reimbursement_recommendation_dupilumab_%28dupixent%29_1.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0667%20Dupixent%20-%20Patient%20Input%20Submission_For%20Posting.pdf,Asthma,Reimburse with clinical criteria and/or conditions,Complete,"Nov 26, 2020","Jun 8, 2021",SR0667-000
patiromer,Veltassa,patiromer,https://www.cadth.ca/sites/default/files/cdr/complete/SR0665%20Veltassa%20-%20Clinician%20Input.pdf; https://www.cadth.ca/sites/default/files/cdr/complete/SR0665%20Veltassa%20-%20Stakeholder%20Feedback.pdf; https://www.cadth.ca/sites/default/files/cdr/complete/SR0665-combined.pdf; https://www.cda-amc.ca/sites/default/files/attachments/2021-06/CADTH_reimbursement_recommendation_patiromer_%28veltassa%29.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0665%20Veltassa%20-%20Patient%20Input%20Submission.pdf,"Hyperkalemia, adults (chronic kidney disease)",Reimburse with clinical criteria and/or conditions,Complete,"Oct 30, 2020","Jun 8, 2021",SR0665-000
dabrafenib and trametinib non small cell lung cancer braf v600 mutation,Tafinlar and Mekinist,Dabrafenib and Trametinib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10226Dabrafenib-TrametinibNSCLC_ClinicianFeedback_Combined_Post28May2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10226Dabrafenib-TrametinibNSCLC_Combined%20ClinicianCOI_Post28Mar2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10226Dabrafenib-TrametinibNSCLC_FnRec_pERC%20Chair%20Approved_Post28May2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10226Dabrafenib-TrametinibNSCLC_PAG%20Feedback_Post28May2021_Final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10226Dabrafenib-TrametinibNSCLC_PatientCOI_LCC_Post19Mar2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10226Dabrafenib-TrametinibNSCLC_PatientFeedback_LCC_Post28May2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10226Dabrafenib-TrametinibNSCLC_SponsorFeedback_Post28May2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10226Dabrafenib-TrametinibNSCLC_fnCGR_REDACT_Post28May2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10226Dabrafenib-TrametinibNSCLC_fnEGR_REDACT-ABBREV_Post28May2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10226Dabrafenib-TrametinibNSCLC_inRec_pERC%20Chair%20Approved_Post01Apr2021_final.pdf,NSCLC BRAF V600,Reimburse with clinical criteria and/or conditions,Complete,"Oct 1, 2020","May 28, 2021",PC0226-000
ranolazine,Corzyna,ranolazine,https://www.cda-amc.ca/sites/default/files/attachments/2021-08/sr0655CL-corzyna.pdf; https://www.cda-amc.ca/sites/default/files/attachments/2021-08/sr0655PE-corzyna.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0655%20Corzyna%20-%20CDEC%20Final%20Recommendation%20May%2031%2C%202021_For%20Posting.pdf,"Stable angina pectoris, adults",Do not reimburse,Complete,"Aug 17, 2020","May 27, 2021",SR0655-000
chronic lymphocytic leukemia,N/A,N/A,https://www.cadth.ca/sites/default/files/attachments/2021-06/PH0004-CLL-Provisional-Algorithm-final-may18-rev.pdf,B-Cell Precursor Acute Lymphoblastic Leukemia,N/A,Complete,N/A,"May 18, 2021",PH0004-000
sonidegib odomzo basal cell carcinoma,Odomzo,Sonidegib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10215SonidegibBCC_ClinicianFeedback_CCO_Post29Apr2021_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10215SonidegibBCC_ClinicianInput_Combined_COIs%20Post29Apr2021_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10215SonidegibBCC_PAGFeedbackSummary_Post29Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10215SonidegibBCC_PatientCOI_Combined_Post29Apr2021_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10215SonidegibBCC_PatientFeedback_Combined_Post29Apr2021_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10215SonidegibBCC_SponsorFeedback_Post29Apr2021_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10215SonidegibBCC_fnCGR_NOREDACT_Post29Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10215SonidegibBCC_fnEGR_NOREDACT-ABBREV_Post29Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10215SonidegibBCC_fnRec_Post29Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10215SonidegibBCC_inRec_Post04Mar2021_final.pdf,Basal Cell Carcinoma,Do not reimburse,Complete,"Jun 19, 2020","Apr 29, 2021",PC0215-000
niraparib zejula first line ovarian cancer,Zejula,Niraparib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10224NiraparibOC_ClinicianFeedback_CCO_Post29Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10224NiraparibOC_Combined%20Clinician%20COIs_Post29Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10224NiraparibOC_PAGFeedbackSummary_Post29Apr2021_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10224NiraparibOC_Patient%20COI_OCC_Post29Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10224NiraparibOC_PatientFeedback_OCC_Post29Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10224NiraparibOC_SponsorFeedback_Post29Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10224NiraparibOC_fnCGR_NOREDACT_Post29Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10224NiraparibOC_fnEGR_REDACT-ABBREV_Post29Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10224NiraparibOC_fnRec_pERC%20Chair%20Approved_Post29Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10224NiraparibOC_inRec_pERC%20Chair%20Approved_Post04Mar2021_final.pdf,First Line OC,Reimburse with clinical criteria and/or conditions,Complete,"Sep 21, 2020","Apr 29, 2021",PC0224-000
infliximab,Remsima,infliximab,https://cadth.ca/sites/default/files/cdr/complete/SR0659%20Remsima%20SC%20-%20CDEC%20Final%20Recommendation%20April%2026%2C%202021_for%20posting.pdf; https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0659%20infliximab%20-%20Patient%20Input%20Submission.pdf; https://www.cadth.ca/sites/default/files/cdr/complete/sr0659-remsima-sc-clinical-and-economic-review-report.pdf,Rheumatoid arthritis,Reimburse with clinical criteria and/or conditions,Complete,"Sep 24, 2020","Apr 22, 2021",SR0659-000
polatuzumab vedotin polivy dlbcl,Polivy,Polatuzumab Vedotin,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10227PolatuzumabDLBCL_ClinicianFeedback_CCO_EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10227PolatuzumabDLBCL_Combined%20Clinician%20COIs%20EC21Apr2021_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10227PolatuzumabDLBCL_PAG%20Feedback_EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10227PolatuzumabDLBCL_Patient%20COI_LC_EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10227PolatuzumabDLBCL_PatientFeedback_LC_Final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10227PolatuzumabDLBCL_SponsorFeedback_EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10227PolatuzumabDLBCL_fnCGR_NOREDACT_EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10227PolatuzumabDLBCL_fnEGR_REDACT-ABBREV_EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10227PolatuzumabDLBCL_fnRec_EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10227PolatuzumabDLBCL_inRec_pERC%20Chair%20Approved_Post01Apr2021_final.pdf,Diffuse large B-cell lymphoma (DLBCL),Reimburse with clinical criteria and/or conditions,Complete,"Sep 29, 2020","Apr 21, 2021",PC0227-000
brigatinib alunbrig anaplastic lymphoma kinase positive non small cell lung cancer,Alunbrig,Brigatinib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10230BrigatinibALK%2BNSCLC_Combined%20ClinicianFeedback_EC21Apr2021.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10230BrigatinibALK%2BNSCLC_Combined_COIs%20EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10230BrigatinibALK%2BNSCLC_PAGFeedback_EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10230BrigatinibALK%2BNSCLC_Patient%20COI_EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10230BrigatinibALK%2BNSCLC_PatientFeedback_LCC_EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10230BrigatinibALK%2BNSCLC_SponsorFeedback_EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10230BrigatinibALK%2BNSCLC_fnCGR_NOREDACT_EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10230BrigatinibALK%2BNSCLC_fnEGR_REDACT-ABBREV_EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10230BrigatinibALK%2BNSCLC_fnRec_EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10230BrigatinibALK%2BNSCLC_inRec_approvedbyChair_Post01Apr2021_final.pdf,(ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC),Reimburse with clinical criteria and/or conditions,Complete,"Sep 30, 2020","Apr 21, 2021",PC0230-000
olaparib lynparza metastatic castration resistant prostate cancer,Lynparza,Olaparib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10223OlaparibmCRPC_ClinicianFeedback_EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10223OlaparibmCRPC_Combined%20Clinician%20COI_EC21Apr2021_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10223OlaparibmCRPC_PAGFeedback_EC21Apr2021_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10223OlaparibmCRPC_Patient%20COI_CCSN_EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10223OlaparibmCRPC_SponsorFeedback_EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10223OlaparibmCRPC_fnCGR_REDACT_EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10223OlaparibmCRPC_fnEGR_NOREDACT-ABBREV_EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10223OlaparibmCRPC_fnRec_REDACT_EC21Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10223OlaparibmCRPC_inRec_approvedbyChair_REDACT_Post01Apr2021_final.pdf,metastatic castration-resistant prostate cancer (mCRPC),Reimburse with clinical criteria and/or conditions,Complete,"Sep 22, 2020","Apr 21, 2021",PC0223-000
unresectable hepatocellular carcinoma,N/A,N/A,https://www.cadth.ca/sites/default/files/pdf/ph0003-000_hcc-report-final.pdf,Unresectable Hepatocellular Carcinoma,N/A,Complete,N/A,"Apr 21, 2021",PH0003-000
satralizumab,Enspryng,satralizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0663-enspryng-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0663%20Enspryng%20-%20CDEC%20Final%20Recommendation%20April%2023%2C%202021_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0663%20Enspryng%20-%20Patient%20Input%20Group%20-%20For%20posting.pdf,Neuromyelitis optica spectrum disorder,Reimburse with clinical criteria and/or conditions,Complete,"Oct 22, 2020","Apr 21, 2021",SR0663-000
amifampridine,Ruzurgi,amifampridine,https://www.cda-amc.ca/sites/default/files/attachments/2021-07/sr0660-ruzurgi-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/attachments/2021-07/sr0660-ruzurgi-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0660%20Ruzurgi%20-%20CDEC%20Final%20Recommendation%20April%2023%2C%202021_For%20posting.pdf,Lambert-Eaton myasthenic syndrome,Reimburse with clinical criteria and/or conditions,Complete,"Oct 5, 2020","Apr 20, 2021",SR0660-000
isatuximab sarclisa multiple myeloma,Sarclisa,Isatuximab,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10220IsatuximabMM_ClinicianFeedback_CCO_Post01Apr2021_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10220IsatuximabMM_Clinician_Combined_COIs_Post_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10220IsatuximabMM_PAGFeedbackSummary_Post01Apr2021_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10220IsatuximabMM_PatientFeedback_MC_Post01Apr2021_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10220IsatuximabMM_Patient_COI_MyelomaCanada_Post01Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10220IsatuximabMM_SponsorFeedback_Post01Apr2021_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10220IsatuximabMM_fnCGR_NOREDACT_Post01Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10220IsatuximabMM_fnEGR_NOREDACT-ABBREV_Post01Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10220IsatuximabMM_fnRec_pERC%20Chair%20Approved_Post01Apr2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10220IsatuximabMM_inRec_pERC%20Chair%20Approved_Post4Feb2021_final.pdf,Multiple Myeloma,Reimburse with clinical criteria and/or conditions,Complete,"Aug 17, 2020","Apr 1, 2021",PC0220-000
sacubitrilvalsartan,Entresto,sacubitril/valsartan,https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0644%20Entresto%20-%20%20CDEC%20Final%20Recommendation%20March%2026%2C%202021%20%28Redacted%29_for%20Posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0644_Entresto%20Resubmission_PI%20Submission.pdf,"Heart failure, NYHA Class II or III",Reimburse with clinical criteria and/or conditions,Complete,"May 22, 2020","Mar 24, 2021",SR0644-000
fremanezumab,Ajovy,fremanezumab,https://cadth.ca/sites/default/files/cdr/complete/SR0641%20Ajovy%20-%20CDEC%20Final%20Recommendation%20April%201%2C%202021_For%20Posting.pdf; https://cadth.ca/sites/default/files/cdr/relatedinfo/SR0641%20Ajovy%20-%20Patient%20Input.pdf; https://www.cadth.ca/sites/default/files/cdr/complete/sr0641-ajovy-clinical-review-report.pdf; https://www.cadth.ca/sites/default/files/cdr/complete/sr0641-ajovy-pharmacoeconomic-review-report.pdf,migraine,Reimburse with clinical criteria and/or conditions,Complete,"Jun 3, 2020","Mar 24, 2021",SR0641-000
onasemnogene abeparvovec,Zolgensma,onasemnogene abeparvovec,https://cadth.ca/sites/default/files/DRR/2021/sg0649-zolgensma-clinical-review-report.pdf; https://cadth.ca/sites/default/files/DRR/2021/sg0649-zolgensma-pharmacoeconomic-review-report.pdf; https://cadth.ca/sites/default/files/cdr/complete/SG0649%20Zolgensma%20-%20CDEC%20Final%20Recommendation%20March%2026%2C%202021%20for%20posting.pdf; https://cadth.ca/sites/default/files/cdr/relatedinfo/SG0649_Zolgensma_PI%20Submission.pdf; https://www.cadth.ca/sites/default/files/DRR/2021/SI0005%20Zolgensma%20-%20CADTH%20Drug%20Implementation%20Advice_KT-pw.pdf,"Spinal muscular atrophy (SMA), pediatrics",Reimburse with clinical criteria and/or conditions,Complete,"Jun 25, 2020","Mar 24, 2021",SG0649-000
avelumab bavencio urothelial carcinoma,Bavencio,Avelumab,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10225AvelumabUC_COI_BCC__Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10225AvelumabUC_COI_CCO_EC23Mar2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10225AvelumabUC_CinicianFeedback_CCO_EC23Mar2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10225AvelumabUC_FnRec_REDACT_EC23Mar2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10225AvelumabUC_PAGFeedbackSummary_EC23Mar2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10225AvelumabUC_PatientFeedback_BCC_EC23Mar2021_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10225AvelumabUC_SponsorFeedback_EC23Mar2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10225AvelumabUC_fnCGR_REDACT_EC23Mar2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10225AvelumabUC_fnEGR_REDACT-ABBREV_EC23Mar2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10225AvelumabUC_inRec_redacted_Post04Mar2021_final.pdf,Urothelial Carcinoma (UC),Reimburse with clinical criteria and/or conditions,Complete,"Sep 18, 2020","Mar 23, 2021",PC0225-000
von willebrand factor recombinant,Vonvendi,von Willebrand Factor [recombinant],https://www.cadth.ca/sites/default/files/cdr/clinical/st0639-vonvendi-clinical-review-report.pdf; https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/st0639-vonvendi-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/ST0639%20Vonvendi%20-%20Final%20CPEC%20Recommendation%20March%2022%2C%202021%20for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/ST0639_Vonvendi_PI%20Submission.pdf,"von Willebrand disease, adults, treatment and perioperative management",Reimburse with clinical criteria and/or conditions,Complete,"Apr 29, 2020","Mar 17, 2021",ST0639-000
nivolumab ipilimumab non small cell lung cancer,Opdivo in combination with Yervoy,Nivolumab in combination with Ipilimumab,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10218Nivolumab-IpilimumabNSCLC_InRec_pERC%20Chair%20Approved_REDACT_Post08Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10218Nivolumab-IpilimumabNSCLC_Combined_COIs_Post04Mar2021_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10218Nivolumab-IpilimumabNSCLC_Combined_ClinicianFeedback_Post04Mar2021_final-Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10218Nivolumab-IpilimumabNSCLC_FnRec_pERC%20Chair%20Approved_redact%20Post04Mar2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10218Nivolumab-IpilimumabNSCLC_PAG%20Feedback_Post04Mar2021_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10218Nivolumab-IpilimumabNSCLC_Patient%20Combined%20COI_Post04Mar2021_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10218Nivolumab-IpilimumabNSCLC_PatientFeedback_LCC__Post04Mar2021_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10218Nivolumab-IpilimumabNSCLC_SponsorFeedback_Post04Mar2021_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10218Nivolumab-IpilimumabNSCLC_fnCGR_REDACT_Post04Mar2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10218Nivolumab-IpilimumabNSCLC_fnEGR_NOREDACT-ABBREV_Post04Mar2021_final.pdf,NSCLC,Reimburse with clinical criteria and/or conditions,Complete,"Jun 23, 2020","Mar 4, 2021",PC0218-000
ofatumumab,Kesimpta,ofatumumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0657-kesimpta-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0657%20Kesimpta%20-%20CDEC%20Final%20Recommendation%20March%201%2C%202021_For%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0657-kesimpta-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0657%20ofatumumab%20-%20Patient%20Input%20Group%20-%20For%20posting.pdf,"Multiple Sclerosis, relapsing",Reimburse with clinical criteria and/or conditions,Complete,"Aug 25, 2020","Feb 25, 2021",SR0657-000
adult b cell precursor acute lymphoblastic leukemia philadelphia chromosome negative,N/A,N/A,https://www.cadth.ca/sites/default/files/pdf/ph0002-000-bcp-all-algorithm-report-v3.5.pdf,B-Cell Precursor Acute Lymphoblastic Leukemia,N/A,Complete,N/A,"Feb 24, 2021",PH0002-000
apomorphine hydrochloride,Kynmobi,apomorphine hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0650-kynmobi-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0650%20Kynmobi%20-%20CDEC%20Final%20Recommendation%20February%2026%2C%202021_For%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0650-kynmobi-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/Kynmobi%20-%20Patient%20Group%20Input_For%20Posting.pdf,Parkinson’s disease,Reimburse with clinical criteria and/or conditions,Complete,"Jun 25, 2020","Feb 24, 2021",SR0650-000
nintedanib,Ofev,nintedanib,https://www.cda-amc.ca/sites/default/files/attachments/2021-07/SR0654%20Ofev%20-%20Final%20CDEC%20Recommendation%20February%2026%2C%202021_For%20Posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0654-ofev-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0654-ofev-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0654%20Ofev%20-%20Consolidated%20Patient%20Input%20for%20Posting.pdf,chronic fibrosing interstitial lung diseases,Reimburse with clinical criteria and/or conditions,Complete,"Jul 24, 2020","Feb 24, 2021",SR0654-000
levetiracetam,pdp-levETIRAcetam,Levetiracetam,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0653-pdp-levETIRAcetam-clinical-and-economic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0653%20pdp-levETIRAcetam%20-%20CDEC%20Final%20Recommendation%20February%208%2C%202021_For%20Posting.pdf,Epilepsy,Reimburse with clinical criteria and/or conditions,Complete,"Jul 17, 2020","Feb 3, 2021",SR0653-000
entrectinib rozlytrek ros1 positive non small cell lung cancer,Rozlytrek,Entrectinib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10206EntrectinibROS1NSCLC_InRec_approvedbyChair_Post08Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10206EntrectinibROS1NSCLC_Clinician_COI_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10206EntrectinibROS1NSCLC_Combined_ClinicianFeedback_EC27Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10206EntrectinibROS1NSCLC_FnRec_EarlyConv_ApprovedbyChair_EC27Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10206EntrectinibROS1NSCLC_PAG%20Feedback_EC27Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10206EntrectinibROS1NSCLC_PatientFeedback_LCC_Post27Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10206EntrectinibROS1NSCLC_Patient_COI_LCC_EC27Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10206EntrectinibROS1NSCLC_SponsorFeedback_27Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10206EntrectinibROS1NSCLC_fnCGR_REDACT_EC27Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2021/10206EntrectinibROS1NSCLC_fnEGR_NOREDACT-ABBREV_EC27Jan2021_final.pdf,ROS1-positive NSCLC,Reimburse with clinical criteria and/or conditions,Complete,"Jan 8, 2020","Jan 27, 2021",PC0206-000
vedolizumab,Entyvio,vedolizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0647-entyvio-clinical-economic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0647%20Entyvio%20-%20CDEC%20Final%20Recommendation%20January%2022%2C%202021_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0647_Entyvio_PI%20Submission.pdf,Crohn’s disease,Reimburse with clinical criteria and/or conditions,Complete,"Jul 23, 2020","Jan 21, 2021",SR0647-000
acalabrutinib calquence previously untreated chronic lymphocytic leukemia,Calquence,Acalabrutinib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10210AcalabrutinibCLL%28previously%20untreated%29_COIs_LC_Post08Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10210AcalabrutinibCLL%28previously%20untreated%29_ClinicianFeedback_CCO_Post08Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10210AcalabrutinibCLL%28previously%20untreated%29_Combined%20COIs_Post08Jan2021_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10210AcalabrutinibCLL%28previously%20untreated%29_FnRec_pERC%20Chair%20Approved_REDACT_Post08Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10210AcalabrutinibCLL%28previously%20untreated%29_PAGFeedbackSummary_Post08Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10210AcalabrutinibCLL%28previously%20untreated%29_PatientFeedback_CLLPAG_Post08Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10210AcalabrutinibCLL%28previously%20untreated%29_SponsorFeedback_Post08Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10210AcalabrutinibCLL%28previously%20untreated%29_fnCGR_REDACT_Post08Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10210AcalabrutinibCLL%28previously%20untreated%29_fnEGR_REDACTABBREV_Post08Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10210AcalabrutinibCLL%28previously%20untreated%29_inRec_pERC%20Chair%20Approved_REDACT_Post29Oct2020_final.pdf,Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL),Reimburse with clinical criteria and/or conditions,Complete,"Apr 7, 2020","Jan 8, 2021",PC0210-000
glasdegib daurismo acute myeloid leukemia,Daurismo,Glasdegib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10207GlasdegibAML_COI_LLSC_Post08Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10207GlasdegibAML_ClinicianInput_Combined_COIs_Post08Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10207GlasdegibAML_Combined_ClinicianFeedback_Post08Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10207GlasdegibAML_FnRec_approvedbyChair_REDACT_Post08Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10207GlasdegibAML_PAGFeedbackSummary_Post08Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10207GlasdegibAML_PatientFeedback_Post08Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10207GlasdegibAML_SponsorFeedback_Post08Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10207GlasdegibAML_fnCGR_REDACT_Post08Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10207GlasdegibAML_fnEGR_NOREDACT-ABBREV_Post08Jan2021_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10207GlasdegibAML_inRec_approvedbyChair.REDACT_Post29Oct2020_final.pdf,Acute Myeloid Leukemia (AML),Do not reimburse,Complete,"May 6, 2020","Jan 8, 2021",PC0207-000
dapagliflozin,Forxiga,dapagliflozin,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0642-forxiga-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0642%20Forxiga%20-%20CDEC%20Final%20Recommendation%20January%2021%2C%202021_revised_redacted_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0642-forxiga-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0642_Forxiga_PI%20Submission.pdf,Heart failure with reduced ejection fraction,Reimburse with clinical criteria and/or conditions,Complete,"Mar 31, 2020","Dec 23, 2020",SR0642-000
pembrolizumab keytruda hnscc,Keytruda,Pembrolizumab,https://www.cda-amc.ca; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10216PembrolizumabHNSCC_ClinicianFeedback_CCO_EC22Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10216PembrolizumabHNSCC_Combined_Clinician%20COIs_EC22Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10216PembrolizumabHNSCC_FnRec_EC22Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10216PembrolizumabHNSCC_InRec_approvedbyChair_Post03Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10216PembrolizumabHNSCC_PAGFeedbackSummary_EC22Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10216PembrolizumabHNSCC_Patient_COI_LSTN_22EC22Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10216PembrolizumabHNSCC_SponsorFeedback_EC22Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10216PembrolizumabHNSCC_fnCGR_REDACT_EC22Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10216PembrolizumabHNSCC_fnEGR_REDACTABBREV_EC22Dec2020_final.pdf,head and neck squamous cell carcinoma (HNSCC),Reimburse with clinical criteria and/or conditions,Complete,"May 1, 2020","Dec 22, 2020",PC0216-000
emicizumab,Hemlibra,emicizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/st0651-hemlibra-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/ST0651%20Hemlibra%20-%20CPEC%20Final%20Recommendation%20December%2023%2C%202020_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/st0651-hemlibra-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/Hemlibra%20-%20Patient%20Group%20Input_For%20Posting.pdf,"Bleeding prevention, hemophilia A",Reimburse with clinical criteria and/or conditions,Complete,"Jun 30, 2020","Dec 21, 2020",ST0651-000
esketamine hydrochloride,Spravato,esketamine hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0621-spravato-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0621%20Spravato%20-%20CDEC%20Final%20Recommendation%20December%2018%2C%202020_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0621-spravato-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0621_Esketamine_PI%20Submission.pdf,"Major depressive disorder (MDD), adults",Do not reimburse,Complete,"Jun 24, 2019","Dec 16, 2020",SR0621-000
brentuximab vedotin adcetris primary cutaneous anaplastic large cell lymphoma or cd30 expressing,Adcetris,Brentuximab Vedotin,https://www.cda-amc.ca; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10213BrentuximabVedotinpcALCLMF_Clinician%20COI_Post03Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10213BrentuximabVedotinpcALCLMF_ClinicianFeedback_CCO_Post03Dec2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10213BrentuximabVedotinpcALCLMF_PAGFeedbackSummary_Post03Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10213BrentuximabVedotinpcALCLMF_PatientCOIs_Post03Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10213BrentuximabVedotinpcALCLMF_SponsorFeedback_Post03Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10213BrentuximabVedotinpcALCLMF_fnCGR_NOREDACT_Post03Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10213BrentuximabVedotinpcALCLMF_fnEGR_NOREDACTABBREV_03Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10213BrentuximabVedotinpcALCLMF_fnRec_Post03Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10213BrentuximabVedotinpcALCLMF_inRec_01Oct2020_Post_final.pdf,Primary cutaneous anaplastic large cell Lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF),Reimburse with clinical criteria and/or conditions,Complete,"Mar 30, 2020","Dec 3, 2020",PC0213-000
brentuximab vedotin adcetris hodgkin lymphoma combination doxorubicin vinblastine and dacarbazine,Adcetris,Brentuximab Vedotin,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10214BrentuximabVedotinHLAVD_ClinicianFeedback_CCO_Post03Dec2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10214BrentuximabVedotinHLAVD_Combined_Clinician%20COIs_Post03Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10214BrentuximabVedotinHLAVD_FnRec_approvedbyChair_REDACT_Post03Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10214BrentuximabVedotinHLAVD_PAGFeedbackSummary_Post03Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10214BrentuximabVedotinHLAVD_Patient%20COIs_Post03Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10214BrentuximabVedotinHLAVD_SponsorFeedback_Post03Dec2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10214BrentuximabVedotinHLAVD_fnCGR_REDACT_Post03Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10214BrentuximabVedotinHLAVD_fnEGR_NOREDACT-ABBREV_03Dec2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10214BrentuximabVedotinHLAVD_inRec_Post15Oct2020_final.pdf,"Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD)",Reimburse with clinical criteria and/or conditions,Complete,"Apr 2, 2020","Dec 3, 2020",PC0214-000
indacaterol mometasone furoate,Atectura Breezhaler,indacaterol /mometasone furoate,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0646-atectura-breezhaler-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0646%20Atectura%20Breezhaler%20-%20CDEC%20Final%20CDEC%20Recommendation%20November%2026%2C%202020_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0646-atectura-breezhaler-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0646%20Atectura%20Breezhaler%20-%20Patient%20Group%20Input_for%20posting.pdf,"Asthma maintenance (adults, children 12 or older)",Reimburse with clinical criteria and/or conditions,Complete,"May 19, 2020","Nov 24, 2020",SR0646-000
indacaterol glycopyrronium mometasone furoate,Enerzair Breezhaler,indacaterol  glycopyrronium  mometasone furoate,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0645-enerzair-breezhaler-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0645%20Enerzair%20Breezhaler%20-%20CDEC%20Final%20Recommendation%20November%2026%2C%202020_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0645-enerzair-breezhaler-pharmaceconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/Indacaterol%20glycopyrronium%20mometasone%20furoate%20-%20Patient%20Group%20Input%20June%204%2C%202020.pdf,"Asthma maintenance, adults",Reimburse with clinical criteria and/or conditions,Complete,"May 19, 2020","Nov 24, 2020",SR0645-000
tecentriq avastin hepatocellular carcinoma,Tecentriq & Avastin,Atezolizumab & Bevacizumab,https://www.cda-amc.ca; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10217AtezolizumabBevacizumabHCC_Clinician%20COIs_Combined_EC_Post17Nov2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10217AtezolizumabBevacizumabHCC_Combined%20ClinicianFeedback_EC_Post17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10217AtezolizumabBevacizumabHCC_PAGFeedbackSummary_EC_Post17Nov2020_finalRedacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10217AtezolizumabBevacizumabHCC_PatientCOIs_Combined_EC_Post17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10217AtezolizumabBevacizumabHCC_SponsorFeedback_EC_Post17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10217AtezolizumabBevacizumabHCC_fnCGR_REDACT_PostEC17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10217AtezolizumabBevacizumabHCC_fnEGR_REDACTABBREV_EC_Post17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10217AtezolizumabBevacizumabHCC_fnRec_EC_Post17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10217AtezolizumabBevacizumabHCC_inRec_ApprovedByChair_REDACT_Post29Oct2020_final.pdf,Hepatocellular Carcinoma (HCC),Reimburse with clinical criteria and/or conditions,Complete,"May 21, 2020","Nov 17, 2020",PC0217-000
venetoclax venclexta combo obinutuzumab cll,Venclexta,Venetoclax Obinutuzumab,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10212VenetoclaxObinutuzumabCLL_Clinician%20Combined_COIs%20EC_Post17Nov2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10212VenetoclaxObinutuzumabCLL_ClinicianFeedback_CCO_EC_Post17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10212VenetoclaxObinutuzumabCLL_PAGFeedbackSummary_EC_Post17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10212VenetoclaxObinutuzumabCLL_Patient%20COIs_EC_Post17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10212VenetoclaxObinutuzumabCLL_PatientFeedback_CLLPAG_EC_Post17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10212VenetoclaxObinutuzumabCLL_SponsorFeedback_EC_Post17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10212VenetoclaxObinutuzumabCLL_fnCGR_REDACT_EC_Post17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10212VenetoclaxObinutuzumabCLL_fnEGR_NOREDACTABBREV_EC_Post17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10212VenetoclaxObinutuzumabCLL_fnRec_EC_Post17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10212VenetoclaxObinutuzumabCLL_inRec_Post29Oct2020_final.pdf,Obinutuzumab for CLL,Reimburse with clinical criteria and/or conditions,Complete,"Apr 17, 2020","Nov 17, 2020",PC0212-000
acalabrutinib calquence chronic lymphocytic leukemia,Calquence,Acalabrutinib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10211AcalabrutinibCLL_COIs_EC_Post17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10211AcalabrutinibCLL_ClinicianFeedback_CCO_EC_Post17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10211AcalabrutinibCLL_Combined%20Clinician%20COIs_EC_Post17Nov2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10211AcalabrutinibCLL_PAGFeedbackSummary_EC_Post17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10211AcalabrutinibCLL_PatientFeedback_CLLPAG_EC_Post17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10211AcalabrutinibCLL_SponsorFeedback_EC_Post_17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10211AcalabrutinibCLL_fnCGR_REDACT_EC_Post17Nov2020_final_v2.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10211AcalabrutinibCLL_fnEGR_REDACTABBREV_EC_Post17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10211AcalabrutinibCLL_fnRec_REDACT_EC_Post17Nov2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10211AcalabrutinibCLL_inRec_pERC%20Chair%20Approved_REDACT_Post29Oct2020_final.pdf,Chronic Lymphocytic Leukemia (CLL),Reimburse with clinical criteria and/or conditions,Complete,"Apr 7, 2020","Nov 17, 2020",PC0211-000
voretigene neparvovec,Luxturna,voretigene neparvovec,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sg0643-luxturna-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SG0643%20Luxturna%20-%20CDEC%20Final%20Recommendation%20November%2016%2C%202020_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sg0643-luxturna-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/Luxturna%20-%20Patient%20Group%20Input_For%20Posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sg0643-luxturna-ethics-review-report.pdf,"Vision loss, inherited retinal dystrophy",Reimburse with clinical criteria and/or conditions,Complete,"Apr 23, 2020","Nov 12, 2020",SG0643-000
blincyto mrd positive b cell precursor all,Blincyto,Blinatumomab,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10204BlinatumomabMRD%2BBCPALL_ClinicianFeedback_Combined_Post29Oct2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10204BlinatumomabMRD%2BBCPALL_Combined%20COIs_Post29Oct2020_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10204BlinatumomabMRD%2BBCPALL_PAGFeedbackSummary_Post29Oct2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10204BlinatumomabMRD%2BBCPALL_PatientGroupFeedback_Ac2orn_Post29Oct2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10204BlinatumomabMRD%2BBCPALL_PtGrp%20Combined%20COIs_Post29Oct2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10204BlinatumomabMRD%2BBCPALL_SponsorFeedback_Post29Oct2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10204BlinatumomabMRD%2BBCPALL_fnCGR_REDACT_Post29Oct2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10204BlinatumomabMRD%2BBCPALL_fnEGR_NOREDACTABBREV_Post29Oct2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10204BlinatumomabMRD%2BBCPALL_fnREC_approvedbyChair_REDACT_Post29Oct2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10204BlinatumomabMRD%2BBCPALL_inREC_ApprovedbyChair_REDACT_Post_03Sep2020_final.pdf,MRD+ ALL Resubmission,Reimburse with clinical criteria and/or conditions,Complete,"Jan 20, 2020","Oct 29, 2020",PC0204-000
budesonide,Jorveza,budesonide,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0634-jorveza-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0634%20Jorveza%20-%20CDEC%20Final%20Recommendation%20October%2030%2C%202020_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0634-jorveza-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0634_Jorveza_PI_Submission.pdf,"Eosinophilic esophagitis, adults",Reimburse with clinical criteria and/or conditions,Complete,"Nov 8, 2019","Oct 28, 2020",SR0634-000
halobetasol propionate and tazarotene,Duobrii,Halobetasol propionate and tazarotene,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0638-duobrii-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0638%20Duobrii%20-%20CDEC%20Final%20Recommendation%20October%2030%2C%202020_For%20Posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0638-duobrii-parmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0638%20Duobrii%20-%20Patient%20Input_For%20posting.pdf,"Psoriasis, moderate to severe plaque",Reimburse with clinical criteria and/or conditions,Complete,"Jan 24, 2020","Oct 28, 2020",SR0638-000
etonogestrel,Nexplanon,etonogestrel,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0648-nexplanon-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0648%20Nexplanon%20-%20CDEC%20Final%20Recommendation%20October%2022%2C%202020_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0648-nexplanon-pharmacoeconomic-review-report.pdf,Prevention of pregnancy,Reimburse with clinical criteria and/or conditions,Complete,"Jun 3, 2020","Oct 20, 2020",SR0648-000
eculizumab,Soliris,eculizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0605-soliris-mg-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0605%20Soliris%20MG%20-%20CDEC%20Final%20Recommendation%20October%2021%2C%202020_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0605-soliris-mg-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0605_Soliris%20MG_PI%20Submission.pdf,"Myasthenia Gravis (gMG), adults",Reimburse with clinical criteria and/or conditions,Complete,"Apr 1, 2020","Oct 19, 2020",SR0605-000
enzalutamide xtandi metastatic castration sensitive prostate cancer,Xtandi,Enzalutamide,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10209EnzalutamidemCSPC_COI_CCS_Post_23Sep2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10209EnzalutamidemCSPC_ClinicianCOI_Post23Sep2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10209EnzalutamidemCSPC_ClinicianFeedback_CCO_Post_23Sep2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10209EnzalutamidemCSPC_PAGFeedbackSummary_Post_23Sep2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10209EnzalutamidemCSPC_SponsorFeedback_Post_23Sep2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10209EnzalutamidemCSPC_fnCGR_REDACT_Post_23Sep2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10209EnzalutamidemCSPC_fnEGR_REDACT-ABBREV_Post_23Sep2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10209EnzalutamidemCSPC_fnRec_EarlyConv_REDACT_ApprovedbyChair_Post23Sep2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10209EnzalutamidemCSPC_inRec_approvedbyChair_REDACT_Post_03Sep2020_final.pdf,mHSPC,Reimburse with clinical criteria and/or conditions,Complete,"Feb 24, 2020","Sep 23, 2020",PC0209-000
niraparib zejula ovarian cancer,Zejula,Niraparib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10203NiraparibOC_ClinicianFeedback_CCO_2020-17-07_Post03Sep2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10203NiraparibOC_CombinedClinician%20COIs_Post03Sep2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10203NiraparibOC_InitialRec_Approved_03Jul2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10203NiraparibOC_PAGFeedbackSummary_Post03Sep2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10203NiraparibOC_PatientFeedback_OCC_2020-14-07_Post03Sep2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10203NiraparibOC_PatientInput_OCC_2020-02-24_revised_Post03Sep2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10203NiraparibOC_SponsorFeedback_2020-17-07_Post03Sep2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10203NiraparibOC_fnCGR_REDACT_Post_03Sep2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10203NiraparibOC_fnEGR_REDACTABBREV_Post03Sep2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10203NiraparibOC_fnRec_pERC%20Chair%20Approved_Post_03Sep2020_final.pdf,Ovarian Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Feb 7, 2020","Sep 3, 2020",PC0203-000
caplacizumab,Cablivi,caplacizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0633-cablivi-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0633%20Cablivi%20-%20CDEC%20Final%20Recommendation%20September%201%2C%202020%20for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0633-cablivi-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/Cablivi%20-%20Patient%20Group%20Input%20for%20posting.pdf,Acquired thrombotic thrombocytopenic purpura (aTTP),Do not reimburse,Complete,"Sep 13, 2019","Aug 26, 2020",SR0633-000
eculizumab,Soliris,eculizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0640-soliris-nmosd-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0640%20Soliris%20-%20CDEC%20Final%20Recommendation%20August%2024%2C%202020%20for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0640-soliris-nmosd-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0640_Soliris%20NMOSD_PI%20Submission.pdf,Neuromyelitis optica spectrum disorder,Reimburse with clinical criteria and/or conditions,Complete,"Feb 25, 2020","Aug 19, 2020",SR0640-000
erenumab,Aimovig,erenumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0578-aimovig-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0578%20Aimovig%20-%20CDEC%20Final%20Recommendation%20July%2024%2C%202020%20%28redacted%29_For%20Posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0578-aimovig-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0578-Aimovig-patient-input.pdf,Migraine,Reimburse with clinical criteria and/or conditions,Complete,"May 2, 2019","Jul 22, 2020",SR0578-000
cabotegravirrilpivirine,Vocabria and Cabenuva,cabotegravir sodium cabotegravir-rilpivirine,https://www.cda-amc.ca/sites/default/files/attachments/2025-03/sr0628-vocabria%2Bcabenuva-clinical-review-report-QC_redacted-gg_0.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0628%20Vocabria%20%2B%20Cabenuva%20-%20Final%20CDEC%20Recommendation%20September%209%2C%202020_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0628-vocabria%2Bcabenuva-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0628%20cabotegravir%20%2B%20rilpivirne%20-%20Group%20Patient%20Input_October%2021%2C%202019.pdf,HIV-1 infection,Reimburse with clinical criteria and/or conditions,Complete,"Aug 19, 2019","Jul 22, 2020",SR0628-000
siponimod,Mayzent,siponimod,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0631-mayzent-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0631%20Mayzent%20-%20CDEC%20Final%20Recommendation%20July%2023%2C%202020%20%28redacted%29_For%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0631-mayzent-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0631_Mayzent_PI%20Submission.pdf,Secondary progressive multiple sclerosis,Reimburse with clinical criteria and/or conditions,Complete,"Sep 26, 2019","Jul 21, 2020",SR0631-000
icosapent ethyl,Vascepa,icosapent ethyl,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0619-vascepa-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0619%20Vascepa%20-%20CDEC%20Final%20Recommendation%20July%2020%2C%202020_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0619-vascepa-pharmacoeconomic-review-report.pdf,Ischemic events in statin-treated patients,Reimburse with clinical criteria and/or conditions,Complete,"Jun 17, 2019","Jul 16, 2020",SR0619-000
ustekinumab,Stelara/Stelara I.V,ustekinumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0627-stelara-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0627%20Stelara%20-%20CDEC%20Final%20Recommendation%20July%2020%2C%202020_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0627-stelara-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0627_Stelara%20UC_PI%20Submission.pdf,Ulcerative colitis,Reimburse with clinical criteria and/or conditions,Complete,"Aug 12, 2019","Jul 16, 2020",SR0627-000
tecentriq avastin non squamous non small cell lung cancer,Tecentriq & Avastin,Atezolizumab & Bevacizumab,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10155AtezolizumabBevacizumabNSQ-NSCLC_COI_LCC_Post03Jul2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10155AtezolizumabBevacizumabNSQ-NSCLC_Combined%20COIs_Post03Jul2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10155AtezolizumabBevacizumabNSQ-NSCLC_Combined%20ClinicianFeedback_Post03Jul2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10155AtezolizumabBevacizumabNSQ-NSCLC_FinalRec_Post03July2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10155AtezolizumabBevacizumabNSQ-NSCLC_PAGFeedbackSummary_Post03Jul2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10155AtezolizumabBevacizumabNSQ-NSCLC_PatientFeedback_Post03Jul2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10155AtezolizumabBevacizumabNSQ-NSCLC_SponsorFeedback_Post03Jul2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10155AtezolizumabBevacizumabNSQ-NSCLC_fnCGR_REDACT_Post03Jul2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10155AtezolizumabBevacizumabNSQ-NSCLC_fnEGR_REDACT-ABBREV_Post03Jul2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10155AtezolizumabBevacizumabNSQ-NSCLC_inRec_REDACT_pERC%20Chair%20Approved_Post30Apr2020_final.pdf,NSQ-NSCLC,Do not reimburse,Complete,"Nov 18, 2019","Jul 3, 2020",PC0155-000
glycopyrrolate,Cuvposa,glycopyrrolate,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0613-cuvposa-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0613%20Cuvposa%20-%20CDEC%20Final%20Recommendation%20June%2026%2C%202020_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0613-cuvposa-pharmacoeconomic-review-report.pdf,"chronic severe drooling, neurologic (pediatric)",Do not reimburse,Complete,"May 31, 2019","Jun 24, 2020",SR0613-000
kisqali advanced or metastatic breast cancer,Kisqali,Ribociclib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10194RibociclibMBC_Clinician%20Combined%20COI_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10194RibociclibMBC_ClinicianFeedback_CCO_Post04Jun2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10194RibociclibMBC_Combined%20COI_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10194RibociclibMBC_Combined_PatientFeedback_Post04Jun2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10194RibociclibMBC_FnRec_Chair%20Approved_Post04Jun2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10194RibociclibMBC_PAGFeedbackSummary_Post04Jun2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10194RibociclibMBC_SponsorFeedback_Post04Jun2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10194RibociclibMBC_fnCGR_NOREDACT_Post04Jun2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10194RibociclibMBC_fnEGR_NOREDACT-ABBREV_Post04Jun2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10194RibociclibMBC_inRec_pERC%20Chair%20Approved_Post02Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/RibociclibKisqali_MBC10194ProvFunding.pdf,"HR+, HER2- advanced or metastatic breast cancer",Reimburse with clinical criteria and/or conditions,Complete,"Aug 26, 2019","Jun 4, 2020",PC0194-000
brentuximab vedotin adcetris peripheral t cell lymphoma,Adcetris,Brentuximab Vedotin,https://www.cda-amc.ca/sites/default/files/pcodr/BrentuximabVedotinAdcetris_PTCL10199ProvFunding.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_ClinicianFeedback_CCO_Post02Jun2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_Combined_Clinician_COIs_Post04Jun2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_FnRec_approved_Post04Jun2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_PAGFeedbackSummary_Post04Jun2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_PatientFeedback_LC_Post04Jun2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_Patient_COI_LC_Post04Jun2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_SponsorFeedback_Post04Jun2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_fnCGR_NOREDACT_Post04Jun2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_fnEGR_NOREDACT-ABBREV_Post04Jun2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10199BrentuximabVedotinPTCL_inRec_approvedbyChair_NOREDACT_Post02Apr2020_final.pdf,peripheral T-cell lymphoma (PTCL),Reimburse,Complete,"Oct 8, 2019","Jun 4, 2020",PC0199-000
naltrexone hydrochloride and bupropion hydrochloride,Contrave,naltrexone hydrochloride and bupropion hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0610-contrave-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0610%20Contrave%20-%20CDEC%20Final%20Recommendation%20June%205%2C%202020%20Final_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0610-contrave-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0610%20Contrave%20-%20Patient%20Group%20Input%20June%2017%2C%202019.pdf,Chronic weight management in adults,Do not reimburse,Complete,"May 1, 2019","May 27, 2020",SR0610-000
burosumab,Crysvita,burosumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0602-crysvita-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0602%20Crysvita%20-%20CDEC%20Final%20Recommendation%20May%2029%2C%202020_For%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0602-crysvita-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/Crysvita%20-%20Patient%20Group%20Input%20-%20For%20posting.pdf,Treatment of X-Linked Hypophosphatemia,Reimburse with clinical criteria and/or conditions,Complete,"Jul 23, 2019","May 27, 2020",SR0602-000
brolucizumab,Beovu,brolucizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0632-beovu-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0632%20Beovu%20-%20CDEC%20Final%20Recommendation%20%E2%80%93%20May%2025%2C%202020_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0632-beovu-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0632_Brolucizumab_PI%20Submission.pdf,"Macular degeneration, age-related",Reimburse with clinical criteria and/or conditions,Complete,"Sep 26, 2019","May 21, 2020",SR0632-000
gilteritinib xospata acute myeloid leukemia,Xospata,Gilteritinib,https://www.cda-amc.ca/sites/default/files/pcodr/GilteritinibXospata__AML10102_ProvFunding.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10202GilteritinibAML_COI-LLSC_Post20May2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10202GilteritinibAML_ClinicianFeedback_CCODAC_Post20May2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10202GilteritinibAML_Combined_ClincianInput_Post20May2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10202GilteritinibAML_FnRec_REDACT_EarlyConv_20May2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10202GilteritinibAML_PAGFeedbackSummary_Post20May2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10202GilteritinibAML_PatientFeedback_LLSC_Post20May2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10202GilteritinibAML_SponsorFeedback_Post20May2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10202GilteritinibAML_fnCGR_REDACT_EarlyConv_20May2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10202GilteritinibAML_fnEGR_REDACT-ABBREV_EarlyConv20May2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10202GilteritinibAML_inRec_REDACT_ApprovedbyChair_Post30Apr2020_final.pdf,N/A,Reimburse with clinical criteria and/or conditions,Complete,"Oct 28, 2019","May 20, 2020",PC0202 -000
vedolizumab,Entyvio,vedolizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0635-entyvio-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0635%20Entyvio%20-%20CDEC%20Final%20Recommendation%20%E2%80%93%20May%2021%2C%202020_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0635-entyvio-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0635_Entyvio_PI%20Submission.pdf,Ulcerative Colitis,Reimburse with clinical criteria and/or conditions,Complete,"Nov 21, 2019","May 19, 2020",SR0635-000
belimumab,Benlysta,Belimumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0616-benlysta-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0616%20Benlysta%20-%20CDEC%20Final%20Recommendation%20April%2024%2C%202020_For%20Posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0616-benlysta-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0616_Benlysta_PI%20Submission1.pdf,systemic lupus erythematosus,Do not reimburse,Complete,"May 29, 2019","Apr 22, 2020",SR0616-000
kisqali fulvestrant advanced or metastatic breast cancer,Kisqali,Ribociclib with Fulvestrant,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10195RibociclibFulvestrantMBC_ClinicianFeedback_CCO_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10195RibociclibFulvestrantMBC_Combined%20COIs_EC_22Apr2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10195RibociclibFulvestrantMBC_Combined%20Clinician%20COI_EC_22Apr2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10195RibociclibFulvestrantMBC_Combined_PatientFeedback.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10195RibociclibFulvestrantMBC_PAGFeedbackSummary__EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10195RibociclibFulvestrantMBC_SponsorFeedback_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10195RibociclibFulvestrantMBC_fnCGR_NOREDACT_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10195RibociclibFulvestrantMBC_fnEGR_NOREDACT-ABBREV_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10195RibociclibFulvestrantMBC_fnRec_pERC%20Chair%20Approved_22April2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10195RibociclibFulvestrantMBC_inRec_pERC%20Chair%20Approved_Post02Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/RibociclibKisqali%2BFulvestrant_MBC10195ProvFunding.pdf,"+Fulvestrant for HR+, HER2- advanced or metastatic breast cancer",Reimburse with clinical criteria and/or conditions,Complete,"Aug 26, 2019","Apr 22, 2020",PC0195-000
darolutamide nubeqa non metastatic castration resistant prostate cancer,Nubeqa,Darolutamide,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10196DarolutamidenmCRPC_COI_CCSN__EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10196DarolutamidenmCRPC_ClinicianFeedback_CCO_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10196DarolutamidenmCRPC_Combined%20COI_EC_22Apr2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10196DarolutamidenmCRPC_PAGFeedbackSummary_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10196DarolutamidenmCRPC_SponsorFeedback_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10196DarolutamidenmCRPC_fnCGR_REDACT_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10196DarolutamidenmCRPC_fnEGR_REDACT-ABBREV_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10196DarolutamidenmCRPC_fnRec_REDACT_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10196DarolutamidenmCRPC_inRec_approvedbyChair_REDACT_Post02Apr2020_final.pdf,non-metastatic castration resistant prostate cancer (nmCRPC),Reimburse with clinical criteria and/or conditions,Complete,"Aug 27, 2019","Apr 22, 2020",PC0196-000
apalutamide erleada metastatic castration sensitive prostate cancer,Erleada,Apalutamide,https://www.cda-amc.ca/sites/default/files/pcodr/ApalutamideErleada_mCSPC10200ProvFunding.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10200ApalutamidemCSPC%20COICCSN_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10200ApalutamidemCSPC_COI_Combined_Clinician%20Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10200ApalutamidemCSPC_ClinicianFeedback_CCO_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10200ApalutamidemCSPC_PAGFeedbackSummary_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10200ApalutamidemCSPC_SponsorFeedback_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10200ApalutamidemCSPC_fnCGR_REDACT__EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10200ApalutamidemCSPC_fnEGR_REDACT-ABBREV_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10200ApalutamidemCSPC_fnRec_ChairApproved_EarlyConv_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10200ApalutamidemCSPC_inRec_ApprovedbyChair_Post02Apr2020_final-updated.pdf,metastatic castration-sensitive prostate cancer (mCSPC),Reimburse with clinical criteria and/or conditions,Complete,"Oct 15, 2019","Apr 22, 2020",PC0200-000
cabozantinib cabometyx hepatocellular carcinoma,Cabometyx,Cabozantinib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10186CabozantinibHCC_COI%20CLF_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10186CabozantinibHCC_Combined%20COI_EC_22Apr2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10186CabozantinibHCC_Combined%20ClinicianFeedback_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10186CabozantinibHCC_FnRec_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10186CabozantinibHCC_PAGFeedbackSummary_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10186CabozantinibHCC_SponsorFeedback_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10186CabozantinibHCC_fnEGR_NOREDACT-ABBREV_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10186CabozantinibHCC_inCGR_NOREDACT_EC_22Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10186CabozantinibHCC_inRec_2020-04-01_ApprovedbyChair_Post02Apr2020_final.pdf,HCC,Reimburse with clinical criteria and/or conditions,Complete,"Oct 16, 2019","Apr 22, 2020",PC0186-000
dupilumab,Dupixent,dupilumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0636-dupixent-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0636%20Dupixent%20-%20CDEC%20Final%20%20Recommendation%20April%2024%2C%202020%20for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0636-dupixent-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0636%20Dupixent%20-%20Patient%20Input%20Summary%20December%202019.pdf,atopic dermatitis,Reimburse with clinical criteria and/or conditions,Complete,"Oct 22, 2019","Apr 22, 2020",SR0636-000
pembrolizumab keytruda renal cell carcinoma,Keytruda,Pembrolizumab,https://www.cadth.ca/sites/default/files/pcodr/Reviews2020/10185PembrolizumabRCC_inRec_2020-01-30_ApprovedbyChair_Post_30Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10185PembrolizumabRCC_ClinicianFeedback_CCOGUDAC_Post02Apr2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10185PembrolizumabRCC_Combined%20COIs_Post02Apr2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10185PembrolizumabRCC_PAGFeedbackSummary_Post02Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10185PembrolizumabRCC_PatientInput_KCC_COI_Post02Apr2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10185PembrolizumabRCC_SponsorFeedback_Post24Mar2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10185PembrolizumabRCC_fnCGR_REDACT_Post02Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10185PembrolizumabRCC_fnEGR_NOREDACT-ABBREV_Post02Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10185PembrolizumabRCC_fnRec_2020-03-31_ApprovedpERCChair_Post02Apr2020_final.pdf,Renal Cell Carcinoma (RCC),Reimburse with clinical criteria and/or conditions,Complete,"Aug 2, 2019","Apr 2, 2020",PC0185-000
gemtuzumab ozogamicin mylotarg acute myeloid leukemia,Mylotarg,Gemtuzumab Ozogamicin,https://www.cda-amc.ca/sites/default/files/pcodr/GemtuzumabOzogamicinMylotarg_AML10190ProvFunding.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10190GemtuzumabOzogamacinAML_FnRec_2020-04-01_approvedbyChair_Post02Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10190GemtuzumabOzogamacinAML_inRec_ApprovedbyChair_Post_30Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10190GemtuzumabOzogamicinAML_ClinicianFeedback_CCO_2020-02-13_Post02Apr2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10190GemtuzumabOzogamicinAML_Combined_COI_Post02Apr2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10190GemtuzumabOzogamicinAML_PAGFeedbackSummary_Post02Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10190GemtuzumabOzogamicinAML_Patient_COI_Post02Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10190GemtuzumabOzogamicinAML_SponsorFeedback_Post02Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10190GemtuzumabOzogamicinAML_fnCGR_NOREDACT_Post02Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10190GemtuzumabOzogamicinAML_fnEGR_NOREDACT-ABBREV_Post02Apr2020_final.pdf,Acute Myeloid Leukemia (AML),Reimburse,Complete,"Aug 9, 2019","Apr 2, 2020",PC0190-000
midostaurin rydapt systemic mastocytosis,Rydapt,Midostaurin,https://www.cda-amc.ca/sites/default/files/pcodr/MidostaurinRydapt_Systemic%20Mastocytosis10193_ProvFunding.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10193MidostaurinSM_COI_Post02Apr2020_final%20Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10193MidostaurinSM_ClinicianFeedback_CCO_Post02Apr2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10193MidostaurinSM_PAGFeedbackSummary_Post02Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10193MidostaurinSM_PatientCOI_CORD_Post02Apr2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10193MidostaurinSM_PatientFeedback_CORD_Post02Apr2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10193MidostaurinSM_SponsorFeedback_2020-02-13_Post02Apr2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10193MidostaurinSM_fnCGR_REDACT_Post_02Apr2020_final.revised.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10193MidostaurinSM_fnEGR_NOREDACT-ABBREV_Post02Apr2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10193MidostaurinSM_fnRec_approvedbyChair_REDACT_Post02Apr2020_draft.revised.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10193MidostaurinSystemicMastocytosis_InRec_approvedbyChair_Post_30Jan2020_REDACT_draft.revised.pdf,Systemic Mastocytosis,Do not reimburse,Complete,"Aug 13, 2019","Apr 2, 2020",PC0193-000
iron iii isomaltoside,Monoferric,Iron (III) Isomaltoside 1000,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0622-monoferric-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0622%20Monoferric%20-%20CDEC%20Final%20%20Recommendation%20March%2027%2C%202020%20for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0622-monoferric-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0622-Monoferric-Patient%20Input%20for%20Posting.pdf,iron deficiency anemia,Reimburse with clinical criteria and/or conditions,Complete,"Jun 26, 2019","Mar 25, 2020",SR0622-000
sodium zirconium cyclosilicate,Lokelma,sodium zirconium cyclosilicate,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0612-lokelma-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0612%20Lokelma%20-%20CDEC%20Final%20Recommendation%20March%2027%2C%202020%20for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0612-lokelma-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0612-Sodium%20zirconium%20cyclosilicate-patient-input.pdf,"Hyperkalemia, adults",Do not reimburse,Complete,"May 17, 2019","Mar 25, 2020",SR0612-000
safinamide,Onstryv,safinamide,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0617-onstryv-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0617%20Onstryv%20-%20CDEC%20Final%20Recommendation%20March%2027_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0617-onstryv-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0617_Onstryv_PI%20Submission.pdf,Parkinson's disease,Do not reimburse,Complete,"May 29, 2019","Mar 25, 2020",SR0617-000
ixekizumab,Taltz,ixekizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0630-taltz-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0630%20Taltz%20-%20CDEC%20Final%20Recommendation%20March%2027%2C%202020_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0630-taltz-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0630_Taltz_PI%20Submission.pdf,Ankylosing spondylitis,Reimburse with clinical criteria and/or conditions,Complete,"Sep 20, 2019","Mar 24, 2020",SR0630-000
trifluridine tipiracil lonsurf gastric cancer,Lonsurf,Trifluridine-Tipiracil,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10197TrifluridineTipiracilGC_ClinicianFeedback_EC24Mar2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10197TrifluridineTipiracilGC_Combined_COIs_EC24Mar2020_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10197TrifluridineTipiracilGC_MGF_COI_EC24Mar2020final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10197TrifluridineTipiracilGC_PAGFeedbackSummary_EC24Mar2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10197TrifluridineTipiracilGC_SponsorFeedback_EC24Mar2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10197TrifluridineTipiracilGC_fnCGR_NOREDACT_EC24Mar2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10197TrifluridineTipiracilGC_fnRec_EarlyConv_ApprovedbypERCChair_Post024Mar2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10197TrifluridineTipiracilGC_inEGR_NOREDACT-ABBREV_EC24Mar2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10197TrifluridineTipiracilGC_inRec_2020-03-03_ApprovedbyChair_Post_05Mar2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Trifluridine-TipiracilLonsurf_GastricCancer10197ProvFunding.pdf,Gastric Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Sep 3, 2019","Mar 24, 2020",PC0197-000
daratumumab darzalex multiple myeloma,Darzalex,Daratumumab,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10189DaratumumabNDMM_inRec_2020_01-03_ApprovedbyChair_Post_03Jan2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10189DaratumumabNDMM_ClinicianFeedback_CCO_Post05Mar2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10189DaratumumabNDMM_Combined_COI_Post_05Mar2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10189DaratumumabNDMM_PAGFeedbackSummary_Post05Mar2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10189DaratumumabNDMM_PatientCOI_Post05Mar2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10189DaratumumabNDMM_SponsorFeedback_Post_05Mar2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10189DaratumumabNDMM_fnCGR_Post05Mar2020_REDACT_Final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10189DaratumumabNDMM_fnEGR_NOREDACTABBREV_Post05Mar2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10189DaratumumabNDMM_fnRec_2020-03-03_ApprovedbyChair_Post_05Mar2020_final.pdf,Rd for MM,Reimburse with clinical criteria and/or conditions,Complete,"Jul 17, 2019","Mar 5, 2020",PC0189-000
tafamidis,Vyndaqel,tafamidis,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0625-vyndaqel-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0625%20Vyndaqel%20-%20CDEC%20Final%20%20Recommendation%20February%2020%2C%202020%20for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0625-vyndaqel-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0625_Tafamidis_PI%20Submission.pdf,transthyretin-mediated amyloidosis,Reimburse with clinical criteria and/or conditions,Complete,"Jul 4, 2019","Feb 19, 2020",SR0625-000
vortioxetine hydrobromide,Trintellix,vortioxetine hydrobromide,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0611-trintellix-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0611%20Trintellix%20-%20Final%20CDEC%20Recommendation%20February%2014%2C%202020_For%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0611-trintellix-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0611-trintellix-pi-submission-redacted.pdf,"Major depressive disorder (MDD), adults.",Reimburse with clinical criteria and/or conditions,Complete,"May 1, 2019","Feb 12, 2020",SR0611-000
upadacitinib,Rinvoq,upadacitinib,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0614-rinvoq-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0614%20Rinvoq%20-%20CDEC%20Final%20Recommendation%20February%206%2C%202020_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0614-rinvoq-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0614%20Upadacitinib%20-%20Group%20Patient%20Input%20September%2012%2C%202019.pdf,"Arthritis, Rheumatoid",Reimburse with clinical criteria and/or conditions,Complete,"Jul 4, 2019","Feb 4, 2020",SR0614-000
lorlatinib lorbrena non small cell lung cancer,Lorbrena,Lorlatinib,https://www.cda-amc.ca/sites/default/files/pcodr/LorlatinibLorbrena_ALK%2BNSCLC10183ProvFunding.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10183LorlatinibNSCLC_ApprovedbyChair_2019-12-03_Post_05Dec2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10183LorlatinibNSCLC_Combined%20Clinician_COIs_Post_30Jan2020_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10183LorlatinibNSCLC_Combined_ClinicianFeedback_Post_30Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10183LorlatinibNSCLC_Combined_PatientFeedback_Post_30Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10183LorlatinibNSCLC_Combined_Patient_COI_Post_30Jan2020.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10183LorlatinibNSCLC_FnRec_ApprovedbyChair_Post_30Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10183LorlatinibNSCLC_PAGFeedbackSummary_2019-12-13FINAL_Post_30Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10183LorlatinibNSCLC_SponsorFeedback_Post_30Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10183LorlatinibNSCLC_fnCGR_NOREDACT_Post_30Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10183LorlatinibNSCLC_fnEGR_NOREDACT-ABBREV_Post_30Jan2020_final.pdf,Non-Small Cell Lung Cancer (NSCLC),Do not reimburse,Complete,"Jun 11, 2019","Jan 30, 2020",PC0183-000
tecentriq small cell lung cancer,Tecentriq,Atezolizumab,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10156AtezolizumabSCLC_ClinicianFeedback_Combined_Post_05Dec2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10156AtezolizumabSCLC_Combined%20COIs_Post_05Dec2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10156AtezolizumabSCLC_Combined_Patient_COI_Post_05Dec2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10156AtezolizumabSCLC_InRec_approvedbyChair_Post_03Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10156AtezolizumabSCLC_PAGFeedbackSummary_2019-10-11_Post_05Dec2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10156AtezolizumabSCLC_PatientFeedback_Combined_Post_05Dec2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10156AtezolizumabSCLC_SponsorFeedback_2019-10-18_Post_05Dec2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10156AtezolizumabSCLC_FnRec_ProceduralReview_approvedbyChair_Post_30Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10156AtezolizumabSCLC_fnCGR_REDACT_Post_30Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10156AtezolizumabSCLC_fnEGR_NOREDACT-ABBREV_Post_30Jan2020_final.pdf,Small Cell Lung Cancer (SCLC),Do not reimburse,Complete,"Mar 4, 2019","Jan 30, 2020",PC0156-000
trastuzumab emtansine kadcyla early breast cancer ebc,Kadcyla,Trastuzumab Emtansine,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10182TrastuzumabEmtansineEBC_inRec_2020-01-02_ChairApproved_NOREDACT_Post_03Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10182TrastuzumabEmtansineEBC_ClinicianFeedback_EarlyConv_22Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10182TrastuzumabEmtansineEBC_Combined%20COIs_EarlyConv_22Jan2020_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10182TrastuzumabEmtansineEBC_Combined%20COIs_EarlyConv_22Jan2020_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10182TrastuzumabEmtansineEBC_PAGFeedbackSummary_EarlyConv_22Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10182TrastuzumabEmtansineEBC_SponsorFeedback_EarlyConv_22Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10182TrastuzumabEmtansineEBC_fnCGR_REDACT_EarlyConv_22Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10182TrastuzumabEmtansineEBC_fnEGR_NOREDACT-ABBREV_EarlyConv_22Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10182TrastuzumabEmtansineEBC_fnRec_ChairApproved_EarlyConv_22Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/TrastuzumabEmtansine%20Kadcyla_EBC10182_ProvFunding.pdf,Early Breast Cancer (EBC),Reimburse,Complete,"Jul 2, 2019","Jan 22, 2020",PC0182-000
cemiplimab libtayo cutaneous squamous cell carcinoma,Libtayo,Cemiplimab,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10187CemiplimabCSCC_inRec__REDACT_approvedbyChair_03Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10187CemiplimabCSCC_Clinician%20Combined%20COIs_EarlyConv_22Jan2020_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10187CemiplimabCSCC_ClinicianFeedback_CCOSkinDAC_EarlyConv_22Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10187CemiplimabCSCC_Combined%20PatientFeedback_EarlyConv_22Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10187CemiplimabCSCC_Combined_COI_EarlyConv_22Jan2020.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10187CemiplimabCSCC_PAGFeedbackSummary_EarlyConv_22Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10187CemiplimabCSCC_SponsorFeedback_EarlyConv_22Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10187CemiplimabCSCC_fnCGR_REDACT_EarlyConv_22Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10187CemiplimabCSCC_fnEGR_REDACT-ABBREV_EarlyConv_22Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2020/10187CemiplimabCSCC_fnRec_REDACT_EarlyConv_22Jan2020_final.pdf,Advanced Cutaneous Squamous Cell Carcinoma (CSCC),Reimburse with clinical criteria and/or conditions,Complete,"Jul 9, 2019","Jan 22, 2020",PC0187-000
glucagon,Baqsimi,glucagon,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0626-baqsimi-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0626%20Baqsimi%20-%20CDEC%20Final%20Recommendation%20for%20Posting%20January%2024%2C%202020.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0626-baqsimi-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0626_glucagon_PI%20Submission.pdf,Severe hypoglycemic reactions,Reimburse with clinical criteria and/or conditions,Complete,"Jul 24, 2019","Jan 22, 2020",SR0626-000
keytruda squamous nsclc,Keytruda,Pembrolizumab,https://www.cda-amc.ca; https://www.cda-amc.ca/sites/default/files/pcodr/PembrolizumabKeytruda_SquamousNSCLC10176_ProvFunding.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC_Combined_ClinicianFeedback_Post_03Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC_Combined_PatientFeedback_Post_03Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC_PAGFeedbackSummary_2019-11-11FINAL_Post_03Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC_Patient_Combined_COIs_Post_03Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC_SponsorFeedback_2019-11-14_Post_03Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC_combined_Clinician%20COI_Post_03Jan2020_finalpdf_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC_fnCGR_REDACT_Post_03Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC_fnEGR_NOREDACT-ABBREV_Post_03Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC_fnRec_NOREDACT_ApprovedbyChair_Post_03Jan2020_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10176PembrolizumabSQ-NSCLC_inRec_ApprovedbyChair_REDACT_Post_31Oct2019_final.pdf,Squamous NSCLC,Reimburse with clinical criteria and/or conditions,Complete,"Feb 8, 2019","Jan 3, 2020",PC0176-000
inotersen,Tegsedi,inotersen,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0603-tegsedi-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0603%20Tegsedi%20-%20Final%20CDEC%20Recommendation%20December%2020%2C%202019%20for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/monograph/Tegsedi-product-monograph.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0603-tegsedi-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0603_Tegsedi_Consolidated%20Patient%20Input_March%2019%2C%202019_Redacted.pdf,hereditary transthyretin amyloidosis,Reimburse with clinical criteria and/or conditions,Complete,"Feb 22, 2019","Dec 18, 2019",SR0603-000
lynparza newly diagnosed ovarian cancer,Lynparza,Olaparib,https://www.cda-amc.ca/sites/default/files/pcodr/OlaparibLynparza_NewlyDiagnosedOC10174ProvFunding.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10174OlaparibOC_ClinicianFeedback_CCO_2019-10-18_Post_05Dec2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10174OlaparibOC_Combined%20COIs_Post_05Dec2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10174OlaparibOC_PAGFeedbackSummary_2019-10-11_Post_05Dec2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10174OlaparibOC_PatientFeedback_OCC_2019-10-16_Post_05Dec2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10174OlaparibOC_PatientInput_COI_2019-05-03_Post_05Dec2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10174OlaparibOC_SponsorFeedback_2019-10-18_Post_05Dec2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10174OlaparibOC_fnCGR_NOREDACT_Post_05Dec2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10174OlaparibOC_fnEGR_NOREDACT-ABBREV_Post_05Dec2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10174OlaparibOC_fnRec_2019-12-04_ChairApproved_Post_05Dec2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10174OlaparibOC_inRec_2019-10-03_Post_03Oct2019_final.pdf,Newly Diagnosed OC,Reimburse with clinical criteria and/or conditions,Complete,"Apr 18, 2019","Dec 5, 2019",PC0174-000
nerlynx hormone receptor positive breast cancer,Nerlynx,Neratinib,https://www.cda-amc.ca/sites/default/files/pcodr/NeratinibNerlynx_BreastCancer10172ProvFunding.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10172NeratinibEBC_ClinicianFeedback_CCO_2019-10-18_Post_05Dec2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10172NeratinibEBC_Combined%20Patient_COI_Post_05Dec2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10172NeratinibEBC_Combined_Clinician%20COIs_Post_05Dec2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10172NeratinibEBC_PAGFeedbackSummary_2019-10-11_Post_05Dec2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10172NeratinibEBC_PatientFeedback_Combined_Post_05Dec2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10172NeratinibEBC_SponsorFeedback_2019-10-18_Post_05Dec2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10172NeratinibEBC_fnCGR_NOREDACT_Post_05Dec2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10172NeratinibEBC_fnRec_Chair%20Approved_Post_05Dec2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10172NeratinibEBC_inEGR_NOREDACT-ABBREV_Post_05Dec2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10172NeratinibEBC_inRec_1%20Oct%202019_Post_03Oct2019_final.pdf,ERBB2-positive breast cancer,Do not reimburse,Complete,"Apr 18, 2019","Dec 5, 2019",PC0172-000
certolizumab pegol,Cimzia,certolizumab pegol,https://www.cadth.ca/sites/default/files/DRR/2023/TSDrugClas/TS0001/TS0001-PsO-Updated-Streamlined-Rec.pdf; https://www.cadth.ca/sites/default/files/cdr/clinical/sr0587-cimzia-clinical-review-report.pdf; https://www.cadth.ca/sites/default/files/cdr/complete/SR0587%20Cimzia%20-%20CDEC%20Final%20Recommendation%20November%2022%2C%202019_for%20posting.pdf; https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/sr0587-cimzia-pharmacoeconomic-review-report.pdf; https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0587%20Cimzia%20-%20Group%20Patient%20Input%20-%20June%2028%2C%202019.pdf,"Psoriasis, moderate to severe plaque",Reimburse with clinical criteria and/or conditions,Complete,"May 13, 2019","Nov 20, 2019",SR0587-000
lanadelumab,Takhzyro,lanadelumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0618-takhzyro-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0618%20Takhzyro%20-%20CDEC%20Final%20Recommendation%20November%2022%2C%202019_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0618-takhzyro-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0618%20Takhzyro%20-%20Patient%20Input%20for%20Posting.pdf,"Hereditary angioedema, prevention",Reimburse with clinical criteria and/or conditions,Complete,"May 29, 2019","Nov 19, 2019",SR0618-000
teduglutide,Revestive,teduglutide,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0606-revestive-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0606%20Revestive%20-%20CDEC%20Final%20Recommendation%20November%2021%2C%202019_For%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0606-revestive-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0606_Revestive_PI%20Submission.pdf,"Short Bowel Syndrome (SBS), pediatrics",Reimburse with clinical criteria and/or conditions,Complete,"May 29, 2019","Nov 19, 2019",SR0606-000
cyclosporine,Verkazia,cyclosporine,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0615-verkazia-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0615%20Verkazia%20-%20CDEC%20Final%20Recommendation%20December%206%2C%202019_For%20Posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0615-verkazia-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0615_Verkazia_PI%20Submission1.pdf,"Severe vernal keratoconjunctivitis, pediatric (≥4 years)",Reimburse with clinical criteria and/or conditions,Complete,"May 22, 2019","Nov 18, 2019",SR0615-000
idhifa acute myeloid leukemia,Idhifa,Enasidenib,https://www.cda-amc.ca/sites/default/files/pcodr/EnasidenibIdhifa_AML10144ProvFunding.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_ClinicianFeedback_CCO_2019-09-11_Post_31Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_Clinician_Combined_COI_Post_31Oct2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_PAGFeedbackSummary_FINAL_Post_31Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_PatientFeedback_LLSC_2019-09-26_FINAL_Post_31Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_PatientInput_LLSC_COI_Post_31Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_SponsorFeedback_2019-09-19_revised_Post_31Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_fnCGR_NOREDACT_Post_31Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_fnEGR_NOREDACT-ABBREV_Post_31Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_fnRec_ApprovedbyChair_Post_31Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10144EnasidenibAML_inRec_approvedbyChair_NOREDACT_Post_29Aug2019_final.pdf,Acute myeloid leukemia (AML),Do not reimburse,Complete,"Apr 5, 2019","Oct 31, 2019",PC0144-000
larotrectinib neurotrophic tyrosine receptor kinase ntrk locally advanced or metastatic solid,Vitrakvi,Larotrectinib,https://www.cda-amc.ca/sites/default/files/pcodr/LarotrectinibVitrakvi_NTRKLocallyAdvancedorMetastaticSolidTumours10159ProvFunding.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_Clombined%20COI_Post_31Oct2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_Combined_COI_Post_31Oct2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_Combined_ClinicianF-B_Post_31Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_PAGFeedbackSummary_FINAL_Post_31Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_PtFeedback_Combined_Post_31Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_SponsorFeedback_2019-09-19_Post_31Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_fnCGR_REDACT_Post_31Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_fnEGR_NOREDACT-ABBREV_Post_31Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_fnRec_REDACT_31Oct201_ChairApproved_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK%2BSolidTumours_inRec_2019-08-27_ChairApproval_REDACT_Post_29Aug2019_final.pdf,NTRKplus solid tumours,Do not reimburse,Complete,"Feb 25, 2019","Oct 31, 2019",PC0159-000
insulin degludec liraglutide,Xultophy,insulin degludec + liraglutide,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0599-xultophy-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0599%20Xultophy%20-%20CDEC%20Final%20Recommendation%20October%2028%2C%202019_redacted_For%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0599-xultophy-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0599-Xultopy-Patient-Input.pdf,"Diabetes mellitus, Type 2",Reimburse with clinical criteria and/or conditions,Complete,"Jan 30, 2019","Oct 24, 2019",SR0599-000
onabotulinumtoxina,Botox,onabotulinumtoxinA,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0584-botox-clinical-review-report-resubmission.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0584%20Botox%20Resubmission%20-%20CDEC%20Final%20Recommendation%20October%2022%2C%202019_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0584-botox-pharmacoeconomic-review-report-resubmission.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0584%20Botox%20Resubmission%20-%20Consolidated%20Patient%20Input_Dec%202018_Redacted.pdf,"Migraine, chronic",Reimburse with clinical criteria and/or conditions,Complete,"Nov 2, 2018","Oct 17, 2019",SR0584-000
keytruda metastatic urothelial carcinoma first line,Keytruda,Pembrolizumab,https://www.cda-amc.ca/sites/default/files/pcodr/PembrolizumabKeytruda_MUCfirstline10177ProvFunding.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10177PembrolizumabMM%28first%20line%29_InRec_REDACT_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10177PembrolizumabMUC%28firstline%29_ClinicianFeedback_CCO_2019-08-16_Post_03Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10177PembrolizumabMUC%28firstline%29_Combined%20ClinicianCOIs_Post_03Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10177PembrolizumabMUC%28firstline%29_FnRec_REDACT_Post_03Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10177PembrolizumabMUC%28firstline%29_PAGFeedbackSummary_FINAL_Post_03Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10177PembrolizumabMUC%28firstline%29_PatientFeedback_BCC_2019-08-16__Post_03Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10177PembrolizumabMUC%28firstline%29_PtGrp_COI_Post_03Oct2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10177PembrolizumabMUC%28firstline%29_SubmitterFeedback_2019-08-16_Post_03Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10177PembrolizumabMUC%28firstline%29_fnCGR_REDACT_Post_03Oct2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10177PembrolizumabMUC%28firstline%29_fnEGR_NOREDACT-ABBREV_Post_03Oct2019_final.pdf,MUC First line,Do not reimburse,Complete,"Feb 20, 2019","Oct 3, 2019",PC0177-000
dolutegravir lamivudine,Dovato,dolutegravir / lamivudine,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0601-dovato-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0601%20Dovato%20-%20CDEC%20Final%20Recommendation%20October%202%2C%202019_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0601-dovato-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sr0601-dovato-patient-input.pdf,HIV-1 infection,Reimburse with clinical criteria and/or conditions,Complete,"Feb 21, 2019","Sep 30, 2019",SR0601-000
fluocinolone acetonide intravitreal implant,Iluvien,fluocinolone acetonide intravitreal implant,https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0608%20Iluvien%20-%20CDEC%20Final%20Recommendation%20September%2030%2C%202019_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0608-Iluvien-patient-input.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sr0608-iIluvien-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sr0608-iIluvien-pharmacoeconomic-review-report.pdf,diabetic macular edema,Do not reimburse,Complete,"Apr 3, 2019","Sep 26, 2019",SR0608-000
pomalyst combination dexamethasone and bortezomib multiple myeloma second line or beyond,Pomalyst,Pomalidomide,https://www.cda-amc.ca/sites/default/files/pcodr/PomalidomidePomalystDex%26Bortez_MM2ndline10165_ProvFunding.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10165PomalidomideBortezomibMM_COI_Post_18Sep2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10165PomalidomideBortezomibMM_ClinicianFeedback_CCO_2019-09-09_Post_18Sep2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10165PomalidomideBortezomibMM_Combined%20Clinician_COI_Post_18Sep2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10165PomalidomideBortezomibMM_InRec_approvedbyChair_Post_29Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10165PomalidomideBortezomibMM_PAGFeedbackSummary_FINAL_Post_18Sep2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10165PomalidomideBortezomibMM_SubmitterFeedback_2019-09-13_Post_18Sep2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10165PomalidomideBortezomibMM_fnCGR_REDACT_EarlyConv_Post_18Sep2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10165PomalidomideBortezomibMM_fnEGR_NOREDACT-ABBREV_EarlyConv_Post_18Sep2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10165PomalidomideBortezomibMM_fnRec_EarlyConv_18Sep2019_final.pdf,Multiple Myeloma,Reimburse with clinical criteria and/or conditions,Complete,"Mar 15, 2019","Sep 18, 2019",PC0165-000
trifluridine and tipiracil lonsurf metastatic colorectal cancer resubmission,Lonsurf,Trifluridine and Tipiracil,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10173Trifluridine-TipiracilmCRC_ClinicianFeedback_Ko_2019-07-19_Post_29Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10173Trifluridine-TipiracilmCRC_Clinicians%20COIs_Post_29Aug2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10173Trifluridine-TipiracilmCRC_PAGFeedbackSummary_FINAL_2019-07-15_Post_29Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10173Trifluridine-TipiracilmCRC_Patient%20COIs_Post_29Aug2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10173Trifluridine-TipiracilmCRC_PatientFeedback_CCC_2019-07-19_Post_29Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10173Trifluridine-TipiracilmCRC_SubmitterFeedback_2019-07-19_Post_29Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10173Trifluridine-TipiracilmCRC_fnCGR_NOREDACT_Post_29Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10173Trifluridine-TipiracilmCRC_fnEGR_NOREDACT-ABBREV_Post_29Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10173Trifluridine-TipiracilmCRC_fnrec_Chair%20Approved_Post_29Aug2019_revised_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10173Trifluridine-TipiracilmCRC_inRec_Chair%20approved_NOREDACT_Post_05Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund-10173-trifluridine-tipiracil_lonsurf_mcrc.pdf,mCRC Resubmission,Do not reimburse,Complete,"Jan 21, 2019","Aug 29, 2019",PC0173-000
darzalex combo bortezomib melphalan and prednisone multiple myeloma newly diagnosed,Darzalex,Daratumumab,https://www.cda-amc.ca/sites/default/files/pcodr/DaratumumabDarzalex_NewlyDiagnosedMM10148_ProvFunding.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10148Daratumumab%2BVMPforMM_ClinicianFeedback_CCO_2019-07-15_Post_29Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10148Daratumumab%2BVMPforMM_Combined%20Clinician%20COIs_Post_28Aug2019_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10148Daratumumab%2BVMPforMM_PAGFeedbackSummary_FINAL_2019-07-16_Post_29Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10148Daratumumab%2BVMPforMM_PatientFeedback_MC_2019-07-08_Post_29Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10148Daratumumab%2BVMPforMM_PatientI_COI_Post_29Aug2019.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10148Daratumumab%2BVMPforMM_SubmitterFeedback_2019-07-19_Post_29Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10148Daratumumab%2BVMPforMM_fnCGR_REDACT_Post_29Aug2910_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10148Daratumumab%2BVMPforMM_fnEGR_NOREDACT-ABBREV_Post_29Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10148Daratumumab%2BVMPforMM_fnRec_REDACT_Post_29Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10148Daratumumab%2BVMPforMM_inRec_ApprovedbyChair_REDACT_Post_05Jul2019_final.pdf,BMP for Multiple Myeloma (newly diagnosed),Reimburse with clinical criteria and/or conditions,Complete,"Jan 4, 2019","Aug 29, 2019",PC0148-000
baricitinib,Olumiant,baricitinib,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0597-olumiant-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0597%20Olumiant%20-%20CDEC%20Final%20Recommendation_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0597-olumiant-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0597%20Olumiant%20-%20Patient%20Group%20Input_February%207%2C%202019.pdf,"Arthritis, Rheumatoid",Reimburse with clinical criteria and/or conditions,Complete,"Dec 20, 2018","Aug 2, 2019",SR0597-000
lutathera gastroenteropancreatic neuroendocrine tumors,Lutathera,Lutetium Lu 177 dotatate,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10142LutetiumLu177dotatateGEP-NET_COI_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10142LutetiumLu177dotatateGEP-NET_PAGFeedbackSummary_FINAL_Post_01Aug2019_draft.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10142LutetiumLu177dotatateGEP-NET_PatientFeedback_CNETS_2019-06-28_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10142LutetiumLu177dotatateGEP-NET_SubmitterFeedback_2019-06-14_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10142LutetiumLu177dotatateGEP-NET_fnCGR_NOREDACT_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10142LutetiumLu177dotatateGEP-NET_fnEGR_NOREDACT-ABBREV_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10142LutetiumLu177dotatateGEP-NET_fnRec_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10142LutetiumLu177dotatateGEP-NET_inRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund-10142-LutetiumLutathera_GEP_NETs.pdf,Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs),Reimburse with clinical criteria and/or conditions,Complete,"Jul 30, 2018","Aug 1, 2019",PC0142-000
brigatinib alunbrig non small cell lung cancer nsclc,Alunbrig,Brigatinib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10167BrigatinibNSCLC_Combined_ClinicianFeedback_2019-06-14_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10167BrigatinibNSCLC_Combined_Clinician_COIs_01Aug2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10167BrigatinibNSCLC_Combined_PtGrp_COIs_Post_01Aug2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10167BrigatinibNSCLC_FnRec_approvedbyChair_NOREDACT_Post_01AUG2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10167BrigatinibNSCLC_PAGFeedbackSummary_FINAL_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10167BrigatinibNSCLC_PatientFeedback_LCC_2019-06-14_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10167BrigatinibNSCLC_SubmitterFeedback_2019-06-14_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10167BrigatinibNSCLC_fnCGR_NOREDACT_POST01AUG2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10167BrigatinibNSCLC_fnEGR_NOREDACT-ABBREV_01AUG2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10167BrigatinibNSCLC_inRec_approvedbyChair_NOREDACT_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund-10167-BrigatinibAlunbrig_NSCLC.pdf,NSCLC,Do not reimburse,Complete,"Dec 5, 2018","Aug 1, 2019",PC0167-000
keytruda melanoma adjuvant treatment,Keytruda,Pembrolizumab,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10168PembolizumabMAT_PAGFeedbackSummary_FINAL_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10168PembrolizumabMAT_ClinicianFeedback_CCO_2019-06-14_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10168PembrolizumabMAT_Combined_Clinician_COIs_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10168PembrolizumabMAT_Combined_Patient_COIs_Post_01Aug2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10168PembrolizumabMAT_FnRec_31%20July%202019__Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10168PembrolizumabMAT_SubmitterFeedback_2019-06-12_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10168PembrolizumabMAT_fnCGR_REDACT_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10168PembrolizumabMAT_fnEGR_NOREDACT-ABBREV_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10168PembrolizumabMAT_inRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund-10168-PembrolizumabKeytruda_MAT.pdf,Melanoma Adjuvant Treatment,Reimburse with clinical criteria and/or conditions,Complete,"Dec 13, 2018","Aug 1, 2019",PC0168-000
patisiran,Onpattro,patisiran,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0598-onpattro-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0598%20Onpattro%20-%20CDEC%20Final%20Recommendation%20July%2029%2C%202019%20for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0598-onpattro-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0598_Onpattro-patient-input.pdf,Polyneuropathy in hereditary transthyretin-mediated amyloidosis,Reimburse with clinical criteria and/or conditions,Complete,"Jan 25, 2019","Jul 25, 2019",SR0598-000
ulipristal acetate,Fibristal,ulipristal acetate,https://www.cda-amc.ca/sites/default/files/cdr/advice/sf0609-fibristal-request-for-advice-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SF0609%20Fibristal%20RfA%20-%20CDEC%20Final%20Recommendation%20July%2030%2C%202019_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SF0609%20Fibristal%20-%20Group%20Patient%20Input%20June%2028%2C%202019.pdf,Uterine fibroids (signs and symptoms),Reimburse with clinical criteria and/or conditions,Complete,"Mar 28, 2019","Jul 24, 2019",SF0609-000
latanoprostene bunod,Vyzulta,latanoprostene bunod,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0590-vyzulta-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0590%20Vyzulta%20-%20CDEC%20Final%20Recommendation%20July%2026%2C%202019%20_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0590-vyzulta-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sr0590-vyzulta-patient-input.pdf,Open-angle glaucoma or ocular hypertension,Reimburse with clinical criteria and/or conditions,Complete,"Nov 23, 2018","Jul 24, 2019",SR0590-000
lenvima hepatocellular carcinoma,Lenvima,Lenvatinib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_Canadian%20Liver%20Foundation%20v2%202019-07-22_Post_24Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_ClinicianFeedback_BCCancer_2019-07-18_Post_24Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_Combined%20Clinician%20COIs_Post_24Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_CombinedPat_Post_24Jul2019_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_PAGFeedbackSummary_FINAL_Post_24Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_SubmitterFeedback_2019-07-19_Post_24Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_fnRec_2019-07-23_ApprovedByChair_Post_24Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_inCGR_NOREDACT_EarlyConv_Post_24Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_inEGR_NOREDACT-ABBREV_EarlyCon_Post_24Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10175LenvatinibHCC_inRec_ApprovedByChair_NOREDACT_Post_05Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-profund-10175-LenvatinibLenvima_HCC.pdf,Hepatocellular Carcinoma (HCC),Reimburse with clinical criteria and/or conditions,Complete,"Feb 8, 2019","Jul 24, 2019",PC0175-000
ninlaro multiple myeloma 2nd beyond,Ninlaro,Ixazomib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10164IxazomibMM_ClinicianFeedback_CCO_2019-05-16_Post_05Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10164IxazomibMM_Combined%20COIs_Post_05Jul2019_final%20Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10164IxazomibMM_PAGFeedbackSummary_FINAL_Post_5Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10164IxazomibMM_PatientFeedback_MC_2019-05-15_Post_05Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10164IxazomibMM_Patient_COI_MC_2018-12-13_Post_05Jul2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10164IxazomibMM_SubmitterFeedback_2019-05-17_Post_05Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10164IxazomibMM_fnCGR_REDACT_Post_05Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10164IxazomibMM_fnEGR_NOREDACT-ABBREV_Post_05Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10164IxazomibMM_fnRec_2019-07-05_ChairApproved_Post_05Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10164IxazomibMM_inRec_2019-05-03_Approved_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund-10164-ixazomib-ninlaro_mm2nd-beyond.pdf,Multiple Myeloma (2nd-beyond),Do not reimburse,Complete,"Nov 30, 2018","Jul 5, 2019",PC0164-000
abemaciclib advanced or metastatic breast cancer,Verzenio,Abemaciclib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10161AbemaciclibMBC_ClinicianFeedback_CCO_2019-05-16_Post_05Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10161AbemaciclibMBC_Combined%20COIs_Post_05Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10161AbemaciclibMBC_Combined%20Patient%20COIs_%20Post_05Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10161AbemaciclibMBC_Combined%20PatientFeedback_Post_05Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10161AbemaciclibMBC_PAGFeedbackSummary_FINAL_Post_05Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10161AbemaciclibMBC_SubmitterFeedback_2019-05-17_Post_05Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10161AbemaciclibMBC_fnCGR_NOREDACT_Post_05Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10161AbemaciclibMBC_fnEGR_NOREDACT-ABBREV_Post_05Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10161AbemaciclibMBC_fnRec_ApprovedbyChair_v01_2019-07-04_Post_05Jul2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10161AbemaciclibMBC_inRec_ApprovedbyChair_v01_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund-10161-AbemaciclibVerzenio_ABC.pdf,Metastatic Breast Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Dec 3, 2018","Jul 5, 2019",PC0161-000
telotristat,Xermelo,telotristat,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0580-xermelo-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0580%20Xermelo%20-%20CDEC%20Final%20Recommendation%20July%203%2C%202019_For%20Posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0580-xermelo-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0580_telotristat_PI%20Submission.pdf,carcinoid syndrome,Do not reimburse,Complete,"Sep 27, 2018","Jun 26, 2019",SR0580-000
buprenorphine,Sublocade,buprenorphine,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0579-sublocade-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0579%20Sublocade%20-%20CDEC%20Final%20Recommendation%20June%2021%2C%202019_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0579-sublocade-pharmacoeconomic-review-report.pdf,"Opioid use disorder, treatment",Reimburse with clinical criteria and/or conditions,Complete,"Dec 20, 2018","Jun 19, 2019",SR0579-000
revlimid combo bortezomib dexamethasone newly diagnosed multiple myeloma,Revlimid,Lenalidomide,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10141LenalidomideBorDexMM_ClinicianFeedback_CCO_2019-06-14__EC-Post_19Jun2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10141LenalidomideBorDexMM_Clinician_Combined_COIs_Post_19Jun2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10141LenalidomideBorDexMM_PAGFeedbackSummary_FINAL__EC-Post_19Jun2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10141LenalidomideBorDexMM_PatientCOI_MC_2019-01-11_EC-Post_19Jun2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10141LenalidomideBorDexMM_SubmitterFeedback_2019-06-14_EC-Post_19Jun2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10141LenalidomideBorDexMM_fnCGR_REDACT_EC-Post_19Jun2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10141LenalidomideBorDexMM_fnEGR_NOREDACT-ABBREV_EC-Post_19Jun2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10141LenalidomideBorDexMM_fnRec_2019-06-19_ApprovedbyChair_EC-Post_19Jun2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10141LenalidomideBorDexMM_inRec_approvedbyChair_NOREDACT_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund-10141-LenalidomideRevlimid_MM.pdf,Multiple Myeloma (+bortezomib+dex),Reimburse with clinical criteria and/or conditions,Complete,"Dec 21, 2018","Jun 19, 2019",PC0141-000
cysteamine,Cystadrops,cysteamine,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0595-cystadrops-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0595%20Cystadrops%20-%20CDEC%20Final%20Recommendation%20June%2020%2C%202019_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0595-cystadrops-pharmacoeconomic-review-report.pdf,Corneal cystine crystal deposits,Reimburse with clinical criteria and/or conditions,Complete,"Dec 10, 2018","Jun 18, 2019",SR0595-000
keytruda non squamous nsclc,Keytruda,Pembrolizumab,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10153PembroNSQ-NSCLC_ClinicianFeedback_CCO_2019-04-18_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10153PembroNSQ-NSCLC_Clinician_Combined%20COIs_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10153PembroNSQ-NSCLC_FnRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10153PembroNSQ-NSCLC_InRec_POST04Apr2019_NOREDACT_corrected.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10153PembroNSQ-NSCLC_PAGFeedbackSummary_FINAL_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10153PembroNSQ-NSCLC_Patient_Combined%20COIs_ForPosting_31May2019.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10153PembroNSQ-NSCLC_SubmitterFeedback_2019-04-18_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10153PembroNSQ-NSCLC_fnCGR_REDACT_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10153PembroNSQ-NSCLC_fnEGR_NOREDACT-ABBREV_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund-10153-pembrolizumab-keytruda-non-squamous_nsclc.pdf,Nonsquamous NSCLC,Reimburse with clinical criteria and/or conditions,Complete,"Sep 14, 2018","May 31, 2019",PC0153-000
venclexta combo rituximab chronic lymphocytic leukemia,Venclexta in combo Rituximab,Venetoclax,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10162VenetoclaxRituximabCLL_ClinicianFeedback_CCO_2019-04-18_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10162VenetoclaxRituximabCLL_Clinician_Combined_COIs_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10162VenetoclaxRituximabCLL_FnRec_approvedbyChair_REDACT_Post_31May2019-final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10162VenetoclaxRituximabCLL_InRec_POST04Apr2019_REDACT_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10162VenetoclaxRituximabCLL_PAGFeedbackSummary_FINAL_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10162VenetoclaxRituximabCLL_PatientFeedback_LC_CLLPAG_2019-04-17_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10162VenetoclaxRituximabCLL_Patient_Combined_COIs_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10162VenetoclaxRituximabCLL_SubmitterFeedback_2019-04-18_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10162VenetoclaxRituximabCLL_fnCGR_REDACT_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10162VenetoclaxRituximabCLL_fnEGR_NOREDACT-ABBREV_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_10162_venetoclax_venclexta_and_rituximab.pdf,Chronic Lymphocytic Leukemia (CLL),Reimburse with clinical criteria and/or conditions,Complete,"Oct 24, 2018","May 31, 2019",PC0162-000
vizimpro non small cell lung cancer,Vizimpro,Dacomitinib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10129DacomitinibNSCLC_ClinicianFeedback_CCO_2019-04-18_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10129DacomitinibNSCLC_Clinician_Combined_COIs_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10129DacomitinibNSCLC_FnRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10129DacomitinibNSCLC_InRec_POST04Apr2019_NOREDACT_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10129DacomitinibNSCLC_PAGFeedbackSummary_FINAL_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10129DacomitinibNSCLC_Patient_Combined_COIs_ForPosting_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10129DacomitinibNSCLC_SubmitterFeedback_2019-04-18_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10129DacomitinibNSCLC_fnCGR_NOREDACT_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10129DacomitinibNSCLC_fnEGR_NOREDACT-ABBREV_Post_31May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund-10129-dacomitinib-vizimpro.pdf,Non-Small Cell Lung Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Sep 19, 2018","May 31, 2019",PC0129-000
risankizumab,Skyrizi,risankizumab,https://www.cda-amc.ca/sites/default/files/attachments/2023-11/TS0001-PsO-Updated-Streamlined-Rec.pdf; https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0583-skyrizi-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0583%20Skyrizi%20-%20CDEC%20Final%20Recommendation%20May%2028%2C%202019_For%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0583-skyrizi-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sr0583-risankizumab-patient-input.pdf,"Psoriasis, moderate to severe plaque",Reimburse with clinical criteria and/or conditions,Complete,"Oct 22, 2018","May 28, 2019",SR0583-000
cerliponase alfa,Brineura,cerliponase alfa,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0574-brineura-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0574%20Brineura%20-%20Final%20CDEC%20Recommendation%20May%2027%2C%202019_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0574-brineura-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sr0574-brineura-patient-input.pdf,Neuronal Ceroid Lipofuscinosis Type 2,Reimburse with clinical criteria and/or conditions,Complete,"Jul 31, 2018","May 23, 2019",SR0574-000
efinaconazole,Jublia,efinaconazole,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0577-jublia-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0577%20Jublia%20-%20%20CDEC%20Final%20Recommendation%20May%2027%2C%202019_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0577-jublia-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sr0577-jublia_patient-input.pdf,Onychomycosis,Do not reimburse,Complete,"Aug 2, 2018","May 23, 2019",SR0577-000
xalkori ros1 positive advanced non small cell lung cancer,Xalkori,Crizotinib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10151CrizotinibNSCLC_ClinicianFeedback_LCC_2019-05-17_Post_23May2019_final_cleaned.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10151CrizotinibNSCLC_Combined_COI_Post_23May2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10151CrizotinibNSCLC_Combined_COIs_Post_23May2019.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10151CrizotinibNSCLC_PAGFeedbackSummary_Post_23May2019_final_cleaned.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10151CrizotinibNSCLC_PatientFeedback_LCC_2019-05-17_Post_23May2019_final_cleaned.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10151CrizotinibNSCLC_SubmitterFeedback_2019-05-17_Post_23May2019_final_cleaned.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10151CrizotinibNSCLC_fnCGR_EC_NOREDACT_Post_23May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10151CrizotinibNSCLC_fnEGR_EC_NOREDACT-ABBREV_Post_23May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10151CrizotinibNSCLC_fnRec_EC_approvedbyChair_Post_23May2019_final_cleaned.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10151CrizotinibNSCLC_inRec_03May2019_approvedbyChair_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund-10151-crizotinib-xalkori-ROS-positive.pdf,ROS1-positive advanced non-small cell lung cancer (NSCLC),Reimburse with clinical criteria and/or conditions,Complete,"Oct 30, 2018","May 23, 2019",PC0151-000
semaglutide,Ozempic,semaglutide,https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf; https://www.cadth.ca/sites/default/files/cdr/clinical/sr0594-ozempic-clinical-review-report.pdf; https://www.cadth.ca/sites/default/files/cdr/complete/SR0594%20Ozempic%20-%20CDEC%20Final%20Recommendation%20May%2017%2C%202019%20%28redacted%29_For%20posting.pdf; https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/sr0594-ozempic-pharmacoeconomic-review-report.pdf; https://www.cadth.ca/sites/default/files/cdr/relatedinfo/sr0594-ozempic-patient-input.pdf,"Diabetes mellitus, type 2",Reimburse with clinical criteria and/or conditions,Complete,"Nov 23, 2018","May 15, 2019",SR0594-000
isavuconazole,Cresemba,isavuconazole,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0586-cresemba-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0586%20Cresemba%20-%20CDEC%20Final%20Recommendation%20May%2017%2C%202019_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0586-cresemba-pharmacoeconomic-review-report.pdf,Treatment of invasive aspergillosis and mucormycosis,Reimburse with clinical criteria and/or conditions,Complete,"Nov 2, 2018","May 15, 2019",SR0586-000
doravirine lamuvidine tenofovir disoproxil fumarate,Delstrigo,doravirine lamuvidine tenofovir disoproxil fumarate,https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0581%20Delstrigo%20-%20CDEC%20Final%20Recommendation%20May%2016%2C%202019%20for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0581%20Delstrigo%20-%20Patient%20Input%20for%20Posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sr0581-delstrigo-cdr-new-combination-report.pdf,HIV-1 infection,Reimburse with clinical criteria and/or conditions,Complete,"Nov 16, 2018","May 14, 2019",SR0581-000
doravirine,Pifeltro,doravirine,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0582-pifeltro-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0582%20Pifeltro%20-%20CDEC%20Final%20Recommendation%20May%2016%2C%202019%20for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0582-pifeltro-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sr0582-pifeltro-patient-input.pdf,HIV-1 infection,Reimburse with clinical criteria and/or conditions,Complete,"Nov 16, 2018","May 14, 2019",SR0582-000
tafinlar mekinist combo melanoma adjuvant therapy,Tafinlar & Mekinist in combo,Dabrafenib & Trametinib in combo,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10152%20Dabrafenib-Trametinib%20MAT_inRec_Approved%20by%20Chair_REDACT_Post_07Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10152DabrafenibTrametinibMAT_ClinicianCOI_Combined_Post_03May2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10152DabrafenibTrametinibMAT_ClinicianFeedback_CCO_2019-03-14_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10152DabrafenibTrametinibMAT_Final%20Recc_Approved%20by%20Chair_2May2019_REDACT_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10152DabrafenibTrametinibMAT_PAGFeedbackSummary_FINAL_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10152DabrafenibTrametinibMAT_PatientCOI_Combined_Post_03May2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10152DabrafenibTrametinibMAT_SubmitterFeedback_2019-03-12_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10152DabrafenibTrametinibMAT_fnCGR_REDACT_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10152DabrafenibTrametinibMAT_fnEGR_NOREDACT-ABBREV_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_10152_dabrafenib_trametinib_and_tafinlar_mekinist.pdf,Melanoma Adjuvant Therapy,Reimburse with clinical criteria and/or conditions,Complete,"Sep 21, 2018","May 3, 2019",PC0152-000
imfinzi non small cell lung cancer,Imfinzi,Durvalumab,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10131DurvalumabNSCLC_ClinicianFeedback_CCO_2019-03-21_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10131DurvalumabNSCLC_Combined_ClinicianCOI_Post_03May2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10131DurvalumabNSCLC_Combined_PatientCOI_2018-10-05_Post_03May2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10131DurvalumabNSCLC_PAGFeedbackSummary_FINAL_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10131DurvalumabNSCLC_SubmitterFeedback_2019-03-21_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10131DurvalumabNSCLC_fnCGR_NOREDACT_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10131DurvalumabNSCLC_fnEGR_NOREDACT-ABBREV_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10131DurvalumabNSCLC_fnRec_02May2019_approvedbyChair_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10131DurvalumabNSCLC_inRec_approvedbyChair_06Mar2019_Post_07Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_durvalumabImfinzi_nsclc.pdf,Unresectable Non-Small Cell Lung Cancer (NSCLC),Reimburse with clinical criteria and/or conditions,Complete,"Sep 21, 2018","May 3, 2019",PC0131-000
ibrance faslodex advanced or metastatic breast cancer,Ibrance (with Faslodex),Palbociclib (with Fulvestrant),https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10150%20PalbociclibFulvestrantMBC_fnRec_2019-05-03_Approved_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10150PalbociclibFulvestrantMBC_ClinicianFeedback_CCO_2019-03-22_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10150PalbociclibFulvestrantMBC_Combined_ClinicianICOI_Post_03May2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10150PalbociclibFulvestrantMBC_Combined_PatientCOI_RBC_Posting_03May2019_Redacted_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10150PalbociclibFulvestrantMBC_PAGFeedbackSummary_FINAL_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10150PalbociclibFulvestrantMBC_SubmitterFeedback_2019-03-21_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10150PalbociclibFulvestrantMBC_fnCGR_NOREDACT_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10150PalbociclibFulvestrantMBC_fnEGR_NOREDACT-ABBREV_Post_03May2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10150PalbociclibFulvestrantMBC_inRec_2019-03-06_ChairApproved_NOREDACT_Post_07Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund-10150-ibrance-faslodex-mbc.pdf,"Palbociclib (Ibrance) in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer",Reimburse with clinical criteria and/or conditions,Complete,"Sep 28, 2018","May 3, 2019",PC0150-000
blincyto philadelphia chromosome positive b cell precursor acute lymphoblastic leukemia,Blincyto,Blinatumomab,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10146BlinatumomabPh%2BALL_ClinicianFeedback_CCO_2019-02-14_Post_04Apr2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10146BlinatumomabPh%2BALL_ClinicianInputCOI_Combined_04Apr2019_post_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10146BlinatumomabPh%2BALL_FnCGR_04April2019_REDACT_POST_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10146BlinatumomabPh%2BALL_FnRec_04Apr2019_REDACT_post_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10146BlinatumomabPh%2BALL_PatientGroupCOI_LLSC_2018-09-14_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10146BlinatumomabPh%2BALL_SubmitterFeedback_2019-02-19_Post_04Apr2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10146BlinatumomabPh%2BALL_fnEGR_NOREDACT-ABBREV_POST04Apr2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10146Blinatumomab_Ph%2BALL_PAGFeedbackSummary_FINAL_Post_04Apr2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10146_BlinatumomabPh%2BALL_InRec_AprovedbyChair_REDACT_31Jan2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profung_10146_blinatumomab_blincyto-all.pdf,Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL),Reimburse with clinical criteria and/or conditions,Complete,"Aug 31, 2018","Apr 4, 2019",PC0146-000
folotyn peripheral t cell lymphoma,Folotyn,Pralatrexate,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10138PralatrexatePTCL_ClinicianCOI_Combined_Post_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10138PralatrexatePTCL_ClinicianFeedback_CCO_2019-02-14_Post_04Apr2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10138PralatrexatePTCL_InRec_31Jan2019_approvedbyChair_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10138PralatrexatePTCL_PatientCOI_LC_2018-06-15_Post_04Apr2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10138PralatrexatePTCL_PatientFeedback_LC_2019-02-14_Post_04Apr2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10138PralatrexatePTCL_SubmitterFeedback_2019-02-14_Post_04Apr2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10138PralatrexatePTCL_fnCGR_NOREDACT_POST04Apr2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10138PralatrexatePTCL_fnEGR_NOREDACT-ABBREV_POST04Apr2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10138PralatrexatePTCL_fnRec__04Apr2019_NOREDACT_post_final2.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10138Pralatrexate_PTCL_PAGFeedbackSummary_FINAL_Post_04Apr2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_10138_pralatrexate_folotyn.pdf,Peripheral T-Cell Lymphoma (PTCL),Reimburse with clinical criteria and/or conditions,Complete,"Jun 1, 2018","Apr 4, 2019",PC0138-000
reslizumab,Cinqair,reslizumab,https://www.cda-amc.ca/sites/default/files/cdr/advice/sf0591-cinqair-request-for-advice.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/sf0591-cinqair-cdec-rec-march-29-19.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sf0591-cinqair-patient-input.pdf,"Asthma, eosinophilic",Reimburse with clinical criteria and/or conditions,Complete,"Oct 24, 2018","Mar 27, 2019",SF0591-000
benralizumab,Fasenra,benralizumab,https://www.cda-amc.ca/sites/default/files/cdr/advice/sf0592-fasenra-request-for-advice.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/sf0592-fasenra-cdec-rec-march-29-19.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sf0592-fasenra-patient-input.pdf,"Asthma, severe eosinophilic",Reimburse with clinical criteria and/or conditions,Complete,"Oct 24, 2018","Mar 27, 2019",SF0592-000
mepolizumab,Nucala,mepolizumab,https://www.cda-amc.ca/sites/default/files/cdr/advice/sf0593-nucala-request-for-advice.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/sf0593-nucala-cdec-rec-march-29-19.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sf0593-nucala-patient-input.pdf,"Asthma, severe eosinophilic",Reimburse with clinical criteria and/or conditions,Complete,"Oct 24, 2018","Mar 27, 2019",SF0593-000
crisaborole,Eucrisa,crisaborole,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0570-eucrisa-clinical-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0570-Eucrisa-cdec-rec-april-2-2019.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0570-eucrisa-pharmacoeconomic-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0570-eucrisa-patient-input.pdf,atopic dermatitis,Do not reimburse,Complete,"May 25, 2018","Mar 27, 2019",SR0570-000
edaravone,Radicava,edaravone,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0573-radicava-clinical-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/sr0573-radicava-cdec-rec-march-29-2019.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0573-radicava-pharmacoeconomic-review-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sr0573_radicava-patient-input.pdf,amyotrophic lateral sclerosis,Reimburse with clinical criteria and/or conditions,Complete,"Jul 5, 2018","Mar 27, 2019",SR0573-000
xtandi non metastatic castration resistant prostate cancer,Xtandi,Enzalutamide,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10149Enzalutamide-CRPC_COI_CCSN_Post_26Mar2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10149Enzalutamide_nmCRPC_PAGFeedbackSummary_FINAL_Post_26Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10149Enzalutamidenm-CRPC_ClinicianFeedback_CCO_2019-03-21_Post_26Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10149Enzalutamidenm-CRPC_FnRec_EarlyConv_2019-03-26-v4_Post_26Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10149Enzalutamidenm-CRPC_InRec_approvedbyChair_NOREDACT_Post_07Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10149Enzalutamidenm-CRPC_SubmitterFeedback_2019-03-21_Post_26Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10149Enzalutamidenm-CRPC_fnCGR_EC_Post_26Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10149Enzalutamidenm-CRPC_fnEGR_EC_NOREDACT-ABBREV_Post_26Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10149EnzalutamidenmCRPC_Combined_Clinician_COI_Post_26Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_enzalutamide_xtandi_non-mcrpc_10149.pdf,Non-metastatic castration-resistant prostate cancer (nm-CRPC),Reimburse with clinical criteria and/or conditions,Complete,"Sep 24, 2018","Mar 26, 2019",PC0149-000
unituxin neuroblastoma,Unituxin,Dinutuximab,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10154DinutuximabNeuroblastoma_ClinicianFeedback_POGO_2019-03-21_Post_26Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10154DinutuximabNeuroblastoma_fnCGR_ECPost_26Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10154DinutuximabNeuroblastoma_fnEGR_NOREDACT-ABBREV_Post_26Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10154DinutuximabNeuroblastoma_fnRec_EC_ApprovedbyChair_2019-03-26_Post_26Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10154DinutuximabNeuroblastoma_inRec_approvedbyChair_05Mar2019_Post_07Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10154Dinutuximab_NeuroblastomaCombined_Clinician%20COI_Post_26Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10154Dinutuximab_Neuroblastoma_COI_Ac2orn_2018-10-15_Post_26Mar2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10154Dinutuximab_Neuroblastoma_PAGFeedback_FINAL_Post_26Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund-10154-dinutuximab-unituxin-neuroblastoma.pdf,Neuroblastoma,Reimburse with clinical criteria and/or conditions,Complete,"Oct 1, 2018","Mar 26, 2019",PC0154-000
opdivo melanoma adjuvant therapy,Opdivo,Nivolumab,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10147NivolumabMAT_ClinicianFeedback_CCO_2019-01-16_Post_07Mar2019_Final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10147NivolumabMAT_Clinician_Combined_COI_Post_07Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10147NivolumabMAT_FnEGR_NOREDACT-ABBREV_POST07Mar2019_Final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10147NivolumabMAT_PatientFeedback_MNC_2019-01-17_Post_07Mar2019_Final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10147NivolumabMAT_Patient_Combined_COIs_Post_07Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10147NivolumabMAT_SubmitterFeedback_2019-01-16_Post_07Mar2019_Final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10147NivolumabMelanoma%28Adjuvant%29_FnRec_ChairApproved_Post_07Mar2019_Final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10147NivolumabMelanoma%28Adjuvant%29_fnCGR_NOREDACT_POST07Mar2019_Final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10147NivolumabMelanoma%28Adjuvant%29_inRec_2019-01-03_ChairApproved_Post_04Jan2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10147_Nivolumab_MAT_PAGFeedbackSummary_FINAL_Post_07Mar2019_Final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_10147_nivolumab_opdivo.pdf,Melanoma Adjuvant Therapy,Reimburse with clinical criteria and/or conditions,Complete,"Aug 27, 2018","Mar 7, 2019",PC0147-000
adcetris hodgkin lymphoma resubmission,Adcetris (Resubmission),Brentuximab Vedotin,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10145BrentuximabHLResubmission_PAGFeedbackSummary_FINAL_post_07Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10145BrentuximabHL_ClinicianInputCOI_Combined_2018-09-10_ForPosting_REDACTED_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10145BrentuximabHL_Combined-ClinicianFeedback_Post_07Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10145BrentuximabHL_FnEGR_NOREDACT-ABBREV_Post_07Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10145BrentuximabHL_FnRec_approvedbyChair_Post_07Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10145BrentuximabHL_InRec_approvedbyChair_Post_04Jan2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10145BrentuximabHL_PatientGroupFeedback_LC_2019-01-18_Post_07Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10145BrentuximabHL_PatientInputCOI_LC_REVISED2018102_Post_07Mar2019_REDACTED_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10145BrentuximabHL_SubmitterFeedback_2019-01-18_Post_07Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10145BrentuximabHL_fnCGR_NOREDACT_Post_07Mar2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_10145_brentuximab_adcetris_hl_resub.pdf,Hodgkin lymphoma (HL),Do not reimburse,Complete,"Aug 27, 2018","Mar 7, 2019",PC0145-000
tofacitinib,Xeljanz,tofacitinib,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0572-xeljanz-clinical-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0572-Xeljanz_UC-Mar-1-19.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0572-xeljanz-pharmacoeconomic-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sr0572-xeljanz-patient-input.pdf,Ulcerative colitis,Reimburse with clinical criteria and/or conditions,Complete,"Jun 27, 2018","Feb 27, 2019",SR0572-000
nusinersen,Spinraza,Nusinersen,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0576-spinraza-resubmission-clinical-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0576-Spinraza-Resubmission-Mar-1-19.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0576-spinraza-resubmission-pharmacoeconomic-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sr0576-spinraza-patient-input.pdf,Spinal Muscular Atrophy,Reimburse with clinical criteria and/or conditions,Complete,"Jul 24, 2018","Feb 27, 2019",SR0576-000
cabometyx renal cell carcinoma resubmission,Cabometyx,Cabozantinib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10163CabozantinibRCCResub_COI_KCC_2017-10-23_Post_20Feb2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10163CabozantinibRCCResub_ClinicianFeedback_CCO_2019-02-11_Post_20Feb2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10163CabozantinibRCCResub_Clinician_Combined%20COI_Post_20Feb2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10163CabozantinibRCCResub_FnRec_2019-02-20_ApprovedByChair_Post_20Feb2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10163CabozantinibRCCResub_PAGFeedbackSummary_FINAL_2019-02-08_Post_20Feb2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10163CabozantinibRCCResub_SubmitterFeedback_2019-02-14_Post_20Feb2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10163CabozantinibRCCResub_fnCGR_EC_NOREDACT_Post_21Feb2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10163CabozantinibRCCResub_fnEGR_EC_NOREDACT-ABBREV_Post_20Feb2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10163CabozantinibResubmissionRCC_inRec_2019-01-30_v10_ChairApproved_Post_31Jan2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_10163_cabozantinib_cabometix.pdf,Renal Cell Carcinoma (RCC),Reimburse with clinical criteria and/or conditions,Complete,"Sep 17, 2018","Feb 20, 2019",PC0163-000
ertugliflozin,Steglatro,ertugliflozin,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0565-steglatro-clinical-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0565%20Steglatro%20-%20CDEC%20Final%20Recommendation%20January%2025%2C%202019%20for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0565-steglatro-pharmacoeconomic-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sr0565-steglatro-patient-input.pdf,"Diabetes mellitus, Type 2",Do not reimburse,Complete,"Apr 30, 2018","Jan 23, 2019",SR0565-000
ertugliflozin and metformin,Segluromet,ertugliflozin and metformin hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0566%20Segluromet%20-%20CDEC%20Final%20Recommendation%20January%2025%2C%202019%20for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sr0566-segluromet-combined-report.pdf,"Diabetes mellitus, Type 2",Do not reimburse,Complete,"Apr 30, 2018","Jan 23, 2019",SR0566-000
lenvima renal cell carcinoma,Lenvima,Lenvatinib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10140LenvatinibRCC_COI_KCC_2018-06-22_Post_04Jan2019_draft_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10140LenvatinibRCC_ClinicianFeedback_Combined_Post_04Jan2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10140LenvatinibRCC_Combined_Clinician%20COIs_Post_04Jan2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10140LenvatinibRCC_FnRec_approvedbyChair_Post_04Jan2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10140LenvatinibRCC_PatientGroupFeedback_KCC_2018-11-15_Post_04Jan2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10140LenvatinibRCC_SubmitterFeedback_2018-11-29_updated_Post_04Jan2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10140LenvatinibRCC_fnCGR_REDACT_Post_04Jan2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10140LenvatinibRCC_fnEGR_NOREDACT-ABBREV_Post_04Jan2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10140_Lenvatinib_RCC_PAGFeedbackSummary_FINAL_Post_04Jan2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_rcc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_lenvatinib_lenvima_rcc_10140.pdf,Renal Cell Carcinoma (RCC),Do not reimburse,Complete,"Jun 8, 2018","Jan 4, 2019",PC0140 -000
tagrisso non small cell lung cancer first line,Tagrisso,Osimertinib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10137OsimertinibNSCLC%28firstline%29_ClinicianFeedback_Combined_Post_04Jan2019_Redacted_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10137OsimertinibNSCLC%28firstline%29_PatientGroupFeedback_LCC_2018-11-15_Post_04Jan2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10137OsimertinibNSCLC%28firstline%29_SubmitterFeedback_2018-11-15_Post_04Jan2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10137OsimertinibNSCLC_COI%20Combined_Post_04Jan2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10137OsimertinibNSCLC_COI_LCC_2018-05-31_Post_04Jan2019_final_Redacted.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10137OsimertinibNSCLC_FnRec_2019-01-02_ChairApproved_Post_04Jan2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10137OsimertinibNSCLC_fnCGR_NOREDACT_Post_04Jan2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10137OsimertinibNSCLC_fnEGR_NOREDACT-ABBREV_Post_04Jan2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10137_Osimertinib_NSCLC_1L_PAGFeedbackSummary_FINAL_Post_04Jan2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_1stln_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_osimertinib_tagrisso_nsclc_1ln.pdf,Non-Small Cell Lung Cancer (NSCLC) (first line),Reimburse with clinical criteria and/or conditions,Complete,"May 16, 2018","Jan 4, 2019",PC0137-000
sucroferric oxyhydroxide,Velphoro,sucroferric oxyhydroxide,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0571-velphoro-clinical-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0571%20Velphoro%20-%20CDEC%20%20Final%20Recommendation%20January%204%2C%202019%20for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0571-velphoro-pharmacoeconomic-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sr0571-velphoro-patient-input.pdf,"Hyperphosphatemia, end-stage renal disease",Reimburse with clinical criteria and/or conditions,Complete,"Jun 12, 2018","Jan 2, 2019",SR0571-000
lixisenatide insulin glargine,Soliqua,lixisenatide + insulin glargine,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0564-soliqua-clinical-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0564%20Soliqua%20-%20CDEC%20Final%20%20Recommendation%20January%203%2C%202019%20for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0564-soliqua-pharmacoeconomic-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sr0564-soliqua-patient-input.pdf,"Diabetes mellitus, Type 2",Reimburse with clinical criteria and/or conditions,Complete,"May 18, 2018","Dec 24, 2018",SR0564-000
fluticasone propionate,Aermony RespiClick,fluticasone propionate,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0539-aermony-respiclick-clinical-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0539%20Aermony%20RespiClick%20-%20CDEC%20Final%20Recommendation%20for%20posting%20December%2021%2C%202018.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0539-aermony-respiclick-pe-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sr0539-aermony-respiclick-PI-submissions.pdf,Asthma,Reimburse with clinical criteria and/or conditions,Complete,"Oct 4, 2017","Dec 19, 2018",SR0539-000
fluticasone propionate salmeterol xinafoate,Arbesda RespiClick,fluticasone propionate / salmeterol xinafoate,https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0540%20Arbesda%20RespiClick%20-%20CDEC%20Final%20Recommendation%20for%20Posting%20December%2021%2C%202018.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/sr0540-arbesda-respiclick_combined-report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/sr0540_arbesda-respiclick_PI_submissions.pdf,Asthma,Reimburse with clinical criteria and/or conditions,Complete,"Oct 4, 2017","Dec 19, 2018",SR0540-000
opdivo hepatocellular carcinoma,Opdivo,Nivolumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_hcc_bmsc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_hcc_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_hcc_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_hcc_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_hcc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_hcc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_hcc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_hcc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_hcc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_nivolumab_opdivo_hcc.pdf,Metastatic Hepatocellular Carcinoma (HCC),Do not reimburse,Complete,"May 8, 2018","Nov 29, 2018",PC0134-000
perjeta herceptin combo pack early breast cancer,Perjeta-Herceptin Combo Pack,Pertuzumab-Trastuzumab Combo Pack,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_hlr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pertuzumab-trastuzumab_perjeta-herceptin-combo_ebc_ptfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_10127perjeta-herceptin-combo_ebc.pdf,Early Breast Cancer,Do not reimburse,Complete,"Apr 9, 2018","Nov 29, 2018",PC0127-000
rivaroxaban,Xarelto,Rivaroxaban,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0569_Xarelto_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0569%20Xarelto%20-%20Confidential%20Final%20CDEC%20Recommendation%20%28redacted%29_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0569_Xarelto_PE_Report.pdf,Prevention of stroke and cardiovascular events in coronary and peripheral artery disease.,Reimburse with clinical criteria and/or conditions,Complete,"May 24, 2018","Nov 20, 2018",SR0569-000
opdivo combo yervoy renal cell carcinoma,Opdivo in combination with Yervoy,Nivolumab in combination with Ipilimumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_opdivo_yervoy_rcc_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_opdivo_yervoy_rcc_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_opdivo_yervoy_rcc_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_opdivo_yervoy_rcc_fdk_bms.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_opdivo_yervoy_rcc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_opdivo_yervoy_rcc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_opdivo_yervoy_rcc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_opdivo_yervoy_rcc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_opdivo_yervoy_rcc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_10132opdivo-yervoy_rcc.pdf,Advanced or Metastatic Renal Cell Carcinoma (RCC).,Reimburse with clinical criteria and/or conditions,Complete,"Apr 26, 2018","Nov 1, 2018",PC0132-000
gazyva follicular lymphoma previously untreated,Gazyva,Obinutuzumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_preun_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_preun_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_preun_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_preun_fdk_hlr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_preun_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_preun_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_preun_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_preun_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_preun_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_10126obinutuzumab_gazyva_fl_preun.pdf,Follicular Lymphoma (previously untreated),Do not reimburse,Complete,"Mar 15, 2018","Nov 1, 2018",PC0126-000
erleada castrate resistant prostate cancer,Erleada,Apalutamide,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_fdk_janssen.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_apalutamide_erleada_crpc_ptfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_apalutamide_erleada_nm-cprc.pdf,non-metastatic castrate resistant prostate cancer (nm-CRPC),Reimburse with clinical criteria and/or conditions,Complete,"Apr 16, 2018","Nov 1, 2018",PC0133-000
bictegraviremtricitabinetenofovir alafenamide,Biktarvy,bictegravir/emtricitabine/tenofovir alafenamide,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0567_Biktarvy_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0567%20Biktarvy%20-%20CDEC%20Final%20Recommendation%20October%2029%2C%202018.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0567_Biktarvy_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0567_Biktarvy_PI_Submissions.pdf,HIV-1 infection,Reimburse with clinical criteria and/or conditions,Complete,"Apr 30, 2018","Oct 25, 2018",SR0567-000
cladribine,Mavenclad,cladribine,https://www.cda-amc.ca/sites/default/files/attachments/2025-03/TS0004-Cladribine-Natalizumab_Updated_Recommendations.pdf; https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0546_Mavenclad_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0546-Mavenclad_Oct-26-18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0546_Mavenclad_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0546_Mavenclad_PI_Submissions.pdf,"Multiple Sclerosis, relapsing-remitting",Reimburse with clinical criteria and/or conditions,Complete,"Dec 1, 2017","Oct 24, 2018",SR0546-000
ozenoxacin,Ozanex,ozenoxacin,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0553_Ozanex_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0553_Ozanex_Oct-26-18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0553_Ozanex_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0553_Ozanex_PI_Submissions.pdf,Impetigo,Do not reimburse,Complete,"Jan 25, 2018","Oct 24, 2018",SR0553-000
dexamethasone,Ozurdex,dexamethasone,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0535_Ozurdex%20_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0535_Ozurdex_Oct-26-18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0535_Ozurdex_PE_Report%20.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0535_Ozurdex_PI_Submissions.pdf,Diabetic macular edema,Do not reimburse,Complete,"Sep 26, 2017","Oct 24, 2018",SR0535-000
tapentadol hydrochloride,Nucynta,tapentadol hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0563_Nucynta_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0563_Nucynta%20-%20CDEC%20Final%20Recommendation%20October%2025%2C%202018.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0563_Nucynta_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0563_Nucynta_PI_Submissions.pdf,"pain, severe",Do not reimburse,Complete,"Apr 17, 2018","Oct 23, 2018",SR0563-000
sebelipase alfa,Kanuma,sebelipase alfa,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0544_Kanuma_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0544%20Kanuma%20-%20CDEC%20Final%20Recommendation%20September%2028%2C%202018.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0544_Kanuma_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0544_Kanuma_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/si0003-kanuma-cadth-drug-implementation-advice.pdf,Lysosomal acid lipase deficiency,Reimburse with clinical criteria and/or conditions,Complete,"Nov 2, 2017","Sep 26, 2018",SR0544-000
lumacaftorivacaftor,Orkambi,lumacaftor/ivacaftor,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0559_Orkambi_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0559%20Orkambi%20-%20CDEC%20Final%20Recommendation%20October%204%2C%202018.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0559_Orkambi_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0559_Orkambi_PI_Submissions.pdf,"Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older",Do not reimburse,Complete,"Feb 22, 2018","Sep 26, 2018",SR0559-000
eluxadoline,Viberzi,eluxadoline,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0560_Viberzi_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0560_cdr_complete_Viberzi_Aug_29_18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0560_Viberzi_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0560_Viberzi_PI_Submissions.pdf,Irritable bowel syndrome with diarrhea,Do not reimburse,Complete,"Feb 23, 2018","Aug 24, 2018",SR0560-000
abobotulinumtoxina,Dysport Therapeutic,abobotulinumtoxinA,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0556_Dysport_Therapeutic_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0556_Dysport_Therapeutic_Aug_23_18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0556_Dysport_Therapeutic_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0556_Dysport_PI_Submissions.pdf,lower limb spasticity,Reimburse with clinical criteria and/or conditions,Complete,"Feb 7, 2018","Aug 23, 2018",SR0556-000
fluticasone furoateumeclidiniumvilanterol,Trelegy Ellipta,fluticasone furoate umeclidinium vilanterol,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0562_TrelegyEllipta_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0562_cdr_complete_Trelegy_Ellipta_Aug_27_18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0562_TrelegyEllipta_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0562_TrelegyEllipta_PI_Submissions.pdf,Chronic obstructive pulmonary disease (COPD),Reimburse with clinical criteria and/or conditions,Complete,"Mar 1, 2018","Aug 23, 2018",SR0562-000
nitisinone,Nitisinone,nitisinone,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0554_Nitisinone_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0554_Nitisinone_Aug_23_18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0554_Nitisinone_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0554_Nitisinone_PI_Submissions.pdf,Hereditary tyrosinemia type 1,Reimburse with clinical criteria and/or conditions,Complete,"Jan 25, 2018","Aug 23, 2018",SR0554-000
buprenorphine hydrochloride,Probuphine,buprenorphine hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0550_Probuphine_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0550_Probuphine_Aug_24_18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0550_Probuphine_PE_Report.pdf,"Opioid drug dependence, treatment",Reimburse with clinical criteria and/or conditions,Complete,"Dec 21, 2017","Aug 22, 2018",SR0550-000
levodopa carbidopa drug plan submission,Duodopa,Levodopa / carbidopa (Drug Plan Submission),https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0557_DuodopaFWG_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0557_Duodopa_Aug_24-18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0557_DuodopaFWG_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0557_Duodopa_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/si0001-duodopa-drug-implementation-advice.pdf,Parkinson's disease,Reimburse with clinical criteria and/or conditions,Complete,"Feb 8, 2018","Aug 22, 2018",SR0557-000
ixekizumab,Taltz,ixekizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0558_TaltzPsA_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0558_Taltz_PsA_Aug_23_18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0558_TaltzPsA_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0558_TaltzPsA_PI_Submissions.pdf,"Arthritis, psoriatic",Reimburse with clinical criteria and/or conditions,Complete,"Feb 20, 2018","Aug 21, 2018",SR0558-000
benralizumab,Fasenra,benralizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0561_Fasenra_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0561_Fasenra_Aug_23_18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0561_Fasenra_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0561_Fasenra_PI_Submissions.pdf,"Asthma, severe eosinophilic",Reimburse with clinical criteria and/or conditions,Complete,"Feb 23, 2018","Aug 21, 2018",SR0561-000
darunavircobicistatemtricitabinetenofovir alafenamide,Symtuza,Darunavir/cobicistat/emtricitabine/tenofovir alafenamide,https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0552_Symtuza_Combined_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0552_cdr_complete_Symtuza_July_27_18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0552_Symtuza_PI_Submissions.pdf,HIV-1 infection,Reimburse with clinical criteria and/or conditions,Complete,"Dec 22, 2017","Jul 25, 2018",SR0552-000
alecensaro non small cell lung cancer first line,Alecensaro,Alectinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_1stln_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_1stln_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_1stln_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_1stln_fdk_hlr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_1stln_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_1stln_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_1stln_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_1stln_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_1stln_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_alectinib_alecensaro_nsclc_1ln.pdf,Locally advanced or metastatic ALK+ NSCLC (first line),Reimburse with clinical criteria and/or conditions,Complete,"Jan 15, 2018","Jul 25, 2018",PC0125-000
lonsurf metastatic colorectal cancer,Lonsurf,Trifluridine and Tipiracil,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_trifluridine_tipiracil_lonsurf_mcrc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_trifluridine-tipiracil_Lonsurf_mCRC_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_trifluridine_tipiracil_lonsurf_mcrc_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_trifluridine_tipiracil_lonsurf_mcrc_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_trifluridine_tipiracil_lonsurf_mcrc_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_trifluridine_tipiracil_lonsurf_mcrc_fdk_taiho.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_trifluridine_tipiracil_lonsurf_mcrc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_trifluridine_tipiracil_lonsurf_mcrc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_trifluridine_tipiracil_lonsurf_mcrc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_trifluridine_tipiracil_lonsurf_mcrc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_trifluridine_tipiracil_lonsurf_mcrc_ptfdk.pdf,Metastatic Colorectal Cancer,Do not reimburse,Complete,"Nov 6, 2017","Jul 6, 2018",PC0122-000
besponsa acute lymphoblastic leukemia,Besponsa,Inotuzumab Ozogamicin,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_inotuzumab_besponsa_ALL_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_inotuzumab_ozogamicin_besponsa_all_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_inotuzumab_ozogamicin_besponsa_all_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_inotuzumab_ozogamicin_besponsa_all_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_inotuzumab_ozogamicin_besponsa_all_fdk_pfizer.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_inotuzumab_ozogamicin_besponsa_all_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_inotuzumab_ozogamicin_besponsa_all_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_inotuzumab_ozogamicin_besponsa_all_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_inotuzumab_ozogamicin_besponsa_all_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_inotuzumab-ozogamicin_besponsa_all.pdf,Acute Lymphoblastic Leukemia (ALL),Reimburse with clinical criteria and/or conditions,Complete,"Nov 13, 2017","Jul 6, 2018",PC0121-000
dupilumab,Dupixent,dupilumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0533_Dupixent_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0533_cdr_complete_Dupixent_July_9_2018.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0533_Dupixent_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0533_Duxipent_Patient_Submsissions.pdf,atopic dermatitis,Do not reimburse,Complete,"Oct 27, 2017","Jun 27, 2018",SR0533-000
netupitant palonosetron,Akynzeo,netupitant / palonosetron,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0548_Akynzeo_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0548_cdr_complete_Akynzeo_June_22_18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0548_Akynzeo_PE_Report.pdf,Nausea and vomiting (chemotherapy induced) prevention,Reimburse with clinical criteria and/or conditions,Complete,"Dec 8, 2017","Jun 20, 2018",SR0548-000
tecentriq non small cell lung cancer,Tecentriq,Atezolizumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_atezolizumab_tecentriq_nsclc_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_atezolizumab_tecentriq_nsclc_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_atezolizumab_tecentriq_nsclc_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_atezolizumab_tecentriq_nsclc_fdk_hlroche.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_atezolizumab_tecentriq_nsclc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_atezolizumab_tecentriq_nsclc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_atezolizumab_tecentriq_nsclc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_atezolizumab_tecentriq_nsclc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_atezolizumab_tecentriq_nsclc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_10115_atezolizumab_tecentriq_nsclc.pdf,Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),Reimburse with clinical criteria and/or conditions,Complete,"Dec 15, 2017","Jun 20, 2018",PC0115-000
dolutegravir rilpivirine,Juluca,Dolutegravir rilpivirine,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0551_Juluca_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0551_cdr_complete_Juluca_June_22_18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0551_Juluca_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0551_Juluca_PI_Submissions.pdf,HIV infection,Reimburse with clinical criteria and/or conditions,Complete,"Dec 21, 2017","Jun 20, 2018",SR0551-000
letermovir,Prevymis,letermovir,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0545_Prevymis_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0545_cdr_complete_Prevymis_June_22_2018.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0545_Prevymis_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0545_Prevymis_PI_Submissions.pdf,"Cytomegalovirus infection, prophylaxis",Reimburse with clinical criteria and/or conditions,Complete,"Dec 7, 2017","Jun 20, 2018",SR0545-000
brodalumab,Siliq,brodalumab,https://www.cda-amc.ca/sites/default/files/attachments/2023-11/TS0001-PsO-Updated-Streamlined-Rec.pdf; https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0547_Siliq_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0547_cdr_complete_Siliq_June_22_18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0547_Siliq_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0547_Brodalumab_PI_Submissions.pdf,"Psoriasis, moderate to severe plaque",Reimburse with clinical criteria and/or conditions,Complete,"Dec 14, 2017","Jun 20, 2018",SR0547-000
opdivo classical hodgkin lymphoma after failure asct,Opdivo,Nivolumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_cHL_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_cHL_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_cHL_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_cHL_fdk_bms.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_cHL_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_cHL_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_cHL_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_cHL_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_cHL_ptfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_chl_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_nivolumab_opdivo_chl_fail_asct.pdf,classical Hodgkin Lymphoma (cHL) after failure of ASCT,Reimburse with clinical criteria and/or conditions,Complete,"Sep 29, 2017","May 3, 2018",PC0120-000
ocrelizumab,Ocrevus,ocrelizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0542_Ocrevus_PPMS_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0542_cdr_complete_Ocrevus_PPMS_Apr_30_18_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0542_Ocrevus_PPMS_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0542_Ocrevus_PPMS_PI_Submissions.pdf,Primary progressive multiple sclerosis,Reimburse with clinical criteria and/or conditions,Complete,"Oct 26, 2017","Apr 26, 2018",SR0542-000
nitisinone,MDK-Nitisinone,nitisinone,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0538_MDK_Nitisinone_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0538_cdr_complete_MDK_Nitisinone_Apr_27_18_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0538_MDK_Nitisinone_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0538_MDK_Nitisinone_PI_Submissions.pdf,Hereditary tyrosinemia type 1,Reimburse with clinical criteria and/or conditions,Complete,"Sep 29, 2017","Apr 25, 2018",SR0538-000
latanoprost,Monoprost,latanoprost,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0541_Monoprost_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0541_cdr_complete_Monoprost_apr-26-18_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0541_Monoprost_PE_Report.pdf,glaucoma and ocular hypertension,Reimburse with clinical criteria and/or conditions,Complete,"Oct 25, 2017","Apr 24, 2018",SR0541-000
lartruvo advanced soft tissue sarcoma,Lartruvo,Olaratumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaratumab_lartruvo_sts_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaratumab_lartruvo_sts_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaratumab_lartruvo_sts_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaratumab_lartruvo_sts_fdk_elc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaratumab_lartruvo_sts_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaratumab_lartruvo_sts_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaratumab_lartruvo_sts_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaratumab_lartruvo_sts_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaratumab_lartruvo_sts_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_olaratumab_lartruvo_sts.pdf,Advanced Soft Tissue Sarcoma,Reimburse with clinical criteria and/or conditions,Complete,"Oct 26, 2017","Apr 18, 2018",PC0111-000
stivarga unresectable hepatocellular carcinoma hcc,Stivarga,Regorafenib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_10119_regorafenib_stivarga_unresectable_hcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_regorafenib_stivarga_hcc_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_regorafenib_stivarga_hcc_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_regorafenib_stivarga_hcc_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_regorafenib_stivarga_hcc_fdk_bayer.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_regorafenib_stivarga_hcc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_regorafenib_stivarga_hcc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_regorafenib_stivarga_hcc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_regorafenib_stivarga_hcc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_regorafenib_stivarga_hcc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_regorafenib_stivarga_hcc_ptfdk.pdf,Unresectable Hepatocellular Carcinoma (HCC),Reimburse with clinical criteria and/or conditions,Complete,"Oct 12, 2017","Apr 18, 2018",PC0119-000
kisqali metastatic breast cancer,Kisqali,Ribociclib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_10112_ribocliclib_kisqali_mbc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_fdk_novartis.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ribociclib_kisqali_mbc_ptfdk.pdf,Advanced or Metastatic Breast Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Oct 17, 2017","Apr 18, 2018",PC0112-000
vectibix left sided metastatic colorectal cancer,Vectibix,Panitumumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_panitumumab_vectibix_ls_mcrc_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_panitumumab_vectibix_ls_mcrc_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_panitumumab_vectibix_ls_mcrc_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_panitumumab_vectibix_ls_mcrc_fdk_amgen.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_panitumumab_vectibix_ls_mcrc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_panitumumab_vectibix_ls_mcrc_fn_egr%20.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_panitumumab_vectibix_ls_mcrc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_panitumumab_vectibix_ls_mcrc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_panitumumab_vectibix_ls_mcrc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_panitumumab_vectibix_ls_mcrc_ptfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_panitumumab_vectibix_ls_mcrc.pdf,Left Sided Metastatic Colorectal Cancer (mCRC),Do not reimburse,Complete,"Sep 8, 2017","Mar 29, 2018",PC0118-000
alecensaro locally advanced or metastatic non small cell lung cancer second line,Alecensaro,Alectinib,https://www.cda-amc.ca/sites/default/files/pcodr/AlectinibAlecensaro_NSCLCsecondline10114ProvFunding.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_2ln_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_2ln_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_2ln_fdk_roche.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_2ln_fn_cgr%20.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_2ln_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_2ln_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_2ln_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_2ln_pagfdk.pdf,"Anaplastic Lymphoma Kinase-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer",Reimburse with clinical criteria and/or conditions,Complete,"Aug 18, 2017","Mar 29, 2018",PC0114-000
tocilizumab,Actemra,tocilizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0534_ActemraGCA_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0534_Actemra_GCA_complete_Mar-27-18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0534_Actemra_GCA_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0534_Actemra_GCA_PI_Submissions.pdf,Giant cell arteritis (GCA),Reimburse with clinical criteria and/or conditions,Complete,"Sep 25, 2017","Mar 27, 2018",SR0534-000
tenofovir alafenamide,Vemlidy,tenofovir alafenamide,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0537_Vemlidy_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0537_Vemlidy_complete_Mar-28-18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0537_Vemlidy_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0537_Vemlidy_PI_Submissions.pdf,"Hepatitis B, chronic",Reimburse with clinical criteria and/or conditions,Complete,"Sep 28, 2017","Mar 26, 2018",SR0537-000
bavencio metastatic merkel cell carcinoma,Bavencio,Avelumab,https://www.cda-amc.ca/sites/default/files/pcodr/AvelumabBavencio_metastaticMerkelcellcarcinoma10124_ProvFunding2019-11-19.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_avelumab_bavencio_mcc_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_avelumab_bavencio_mcc_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_avelumab_bavencio_mcc_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_avelumab_bavencio_mcc_espa.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_avelumab_bavencio_mcc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_avelumab_bavencio_mcc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_avelumab_bavencio_mcc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_avelumab_bavencio_mcc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_avelumab_bavencio_mmcc_in_rec.pdf,metastatic Merkel Cell Carcinoma (mMCC),Reimburse with clinical criteria and/or conditions,Complete,"Oct 10, 2017","Mar 21, 2018",PC0124-000
venclexta chronic lymphocytic leukemia,Venclexta,Venetoclax,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_venetoclax_venclexta_cll.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_fdk_abbvie.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_venetoclax_venclexta_cll_ptfdk.pdf,Chronic Lymphocytic Leukemia,Reimburse with clinical criteria and/or conditions,Complete,"Jul 10, 2017","Mar 2, 2018",PC0105-000
keytruda metastatic urothelial carcinoma,Keytruda,Pembrolizumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_muc_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_muc_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_muc_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_muc_fdk_merck.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_muc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_muc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_muc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_muc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_muc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_pembrolizumab_keytruda_MUC.pdf,For locally advanced or metastatic urothelial carcinoma,Reimburse with clinical criteria and/or conditions,Complete,"Jul 24, 2017","Mar 2, 2018",PC0117-000
guselkumab,Tremfya,guselkumab,https://www.cda-amc.ca/sites/default/files/attachments/2023-11/TS0001-PsO-Updated-Streamlined-Rec.pdf; https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0530_Tremfya_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0530_Tremfya_complete_Feb-23-18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0530_Tremfya_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0530_Tremfya_PI_Submissions.pdf,"Psoriasis, moderate to severe plaque",Reimburse with clinical criteria and/or conditions,Complete,"Aug 25, 2017","Feb 21, 2018",SR0530-000
nitisinone,Orfadin,nitisinone,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0531_Orfadin_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0531_Orfadin_complete_Feb-23-18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0531_Orfadin_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0531_Orfadin_PI.pdf,Hereditary tyrosinemia type 1,Reimburse with clinical criteria and/or conditions,Complete,"Aug 29, 2017","Feb 21, 2018",SR0531-000
adcetris hodgkins lymphoma post asct resubmission,Adcetris,Brentuximab Vedotin,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_brentuximab_adcetris_hl_post-asct_resub_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_brentuximab_adcetris_hl_post-asct_resub_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_brentuximab_adcetris_hl_post-asct_resub_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_brentuximab_adcetris_hl_post-asct_resub_fdk_sgi.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_brentuximab_adcetris_hl_post-asct_resub_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_brentuximab_adcetris_hl_post-asct_resub_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_brentuximab_adcetris_hl_post-asct_resub_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_brentuximab_adcetris_hl_post-asct_resub_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_brentuximab_adcetris_hl_post-asct_resub_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_brentuximab_adcetris_hl_post-asct_resub.pdf,HL at high risk of relapse or progression post-ASCT,Reimburse with clinical criteria and/or conditions,Complete,"Aug 10, 2017","Feb 21, 2018",PC0116-000
infliximab,Renflexis,infliximab,https://www.cda-amc.ca/sites/default/files/attachments/2023-11/TS0001-PsO-Updated-Streamlined-Rec.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SE0532%20Renflexis%20-%20CDEC%20Final%20Recommendation%20February%2020%2C%202018%28redacted%29_for%20posting.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SE0532_Renflexis_Combined_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SE0532_Renflexis_PI.pdf,"rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis",Reimburse with clinical criteria and/or conditions,Complete,"Sep 5, 2017","Feb 20, 2018",SE0532-000
faslodex locally advanced or metastatic breast cancer,Faslodex,Fulvestrant,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_fulvestrant_faslodex_mbc_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_fulvestrant_faslodex_mbc_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_fulvestrant_faslodex_mbc_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_fulvestrant_faslodex_mbc_fdk_asz.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_fulvestrant_faslodex_mbc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_fulvestrant_faslodex_mbc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_fulvestrant_faslodex_mbc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_fulvestrant_faslodex_mbc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_fulvestrant_faslodex_mbc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_fulvestrant_faslodex_mbc_ptfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_fulvestrant_faslodex_mbc.pdf,Locally advanced or metastatic breast cancer,Reimburse with clinical criteria and/or conditions,Complete,"Jul 17, 2017","Feb 1, 2018",PC0110-000
migalastat,Galafold,migalastat,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0522_Galafold_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0522_Galafold_complete_Jan-26-18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0522_Galafold_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0522_Galafold_Patient_Input.pdf,Fabry Disease,Reimburse with clinical criteria and/or conditions,Complete,"Jun 9, 2017","Jan 24, 2018",SR0522-000
cysteamine bitartrate,Procysbi,cysteamine bitartrate,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0526_Procysbi_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0526_Procysbi_complete_Jan-26-18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0526_Procysbi_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SI0002-procysbi-drug-implementation-advice.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0526_Procysbi_Patient_Input.pdf,Nephropathic cystinosis,Reimburse with clinical criteria and/or conditions,Complete,"Aug 8, 2017","Jan 24, 2018",SR0526-000
glecaprevir pibrentasvir,Maviret,glecaprevir pibrentasvir,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0523_Maviret_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0523_Maviret_complete-Jan-25-18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0523_Maviret_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0523_Maviret_Patient_Input.pdf,"Hepatitis C, chronic",Reimburse with clinical criteria and/or conditions,Complete,"Jun 9, 2017","Jan 23, 2018",SR0523-000
apomorphine,Movapo,apomorphine hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0527_Movapo_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0527_Movapo_complete-Jan-25-18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0527_Movapo_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0527_Movapo_Patient_Input.pdf,Parkinson's disease,Reimburse with clinical criteria and/or conditions,Complete,"Jul 6, 2017","Jan 23, 2018",SR0527-000
sofosbuvir velpatasvir voxilaprevir,Vosevi,sofosbuvir velpatasvir voxilaprevir,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0529_Vosevi_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0529_Vosevi_complete_Jan-25-18.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0529_Vosevi_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0529%20Vosevi_Patient_Input.pdf,"Hepatitis C, chronic",Reimburse with clinical criteria and/or conditions,Complete,"Jul 28, 2017","Jan 23, 2018",SR0529-000
onivyde metastatic pancreatic cancer,Onivyde,Irinotecan Liposome,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_irinotecan_liposome_onivyde_mpc_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_irinotecan_liposome_onivyde_mpc_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_irinotecan_liposome_onivyde_mpc_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_irinotecan_liposome_onivyde_mpc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_irinotecan_liposome_onivyde_mpc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_irinotecan_liposome_onivyde_mpc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_irinotecan_liposome_onivyde_mpc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_irinotecan_liposome_onivyde_mpc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_irinotecan_liposome_onivyde_mpc.pdf,Metastatic Pancreatic Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Apr 27, 2017","Jan 5, 2018",PC0107-000
pembrolizumab keytruda classical hodgkin lymphoma,Keytruda,Pembrolizumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_fdk_merck.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_ptfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_pembrolizumab_keytruda_chl.pdf,classical Hodgkin Lymphoma (cHL),Reimburse with clinical criteria and/or conditions,Complete,"Jul 7, 2017","Jan 5, 2018",PC0109-000
nusinersen,Spinraza,nusinersen,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0525_Spinraza_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0525_Spinraza_complete_Dec_22_17.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0525_Spinraza_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0525_Spinraza_Patient_Input.pdf,Spinal Muscular Atrophy,Reimburse with clinical criteria and/or conditions,Complete,"Jun 28, 2017","Dec 22, 2017",SR0525-000
rydapt acute myeloid leukemia,Rydapt,Midostaurin,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_midostaurin_rydapt_all_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_midostaurin_rydapt_all_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_midostaurin_rydapt_all_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_midostaurin_rydapt_all_fdk_novartis.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_midostaurin_rydapt_all_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_midostaurin_rydapt_all_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_midostaurin_rydapt_all_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_midostaurin_rydapt_all_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_midostaurin_rydapt_all_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_midostaurin_rydapt_aml.pdf,Acute Myeloid Leukemia,Reimburse,Complete,"Jun 12, 2017","Dec 19, 2017",PC0108-000
opdivo combo yervoy metastatic melanoma,Opdivo & Yervoy in combo,Nivolumab & Ipilimumab in combo,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_clfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_coi_cl.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_fdk_bms.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_ptfdk_mnc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_opdivo_yervoy_metmela_ptfdk_sys.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_opdivo_yervoy_metmela.pdf,Metastatic Melanoma,Reimburse with clinical criteria and/or conditions,Complete,"Nov 30, 2016","Nov 30, 2017",PC0098-000
lixisenatide,Adlyxine,lixisenatide,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0520_Adlyxine_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0520_Adlyxine_complete_Nov-23-17.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0520_Adlyxine_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0520_Adlyxine_PI_Submissions.pdf,"Diabetes mellitus, Type 2",Reimburse with clinical criteria and/or conditions,Complete,"May 29, 2017","Nov 23, 2017",SR0520-000
brexpiprazole,Rexulti,Brexpiprazole,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0514_Rexulti_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0514_Rexulti_complete_Nov_24_17.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0514_Rexulti_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0514_Rexulti_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0514_TBC.pdf,schizophrenia,Reimburse with clinical criteria and/or conditions,Complete,"Feb 3, 2017","Nov 22, 2017",SR0514-000
evolocumab,Repatha,Evolocumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0515_Repatha_Resubmission_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0515_Repatha_Resubmission_complete_Nov_24_17.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0515_Repatha_Resubmission_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0515_Repatha_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0515_Repatha.pdf,Primary hyperlipidemia and mixed dyslipidemia,Reimburse with clinical criteria and/or conditions,Complete,"Feb 17, 2017","Nov 22, 2017",SR0515-000
ulipristal acetate,Fibristal,ulipristal acetate,https://www.cda-amc.ca/sites/default/files/cdr/advice/SF0528_Fibristal_RFA_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SF0528_Fibristal_RFA_complete_Nov_22_17.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SF0528_Fibristal_PI_Submissions.pdf,Uterine fibroids (signs and symptoms),Reimburse with clinical criteria and/or conditions,Complete,"Jun 21, 2017","Nov 22, 2017",SF0528-000
ocrelizumab,Ocrevus,ocrelizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0519_Ocrevus_RMS_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0519_Ocrevus_RMS_complete_Nov-23-17.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0519_Ocrevus_RMS%20_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0519_Ocrevus_RMS_PI_Submissions.pdf,"multiple sclerosis, relapsing",Reimburse with clinical criteria and/or conditions,Complete,"May 16, 2017","Nov 21, 2017",SR0519-000
insulin degludec,Tresiba,insulin degludec,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0521_Tresiba_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0521_Tresiba_complete_Nov-22-17_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0521_Tresiba_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0521_Tresiba_PI_Submissions.pdf,"Diabetes mellitus, Type 1 & 2",Reimburse with clinical criteria and/or conditions,Complete,"May 31, 2017","Nov 20, 2017",SR0521-000
tafinlar mekinist combo non small cell lung cancer,Tafinlar & Mekinist in combo,Dabrafenib & Trametinib in combo,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_tafinlar_mekinist_nsclc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_tafinlar_mekinist_nsclc_clfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_tafinlar_mekinist_nsclc_coi-cl.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_tafinlar_mekinist_nsclc_coi-pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_tafinlar_mekinist_nsclc_fdk_novartis.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_tafinlar_mekinist_nsclc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_tafinlar_mekinist_nsclc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_tafinlar_mekinist_nsclc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_tafinlar_mekinist_nsclc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_tafinlar_mekinist_nsclc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_tafinlar_mekinist_nsclc_ptfdk.pdf,Non-Small Cell Lung Cancer,Do not reimburse,Complete,"Mar 31, 2017","Nov 2, 2017",PC0106-000
travoprost ophthalmic solution,Izba,travoprost ophthalmic solution,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0516_Izba_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0516_Izba_complete_Oct-30-17.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0516_Izba_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0516_Izba.pdf,Glaucoma and ocular hypertension,Reimburse with clinical criteria and/or conditions,Complete,"Mar 1, 2017","Oct 25, 2017",SR0516-000
abobotulinumtoxina,Dysport Therapeutic,abobotulinumtoxinA,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0517_Dysport_Therapeutic_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0517_complete_Dysport_Therapeutic_ULS_Oct_26-17_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/monograph/dysport-therapeutic-product-monograph.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0517_Dysport_Therapeutic_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0517_Dysport_ULS_PI_Submissions_Consolidated.pdf,Upper limb spasticity,Reimburse with clinical criteria and/or conditions,Complete,"Apr 24, 2017","Oct 24, 2017",SR0517-000
darzalex multiple myeloma second line or beyond,Darzalex,Daratumumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_clfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_coi_cl.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_fdk_janssen.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_2ndln_ptfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_10104_daratumumab_darzalex_mm_2ln_beyond.pdf,Multiple Myeloma (second-line),Reimburse with clinical criteria and/or conditions,Complete,"Mar 3, 2017","Oct 5, 2017",PC0104-000
lynparza ovarian cancer resubmission,Lynparza (Resubmission),Olaparib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_clinfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_coi_clin.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_fdk_astrazeneca.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_resub_ptfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_olaparib_lynparza_resub.pdf,Ovarian Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Mar 17, 2017","Sep 20, 2017",PC0103-000
blincyto acute lymphoblastic leukemia resubmission,Blincyto (Resubmission),Blinatumomab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_resub_coi_clinician.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_resub_coi_ptgrp.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_resub_fdk_amgen.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_resub_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_resub_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_resub_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_resub_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_resub_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_blinatumomab_blincyto_all_resub.pdf,Acute Lymphoblastic Leukemia (ALL),Reimburse with clinical criteria and/or conditions,Complete,"Feb 24, 2017","Aug 31, 2017",PC0097-000
rituxan acute lymphoblastic leukemia,Rituxan,Rituximab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_rituximab_rituxan_all.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_rituximab_rituxan_all_coi_clinician.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_rituximab_rituxan_all_fdk_hlroche.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_rituximab_rituxan_all_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_rituximab_rituxan_all_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_rituximab_rituxan_all_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_rituximab_rituxan_all_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_rituximab_rituxan_all_pagfdk.pdf,Acute Lymphoblastic Leukemia,Do not reimburse,Complete,"Feb 13, 2017","Aug 31, 2017",PC0102-000
opdivo squamous cell carcinoma head and neck scchn,Opdivo,Nivolumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_scchn_coi_ptgrp.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_scchn_fdk_bms.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_scchn_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_scchn_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_scchn_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_scchn_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_scchn_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_nivolumab_opdivo_scchn.pdf,Squamous Cell Carcinoma of Head and Neck (SCCHN),Reimburse with clinical criteria and/or conditions,Complete,"Jan 31, 2017","Aug 31, 2017",PC0095-000
keytruda advanced non small cell lung carcinoma first line,Keytruda,Pembrolizumab,https://www.cda-amc.ca/sites/default/files/pcodr/PembrolizumabKeytruda_AdvancedNSCLCfirstline10101_ProvFunding.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_1stln_coi_clinician.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_1stln_coi_ptgrp.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_1stln_fdk_merck.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_1stln_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_1stln_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_1stln_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_1stln_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_1stln_pagfdk.pdf,Advanced non-small cell lung carcinoma (first line),Reimburse with clinical criteria and/or conditions,Complete,"Dec 12, 2016","Aug 23, 2017",PC0101-000
blinatumomab blincyto acute lymphoblastic leukemia pediatric,Blincyto,Blinatumomab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_pediatric_coi_clinician.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_pediatric_coi_ptgrp.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_pediatric_fdk_amgen.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_pediatric_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_pediatric_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_pediatric_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_pediatric_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_pediatric_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_blinatumomab_blincyto_all_pediatric.pdf,Acute Lymphoblastic Leukemia (pediatric),Reimburse with clinical criteria and/or conditions,Complete,"Feb 24, 2017","Aug 23, 2017",PC0099 -000
eliglustat,Cerdelga,Eliglustat,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0511_Cerdelga_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0511_complete_Cerdelga_Jul_28_17_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0511_Cerdelga_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0511_Cerdelga_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0511_Cerdelga.pdf,Gaucher disease,Reimburse with clinical criteria and/or conditions,Complete,"Jan 20, 2017","Jul 26, 2017",SR0511-000
abobotulinumtoxina,Dysport Therapeutic,abobotulinumtoxinA,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0512_Dysport_Therapeutic_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0512_complete_Dysport_Therapeutic_Jul_28_17_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0512_Dysport_Therapeutic_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0512_Dysport_Therapeutic_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0512_Dysport_Therapeutic.pdf,Cervical dystonia,Reimburse with clinical criteria and/or conditions,Complete,"Jan 31, 2017","Jul 26, 2017",SR0512-000
glatiramer acetate,Glatect,Glatiramer acetate,https://www.cda-amc.ca/sites/default/files/cdr/complete/SE0510_Glatect_SENB_Complex_Drug_Submission_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SE0510_complete_Glatect-Jul-27-e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SE0510_Glatect%20_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SE0510_Glatect.pdf,Relapsing Remitting Multiple Sclerosis (RRMS),Reimburse with clinical criteria and/or conditions,Complete,"Jan 20, 2017","Jul 25, 2017",SE0510-000
etanercept,Erelzi,Etanercept,https://www.cda-amc.ca/sites/default/files/cdr/complete/SE0513_complete_Erelzi_Jul_28_17_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SE0513_Erelzi_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/seb/SE0513_Erelzi_SEB_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SE0513_TBC.pdf,"Rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis",Reimburse with clinical criteria and/or conditions,Complete,"Feb 2, 2017","Jul 25, 2017",SE0513-000
obeticholic acid,Ocaliva,Obeticholic Acid,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0509_Ocaliva_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0509_complete_Ocaliva_Jul_27_17_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0509_Ocaliva_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0509%20Ocaliva_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0509_TBC.pdf,Primary Biliary Cholangitis,Reimburse with clinical criteria and/or conditions,Complete,"Dec 22, 2016","Jul 25, 2017",SR0509-000
ninlaro multiple myeloma,Ninlaro,Ixazomib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ixazomib_ninlaro_mm_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ixazomib_ninlaro_mm_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ixazomib_ninlaro_mm_coi_mmc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ixazomib_ninlaro_mm_fdk_takeda.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ixazomib_ninlaro_mm_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ixazomib_ninlaro_mm_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ixazomib_ninlaro_mm_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ixazomib_ninlaro_mm_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ixazomib_ninlaro_mm_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ixazomib_ninlaro_mm_ptfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_ixazomib_ninlaro_mm.pdf,Multiple Myeloma,Do not reimburse,Complete,"Dec 16, 2016","Jun 29, 2017",PC0088-000
daclizumab beta,Zinbryta,Daclizumab beta,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0508_Zinbryta_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0508_compelte_Zinbryta_Jun-22-17_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0508_Zinbryta_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0508_Zinbryta_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0508_Zinbryta.pdf,"Multiple Sclerosis, relapsing-remitting",Reimburse with clinical criteria and/or conditions,Complete,"Dec 20, 2016","Jun 20, 2017",SR0508-000
gazyva follicular lymphoma,Gazyva,Obinutuzumab,https://www.cda-amc.ca; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_fdk_roche.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_obinutuzumab_gazyva_fl_ptfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_obinutuzumab_gazyva_fl.pdf,Follicular Lymphoma,Reimburse with clinical criteria and/or conditions,Complete,"Nov 4, 2016","Jun 2, 2017",PC0091-000
edoxaban,Lixiana VTE,Edoxaban,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0499_Lixiana_VTE_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0499_complete_Lixiana_VTE_May_29_17_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0499_Lixiana_VTE_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0499_Lixiana_VTE.pdf,"Venous thromboembolism, treatment and recurrence prevention.",Reimburse with clinical criteria and/or conditions,Complete,"Sep 9, 2016","May 25, 2017",SR0499-000
emtricitabinerilpivirine tenofovir alafenamide,Odefsey,emtricitabine/rilpivirine/ tenofovir alafenamide,https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0507_Odefsey_Combined_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0507_complete_Odefsey-%20May-25-17_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0507_Odefsey_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0507_TBC.pdf,HIV-1 infection,Reimburse with clinical criteria and/or conditions,Complete,"Nov 24, 2016","May 25, 2017",SR0507-000
ivabradine,Lancora,Ivabradine,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0506_%20Lancora_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0506_complete_Lancora-Jun15-17_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0506_%20Lancora_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0506_Lancora_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0506_Lancora.pdf,"Heart failure, NYHA class II or III",Reimburse with clinical criteria and/or conditions,Complete,"Nov 8, 2016","May 24, 2017",SR0506-000
tagrisso non small cell lung cancer,Tagrisso,Osimertinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_fdk_azc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_osimertinib_tagrisso_nsclc_ptfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_10076_osimertinib_tagrisso_nsclc.pdf,Non-Small Cell Lung Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Apr 1, 2016","May 4, 2017",PC0076-000
alecensaro non small cell lung cancer cns metastases,Alecensaro,Alectinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_clnfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_coi_pt.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_fdk_roche.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_alectinib_alecensaro_nsclc_ptfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_alectinib_alecensaro_nsclc.pdf,Non-Small Cell Lung Cancer,Do not reimburse,Complete,"Oct 3, 2016","May 4, 2017",PC0092-000
propiverine hydrochloride,Mictoryl,Propiverine hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0504_Mictoryl_CL%20Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0504_complete_Mictoryl_Apr-21-17-e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0504_Mictoryl_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0504_Mictoryl_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0504_Mictoryl.pdf,Overactive bladder (OAB),Reimburse with clinical criteria and/or conditions,Complete,"Oct 14, 2016","Apr 19, 2017",SR0504-000
sarilumab,Kevzara,sarilumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0503_Kevzara_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0503_complete_Kevzara-Apr-20-17.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0503_Kevzara_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0503_Kevzara_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0503_TBC.pdf,"Arthritis, Rheumatoid",Reimburse with clinical criteria and/or conditions,Complete,"Oct 12, 2016","Apr 18, 2017",SR0503-000
mifepristone and misoprostol,Mifegymiso,Mifepristone and misoprostol,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0502_Mifegymiso_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0502_complete_Mifegymiso-Apr-20-17-e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0502_Mifegymiso_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0502_Mifegymiso.pdf,Medical termination of pregnancy (gestational age up to 49 days),Reimburse,Complete,"Oct 7, 2016","Apr 18, 2017",SR0502-000
caprelsa medullary thyroid cancer,Caprelsa,Vandetanib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_vandetanib_caprelsa_mtc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_vandetanib_caprelsa_mtc_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_vandetanib_caprelsa_mtc_coi_tcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_vandetanib_caprelsa_mtc_fdk_sanofig.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_vandetanib_caprelsa_mtc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_vandetanib_caprelsa_mtc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_vandetanib_caprelsa_mtc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_vandetanib_caprelsa_mtc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_vandetanib_caprelsa_mtc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_vandetanib_caprelsa_mtc_ptfdk_tcc.pdf,Medullary Thyroid Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Aug 15, 2016","Mar 30, 2017",PC0090-000
kyprolis multiple myeloma relapsed,Kyprolis,Carfilzomib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_coi_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_coi_mmc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_fdk_amgen.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_fdk_cln.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_rel_ptfdk_mmc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_carfilzomib_kyprolis_mm_rel.pdf,Multiple Myeloma (relapsed),Reimburse with clinical criteria and/or conditions,Complete,"Sep 9, 2016","Mar 30, 2017",PC0084-000
reslizumab,Cinqair,Reslizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0495_Cinqair_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0495_complete_Cinqair-Mar-24-17.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0495_Cinqair_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0495_Cinqair_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0495_Cinqair.pdf,"Asthma, eosinophilic",Reimburse with clinical criteria and/or conditions,Complete,"Aug 4, 2016","Mar 22, 2017",SR0495-000
fluorouracil and salicylic acid,Actikerall,Fluorouracil and Salicylic Acid,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0498_Actikerall_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0498_complete_Actikerall-Mar-24-17.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0498_Actikerall_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0498_Actikerall.pdf,Hyperkeratotic actinic keratosis,Reimburse with clinical criteria and/or conditions,Complete,"Aug 31, 2016","Mar 22, 2017",SR0498-000
budesonide,Cortiment,Budesonide,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0491_Cortiment_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0491_complete_Cortiment-Mar-24-17.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0491_Cortiment_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0491%20Cortiment_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0491_TBC.pdf,Ulcerative Colitis,Do not reimburse,Complete,"May 24, 2016","Mar 22, 2017",SR0491-000
edoxaban,Lixiana NVAF,Edoxaban,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0500_Lixiana_NVAF_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0500_complete_Lixiana-NVAF_Mar-23-17.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0500_Lixiana_NVAF_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0500_Lixiana_NVAF.pdf,"Nonvalvular atrial fibrillation, prevention of stroke and systemic embolism.",Reimburse with clinical criteria and/or conditions,Complete,"Sep 9, 2016","Mar 21, 2017",SR0500-000
glycerol phenylbutyrate,Ravicti,glycerol phenylbutyrate,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0497_Ravicti_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0497_complete_Ravicti_Mar-23-17.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0497_Ravicti_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0497_Ravicti_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0497_Ravicti.pdf,Urea cycle disorders,Reimburse with clinical criteria and/or conditions,Complete,"Aug 30, 2016","Mar 21, 2017",SR0497-000
ustekinumab,Stelara/Stelara I.V.,ustekinumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0501_Stelara_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0501_complete_Stelara_Mar-23-17.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0501_Stelara_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0501_Stelara_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0501_Stelara.pdf,Crohn’s disease,Reimburse with clinical criteria and/or conditions,Complete,"Sep 12, 2016","Mar 21, 2017",SR0501-000
zykadia non small cell lung cancer resubmission,Zykadia (Resubmission),Ceritinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_resub_clinfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_resub_coi_clin.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_resub_coi_lcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_resub_fdk_novartis.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_resub_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_resub_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_resub_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_resub_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_resub_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_resub_ptfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_ceritinib_zykadia_nsclc_resub.pdf,metastatic non-small cell lung cancer,Reimburse with clinical criteria and/or conditions,Complete,"Oct 19, 2016","Mar 21, 2017",PC0094-000
fentanyl buccal,Fentora,Fentanyl buccal,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0494_Fentora_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0494_complete_Fentora_Feb-23-17.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0494_Fentora_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0494_Fentora.pdf,"Pain (breakthrough), cancer (adults)",Do not reimburse,Complete,"Jul 12, 2016","Feb 21, 2017",SR0494-000
propranolol oral solution,Hemangiol,Propranolol oral solution,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0496_Hemangiol_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0496_complete_Hemangiol-Feb-23_17.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0496_Hemangiol_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0496_Hemangiol_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0496_Hemangiol.pdf,Infantile hemangioma,Reimburse with clinical criteria and/or conditions,Complete,"Aug 25, 2016","Feb 21, 2017",SR0496-000
brivaracetam,Brivlera,Brivaracetam,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0484_Brivlera_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/sr0484_complete_brivlera_jan-27-17.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0484_Brivlera_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0484_Brivlera.pdf,"Epilepsy, partial-onset seizures",Reimburse with clinical criteria and/or conditions,Complete,"Apr 19, 2016","Jan 25, 2017",SR0484-000
darzalex multiple myeloma,Darzalex,Daratumumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_coi_clinician.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_coi_mc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_fdk_clinician.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_fdk_janssen.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_fdk_mc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_daratumumab_darzalex_mm_pagfdk.pdf,Multiple Myeloma,Do not reimburse,Complete,"Apr 21, 2016","Dec 1, 2016",PC0079-000
afinitor neuroendocrine tumors gastrointestinal or lung origin,Afinitor,Everolimus,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_everolimus_afinitor_net-gil_coi_cnets.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_everolimus_afinitor_net-gil_fdk_cnets.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_everolimus_afinitor_net-gil_fdk_novartis.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_everolimus_afinitor_net-gil_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_everolimus_afinitor_net-gil_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_everolimus_afinitor_net-gil_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_everolimus_afinitor_net-gil_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_everolimus_afinitor_net-gil_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_everolimus_afinitor_net-gil.pdf,Neuroendocrine tumors (NET) of Gastrointestinal or Lung origin,Reimburse with clinical criteria and/or conditions,Complete,"May 30, 2016","Dec 1, 2016",PC0083-000
levofloxacin,Quinsair,Levofloxacin,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0493_Quinsair_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0493_complete_Quinsair_Nov-23-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0493_Quinsair_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0493_Quinsair_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0493_Quinsair.pdf,Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections,Reimburse with clinical criteria and/or conditions,Complete,"May 31, 2016","Nov 21, 2016",SR0493-000
ibrance advanced breast cancer resubmission,Ibrance Resubmission,Palbociclib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_abc_coi_cbcn-rethink.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_abc_coi_clinician.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_abc_fdk_pfizer.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_abc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_abc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_abc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_abc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_abc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_abc_ptfdk_cbcn.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_palbociclib_ibrance_resub_abc_ptfdk_rethink.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_10093_palbociclib_ibrance_abc_resub.pdf,Advanced breast cancer,Reimburse with clinical criteria and/or conditions,Complete,"Jun 10, 2016","Nov 21, 2016",PC0093-000
keytruda non small cell lung cancer second line or beyond,Keytruda,Pembrolizumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_coi_clinician.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_coi_lcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_fdk_clinician.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_fdk_merck.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_nsclc_ptfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_pembrolizumab_keytruda_nsclc_2lnbeyond.pdf,Non-Small Cell Lung Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Apr 21, 2016","Nov 3, 2016",PC0077-000
imbruvica chronic lymphocytic leukemia previously untreated,Imbruvica,Ibrutinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_ibrutinib_imbruvica-cll-sll-preun.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_coi_clinician.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_coi_cllpag.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_coi_lc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_fdk_janssen.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_ptfdk_cllpag.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_cll-sll_ptfdk_lc.pdf,Chronic Lymphocytic Leukemia (previously untreated),Reimburse with clinical criteria and/or conditions,Complete,"Apr 20, 2016","Nov 3, 2016",PC0085-000
imbruvica waldenstroms macroglobulinemia,Imbruvica,Ibrutinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_ibrutinib_imbruvica-wm.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_wm_coi_lc_cord.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_wm_fdk_janssen.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_wm_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_wm_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_wm_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_wm_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_wm_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_wm_ptfdk_cord.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_wm_ptfdk_lc.pdf,Waldenstrom's Macroglobulinemia,Do not reimburse,Complete,"Apr 21, 2016","Nov 3, 2016",PC0082-000
vedolizumab,Entyvio,Vedolizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0487_Entyvio_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0487_complete_Entyvio-Oct-31-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0487_Entyvio_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0487_Entyvio_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0487_Entyvio.pdf,Crohn's disease,Reimburse with clinical criteria and/or conditions,Complete,"Apr 27, 2016","Oct 31, 2016",SR0487-000
selexipag,Uptravi,Selexipag,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0482_Uptravi_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0482_complete_Uptravi-Oct-28-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0482_Uptravi_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0482_Uptravi_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0482_Uptravi.pdf,Pulmonary arterial hypertension (WHO class II and III),Reimburse with clinical criteria and/or conditions,Complete,"Mar 31, 2016","Oct 28, 2016",SR0482-000
sofosbuvir velpatasvir,Epclusa,Sofosbuvir/ velpatasvir,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0486_Epclusa_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0486_complete_Epclusa-Oct-28-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0486_Epclusa_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0486_Epclusa_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0486_TBC.pdf,"Hepatitis C, chronic",Reimburse with clinical criteria and/or conditions,Complete,"Apr 22, 2016","Oct 26, 2016",SR0486-000
empagliflozin,Jardiance,Empagliflozin,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0488_Jardiance_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0488_complete_Jardiance-Oct-28-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0488_Jardiance_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0488_Jardiance_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0488_Jardiance.pdf,"Diabetes mellitus, type 2 with high cardiovascular risk",Reimburse with clinical criteria and/or conditions,Complete,"Apr 27, 2016","Oct 26, 2016",SR0488-000
apremilast,Otezla,Apremilast,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0478_Otezla_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0478_complete_Otezla-Oct-28-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0478_Otezla_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0478_Otezla_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0478_Otezla_Resub.pdf,"Psoriasis, moderate to severe plaque",Reimburse with clinical criteria and/or conditions,Complete,"Mar 3, 2016","Oct 26, 2016",SR0478-000
perindopril arginine amlodipine,Viacoram,perindopril arginine / amlodipine,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0490_Viacoram_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0490_complete_Viacoram-Oct-28-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0490_Viacoram_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0490_Viacoram.pdf,"Hypertension, essential",Reimburse with clinical criteria and/or conditions,Complete,"May 2, 2016","Oct 26, 2016",SR0490-000
sapropterin dihydrochloride,Kuvan,Sapropterin dihydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0472_Kuvan_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0472_complete_Kuvan-Oct-28-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0472_Kuvan_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0472_Kuvan_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0472_Kuvan.pdf,Phenylketonuria (PKU),Reimburse with clinical criteria and/or conditions,Complete,"Feb 1, 2016","Oct 26, 2016",SR0472-000
lumacaftorivacaftor,Orkambi,lumacaftor/ivacaftor,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0471_Orkambi_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0471_complete_Orkambi-Oct-28-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0471_Orkambi_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0471_Orkambi_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0471_Orkambi.pdf,"Cystic Fibrosis, F508del CFTR mutation",Do not reimburse,Complete,"Jan 28, 2016","Oct 26, 2016",SR0471-000
infliximab,Inflectra (Subsequent Entry Biologic),Infliximab,https://www.cda-amc.ca/sites/default/files/cdr/complete/SE0483_IBD_Inflectra-Oct-28-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SE0483_Inflectra_PI_Submission_Consolidated.pdf; https://www.cda-amc.ca/sites/default/files/cdr/seb/SE0483_Inflectra_SEB_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SE0483_Inflectra.pdf,Crohn’s disease and Ulcerative Colitis,Reimburse with clinical criteria and/or conditions,Complete,"Apr 12, 2016","Oct 25, 2016",SE0483-000
etanercept,Brenzys,Etanercept,https://www.cda-amc.ca/sites/default/files/cdr/complete/SE0485_complete_Brenzys-Oct-27-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/se0485_brenzys_pi.pdf; https://www.cda-amc.ca/sites/default/files/cdr/seb/se0485_brenzys_seb_report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SE0485_TBC.pdf,"Rheumatoid arthritis, Ankylosing spondylitis",Reimburse with clinical criteria and/or conditions,Complete,"Apr 20, 2016","Oct 25, 2016",SE0485-000
ixekizumab,Taltz,Ixekizumab,https://www.cda-amc.ca/sites/default/files/attachments/2023-11/TS0001-PsO-Updated-Streamlined-Rec.pdf; https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0481_Taltz_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0481_complete_Taltz-oct-27-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0481_Taltz_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0481_Taltz_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0481_TBC.pdf,"Psoriasis, moderate to severe plaque",Reimburse with clinical criteria and/or conditions,Complete,"Mar 23, 2016","Oct 25, 2016",SR0481-000
empagliflozin and metformin,Synjardy,Empagliflozin and metformin,https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf; https://www.cadth.ca/sites/default/files/cdr/clinical/SR0489_Synjardy_CL_Report.pdf; https://www.cadth.ca/sites/default/files/cdr/complete/SR0489_complete_Synjardy-oct-27-16.pdf; https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0489_Synjardy_PE_Report.pdf; https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0489_Synjardy_PI_Submissions.pdf; https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_SR0489_Synjardy.pdf,Diabetes mellitus (Type 2),Reimburse with clinical criteria and/or conditions,Complete,"Apr 29, 2016","Oct 25, 2016",SR0489-000
lynparza ovarian cancer 2nd line,Lynparza,Olaparib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_oc_coi_clinician.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_oc_coi_occ.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_oc_fdk_azc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_oc_fdk_clinician.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_oc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_oc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_oc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_oc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_oc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_olaparib_lynparza_oc_ptfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_olaparib_lynparza_oc.pdf,Ovarian Cancer,Do not reimburse,Complete,"Apr 1, 2016","Sep 29, 2016",PC0081-000
zydelig follicular lymphoma,Zydelig,Idelalisib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_idelalisib-zydelig-fl.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_idelalisib_zydelig_fl_coi_lc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_idelalisib_zydelig_fl_fdk_gilead.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_idelalisib_zydelig_fl_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_idelalisib_zydelig_fl_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_idelalisib_zydelig_fl_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_idelalisib_zydelig_fl_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_idelalisib_zydelig_fl_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_idelalisib_zydelig_fl_ptfdk_lc.pdf,Follicular Lymphoma,Do not reimburse,Complete,"Apr 12, 2016","Sep 29, 2016",PC0075-000
lenvima differentiated thyroid cancer,Lenvima,Lenvatinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_lenvatinib-lenvima-dtc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_dtc_coi_clinicians.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_dtc_coi_tcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_dtc_fdk_eisailtd.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_dtc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_dtc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_dtc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_dtc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_dtc_pagfdk.pdf,Differentiated Thyroid Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Apr 18, 2016","Sep 20, 2016",PC0080-000
opdivo metastatic renal cell carcinoma,Opdivo,Nivolumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_nivolumab-opdivo-mrcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_mrcc_coi_kcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_mrcc_fdk_bms.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_mrcc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_mrcc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_mrcc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_mrcc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_mrcc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_mrcc_ptfdk_kcc.pdf,Metastatic Renal Cell Carcinoma,Reimburse with clinical criteria and/or conditions,Complete,"Feb 24, 2016","Sep 1, 2016",PC0074-000
canagliflozin and metformin hydrochloride,Invokamet,Canagliflozin and metformin hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0480_Invokamet_Combination_Product_Subsmission_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0480_complete_Invokamet-Aug-29-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0480_Invokamet_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0480_TBC.pdf,"diabetes mellitus, type 2",Reimburse with clinical criteria and/or conditions,Complete,"Mar 3, 2016","Aug 25, 2016",SR0480-000
ticagrelor,Brilinta,ticagrelor,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0474_Brilinta_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0474_complete_Brilinta-Aug-29-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0474_Brilinta_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0474_Brilinta_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0474_Brilinta.pdf,Prevention of atherothrombotic events with history of myocardial infarction,Reimburse with clinical criteria and/or conditions,Complete,"Feb 18, 2016","Aug 25, 2016",SR0474-000
tesamorelin,Egrifta,Tesamorelin,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0477_Egrifta_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0477_complete_Egrifta_Aug-26-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0477_Egrifta_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0477_Egrifta_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0477_Egrifta.pdf,"Lipodystrophy, HIV-infected patients",Do not reimburse,Complete,"Mar 2, 2016","Aug 24, 2016",SR0477-000
emtricitabinetenofovir disoproxil fumarate,Truvada,Emtricitabine/tenofovir disoproxil fumarate,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0479_Truvada_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0479_complete_Truvada_Aug-26-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0479_Truvada_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0479_Truvada_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0479_Truvada.pdf,"HIV-1 infection, pre-exposure prophylaxis",Reimburse with clinical criteria and/or conditions,Complete,"Mar 3, 2016","Aug 24, 2016",SR0479-000
emtricitabine tenofovir alafenamide,Descovy,Emtricitabine /tenofovir alafenamide,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0470_Descovy_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0470_complete_Descovy-Aug-26-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0470_Descovy_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0470_Descovy_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0470_TBC.pdf,HIV-1 infection,Reimburse with clinical criteria and/or conditions,Complete,"Jan 29, 2016","Aug 24, 2016",SR0470-000
secukinumab,Cosentyx,Secukinumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0475_CosentyxAS_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0475_complete_Cosentyx_AS_Aug-25-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0475_CosentyxAS_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0475_CosentyxAS_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0475_Cosentyx_AS.pdf,ankylosing spondylitis,Reimburse with clinical criteria and/or conditions,Complete,"Feb 19, 2016","Aug 23, 2016",SR0475-000
secukinumab,Cosentyx,Secukinumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0476_CosentyxPsA_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0476_complete_Cosentyx_PsA_Aug-25-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0476_CosentyxPsA_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0476_CosentyxPsA_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0476_Cosentyx_PsA.pdf,"Arthritis, psoriatic",Reimburse with clinical criteria and/or conditions,Complete,"Feb 19, 2016","Aug 23, 2016",SR0476-000
yondelis liposarcoma or leiomyoscarcoma,Yondelis,Trabectedin,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_trabectedin_yondelis_lipo-leio.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_trabectedin_yondelis_lile_scarcoma_coi_scfc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_trabectedin_yondelis_lile_scarcoma_fdk_janssen.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_trabectedin_yondelis_lile_scarcoma_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_trabectedin_yondelis_lile_scarcoma_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_trabectedin_yondelis_lile_scarcoma_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_trabectedin_yondelis_lile_scarcoma_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_trabectedin_yondelis_lile_scarcoma_pagfdk.pdf,Metastatic Liposarcoma or Leiomyosarcoma,Do not reimburse,Complete,"Dec 22, 2015","Aug 5, 2016",PC0071-000
aflibercept,Eylea,Aflibercept,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0460_Eylea_BRVO_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0460_Eylea%20BRVO_complete_Jul-29_16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0460_Eylea_BRVO_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/SR0460%20Eylea.pdf,"Macular edema, branch retinal vein occlusion",Reimburse with clinical criteria and/or conditions,Complete,"Dec 14, 2015","Jul 27, 2016",SR0460-000
teduglutide,Revestive,Teduglutide,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0459_Revestive_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0459_Revestive_complete_Jul-29_16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0459_Revestive_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0459_Revestive_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0459_Revestive.pdf,Short bowel syndrome,Reimburse with clinical criteria and/or conditions,Complete,"Nov 26, 2015","Jul 27, 2016",SR0459-000
asunaprevir,Sunvepra,Asunaprevir,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0418_Sunvepra_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0418_complete_Sunvepra_Jul-20_16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0418_Sunvepra_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0418_Sunvepra_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/SR0418%20Sunvepra.pdf,"Hepatitis C, chronic",Reimburse with clinical criteria and/or conditions,Complete,"Feb 13, 2015","Jul 20, 2016",SR0418-000
dapagliflozinmetformin hydrochloride,XigDuo,dapagliflozin/metformin hydrochloride,https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf; https://www.cadth.ca/sites/default/files/cdr/complete/SR0468_XigDuo_Summary_f.pdf; https://www.cadth.ca/sites/default/files/cdr/complete/SR0468_complete_Xigduo_Jul_20-16.pdf; https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0468_XigDuo_FDC_Report.pdf; https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0468_XigDuo_PI_Submissions.pdf; https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_SR0468_XigDuo.pdf,"Diabetes Mellitus, Type 2",Reimburse with clinical criteria and/or conditions,Complete,"Jan 7, 2016","Jul 20, 2016",SR0468-000
alirocumab,Praluent,Alirocumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0469_Praluent_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0469_complete_Praluent_Jul-20-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0469_Praluent_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0469_Praluent_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0469_Praluent.pdf,"Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia",Reimburse with clinical criteria and/or conditions,Complete,"Jan 12, 2016","Jul 20, 2016",SR0469-000
imbruvica mantle cell lymphoma relapsedrefractory,Imbruvica,Ibrutinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_ibrutinib_imbruvica_mcl.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_mcl_coi_lfc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_mcl_coi_llsc-ccsn.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_mcl_fdk_janssen.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_mcl_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_mcl_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_mcl_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_mcl_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_mcl_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_mcl_ptfdk_lfc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica_mcl_ptfdk_llsc-ccsn.pdf,Mantle Cell Lymphoma (relapsed/refractory),Reimburse with clinical criteria and/or conditions,Complete,"Jan 29, 2016","Jul 19, 2016",PC0073-000
cotellic metastatic melanoma,Cotellic,Cobimetinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_cobimetinib_cotellic_metmela_coi_mnc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_cobimetinib_cotellic_metmela_coi_sysf.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_cobimetinib_cotellic_metmela_fdk_roche.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_cobimetinib_cotellic_metmela_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_cobimetinib_cotellic_metmela_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_cobimetinib_cotellic_metmela_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_cobimetinib_cotellic_metmela_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_cobimetinib_cotellic_metmela_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_cobimetinib_cotellic_metmela_ptgrpfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_cobimetinib_cotellic_metmela.pdf,Metastatic melanoma,Reimburse with clinical criteria and/or conditions,Complete,"Dec 11, 2015","Jun 30, 2016",PC0070-000
kyprolis lenalidomide multiple myeloma,Kyprolis (with lenalidomide),Carfilzomib (with lenalidomide),https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_coi_mc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_fdk_amgen.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_carfilzomib_kyprolis_mm_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_10067carfilzomib_kyprolis_lenalidomide_mm.pdf,Multiple Myeloma,Reimburse with clinical criteria and/or conditions,Complete,"Dec 11, 2015","Jun 21, 2016",PC0067-000
canakinumab,Ilaris,Canakinumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0463_Ilaris_sJIA_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0463_complete_Ilaris_sJIA_June_21_16_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0463_Ilaris_sJIA_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0463_Ilaris_SJIA_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0463_Ilaris.pdf,Systemic Juvenile Idiopathic Arthritis,Reimburse with clinical criteria and/or conditions,Complete,"Dec 23, 2015","Jun 17, 2016",SR0463-000
dulaglutide,Trulicity,dulaglutide,https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf; https://www.cadth.ca/sites/default/files/cdr/clinical/SR0462_Trulicity_CL_Report.pdf; https://www.cadth.ca/sites/default/files/cdr/complete/SR0462_complete_Trulicity_June_21_16_e.pdf; https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0462_Trulicity_PE_Report.pdf; https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0462_Trulicity_PI_Submissions.pdf; https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_SR0462_Trulicity.pdf,"Diabetes mellitus, Type 2",Reimburse with clinical criteria and/or conditions,Complete,"Dec 22, 2015","Jun 16, 2016",SR0462-000
mepolizumab,Nucala,Mepolizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0461_Nucala_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0461_complete_Nucala_June-20-16_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0461_Nucala_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0461_Nucala_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0461_Nucala.pdf,"Asthma, severe eosinophilic",Reimburse with clinical criteria and/or conditions,Complete,"Dec 18, 2015","Jun 16, 2016",SR0461-000
opdivo non small cell lung cancer,Opdivo,Nivolumab,https://www.cda-amc.ca/sites/default/files/pcodr/nivolumab_opdivo_nsclc_coi_lcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/nivolumab_opdivo_nsclc_fdk_bms.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/nivolumab_opdivo_nsclc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/nivolumab_opdivo_nsclc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/nivolumab_opdivo_nsclc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/nivolumab_opdivo_nsclc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/nivolumab_opdivo_nsclc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_nivolumab_opdivo_nsclc.pdf,Metastatic non small cell lung cancer,Reimburse with clinical criteria and/or conditions,Complete,"Oct 29, 2015","Jun 3, 2016",PC0069-000
denosumab,Prolia,Denosumab,https://www.cda-amc.ca/sites/default/files/cdr/advice/SF0453_Prolia_RfA_Review_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SF0453_complete_RFA-Prolia_May-25-16_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SF0453%20Prolia_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SF0453_Prolia.pdf,Osteoporosis,Reimburse with clinical criteria and/or conditions,Complete,"Oct 26, 2015","May 20, 2016",SF0453-000
elosulfase alfa,Vimizim,Elosulfase alfa,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0456_Vimizim_Resubmission_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0456_complete_Vimizim_May-26_16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0456_Vimizim_Resubmission_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0456_Vimizim_Resubmission_PI_Submissions_Consolidated_validated.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/SR0456%20Vimizim%20Resubmission.pdf,Mucopolysaccharidosis IVA (Morquio A syndrome),Reimburse with clinical criteria and/or conditions,Complete,"Nov 10, 2015","May 20, 2016",SR0456-000
elbasvirgrazoprevir,Zepatier,Elbasvir/grazoprevir,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0454_Zepatier_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0454_complete_Zepatier_May_25-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0454_Zepatier_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0454_grazoprevir%2Belbasvir_PI_Submissions_Consolidated_validated.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0454_grazoprevir_elbasvir.pdf,"Hepatitis C, chronic",Reimburse with clinical criteria and/or conditions,Complete,"Oct 27, 2015","May 19, 2016",SR0454-000
ombitasvirparitaprevirritonavir and dasabuvir,Holkira Pak,ombitasvir/paritaprevir/ritonavir and dasabuvir,https://www.cda-amc.ca/sites/default/files/cdr/advice/SF0466_HolkiraPak_RfA_Review_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SF0466_complete_Holkira_Pak_May-25-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SF0466_HolkiraPak_RfA_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SF0466_Holkira_Pak.pdf,"Hepatitis C, chronic",Reimburse with clinical criteria and/or conditions,Complete,"Jan 6, 2016","May 19, 2016",SF0466-000
daclatasvir,Daklinza,daclatasvir,https://www.cda-amc.ca/sites/default/files/cdr/advice/SF0467_Daklinza_RfA_Review_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SF0467_complete_Daklinza_May_25-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SF0467_Daklinza_RfA_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SF0467_Daklinza.pdf,"Hepatitis C, Chronic",Reimburse with clinical criteria and/or conditions,Complete,"Jan 6, 2016","May 19, 2016",SF0467-000
adalimumab,Humira,Adalimumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0455_HumiraHS_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0455_complete_Humira-HS_May-24-16_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0455_HumiraHS_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0455%20Humira%20HS%20-%20_PI_Submissions_Consolidated_validated.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/SR0455%20Humira%20HS.pdf,Hidradenitis suppurativa,Reimburse with clinical criteria and/or conditions,Complete,"Nov 3, 2015","May 19, 2016",SR0455-000
perampanel,Fycompa,Perampanel,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0458_Fycompa_PGTCS_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0458_complete_Fycompa_May-20-16_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0458_Fycompa_PE.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0458_Fycompa_PI_Submissions_Consolidated_validated.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/SR0458%20Fycompa%20PGTCS%20.pdf,"Epilepsy, primary generalized tonic-clonic seizures",Reimburse with clinical criteria and/or conditions,Complete,"Nov 24, 2015","May 18, 2016",SR0458-000
ledipasvir sofosbuvir,Harvoni,"ledipasvir, sofosbuvir",https://www.cda-amc.ca/sites/default/files/cdr/complete/SF0465_complete_Harvoni%20RFA_May_19-16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SF0465%20Harvoni.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SF0465_Harvoni_Hep_C_RfA_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SF0465_Harvoni_RfA_Review_Report.pdf,"Hepatitis C, chronic",Reimburse with clinical criteria and/or conditions,Complete,"Jan 6, 2016","May 18, 2016",SF0465-000
sofosbuvir,Sovaldi,sofosbuvir,https://www.cda-amc.ca/sites/default/files/cdr/advice/SF0464_Sovaldi_RfA_Review_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SF0464_complete_Sovaldi-May_19_16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SF0464_Sovaldi_RFA_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SF0464_Sovaldi.pdf,"Hepatitis C, chronic",Reimburse with clinical criteria and/or conditions,Complete,"Jan 6, 2016","May 18, 2016",SF0464-000
omalizumab drug plan submission,Xolair,Omalizumab (Drug Plan Submission),https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0457_Xolair_Resubmission_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0457_complete_Xolair_Resub-May_19_16.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0457_Xolair_Resubmission_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0457_Xolair_Resub_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0457_Xolair_Resub.pdf,"Asthma, severe persistent",Reimburse with clinical criteria and/or conditions,Complete,"Nov 18, 2015","May 18, 2016",SR0457-000
avastin platinum resistant ovarian cancer,Avastin,Bevacizumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_bevacizumab_avastin_proc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bevacizumab_avastin_proc-in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bevacizumab_avastin_proc_coi_occ.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bevacizumab_avastin_proc_fdk_roche.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bevacizumab_avastin_proc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bevacizumab_avastin_proc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bevacizumab_avastin_proc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bevacizumab_avastin_proc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bevacizumab_avastin_proc_ptfdk_occ.pdf,Platinum Resistant Ovarian Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Oct 29, 2015","May 5, 2016",PC0066-000
dapagliflozin,Forxiga,Dapagliflozin,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0445_Forxiga_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0445_complete_Forxiga-May_2_16-e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0445_Forxiga_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0445_Forxiga.pdf,"Diabetes mellitus, type 2",Do not list,Complete,"Sep 4, 2015","Apr 27, 2016",SR0445-000
adalimumab,Humira,Adalimumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0450_Humira_UC_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0450_complete_Humira-Apr-19-16_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0450_Humira_UC_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0450_Humira_UC_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0450_Humira.pdf,Ulcerative colitis,Do not list at the submitted price,Complete,"Sep 25, 2015","Apr 15, 2016",SR0450-000
sodium phenylbutyrate,Pheburane,Sodium phenylbutyrate,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0452_Pheburane_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0452_complete_Pheburane-Apr-25_16-e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0452_Pheburane_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/SR0452%20Pheburane.pdf,Urea cycle disorders,List,Complete,"Oct 20, 2015","Apr 15, 2016",SR0452-000
insulin glargine,Basaglar,Insulin glargine,https://www.cda-amc.ca/sites/default/files/cdr/complete/SE0451_complete_Basaglar-Apr_19-16-e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SE0451_Basaglar_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/seb/SE0451_Basaglar_SEB_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SE0451_Basaglar.pdf,"Diabetes mellitus, type 1; diabetes mellitus, type 2",List with clinical criteria and/or conditions,Complete,"Oct 5, 2015","Apr 14, 2016",SE0451-000
blinatumomab blincyto ph all,Blincyto,Blinatumomab,https://www.cda-amc.ca/sites/default/files/pcodr/blinatumomab_blincyto_all_coi_ccsn.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/blinatumomab_blincyto_all_fdk_amgen.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/blinatumomab_blincyto_all_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/blinatumomab_blincyto_all_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/blinatumomab_blincyto_all_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/blinatumomab_blincyto_all_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/blinatumomab_blincyto_all_ptfdk_ccsn.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_blinatumomab_blincyto_all_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_blinatumomab_blincyto_all.pdf,Acute Lymphoblastic Leukemia,Reimburse with clinical criteria and/or conditions,Complete,"Aug 24, 2015","Apr 1, 2016",PC0064-000
opdivo metastatic melanoma,Opdivo,Nivolumab,https://www.cda-amc.ca/sites/default/files/pcodr/nivolumab_opdivo_mm_coi_mnc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/nivolumab_opdivo_mm_fdk_bms.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/nivolumab_opdivo_mm_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/nivolumab_opdivo_mm_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/nivolumab_opdivo_mm_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/nivolumab_opdivo_mm_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/nivolumab_opdivo_mm_ptfdk_mnc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_nivolumab_opdivo_metmela_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_nivolumab_opdivo_metmela.pdf,Metastatic Melanoma,Reimburse with clinical criteria and/or conditions,Complete,"Aug 13, 2015","Apr 1, 2016",PC0063-000
denosumab drug plan submission,Xgeva,Denosumab (Drug Plan Submission),https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0433-001%20Xgeva_FWG_OST_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0433-001_complete_Xgeva_OST-Mar-28_16-e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0433-001%20Xgeva_FWG_OST_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0433-001_Xgeva_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0433-001_Xgeva.pdf,"Prevention of skeletal-related events due to bone metastases from other solid tumors (excluding breast and prostate cancer), including non-small cell lung cancer",List with clinical criteria and/or conditions,Complete,"Jul 31, 2015","Mar 23, 2016",SR0433-001
asfotase alfa,Strensiq,Asfotase alfa,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0443_Strensiq_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0443_complete_Strensiq-Apr-4-16_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0443_Strensiq_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0443%20Strensiq%20_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0443_Strensiq.pdf,"Hypophosphatasia, pediatric-onset",List with criteria/condition,Complete,"Aug 21, 2015","Mar 23, 2016",SR0443-000
filgrastim,Grastofil,Filgrastim,https://www.cda-amc.ca/sites/default/files/cdr/complete/SE0446_cdr_complete_Grastofil_March-22-16_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SE0446_Grastofil_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/seb/SE0446_Grastofil_SEB_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SE0446_Grastofil.pdf,Neutropenia,List with clinical criteria and/or conditions,Complete,"Sep 11, 2015","Mar 18, 2016",SE0446-000
deferiprone,Ferriprox,Deferiprone,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0448_Ferriprox_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0448_cdr_complete_Ferriprox_March-23-16_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0448_Ferriprox_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0448_Ferriprox_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0448_Ferriprox.pdf,Transfusional iron overload,List with clinical criteria and/or conditions,Complete,"Sep 24, 2015","Mar 18, 2016",SR0448-000
elvitegravircobicistatemtricitabinetenofovir alafenamide,Genvoya,Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0449_Genvoya_CL_Report-e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0449_complete_Genvoya-March_22-16_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0449_Genvoya_PE_Report-e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0449%20Genvoya_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0449_ECFTAF.pdf,HIV infection,List,Complete,"Sep 24, 2015","Mar 18, 2016",SR0449-000
sacubitrilvalsartan,Entresto,Sacubitril/valsartan,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0447_Entresto_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0447_complete_Entresto-Mar-22_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0447_Entresto_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0447%20Entresto%20Template_PI_Submissions_Consolidated_validated.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0447_sacubitril_valsartan.pdf,"Heart failure, NYHA class II or III",List with clinical criteria and/or conditions,Complete,"Sep 18, 2015","Mar 18, 2016",SR0447-000
ombitasvir paritaprevir ritonavir,Technivie,Ombitasvir/ paritaprevir/ ritonavir,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0444_Technivie_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0444_cdr_complete_Technivie_March-23-16_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0444_Technivie_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0444%20Technivie%20-%20PI_Submissions_Consolidated_validated.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0444_ombitasvir-paritaprevir-ritonavir.pdf,"Hepatitis C, chronic",List with clinical criteria and/or conditions,Complete,"Sep 4, 2015","Mar 18, 2016",SR0444-000
jakavi polycythemia vera,Jakavi,Ruxolitinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_ruxolitinib_jakavi_pv.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ruxolitinib_jakavi_pv_coi_mpn.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ruxolitinib_jakavi_pv_fdk_novartis.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ruxolitinib_jakavi_pv_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ruxolitinib_jakavi_pv_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ruxolitinib_jakavi_pv_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ruxolitinib_jakavi_pv_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ruxolitinib_jakavi_pv_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ruxolitinib_jakavi_pv_ptfdk_mpn.pdf,Polycythemia vera,Reimburse with clinical criteria and/or conditions,Complete,"Aug 27, 2015","Mar 3, 2016",PC0065-000
denosumab drug plan submission,Xgeva,Denosumab  (Drug Plan Submission),https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0433_000_XgevaBC_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0433-000_complete_Xgeva_BC-Mar_1_16_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0433_000_XgevaBC_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/SR0433-000%20Xgeva.pdf,Prevention of skeletal-related events due to bone metastases from breast cancer,List with clinical criteria and/or conditions,Complete,"Jul 31, 2015","Feb 25, 2016",SR0433-000
tolvaptan,Jinarc,Tolvaptan,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0435_Jinarc_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0435_complete_Jinarc-Feb_26_16_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0435_Jinarc_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0435%20Jinarc%20Template_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/SR0435%20Jinarc.pdf,Autosomal dominant polycystic kidney disease,Do not list,Complete,"May 29, 2015","Feb 24, 2016",SR0435-000
galsulfase drug plan submission,Naglazyme,Galsulfase (Drug Plan Submission),https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0434_Naglazyme_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0434_complete_Naglazyme-Feb-23_16_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0434_Naglazyme_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0434_Naglazyme_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0434_Naglazyme.pdf,Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome),List with clinical criteria and/or conditions,Complete,"Aug 20, 2015","Feb 19, 2016",SR0434-000
evolocumab,Repatha,Evolocumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0441_Repatha_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0441_complete_Rapatha-Feb-23_16_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0441_Repatha_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0441_Repatha_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0441_Repatha.pdf,Primary hyperlipidemia; mixed dyslipidemia,List with clinical criteria and/or conditions,Complete,"Jun 30, 2015","Feb 19, 2016",SR0441-000
fluticasone furoate and vilanterol trifenatate,Breo Ellipta,Fluticasone Furoate and Vilanterol (as trifenatate),https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0442_BreoEllipta_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0442_complete_Breo%20Ellipta-Feb-22-16_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0442_BreoEllipta_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0442_BreoEllipta_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0442_Breo-Ellipta.pdf,Asthma,List with clinical criteria and/or conditions,Complete,"Aug 10, 2015","Feb 18, 2016",SR0442-000
apremilast,Otezla,Apremilast,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0437_OtezlaPsA_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0437_complete_Otezla_PsA-Dec-21-15_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0437_OtezlaPsA_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0437_OtezlaPsA_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0437_Otezla_PsA.pdf,"Arthritis, psoriatic",List with criteria/condition,Complete,"Jun 8, 2015","Dec 17, 2015",SR0437-000
fluticasone furoate,Arnuity Ellipta,Fluticasone furoate,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0439_Arnuity_Ellipta_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0439_complete_Arnuity-Ellipta-Dec-21-15_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0439_Arnuity_Ellipta_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0439_Arnuity_Ellipta_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0439_fluticasone_furoate.pdf,Asthma,List with criteria/condition,Complete,"Jun 26, 2015","Dec 17, 2015",SR0439-000
tiotropium olodaterol,Inspiolto Respimat,Tiotropium / olodaterol,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0436_Inspiolto_Respimat_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0436_complete_Inspiolto-Respimat-Dec_21-15-e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0436_Inspiolto_Respimat_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0436_Inspiolto_Respimat_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0436_Inspiolto_Respimat.pdf,Chronic obstructive pulmonary disease,List with criteria/condition,Complete,"Jun 4, 2015","Dec 17, 2015",SR0436-000
riociguat,Adempas,Riociguat,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0438_Adempas_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0438_complete_Adempas-Dec-21-15_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0438_Adempas_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0438_Adempas_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0438_Adempas-PAH.pdf,Pulmonary arterial hypertension (WHO group 1),List with clinical criteria and/or conditions,Complete,"Jun 25, 2015","Dec 17, 2015",SR0438-000
peginterferon beta 1a,Plegridy,Peginterferon beta-1a,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0440_Plegridy_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0440_complete_Plegridy-Dec-21-15_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0440_Plegridy_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0440_Plegridy%20Patient%20Input%20Submission.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/SR0440%20Plegridy.pdf,"Multiple sclerosis, relapsing-remitting",List with criteria/condition,Complete,"Jun 26, 2015","Dec 17, 2015",SR0440-000
vectibix mcrc,Vectibix,Panitumumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_panitumumab_vectibix_mcrc_coi_ccac.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_panitumumab_vectibix_mcrc_fdk_amgen.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_panitumumab_vectibix_mcrc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_panitumumab_vectibix_mcrc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_panitumumab_vectibix_mcrc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_panitumumab_vectibix_mcrc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_panitumumab_vectibix_mcrc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_panitumumab_vectibix_mcrc.pdf,Metastatic Colorectal Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Apr 15, 2015","Dec 3, 2015",PC0060-000
revlimid newly diagnosed mm,Revlimid,Lenalidomide,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_lenalidomide_revlimid_mm_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_lenalidomide_revlimid_nd-mm_coi_mc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_lenalidomide_revlimid_nd-mm_fdk_celgene.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_lenalidomide_revlimid_nd-mm_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_lenalidomide_revlimid_nd-mm_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_lenalidomide_revlimid_nd-mm_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_lenalidomide_revlimid_nd-mm_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_lenalidomide_revlimid_nd-mm.pdf,"Multiple Myeloma, newly diagnosed",Reimburse with clinical criteria and/or conditions,Complete,"May 4, 2015","Dec 3, 2015",PC0061-000
zykadia metastatic non small cell lung cancer,Zykadia,Ceritinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_coi_lcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_fdk_novartis.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_ptfdk_lcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_ceritinib_zykadia_nsclc.pdf,Metastatic Non-Small Cell Lung Cancer,Do not reimburse,Complete,"Jun 5, 2015","Dec 3, 2015",PC0062-000
dapagliflozin,Forxiga,Dapagliflozin,https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf; https://www.cadth.ca/sites/default/files/cdr/clinical/SR0428_Forxiga_CL_Report.pdf; https://www.cadth.ca/sites/default/files/cdr/complete/SR0428_complete_Forxiga_Nov-24-15_e.pdf; https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0428_Forxiga_PE_Report.pdf; https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0428%20Forxiga_PI_Submissions_Consolidated_validated.pdf; https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_SR0370_Invokana.pdf,"Diabetes mellitus, type 2",List with clinical criteria and/or conditions,Complete,"Apr 30, 2015","Nov 20, 2015",SR0428-000
ivermectin,Rosiver,Ivermectin,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0429_Rosiver_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0429_complete_Rosiver_Nov-23-15_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0429_Rosiver_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0429%20Rosiver_PI_Submissions_Consolidated_validated.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/SR0429%20Rosiver.pdf,Rosacea,List with criteria/condition,Complete,"Apr 30, 2015","Nov 19, 2015",SR0429-000
ivacaftor,Kalydeco,Ivacaftor,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0430_KalydecoR117H_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0430_complete_Kalydeco_R117H_Nov-23-15_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0430_KalydecoR117H_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0430_KalydecoR117H_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0430_Kalydeco_R117H.pdf,"Cystic fibrosis, R117H CFTR gating mutation",List with criteria/condition,Complete,"May 8, 2015","Nov 19, 2015",SR0430-000
rotigotine,Neupro,Rotigotine,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0432_Neupro_CL_Report_resub.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0432_complete_Neupro_Resb_Nov-24-15_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0432_Neupro_PE_Report_resub.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0432_Neupro_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0432_Neupro_Resubmission.pdf,Parkinson’s disease,List with clinical criteria and/or conditions,Complete,"May 21, 2015","Nov 19, 2015",SR0432-000
keytruda metastatic melanoma,Keytruda,Pembrolizumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_coi_cspa.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_coi_mnc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_coi_sysf.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_fdk-merck.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_ptfdk_mnc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_mm_ptfdk_sysf.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_pembrolizumab_keytruda_mm.pdf,Metastatic Melanoma,Reimburse with clinical criteria and/or conditions,Complete,"Apr 16, 2015","Nov 16, 2015",PC0058-000
cyramza advanced gc or gej adenocarcinoma,Cyramza,Ramucirumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_ramucirumab_cyramza_gc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ramucirumab_cyramza_gc-fdk-elc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ramucirumab_cyramza_gc-pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ramucirumab_cyramza_gc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ramucirumab_cyramza_gc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ramucirumab_cyramza_gc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ramucirumab_cyramza_gc_in_rec.pdf,Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma,Reimburse with clinical criteria and/or conditions,Complete,"Apr 15, 2015","Oct 29, 2015",PC0059-000
secukinumab,Cosentyx,Secukinumab,https://www.cda-amc.ca/sites/default/files/attachments/2023-11/TS0001-PsO-Updated-Streamlined-Rec.pdf; https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0407_Cosentyx_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0407_Cosentyx_Oct-30-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0407_Cosentyx_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0407_Cosentyx_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0407_Cosentyx.pdf,Plaque psoriasis,List with criteria/condition,Complete,"Dec 8, 2014","Oct 28, 2015",SR0407-000
vedolizumab,Entyvio,Vedolizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0421_Entyvio_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0421_cdr_complete_Entyvio_Nov-2-15_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0421_Entyvio_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0421_Entyvio_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0421_Entyvio.pdf,Ulcerative colitis,List with clinical criteria and/or conditions,Complete,"Feb 20, 2015","Oct 28, 2015",SR0421-000
taliglucerase alfa,Elelyso,Taliglucerase alfa,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0390_Elelyso_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0390_Elelyso_Oct-30-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0390_Elelyso_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0390_Elelyso.pdf,Gaucher disease,Do not list,Complete,"Aug 15, 2014","Oct 28, 2015",SR0390-000
nintedanib,Ofev,Nintedanib,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0426_Ofev_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0426_Ofev_Oct-19-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0426_Ofev_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0426_Ofev_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0426_Ofev.pdf,Idiopathic pulmonary fibrosis,List with clinical criteria and/or conditions,Complete,"Apr 23, 2015","Oct 15, 2015",SR0426-000
empagliflozin,Jardiance,Empagliflozin,https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf; https://www.cadth.ca/sites/default/files/cdr/clinical/SR0427_Jardiance_CL_Report.pdf; https://www.cadth.ca/sites/default/files/cdr/complete/sr0427_jardiance_oct-19-15.pdf; https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0427_Jardiance_PE_Report.pdf; https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0427%20Jardiance.pdf; https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0427_Jardiance_PI_Submissions.pdf,"Diabetes mellitus, type 2",List with clinical criteria and/or conditions,Complete,"Apr 23, 2015","Oct 15, 2015",SR0427-000
iclusig chronic myeloid leukemia acute lymphoblastic leukemia,Iclusig,Ponatinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ponatinib_iclusig_cml-all_fdk_ariad.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ponatinib_iclusig_cml-all_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ponatinib_iclusig_cml-all_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ponatinib_iclusig_cml-all_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ponatinib_iclusig_cml-all_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_ponatinib_iclusig_cml_all_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_iclusig_cml-all.pdf,Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia,Reimburse with clinical criteria and/or conditions,Complete,"Mar 13, 2015","Oct 1, 2015",PC0056 -000
linaclotide,Constella,Linaclotide,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0409_Constella_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0409_Constella_%20Sept_25-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0409_Constella_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0409_Constella_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0409_Constella.pdf,Irritable bowel syndrome with constipation,Do not list,Complete,"Dec 17, 2014","Sep 23, 2015",SR0409-000
daclatasvir,Daklinza,Daclatasvir,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0417_Daklinza_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0417_cdr_complete_Daklinza_Sept-23-15_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0417_Daklinza_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0417%20Daklinza_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0417_Daklinza.pdf,"Hepatitis C, Chronic",List with clinical criteria and/or conditions,Complete,"Feb 13, 2015","Sep 21, 2015",SR0417-000
denosumab drug plan submission,Prolia,Denosumab (Drug Plan Submission),https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0414_ProliaMen_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0414_cdr_complete_Prolia-Men_Sept-21-15-e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0414_ProliaMen_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0414_ProliaMen_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0414_Prolia-Men.pdf,"Osteoporosis, men",List with clinical criteria and/or conditions,Complete,"Mar 10, 2015","Sep 21, 2015",SR0414-000
umeclidinium,Incruse Ellipta,Umeclidinium,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0422_Incruse_Ellipta_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0422_Incruse_Ellipta_Sept-22-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0422_Incruse_Ellipta_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0422_Incruse-Ellipta.pdf,Chronic obstructive pulmonary disease,List with criteria/condition,Complete,"Mar 4, 2015","Sep 18, 2015",SR0422-000
aclidinium bromideformoterol fumarate dihydrate,Duaklir Genuair,Aclidinium bromide/formoterol fumarate dihydrate,https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0423_Duaklir_Genuair_Sept-22-15-e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0423_DuaklirGenuair_FDC_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0423_DuaklirGenuair_PI.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0423_Duaklir_Genuair.pdf,Chronic obstructive pulmonary disease,List with clinical criteria and/or conditions,Complete,"Apr 1, 2015","Sep 18, 2015",SR0423-000
zydelig chronic lymphocytic leukemia,Zydelig,Idelalisib,https://www.cda-amc.ca/sites/default/files/pcodr/Idelalisib%20Initial%20Recommendation_%202015-07-30_AC_30July2015_FinalPost.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_idelalisib-zydelig-cll.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_idelalisib_zydelig_cll_API.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_idelalisib_zydelig_cll_coi_cllpag.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_idelalisib_zydelig_cll_coi_lc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_idelalisib_zydelig_cll_coi_llsc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_idelalisib_zydelig_cll_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_idelalisib_zydelig_cll_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_idelalisib_zydelig_cll_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_idelalisib_zydelig_cll_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_idelalisib_zydelig_cll_ptfdk_cllpag_llsc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_idelalisib_zydelig_cll_ptfdk_lc.pdf,Chronic lymphocytic leukemia,Reimburse with clinical criteria and/or conditions,Complete,"Apr 7, 2015","Aug 18, 2015",PC0057-000
apremilast,Otezla,Apremilast,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0400_Otezla_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0400-Otezla-Aug-10-15-e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0400_Otezla_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0400_Otezla.pdf,Plaque psoriasis,Do not list,Complete,"Oct 8, 2014","Jul 22, 2015",SR0400-000
xalkori resubmission first line advanced nsclc,Xalkori,Crizotinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_xalkori_nsclc1stline.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_xalkori_1stln_nsclc_coi_lcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_xalkori_1stln_nsclc_coi_ola.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_xalkori_1stln_nsclc_fdk_pfizer.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_xalkori_1stln_nsclc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_xalkori_1stln_nsclc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_xalkori_1stln_nsclc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_xalkori_1stln_nsclc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_xalkori_1stln_nsclc_pagfdk.pdf,First Line ALK Positive Advanced NSCLC,Reimburse with clinical criteria and/or conditions,Complete,"Feb 17, 2015","Jul 21, 2015",PC0054-000
tafinlar mekinist combo metastatic melanoma,Tafinlar & Mekinist in combo,Dabrafenib & Trametinib in combo,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_tafinlarmekinist_melanoma.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_tafinlar_mekinist_metmelanoma_coi_mnc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_tafinlar_mekinist_metmelanoma_coi_sysf.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_tafinlar_mekinist_metmelanoma_fdk_gsm.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_tafinlar_mekinist_metmelanoma_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_tafinlar_mekinist_metmelanoma_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_tafinlar_mekinist_metmelanoma_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_tafinlar_mekinist_metmelanoma_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_tafinlar_mekinist_metmelanoma_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_tafinlar_mekinist_metmelanoma_ptfdk_mnc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_tafinlar_mekinist_metmelanoma_ptfdk_sysf.pdf,Metastatic Melanoma,Reimburse with clinical criteria and/or conditions,Complete,"Feb 13, 2015","Jul 21, 2015",PC0053-000
avastin capecitabine metastatic colorectal cancer,Avastin (with capecitabine),Bevacizumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_avastin_capecitabine_mcrc_coi_ccac.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_avastin_capecitabine_mcrc_fdk_roche.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_avastin_capecitabine_mcrc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_avastin_capecitabine_mcrc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_avastin_capecitabine_mcrc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_avastin_capecitabine_mcrc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_avastin_capecitabine_mcrc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_avastin_capecitabine_mcrc_ptfdk_ccac.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_avastin-capecitabine_mcrc.pdf,Metastatic Colorectal Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Feb 18, 2015","Jul 21, 2015",PC0055-000
tiotropium bromide,Spiriva Respimat,Tiotropium bromide,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0412_SpirivaRespimat_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0412-complete-Spiriva-Respimat-July-20-15-e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0412_SpirivaRespimat_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0412%20Spiriva%20Respimat.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0412_SpirivaRespimat_PI_Submissions.pdf,Chronic obstructive pulmonary disease,List with clinical criteria and/or conditions,Complete,"Dec 23, 2014","Jul 16, 2015",SR0412-000
nexavar metastatic progressive differentiated thyroid carcinoma,Nexavar,Sorafenib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_sorafenib_nexavar_dtc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_sorafenib_nexavar_dtc_coi_tcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_sorafenib_nexavar_dtc_fdk_bayer.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_sorafenib_nexavar_dtc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_sorafenib_nexavar_dtc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_sorafenib_nexavar_dtc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_sorafenib_nexavar_dtc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_sorafenib_nexavar_dtc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_sorafenib_nexavar_dtc_ptfdk_tcc.pdf,Metastatic Progressive Differentiated Thyroid Carcinoma (DTC),Do not reimburse,Complete,"Dec 19, 2014","Jul 16, 2015",PC0049-000
perjeta or perjeta herceptin combo pack neoadjuvant breast cancer,Perjeta or Perjeta-Herceptin Combo Pack,Pertuzumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_pertuzumab_perjeta_nbc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pertuzumab_perjeta_nbc_coi_cbcn.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pertuzumab_perjeta_nbc_fdk_roche.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pertuzumab_perjeta_nbc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pertuzumab_perjeta_nbc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pertuzumab_perjeta_nbc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pertuzumab_perjeta_nbc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pertuzumab_perjeta_nbc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_pertuzumab_perjeta_nbc_ptfdk_cbcn.pdf,Neoadjuvant Breast Cancer,Do not reimburse,Complete,"Dec 19, 2014","Jul 16, 2015",PC0050-000
stivarga resubmission mcrc,Stivarga Resubmission (CRC),Regorafenib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_regorafenib_stivarga-resub_mcrc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_regorafenib_stivarga_resub_mcrc_coi_ccac.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_regorafenib_stivarga_resub_mcrc_fdk_bayer.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_regorafenib_stivarga_resub_mcrc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_regorafenib_stivarga_resub_mcrc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_regorafenib_stivarga_resub_mcrc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_regorafenib_stivarga_resub_mcrc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_regorafenib_stivarga_resub_mcrc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_regorafenib_stivarga_resub_mcrc_ptfdk_ccac.pdf,Metastatic Colorectal Cancer,Do not reimburse,Complete,"Dec 19, 2014","Jul 16, 2015",PC0046-000
xtandi first line mcrpc,Xtandi,Enzalutamide,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_xtandi_mcrpc1stline.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_enzalutamide_xtandi_1stln_mcrpc_coi_pcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_enzalutamide_xtandi_1stln_mcrpc_fdbk_astellas.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_enzalutamide_xtandi_1stln_mcrpc_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_enzalutamide_xtandi_1stln_mcrpc_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_enzalutamide_xtandi_1stln_mcrpc_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_enzalutamide_xtandi_1stln_mcrpc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_enzalutamide_xtandi_1stln_mcrpc_ptfdk_pcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr_enzalutamide_xtandi_1stln_mcrcp_in_rec.pdf,First Line Metastatic Castration-Resistant Prostate Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Oct 2, 2014","Jun 22, 2015",PC0044-000
proleukin transit melanoma,Proleukin,Aldesleukin (IL-2),https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-aldesleukin-proleukin-in-transit-melanoma-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_proleukin-melanoma.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_adesleukin_proleukin_coi_mnc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_adesleukin_proleukin_coi_sysf.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_adesleukin_proleukin_fdk_novartis.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_adesleukin_proleukin_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_adesleukin_proleukin_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_adesleukin_proleukin_pagfdk_0.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_adesleukin_proleukin_ptfdk_mnc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_aldesleukin_proleukin_fn_rec.pdf,In-transit Melanoma,Reimburse,Complete,"Jan 30, 2015","Jun 22, 2015",PC0051-000
sylvant multicentric castlemans disease,Sylvant,Siltuximab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_sylvant_mcd.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_siltuximab_sylvant_mcd_coi_cord.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_siltuximab_sylvant_mcd_fdk_janssen.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_siltuximab_sylvant_mcd_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_siltuximab_sylvant_mcd_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_siltuximab_sylvant_mcd_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_siltuximab_sylvant_mcd_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_siltuximab_sylvant_mcd_pagfdk.pdf,Multicentric Castleman's disease (MCD),Reimburse with clinical criteria and/or conditions,Complete,"Jan 30, 2015","Jun 22, 2015",PC0052-000
alemtuzumab,Lemtrada,Alemtuzumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0405_Lemtrada_RRMS_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr-complete-SR0405-Lemtrada-June-22-2015.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0405_Lemtrada_RRMS_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0405%20Lemtrada_RRMS_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0405_Lemtrada.pdf,"Multiple sclerosis, relapsing-remitting",List with criteria/condition,Complete,"Nov 27, 2014","Jun 18, 2015",SR0405-000
ombitasvirparitaprevirritonavir and dasabuvir,Holkira Pak,Ombitasvir/paritaprevir/ritonavir and dasabuvir,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0406_HolkiraPak_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0406-Holkira-Pak-July-22-15-e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0406_HolkiraPak_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0406_HolkiraPak_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/SR0406%20Holkira%20Pak.pdf,"Hepatitis C, chronic",List with clinical criteria and/or conditions,Complete,"Dec 3, 2014","Jun 18, 2015",SR0406-000
brinzolamide brimonidine,Simbrinza,Brinzolamide / brimonidine,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0403_Simbrinza_June-19_2015.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0403_Simbrinza_FDC_Review_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0403_Simbrinza_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0403_Simbrinza.pdf,Glaucoma and ocular hypertension,List,Complete,"Nov 3, 2014","Jun 17, 2015",SR0403-000
azelastine hcl and fluticasone propionate,Dymista,Azelastine  HCl and fluticasone propionate,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0408_Dymista_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0408_Dymista_June-19-2015.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0408_Dymista_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0408_Dymista_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0408_Dymista.pdf,Seasonal allergic rhinitis,Do not list,Complete,"Dec 9, 2014","Jun 17, 2015",SR0408-000
avastin ovarian cancer,Avastin,Bevacizumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bevacizumab_avastin_oc-fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bevacizumab_avastin_oc-fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bevacizumab_avastin_oc-fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bevacizumab_avastin_oc_coi_occ_0.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bevacizumab_avastin_oc_fdk_hlroche.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bevacizumab_avastin_oc_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bevacizumab_avastin_oc_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bevacizumab_avastin_oc_ptfdk_occ.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_avastin-oc.pdf,Ovarian Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Nov 28, 2014","Jun 4, 2015",PC0047-000
istodax peripheral t cell lymphoma,Istodax,Romidepsin,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_istodax_ptcl.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_romidepsin_istodax_ptcl_fdk_celgene.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_romidepsin_istodax_ptcl_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_romidepsin_istodax_ptcl_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_romidepsin_istodax_ptcl_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_romidepsin_istodax_ptcl_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_romidepsin_istodax_ptcl_pagfdk.pdf,Peripheral T-Cell Lymphoma,Reimburse with clinical criteria and/or conditions,Complete,"Dec 1, 2014","May 19, 2015",PC0048-000
aflibercept,Eylea,Aflibercept,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0401_EyleaCRVO_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0401_Eylea-CRVO_May-11-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0401_EyleaCRVO_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0401_EyleaCRVO_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0401_Eylea_CRVO.pdf,"Macular edema, central retinal vein occlusion",List with clinical criteria and/or conditions,Complete,"Oct 17, 2014","May 7, 2015",SR0401-000
apixaban,Eliquis,Apixaban,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0397_EliquisVTE_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0397_Eliquis-VTE_May-11-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0397_EliquisVTE_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0397_Eliquis_VTE_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0397_Eliquis_VTE.pdf,"Venous thromboembolic events, treatment and prevention of recurrence",List with clinical criteria and/or conditions,Complete,"Sep 18, 2014","May 7, 2015",SR0397-000
omalizumab,Xolair,Omalizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0398_XolairCIU_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0398_Xolair-CIU_May-11-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0398_XolairCIU_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0398%20Xolair_Template_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0398_Xolair_CIU.pdf,Chronic idiopathic urticaria,List with clinical criteria and/or conditions,Complete,"Sep 22, 2014","May 7, 2015",SR0398-000
aflibercept,Eylea,Aflibercept,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0396_EyleaDME_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0396_Eylea-DME_May-11-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0396_EyleaDME_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0396%20Eylea%20DME_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0396_Eylea_DME.pdf,"Macular edema, diabetic",List with clinical criteria and/or conditions,Complete,"Sep 16, 2014","May 7, 2015",SR0396-000
bosulif chronic myeloid leukemia,Bosulif,Bosutinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bosutinib_bosulif_cml_coi_cmlsc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bosutinib_bosulif_cml_fdk_pfizer.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bosutinib_bosulif_cml_fn_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bosutinib_bosulif_cml_fn_egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bosutinib_bosulif_cml_fn_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bosutinib_bosulif_cml_in_rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_bosutinib_bosulif_cml_pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_boustinib_bosulif_cml.pdf,Chronic Myeloid Leukemia,Reimburse with clinical criteria and/or conditions,Complete,"May 30, 2014","Apr 21, 2015",PC0039-000
tofacitinib,Xeljanz,Tofacitinib,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0380_Xeljanz_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0380_Xeljanz_Apr-21-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0380_Xeljanz_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0380_Xeljanz.pdf,"Arthritis, rheumatoid",List with criteria/condition,Complete,"May 5, 2014","Apr 17, 2015",SR0380-000
certolizumab pegol,Cimzia,Certolizumab pegol,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0385_CimziaAS_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0385_Cimzia-AS_Apr-21-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0385_CimziaAS_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0385_Cimzia_AS_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0385_Cimzia.pdf,Ankylosing spondylitis,List with criteria/condition,Complete,"Jun 23, 2014","Apr 17, 2015",SR0385-000
lomitapide,Juxtapid,Lomitapide,https://www.cda-amc.ca; https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0386_Juxtapid_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0386_Juxtapid-Apr-21_15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0386_Juxtapid_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0386_Juxtapid.pdf,"Hypercholesterolemia, homozygous familial",Do not list,Complete,"Jul 8, 2014","Apr 17, 2015",SR0386-000
certolizumab pegol,Cimzia,Certolizumab pegol,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0394_CimziaPsA_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0394_Cimzia-PsA_Apr-21-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0394_CimziaPsA_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0394%20Cimzia%20PsA_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/SR0394%20Cimzia%20PsA.PDF,"Arthritis, psoriatic",List with criteria/condition,Complete,"Sep 2, 2014","Apr 17, 2015",SR0394-000
dolutegravir abacavir lamivudine,Triumeq,Dolutegravir / abacavir / lamivudine,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0387_Triumeq_Apr-21-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0387_Triumeq_FDC_Review_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0387_Triumeq.pdf,HIV Infection,List with criteria/condition,Complete,"Jul 31, 2014","Apr 17, 2015",SR0387-000
rifaximin,Zaxine,Rifaximin,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0388_Zaxine_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0388_Zaxine-Apr-20-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0388_Zaxine_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0388%20Zaxine_PI_Submissions_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0388_Zaxine.pdf,Hepatic encephalopathy,List with criteria/condition,Complete,"Aug 5, 2014","Apr 16, 2015",SR0388-000
eslicarbazepine acetate,Aptiom,Eslicarbazepine acetate,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0391_Aptiom_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0391_Aptiom_Apr-20-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0391_Aptiom_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0391%20Aptiom_PI_Submissions_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0391_Aptiom.pdf,"Epilepsy, partial-onset seizures",List with criteria/condition,Complete,"Aug 15, 2014","Apr 16, 2015",SR0391-000
everolimus,Afinitor,Everolimus,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0376_AfinitorSEGA_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_compelte_SR0376_Afinitor_Apr-17-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0376_AfinitorSEGA_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0376%20Afinitor%20SEGA_Template_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0376_Afinitor_SEGA.pdf,Subependymal giant cell astrocytoma associated with tuberous sclerosis complex,Do not list,Complete,"Mar 19, 2014","Apr 15, 2015",SR0376-000
pirfenidone,Esbriet,Pirfenidone,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0393_Esbriet_CL_Report_resub.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_compelte_SR0393_Esbriet_Apr-17-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0393_Esbriet_PE_Report_resub.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0393_Esbriet.pdf,Idiopathic pulmonary fibrosis,List with criteria/condition,Complete,"Aug 29, 2014","Apr 15, 2015",SR0393-000
elosulfase alfa,Vimizim,Elosulfase alfa,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0389_Vimizim_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0389_complete_Vimizim_Mar-27-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0389_Vimizim_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0389%20Vimizim_PI_Submissions_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0389_Vimizim.pdf,Mucopolysaccharidosis IVA (Morquio A syndrome),Do not list,Complete,"Aug 5, 2014","Mar 25, 2015",SR0389-000
avastin cervical cancer,Avastin,Bevacizumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-avastin-cc-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-avastin-cc-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-avastin-cc-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-avastincc-coi-occ.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-avastincc-fdk-hlr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-avastincc-fdk-occ.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-avastincc-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-avastincc-pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_avastin-cc.pdf,Cervical Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Oct 27, 2014","Mar 23, 2015",PC0045-000
eltrombopag,Revolade,Eltrombopag,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0377_RevoladeTCP_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0377_Revolade_Mar-23-2015_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0377_RevoladeTCP_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0377%20Revolade%20TCP_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0377_Revolade.pdf,Thrombocytopenia associated with chronic hepatitis c infection,List with criteria/condition,Complete,"Mar 31, 2014","Mar 18, 2015",SR0377-000
darunavircobicistat,Prezcobix,Darunavir/cobicistat,https://www.cda-amc.ca; https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0381_Prezcobix_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_%20SR0381_Prezcobix_Mar_20-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0381_Prezcobix_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0381_Prezcobix.pdf,HIV Infection,List with criteria/condition,Complete,"May 22, 2014","Mar 18, 2015",SR0381-000
ledipasvir sofosbuvir,Harvoni,Ledipasvir / Sofosbuvir,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0395_Harvoni_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0395_Harvoni_Mar_20-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0395_Harvoni_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0395%20Harvoni_PI_Submissions_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0395_Harvoni.pdf,"Hepatitis C, chronic",List with criteria/condition,Complete,"Sep 15, 2014","Mar 18, 2015",SR0395-000
imbruvica chronic lymphocytic leukemiasmall lymphocytic lymphoma previously treated,Imbruvica,Ibrutinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-ibrutinib-cll-sll-coi-lc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-ibrutinib-cll-sll-fdk-lc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-ibrutinib-cll-sll-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-ibrutinib-cll-sll-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-ibrutinib-cll-sll-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-ibrutinib-cll-sll-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-ibrutinib-coi-cllpag.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-ibrutinib-coi-llsc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-ibrutinib-fdk-janssen.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-ibrutinib-fdk-llsccllpag.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-ibrutinib-pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_ibrutinib_imbruvica-CLL.pdf,Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma,Reimburse with clinical criteria and/or conditions,Complete,"Aug 15, 2014","Mar 5, 2015",PC0043-000
pasireotide diaspartate,Signifor,Pasireotide diaspartate,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0372_Signifor_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0372_Signifor_Feb-26-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0372_Signifor_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0372%20Signifor_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0372_Signifor.pdf,Cushing’s disease,Do not list,Complete,"Feb 27, 2014","Feb 24, 2015",SR0372-000
ranibizumab,Lucentis,Ranibizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0373_LucentisCNV_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0373_Lucentis_CNV_Feb-20-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0373_LucentisCNV_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0373_Lucentis_PI_Submissions_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0373_Lucentis.pdf,Myopic choroidal neovascularisation,List with criteria/condition,Complete,"Feb 28, 2014","Feb 19, 2015",SR0373-000
tocilizumab,Actemra,Tocilizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0374_ActemraSC_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0374_Actemra_SC_Feb-23-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0374_ActemraSC_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0374_Actemra%20SC_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0374_Actemra%20SC.pdf,"Arthritis, rheumatoid",List with criteria/condition,Complete,"Mar 3, 2014","Feb 19, 2015",SR0374-000
arzerra chronic lymphocytic leukemia,Arzerra,Ofatumumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-arzerra-cll-coi-cllpag.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-arzerra-cll-coi-llsc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-arzerra-cll-fdk-gsk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-arzerra-cll-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-arzerra-cll-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-arzerra-cll-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-arzerra-cll-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-arzerra-cll-pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_ofatumumab_arzerra_cll.pdf,Chronic Lymphocytic Leukemia,Do not reimburse,Complete,"Apr 14, 2014","Jan 29, 2015",PC0038-000
macitentan,Opsumit,Macitentan,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0364_Opsumit_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0364_Opsumit_Jan-30-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0364_Opsumit_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0364_Opsumit_PI_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0364_Opsumit.pdf,Pulmonary arterial hypertension,List with clinical criteria and/or conditions,Complete,"Dec 18, 2013","Jan 28, 2015",SR0364-000
gazyva chronic lymphocytic leukemia,Gazyva,Obinutuzumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-gazyva-cll-coi-cllpag.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-gazyva-cll-coi-lc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-gazyva-cll-coi-llsc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-gazyva-cll-fdk-lc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-gazyva-cll-fdk-roche.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-gazyva-cll-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-gazyva-cll-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-gazyva-cll-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-gazyva-cll-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-gazyva-cll-pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-gazyva-cll-ptfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_gazyva-cll.pdf,Chronic Lymphocytic Leukemia,Reimburse,Complete,"Aug 11, 2014","Jan 27, 2015",PC0041-000
alogliptin,Nesina,Alogliptin,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0368_Nesina_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0368_Nesina_Jan-19-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0368_Nesina_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0368_Nesina_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0368_Nesina.pdf,"Diabetes mellitus, type 2",Do not list,Complete,"Jan 30, 2014","Jan 15, 2015",SR0368-000
alogliptin plus metformin,Kazano,Alogliptin plus metformin,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0367_Kazano_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0367_Kazano_Jan-19-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0367_Kazano_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0367_Kazano_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0367_Kazano.pdf,"Diabetes mellitus, type 2",Do not list,Complete,"Jan 30, 2014","Jan 15, 2015",SR0367-000
canagliflozin,Invokana,Canagliflozin,https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf; https://www.cadth.ca/sites/default/files/cdr/clinical/SR0370_Invokana_CL_Report.pdf; https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_SR0370_Invokana_Jan-19_15.pdf; https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0370_Invokana_PE_Report.pdf; https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0370%20Invokana_PI_Submissions.pdf; https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_SR0370_Invokana.pdf,"Diabetes mellitus, type 2",List with criteria/condition,Complete,"Feb 24, 2014","Jan 15, 2015",SR0370-000
umeclidiniumvilanterol,Anoro Ellipta,Umeclidinium/vilanterol,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0371_Anoro_Ellipta_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0371_Anoro_Ellipta_Jan-23-15.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0371_Anoro_Ellipta_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0371_Anoro_Ellipta_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0371_Anoro_Ellipta.pdf,Chronic obstructive pulmonary disease,List with criteria/condition,Complete,"Feb 26, 2014","Jan 15, 2015",SR0371-000
yervoy first line advanced melanoma,Yervoy,Ipilimumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-yervoy1st-coi-mnc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-yervoy1st-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-yervoy1st-mncfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-yervoy1stsub-bms.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-yervoy1stsub-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-yervoy1stsub-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-yervoy1stsub-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-yervoy1stsub-pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_ipilimumab_yervoy_melanoma1stline.pdf,First Line Advanced Melanoma,Reimburse with clinical criteria and/or conditions,Complete,"Aug 15, 2014","Dec 22, 2014",PC0042-000
aripiprazole,Abilify Maintena,Aripiprazole,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0366_Abilify%20Maintena_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0366_Abilify-Maintena_Dec-23-14.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0366_Abilify%20Maintena_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0366_Abilify%20Maintena_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0366_Abilify_Maintena.pdf,Schizophrenia,List with criteria/condition,Complete,"Jan 6, 2014","Dec 19, 2014",SR0366-000
indacaterolglycopyrronium,Ultibro Breezhaler,Indacaterol/glycopyrronium,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0369_UltibroBreezhaler_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0369_Ultibro%20Breezhaler_Jan30_2015.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0369_UltibroBreezhaler_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0369_Ultibro%20Breezhaler_PI.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0369_Ultibro_Breezhaler.pdf,Chronic obstructive pulmonary disease,List with criteria/condition,Complete,"Feb 3, 2014","Dec 19, 2014",SR0369-000
icatibant,Firazyr,Icatibant,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0375_Firazyr_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0375_Firazyr_Dec-23-14.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0375_Firazyr_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0375_Firazyr.pdf,Hereditary angioedema,List with clinical criteria and/or conditions,Complete,"Mar 4, 2014","Dec 19, 2014",SR0375-000
ivacaftor,Kalydeco,Ivacaftor,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0379_KalydecoCF_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0379_Kalydeco_Dec-23-14.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0379_KalydecoCF_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0379_Kalydeco_PI_Submissions_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0379_Kalydeco%20CF.pdf,"Cystic Fibrosis, CFTR gating mutations",List with criteria/condition,Complete,"May 1, 2014","Dec 19, 2014",SR0379-000
infliximab,Inflectra,Infliximab,https://www.cda-amc.ca/sites/default/files/attachments/2023-11/TS0001-PsO-Updated-Streamlined-Rec.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SE0384_Inflectra_Dec-23-14.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SE0384%20Inflectra_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/seb/SE0384_Inflectra_SEB_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SE0384_Inflectra.pdf,"Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis",List with criteria/condition,Complete,"Jun 17, 2014","Dec 19, 2014",SE0384-000
onabotulinumtoxina,Botox,OnabotulinumtoxinA,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0362_BotoxOAB_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0362_Botox-OAB_nov14_2014.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0362_BotoxOAB_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0362_Botox%20OAB_PI_Submissions_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0362_Botox_OAB.pdf,Urinary incontinence,List with criteria/condition,Complete,"Nov 25, 2013","Nov 12, 2014",SR0362-000
mirabegron,Myrbetriq,Mirabegron,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0363_Myrbetriq_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0363_Myrbetriq_nov14_2014.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0363_Myrbetriq_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0363_Myrbetriq_PI_Submissions_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0363_Myrbetriq.pdf,Overactive bladder,List with criteria/condition,Complete,"Nov 27, 2013","Nov 12, 2014",SR0363-000
aripiprazole,Abilify,Aripiprazole,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0354_AbilifyMDD_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0354_Abilify-MDD_Oct-24_2014.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0354_AbilifyMDD_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0354_Abilify.pdf,"Depression, Major Depressive Disorder",Do not list,Complete,"Oct 1, 2013","Oct 22, 2014",SR0354-000
ustekinumab,Stelara,Ustekinumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0359_Stelara_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0359_Stelara_Oct-22-14.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0359_Stelara_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0359_Stelara_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0359_Stelara.pdf,"Arthritis, psoriatic",Do not list at the submitted price,Complete,"Oct 30, 2013","Oct 20, 2014",SR0359-000
aflibercept,Eylea,Aflibercept,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0361_Eylea_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0361-000_eylea_october_22_2014.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0361_Eylea_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SR0361_Eylea_PI_Submissions.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0361_Eylea.pdf,"Macular degeneration, age-related",List with criteria/condition,Complete,"Nov 18, 2013","Oct 20, 2014",SR0361-000
stiripentol,Diacomit,Stiripentol,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0360_diacomit_cl_report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0360_Diacomit_October_20_2014.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0360_diacomit_pe_report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0360_Diacomit.pdf,Dravet Syndrome,List with criteria/condition,Complete,"Oct 30, 2013","Oct 16, 2014",SR0360-000
guanfacine hydrochloride,Intuniv XR,Guanfacine hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0349_IntunivXR_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0349_Intuniv-XR_sep-26_14.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0349_IntunivXR_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0349_Intuniv-XR.pdf,Attention-deficit/hyperactivity disorder (ADHD),Do not list,Complete,"Aug 27, 2013","Sep 24, 2014",SR0349-000
phleum pratense,Grastek,Phleum pratense,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0352_Grastek_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0352_Grastek_sep-26_14.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0352_Grastek_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0352_Grastek.pdf,Allergic rhinitis,Do not list,Complete,"Sep 30, 2013","Sep 24, 2014",SR0352-000
abraxane metastatic pancreatic cancer,Abraxane,Nab-paclitaxel,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-abraxane-mpc-coi-cc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-abraxane-mpc-coi-pcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-abraxane-mpc-fdk-celgene.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-abraxane-mpc-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-abraxane-mpc-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-abraxane-mpc-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-abraxane-mpc-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-abraxane-mpc-pag-fdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_nabpaclitaxel_abraxane_pc.pdf,Metastatic Pancreatic Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Feb 14, 2014","Sep 23, 2014",PC0037-000
zaltrap metastatic colorectal cancer,Zaltrap,Aflibercept,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_zaltrap-mcrc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zaltrap-mcrc-coi-ccac.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zaltrap-mcrc-fdk-ccac.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zaltrap-mcrc-fdk-sanofi.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zaltrap-mcrc-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zaltrap-mcrc-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zaltrap-mcrc-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zaltrap-mcrc-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zaltrap-mcrc-pag-fdk.pdf,Metastatic Colorectal Cancer,Do not reimburse,Complete,"Nov 26, 2013","Sep 5, 2014",PC0035-000
dolutegravir,Tivicay,Dolutegravir,https://www.cda-amc.ca/sites/default/files/cdr/clinical/sr0357_tivicay_cl_report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_tivicay_august_20_2014.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/sr0357_tivicay_pe_report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0357_Tivicay.pdf,HIV infection,List,Complete,"Oct 18, 2013","Aug 18, 2014",SR0357-000
fluticasone furoate vilanterol,Breo Ellipta,Fluticasone furoate /vilanterol,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0358_BreoEllipta_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_breo_ellipta_august_20_2014.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0358_BreoEllipta_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0358_Breo_Ellipta.pdf,Chronic Obstructive Pulmonary Disease (COPD),List with criteria/condition,Complete,"Oct 29, 2013","Aug 18, 2014",SR0358-000
sofosbuvir,Sovaldi,Sofosbuvir,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0356_Sovaldi_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_sovaldi_august_20_2014.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0356_Sovaldi_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0356_TBC_%28Sofosbuvir%29.pdf,"Hepatitis C, chronic",List with criteria/condition,Complete,"Oct 1, 2013","Aug 18, 2014",SR0356-000
pomalyst multiple myeloma,Pomalyst,Pomalidomide,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-pomalyst-mm-coi-myelcan.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-pomalyst-mm-fdk-celgene.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-pomalyst-mm-fdk-myelcan.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-pomalyst-mm-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-pomalyst-mm-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-pomalyst-mm-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-pomalyst-mm-pag-fdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_pomalidomide_pomalyst_mm.pdf,Multiple Myeloma,Reimburse with clinical criteria and/or conditions,Complete,"Jan 13, 2014","Jul 31, 2014",PC0036-000
riociguat,Adempas,Riociguat,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0353_Adempas_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0353_complete_Adempas_Jul-21-14.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0353_Adempas_PE_Report-e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0353_Adempas.pdf,Chronic thromboembolic pulmonary hypertension,List with criteria/condition,Complete,"Sep 30, 2013","Jul 17, 2014",SR0353-000
golimumab,Simponi I.V.,Golimumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0351_SimponiIV_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0351_complete_Simponi_IV_Jul-21-14.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0351_SimponiIV_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0351_Simponi-IV.pdf,"Arthritis, rheumatoid",List with criteria/condition,Complete,"Sep 12, 2013","Jul 17, 2014",SR0351-000
saxagliptin metformin,Komboglyze,Saxagliptin + metformin,https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf; https://www.cadth.ca/sites/default/files/cdr/complete/SR0348_complete_Komboglyze-Jun-24-14.pdf; https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0348_Komboglyze_FDC_Report_e.pdf; https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_SR0348_Komboglyze-TL.pdf,"Diabetes Mellitus, type 2",List with criteria/condition,Complete,"Aug 23, 2013","Jun 20, 2014",SR0348-000
simeprevir,Galexos,Simeprevir,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0347_Galexos_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0347_complete_Galexos-Jun-20-14.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0347_Galexos_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0347_TBC.pdf,"Hepatitis C, chronic",List with criteria/condition,Complete,"Aug 22, 2013","Jun 18, 2014",SR0347-000
teriflunomide,Aubagio,Teriflunomide,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0350_Aubagio_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0350_complete_Aubagio_Jun-19-14.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0350_Aubagio_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0350_Aubagio.pdf,"Multiple sclerosis, relapsing-remitting",Do not list at the submitted price,Complete,"Aug 28, 2013","Jun 18, 2014",SR0350-000
onabotulinumtoxina,Botox,OnabotulinumtoxinA,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0345_Botox_Migraine_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0345_complete_Botox-May-30-14.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0345_Botox_Migraine_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0345_Botox-Migraine.pdf,Migraine,Do not list,Complete,"Aug 15, 2013","May 28, 2014",SR0345-000
rotigotine,Neupro,Rotigotine,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0344_Neupro_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0344_complete_Neupro_May-30-14.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0344_Neupro_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0344_Neupro.pdf,Parkinson's disease,Do not list,Complete,"Jul 31, 2013","May 28, 2014",SR0344-000
giotrif advanced non small cell lung cancer,Giotrif,Afatinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-giotrif-nsclc-coi-lcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-giotrif-nsclc-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-giotrif-nsclc-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-giotrif-nsclc-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-giotrif-nsclc-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-giotrif-nsclc-infdk-bicl.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-giotrif-nsclc-pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-giotrif-nsclc-ptfdbk-lcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_giotrif-nsclc.pdf,Advanced or Metastatic Non-Small Cell Lung Cancer,Reimburse,Complete,"Jun 7, 2013","May 2, 2014",PC0032-000
stivarga gastrointestinal stromal tumours,Stivarga (GIST),Regorafenib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-stivarga-gist-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-stivarga-gist-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-stivarga-gist-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-stivarga-gist-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-stivargagist-coi-scfc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-stivargagist-fdk-bayer.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-stivargagist-fdk-scfc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-stivargagist-pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_regorafenib_stivarga_gist.pdf,Gastrointestinal Stromal Tumour,Reimburse with clinical criteria and/or conditions,Complete,"Oct 11, 2013","May 2, 2014",PC0034-000
eplerenone,Inspra,Eplerenone,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0342_InspraHF_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0342_Inspra_Apr-28_14.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0342_Inspra%20HF_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0342%20Inspra%20HF.pdf,"Heart failure, NYHA class II",Do not list at the submitted price,Complete,"Jul 12, 2013","Apr 24, 2014",SR0342-000
aclidinium bromide,Tudorza Genuair,Aclidinium bromide,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0346_TudorzaGenuair_CL_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SR0346_Tudorza%20Genuair_Ap_23_2014.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0346_TudorzaGenuair_PE_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0346_Tudorza_Genuair.pdf,Chronic Obstructive Pulmonary Disease,List with criteria/condition,Complete,"Aug 21, 2013","Apr 21, 2014",SR0346-000
rivaroxaban,Xarelto,Rivaroxaban,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0327_Xarelto%20PEm_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0327_complete_Xarelto%20PEm_Mar-28-14.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0327_Xarelto%20PEm_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0327_Xarelto_PEm.pdf,"Venous thromboembolic events, pulmonary embolism",List with criteria/condition,Complete,"May 6, 2013","Mar 26, 2014",SR0327-000
tocilizumab,Actemra,Tocilizumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0343_Actemra%20pJIA_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Actemra_Mar_24_14_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0343_Actemra%20pJIA_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0343_Actemra-pJIA.pdf,"Arthritis, polyarticular juvenile idiopathic",List with criteria/condition,Complete,"Jul 29, 2013","Mar 19, 2014",SR0343-000
golimumab,Simponi,Golimumab,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0341_Simponi_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0341_complete_Simponi_Mar-28-14.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0341_Simponi_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0341%20Simponi%20UC.pdf,Ulcerative colitis,Do not list at the submitted price,Complete,"Jul 12, 2013","Mar 19, 2014",SR0341-000
trisenox acute promyelocytic leukemia,Trisenox,Arsenic Trioxide,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_trisenox-apl.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-trisenox-apl-coi-llsc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-trisenox-apl-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-trisenox-apl-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-trisenox-apl-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-trisenox-apl-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-trisenox-apl-pag-fdbdk.pdf,Acute Promyelocytic Leukemia,Reimburse,Complete,"Aug 30, 2013","Feb 18, 2014",PC0033-000
ingenol mebutate,Picato,Ingenol mebutate,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0330_Picato_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0330_complete_Picato-30-Jan-14.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0330_Picato_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0330_Picato.pdf,Actinic keratosis,Do not list,Complete,"May 9, 2013","Jan 22, 2014",SR0330-000
erbitux metastatic colorectal cancer,Erbitux,Cetuximab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-erbitux-mcrc-coi-ccac.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-erbitux-mcrc-fdbk-ccac.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-erbitux-mcrc-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-erbitux-mcrc-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-erbitux-mcrc-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-erbitux-mcrc-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-erbitux-mcrc-pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_erbitux-mcrc.pdf,Metastatic Colorectal Cancer,Do not reimburse,Complete,"Jun 10, 2013","Jan 10, 2014",PC0031-000
vismodegib erivedge advanced bcc,Erivedge,Vismodegib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-erivedge-bcc-coi-mnc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-erivedge-bcc-coi-sys.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-erivedge-bcc-fdk-roche.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-erivedge-bcc-fdk-sys.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-erivedge-bcc-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-erivedge-bcc-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-erivedge-bcc-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-erivedge-bcc-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-erivedge-bcc-pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_erivedge-abcc.pdf,Basal Cell Carcinoma,Reimburse with clinical criteria and/or conditions,Complete,"Jun 14, 2013","Jan 10, 2014",PC0015-000
trastuzumab emtansine metastatic breast cancer,Kadcyla,Trastuzumab emtansine,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-kadcyla-mbc-coi-cbcn.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-kadcyla-mbc-coi-rebc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-kadcyla-mbc-fdk-roche.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-kadcyla-mbc-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-kadcyla-mbc-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-kadcyla-mbc-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-kadcyla-mbc-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-kadcyla-mbc-pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_kadcyla-mbc.pdf,Advanced or Metastatic Breast Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Mar 15, 2013","Jan 10, 2014",PC0024-000
lurasidone,Latuda,Lurasidone,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0331_Latuda_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0331_complete_Latuda_Dec-24-13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0331_Latuda_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0331_Latuda-Resub-1.pdf,Schizophrenia,List with criteria/condition,Complete,"May 9, 2013","Dec 20, 2013",SR0331-000
somatropin,Genotropin,Somatropin,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0332_GenotropinGHD-A_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0332_complete_Genotropin-GHD-Adults_Dec-23-13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0332_GenotropinGHD-A_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0332_Genotropin_GHD-A.pdf,"Growth hormone deficiency, adult",List with criteria/condition,Complete,"May 27, 2013","Dec 20, 2013",SR0332-000
somatropin,Genotropin,Somatropin,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0333_GenotropinGHD-P_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0333_complete_Genotropin-GHD-P_Dec-23-13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0333_GenotropinGHD-P_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0333_Genotropin_GHD-P.pdf,"Growth hormone deficiency, children",List with criteria/condition,Complete,"May 27, 2013","Dec 20, 2013",SR0333-000
somatropin,Genotropin,Somatropin,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0334_GenotropinTS_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0334_complete_Genotropin-TS_Dec-23-13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0334_GenotropinTS_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0334_Genotropin_TS.pdf,Turner Syndrome,List with criteria/condition,Complete,"May 27, 2013","Dec 20, 2013",SR0334-000
ocriplasmin,Jetrea,Ocriplasmin,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0337_Jetrea_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/SR0337_complete_Jetrea_Dec-23-13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0337_Jetrea_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0337_Jetrea.pdf,Vitreomacular adhesion,List with criteria/condition,Complete,"Jun 6, 2013","Dec 20, 2013",SR0337-000
adcetris systemic anaplastic large cell lymphoma,Adcetris,Brentuximab vedotin,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-adcetris-salcl-coi-lfc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-adcetris-salcl-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-adcetris-salcl-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-adcetris-salcl-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-adcetris-salcl-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-adcetris-salcl-pagfdk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_adcetris-salcl.pdf,Systemic Anaplastic Large Cell Lymphoma,Reimburse with clinical criteria and/or conditions,Complete,"Mar 15, 2013","Dec 5, 2013",PC0021-000
tafinlar metastatic melanoma,Tafinlar,Dabrafenib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_tafinlar-metmel.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-tafinlar-coi-mnc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-tafinlar-coi-sysf.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-tafinlar-in-fdk-gsk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-tafinlar-metmla-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-tafinlar-metmla-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-tafinlar-metmla-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-tafinlar-metmla-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-tafinlar-pag-fdk-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-tafinlar-ptfdk-mnc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-tafinlar-ptfdk-sysf.pdf,Metastatic Melanoma,Reimburse with clinical criteria and/or conditions,Complete,"Mar 18, 2013","Dec 5, 2013",PC0025-000
pemetrexed alimta advanced non squamous non small cell lung cancer ns nsclc,Alimta,Pemetrexed,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-alimta-coi-ccsn.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-alimta-coi-lcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-alimta-infdk-elilc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-alimta-ns-nsclc-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-alimta-ns-nsclc-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-alimta-ns-nsclc-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-alimta-ns-nsclc-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-alimta-pagfdk-inrec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_alimta-nsclc.pdf,Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer,Reimburse with clinical criteria and/or conditions,Complete,"May 31, 2013","Nov 19, 2013",PC0027-000
ulipristal acetate,Fibristal,Ulipristal acetate,https://www.cda-amc.ca/sites/default/files/cdr/clinical/SR0326_Fibristal_CL_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/complete_SR0326_Fibristal_19-Nov-13_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/pharmacoeconomic/SR0326_Fibristal_PE_Report_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0326_Fibristal.pdf,Uterine fibroids,List with criteria/condition,Complete,"Apr 17, 2013","Nov 15, 2013",SR0326-000
saxagliptin,Onglyza,Saxagliptin,https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf; https://www.cadth.ca/sites/default/files/cdr/clinical/SR0329_Onglyza_CL_Report_e.pdf; https://www.cadth.ca/sites/default/files/cdr/complete/complete_SR0329_Onglyza-preNOC_19-Nov-13_e.pdf; https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0329_Onglyza_PE_Report_e.pdf; https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_SR0329_Onglyza-2.pdf,"Diabetes mellitus, type 2",List with criteria/condition,Complete,"May 9, 2013","Nov 15, 2013",SR0329-000
stivarga metastatic colorectal cancer,Stivarga (CRC),Regorafenib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-stivarga-mcrc-coi-ccac.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-stivarga-mcrc-fdk-bayer.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-stivarga-mcrc-pagfdk-inr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-stivarga-mcrc-ptfdk-ccac.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-stivargamcrc-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-stivargamcrc-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-stivargamcrc-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-stivargamcrc-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_stivarga-mcrc.pdf,Metastatic Colorectal Cancer,Do not reimburse,Complete,"Mar 22, 2013","Nov 15, 2013",PC0026-000
zytiga metastatic castration resistant prostate cancer,Zytiga,Abiraterone acetate,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zytiga-coi-ccsn.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zytiga-coi-pcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zytiga-in-fdk-ccsn.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zytiga-in-fdk-janssen.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zytiga-in-fdk-pcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zytiga-mcrpc-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zytiga-mcrpc-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zytiga-mcrpc-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zytiga-mcrpc-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zytiga-pag-fdk-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_abiraterone_zytiga_mcrpc.pdf,Metastatic Castration Resistant Prostate Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Mar 28, 2013","Oct 22, 2013",PC0028-000
mekinist metastatic melanoma,Mekinist,Trametinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-mekinist-coi-mnc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-mekinist-in-fdk-gsk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-mekinist-in-fdk-mnc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-mekinist-metmela-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-mekinist-metmela-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-mekinist-metmela-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-mekinist-mm-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-mekinist-pag-fdk-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_mekinist-metmel.pdf,Metastatic Melanoma,Reimburse with clinical criteria and/or conditions,Complete,"May 6, 2013","Oct 22, 2013",PC0030-000
revlimid multiple myeloma,Revlimid,Lenalidomide,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-revlimid-coi-mc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-revlimid-in-fdk-celgene.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-revlimid-mm-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-revlimid-mm-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-revlimid-mm-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-revlimid-mm-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-revlimid-pag-fdk-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_revlimid-mm.pdf,Multiple Myeloma (as maintenance therapy),Reimburse with clinical criteria and/or conditions,Complete,"Apr 5, 2013","Oct 22, 2013",PC0029-000
perampanel,Fycompa,Perampanel,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Fycompa_October-21-13_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0316_Fycompa.pdf,"Epilepsy, partial onset seizures",List with criteria/condition,Complete,"Mar 8, 2013","Oct 17, 2013",SR0316-000
azilsartan medoxomil,Edarbi,Azilsartan medoxomil,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Edarbi_October-21-13_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0317_Edarbi.pdf,Hypertension,Do not list at the submitted price,Complete,"Mar 8, 2013","Oct 17, 2013",SR0317-000
azilsartan medoxomil chlorthalidone,Edarbyclor,Azilsartan medoxomil + chlorthalidone,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Edarbyclor_October-21-13_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0318_Edarbyclor.pdf,Hypertension,Do not list,Complete,"Mar 8, 2013","Oct 17, 2013",SR0318-000
linagliptin metformin,Jentadueto,Linagliptin-metformin,https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf; https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Jentadueto_October-21-13_e.pdf; https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_SR0306_Jentadeuto.pdf,"Diabetes mellitus, type 2",List with criteria/condition,Complete,"Mar 8, 2013","Oct 17, 2013",SR0306-000
zolpidem tartrate,Sublinox,Zolpidem tartrate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Sublinox_September_27_13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0314_Sublinox.pdf,Insomnia,Do not list,Complete,"Mar 7, 2013","Sep 25, 2013",SR0314-000
dimethyl fumarate,Tecfidera,Dimethyl fumarate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Tecfidera_September_30-13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0309_Tecfidera.pdf,"Multiple sclerosis, relapsing-remitting",List with criteria/condition,Complete,"Feb 4, 2013","Sep 25, 2013",SR0309-000
everolimus,Afinitor,Everolimus,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_compete_Afinitor_September_27_13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0315_Afinitor.pdf,Renal angiomyolipoma associated with tuberous sclerosis complex (TSC),Do not list,Complete,"Mar 8, 2013","Sep 25, 2013",SR0315-000
votrient metastatic renal cell carcinoma resubmission,Votrient,Pazopanib hydrochloride,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_votrientmrcc-re.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientmrccre-coi-kcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientmrccre-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientmrccre-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientmrccre-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientmrccre-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientmrccre-infdk-gsk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientmrccre-pag-fdbk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientmrccre-ptfdk-kcc.pdf,Metastatic Renal Cell Carcinoma,Reimburse,Complete,"Feb 20, 2013","Aug 29, 2013",PC0022-000
adcetris hodgkin lymphoma,Adcetris,Brentuximab vedotin,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-adcetrishl-coi-lfc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-adcetrishl-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-adcetrishl-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-adcetrishl-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-adcetrishl-in-fdk-sg.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-adcetrishl-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-adcetrishl-pag-fdk-inrec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-adcetrishl-pt-fdk-lfc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_adcetris-hl.pdf,Hodgkin Lymphoma,Reimburse with clinical criteria and/or conditions,Complete,"Mar 14, 2013","Aug 29, 2013",PC0020-000
interferon beta 1a,Rebif,Interferon beta-1a,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Rebif_Aug-19-13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0298_Rebif.pdf,Clinically isolated syndrome,Do not list,Complete,"Mar 8, 2013","Aug 15, 2013",SR0298-000
perjeta metastatic breast cancer,Perjeta Herceptin Combo Pack,Pertuzumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-perjetacp-mbc-coi-cbcn.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-perjetacp-mbc-coi-rethin.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-perjetacp-mbc-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-perjetacp-mbc-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-perjetacp-mbc-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-perjetacp-mbc-in-fdk-hlr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-perjetacp-mbc-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-perjetacp-pag-fdk-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_pertuzumab_perjeta_mbc.pdf,Metastatic Breast Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Nov 2, 2012","Aug 1, 2013",PC0018-000
xtandi metastatic castration resistant prostate cancer,Xtandi,Enzalutamide,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xtandi-coi-ccsn.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xtandi-coi-pcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xtandi-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xtandi-in-fdk-astellas.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xtandi-mcrpc-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xtandi-mcrpc-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xtandi-mcrpc-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xtandi-pag-fdk-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_enzalutamide_xtandi_mcrpc.pdf,Metastatic Castration Resistant Prostate Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Mar 4, 2013","Jul 23, 2013",PC0023-000
dabigatran etexilate,Pradaxa,Dabigatran etexilate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Pradaxa-SPAF-RfA_July-22-13_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SF0320_Pradaxa_SPAF_RfA.pdf,Atrial fibrillation prevention of stroke and systemic embolism,List with clinical criteria and/or conditions,Complete,"Mar 18, 2013","Jul 18, 2013",SF0320-000
rivaroxaban,Xarelto,Rivaroxaban,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Xarelto-SPAF-RfA_July-22-13_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SF0321_Xarelto_SPAF_RfA.pdf,N/A,List with clinical criteria and/or conditions,Complete,"Mar 18, 2013","Jul 18, 2013",SF0321-00
abatacept,Orencia,Abatacept,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Orencia-RA_July-22-13_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Orencia_RA.pdf,"Arthritis, rheumatoid",List with clinical criteria and/or conditions,Complete,"Nov 29, 2012","Jul 18, 2013",SR0299-000
eculizumab,Soliris,Eculizumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Soliris-aHUS_July-23-13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Soliris.pdf,"Hemolytic Uremic Syndrome, Atypical",Do not list,Complete,"Jan 7, 2013","Jul 18, 2013",SR0304-000
adalimumab,Humira,Adalimumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Humira-JIA_July-22-13_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0308_Humira-JIA.pdf,"Arthritis, juvenile idiopathic",List with clinical criteria and/or conditions,Complete,"Feb 4, 2013","Jul 18, 2013",SR0308-000
nebivolol,Bystolic,Nebivolol,https://www.cda-amc.ca/sites/default/files/cdr/complete/CDR_complete_Bystolic_July-22-13_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0307_Bystolic.pdf,Hypertension,Do not list at the submitted price,Complete,"Feb 4, 2013","Jul 18, 2013",SR0307-000
tykerb letrozole metastatic breast cancer,Tykerb (in combination with Letrozole),Lapatinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_tykerb-mbc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-tykerb-mbc-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-tykerb-mbc-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-tykerb-mbc-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-tykerb-mbc-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-tykerbmbc-in-fdk-gsk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-tykerbmbc-pag-fdk-in-rec.pdf,Metastatic Breast Cancer,Do not reimburse,Complete,"Dec 14, 2012","Jul 5, 2013",PC0019-000
telaprevir,Incivek,Telaprevir,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Incivek%20RFA-SR0311-June-14-13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SF0311_Incivek-HCV-HIV_RfA.pdf,"Hepatitis C, chronic",List with criteria/condition,Complete,"Feb 19, 2013","Jun 13, 2013",SF0311-000
boceprevir,Victrelis,Boceprevir,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SF0312-Victrelis_RFA_June-14-13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SF0312_Victrelis-HIV-HCV_RfA.pdf,"Hepatitis C, chronic",List with criteria/condition,Complete,"Feb 19, 2013","Jun 13, 2013",SF0312-000
telaprevir,Incivek,Telaprevir,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Incivek%20RFA-SR0305-June-14-13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Incivek_RfA.pdf,"Hepatitis C, chronic",List with criteria/condition,Complete,"Dec 21, 2012","Jun 13, 2013",SF0305-000
boceprevir,Victrelis,Boceprevir,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SF0303-Victrelis-RFA_June-14-13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Victrelis_RfA.pdf,"Hepatitis C, chronic",List with criteria/condition,Complete,"Dec 21, 2012","Jun 13, 2013",SF0303-000
palonosetron hydrochloride,Aloxi (injection),Palonosetron hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Aloxi%20IV_may-17-13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Aloxi-IV.pdf,Chemotherapy-induced nausea and vomiting,Do not list at the submitted price,Complete,"Oct 5, 2012","May 15, 2013",SR0293-000
elvitegravir cobicistat emtricitabine tenofovir disoproxil fumarate,Stribild,Elvitegravir/  Cobicistat/  Emtricitabine/  Tenofovir Disoproxil Fumarate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Stribild_May-17-13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Stribild.pdf,HIV infection,List with criteria/condition,Complete,"Nov 30, 2012","May 15, 2013",SR0301-000
glycopyrronium bromide,Seebri,Glycopyrronium bromide,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Seebri-May-17-13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Seebri.pdf,Chronic obstructive pulmonary disease,List with criteria/condition,Complete,"Nov 30, 2012","May 15, 2013",SR0300-000
xalkori advanced nsclc resubmission,Xalkori,Crizotinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_xalkorire-nsclc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xalkorire-fdk-lcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xalkorire-pag-fdk-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xalkoriresub-coi-lcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xalkoriresub-fdk-pfizer.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xalkoriresub-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xalkoriresub-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xalkoriresub-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xalkoriresub-in-rec.pdf,Advanced or Metastatic Non-Small Cell Lung Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Oct 23, 2012","May 2, 2013",PC0017-000
palonosetron hydrochloride,Aloxi (capsule),Palonosetron hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Aloxi%20PO_April-25-13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Aloxi-capsules.pdf,Chemotherapy-induced nausea and vomiting,Do not list,Complete,"Oct 5, 2012","Apr 24, 2013",SR0294-000
pirfenidone,Esbriet,Pirfenidone,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Esbriet_April-24-13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Esbriet.pdf,Idiopathic pulmonary fibrosis,Do not list,Complete,"Oct 5, 2012","Apr 18, 2013",SR0292-000
doxycycline monohydrate,Apprilon,Doxycycline monohydrate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Apprilon_April-1-13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Apprilon.pdf,Rosacea,Do not list,Complete,"Apr 27, 2012","Mar 27, 2013",SR0279-000
collagenase clostridium histolyticum,Xiaflex,Collagenase clostridium histolyticum,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Xiaflex_April-1-13.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Xiaflex.pdf,Dupuytren’s contracture,List with criteria/condition,Complete,"Aug 30, 2012","Mar 27, 2013",SR0287-000
velcade multiple myeloma,Velcade,Bortezomib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_velcade-mm.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-velcademm-coi-mc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-velcademm-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-velcademm-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-velcademm-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-velcademm-in-fdk-ccohdsg.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-velcademm-in-fdk-janssen.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-velcademm-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-velcademm-pag-fdk-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-velcademm-ptfdk-inrec-mc.pdf,Multiple Myeloma,Reimburse,Complete,"Oct 29, 2012","Mar 25, 2013",PC0016-000
afinitor advanced breast,Afinitor,Everolimus,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-afinitorab-coi-cbcn.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-afinitorab-coi-rebc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-afinitorab-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-afinitorab-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-afinitorab-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-afinitorab-in-fdk-novart.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-afinitorab-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-afinitorab-pag-fdk-inrec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_afinitor-ab.pdf,Advanced Breast Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Sep 5, 2012","Mar 25, 2013",PC0014-000
ivacaftor,Kalydeco,Ivacaftor,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Kalydeco_March-25-13_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Kalydeco.pdf,"Cystic fibrosis, G551D mutation",List with criteria/condition,Complete,"Sep 27, 2012","Mar 22, 2013",SR0291-000
grass pollen allergen extract,Oralair,Grass Pollen Allergen Extract,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Oralair_March-25-13_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Oralair.pdf,Allergic rhinitis,List with criteria/condition,Complete,"Sep 21, 2012","Mar 20, 2013",SR0290-000
apixaban,Eliquis,Apixaban,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Eliquis_SPAF_Mar-22-13-e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Eliquis-SPAF_2.pdf,"Thromboembolic events prevention, (atrial fibrillation)",List with clinical criteria and/or conditions,Complete,"Sep 25, 2012","Mar 20, 2013",SR0288-000
inlyta metastatic renal cell carcinoma mrcc,Inlyta,Axitinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-inlytamrcc-coi-kcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-inlytamrcc-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-inlytamrcc-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-inlytamrcc-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-inlytamrcc-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-inlytamrcc-infdk-kcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-inlytamrcc-infdk-pfizer.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-inlytamrcc-pag-fdk-inrec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_inlyta-mrcc.pdf,Metastatic Renal Cell Carcinoma,Reimburse,Complete,"Aug 16, 2012","Mar 7, 2013",PC0013-000
treanda chronic lymphocytic leukemia first line,Treanda,Bendamustine hydrochloride,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-cll1st-coi-cllpag.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-cll1st-coi-llsc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-cll1st-infdk-lundbeckcan.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-cll1stline-pag-fdk-inrec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandacll1st-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandacll1st-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandacll1st-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandacll1st-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_profund_treandacllrel.pdf,Chronic Lymphocytic Leukemia (first-line),Reimburse with clinical criteria and/or conditions,Complete,"Apr 24, 2012","Feb 19, 2013",PC0011-000
tolvaptan,Samsca,Tolvaptan,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Samsca_Feb-12-13-e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Samsca.pdf,"Hyponatremia, non-hypovolemic",Do not list,Complete,"Jul 3, 2012","Feb 13, 2013",SR0283-000
lurasidone,Latuda,Lurasidone,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Latuda_Jan-25-13_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Latuda.pdf,Schizophrenia,Do not list,Complete,"Jul 3, 2012","Jan 23, 2013",SR0284-000
jakavi myelofibrosis,Jakavi,Ruxolitinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-jakavi-coi-cml.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-jakavi-coi-cpmnn.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-jakavi-in-fdk-novartis.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-jakavi-myelofibro-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-jakavi-myelofibro-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-jakavi-myelofibro-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-jakavi-pag-fdk-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-jakavi-pt-fdk-in-rec-cml.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-jakavi-pt-fdkinrec-cpmnn.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-jakavimyelofibro-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_jakavi_myelo.pdf,Myelofibrosis,Reimburse with clinical criteria and/or conditions,Complete,"Jun 25, 2012","Jan 14, 2013",PC0012-000
colesevelam hydrochloride,Lodalis,Colesevelam hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Lodalis_Decembe_21_12.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_lodalis.pdf,Hypercholesterolemia,Do not list at the submitted price,Complete,"Apr 27, 2012","Dec 19, 2012",SR0274-000
mometasoneformoterol,Zenhale,Mometasone/formoterol,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Zenhale%20RfA_December_21_12.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdrr_tracking_Zenhale-RfA.pdf,Asthma,List with clinical criteria and/or conditions,Complete,"Jun 6, 2012","Dec 19, 2012",SF0281-000
fidaxomicin,Dificid,Fidaxomicin,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Dificid_December_21_12.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Dificid.pdf,Clostridium difficile infection,Do not list at the submitted price,Complete,"Jul 10, 2012","Dec 19, 2012",SR0285-000
votrient soft tissue sarcoma,Votrient,Pazopanib Hydrochloride,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_votrient-sts.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientsts-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientsts-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientsts-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientsts-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientsts-pcodr10.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientsts-pcodr11.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientsts-pcodr9.pdf,Soft Tissue Sarcoma,Do not reimburse,Complete,"Jun 4, 2012","Nov 29, 2012",PC0009-000
treanda chronic lymphocytic leukemia relapsed refractory,Treanda,Bendamustine hydrochloride,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandacll-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandacll-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandacll-fn-pcodr1.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandacll-fn-pcodr12.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandacll-fn-pcodr2.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandacll-fn-pcodr3.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandacll-fn-pcodr4.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandacll-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandacll-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_treandacllrel.pdf,Chronic Lymphocytic Leukemia (relapsed/refractory),Do not reimburse,Complete,"Apr 24, 2012","Nov 29, 2012",PC0011-000
treanda indolent non hodgkin lymphoma,Treanda,Bendamustine hydrochloride,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandanhl-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandanhl-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandanhl-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandanhl-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandanhl-pcodr13.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandanhl-pcodr5.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandanhl-pcodr6.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandanhl-pcodr7.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-treandanhl-pcodr8.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_treandanhl.pdf,Non-Hodgkin Lymphoma  and Mantle Cell Lymphoma,Reimburse,Complete,"Apr 24, 2012","Nov 29, 2012",PC0010-000
fampridine,Fampyra,Fampridine,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Fampyra_Nov-30-12.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Fampyra.pdf,"Multiple sclerosis, improve walking disability",Do not list,Complete,"Apr 16, 2012","Nov 28, 2012",SR0275-000
ranibizumab injection,Lucentis,Ranibizumab injection,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Lucentis%20RVO_Oct-22-12_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Lucentis-RVO-2.pdf,"Macular edema, secondary to retinal vein occlusion",List with clinical criteria and/or conditions,Complete,"Apr 25, 2012","Oct 18, 2012",SR0276-000
fesoterodine fumarate,Toviaz,Fesoterodine fumarate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Toviaz_Oct-22-12_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Toviaz.pdf,Overactive bladder,List in a similar manner,Complete,"Apr 27, 2012","Oct 18, 2012",SR0277-000
xalkori advanced non small cell lung cancer,Xalkori,Crizotinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xalkori-coi-lcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xalkori-in-fdk-pfizer.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xalkori-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xalkori-pag-fdk-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xalkorinsclc-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xalkorinsclc-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-xalkorinsclc-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_xalkorinsclc_lcc_in_fdk.pdf,Advanced Non-Small Cell Lung Cancer,Do not reimburse,Complete,"Mar 26, 2012","Oct 4, 2012",PC0008-000
plerixafor,Mozobil,Plerixafor,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Mozobil_Sept-28-12_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Mozobil.pdf,Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma,Do not list,Complete,"Jan 24, 2012","Sep 26, 2012",SR0265-000
afinitor pancreatic neuroendocrine tumours,Afinitor,Everolimus,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-afinitor-coi-cnets.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-afinitor-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-afinitor-in-fdk-novartis.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-afinitor-pag-fdk-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-afinitor-pnets-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-afinitor-pnets-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-afinitor-pnets-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_afinitor-pnet.pdf,Pancreatic Neuroendocrine Tumour,Reimburse with clinical criteria and/or conditions,Complete,"Feb 27, 2012","Aug 30, 2012",PC0007-000
indacaterol,Onbrez,Indacaterol,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Onbrez_Aug-20-12_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Onbrez.pdf,Chronic obstructive pulmonary disease,List in a similar manner,Complete,"Feb 29, 2012","Aug 16, 2012",SR0273-000
rivaroxaban,Xarelto,Rivaroxaban,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Xarelto%20DVT_Aug-20-12_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Xarelto_DVT.pdf,Deep-vein thrombosis without symptomatic pulmonary embolism,List with clinical criteria and/or conditions,Complete,"Feb 27, 2012","Aug 16, 2012",SR0271-000
rituximab,Rituxan,Rituximab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Rituxan-Aug_16-12_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Rituxan-2.pdf,Granulomatosis with polyangiitis and microscopic polyangiitis,List with clinical criteria and/or conditions,Complete,"Feb 24, 2012","Aug 16, 2012",SR0270-000
halaven metastatic breast cancer,Halaven,Eribulin Mesylate,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-halaven-in-fdk-eisai.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-halaven-metbreast-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-halaven-pag-fdk-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-halavenmb-coi-cbcn.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-halavenmb-coi-ccsn.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-halavenmb-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-halavenmb-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-halavenmb-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_halaven-mbc.pdf,Metastatic Breast Cancer,Reimburse with clinical criteria and/or conditions,Complete,"Feb 9, 2012","Aug 2, 2012",PC0005-000
exenatide,Byetta,Exenatide,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Byetta_July-23-12.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Byetta.pdf,"Diabetes mellitus, type 2",Do not list,Complete,"Aug 23, 2011","Jul 19, 2012",SR0246-000
prucalopride,Resotran,Prucalopride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Resotran_July-23-12.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Resotran.pdf,"Constipation, chronic",Do not list,Complete,"Jan 30, 2012","Jul 19, 2012",SR0266-000
onabotulinumtoxina,Botox,OnabotulinumtoxinA,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Botox_July-23-12.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Botox.pdf,Neurogenic detrusor overactivity,List with clinical criteria and/or conditions,Complete,"Jan 31, 2012","Jul 19, 2012",SR0268-000
tocilizumab,Actemra,Tocilizumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Actemra-sJIA_July-23-12_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Actemra-2.pdf,"Arthritis, juvenile idiopathic",List with clinical criteria and/or conditions,Complete,"Jan 30, 2012","Jul 19, 2012",SR0267-000
asenapine,Saphris,Asenapine,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Saphris-000-June%2018_2012.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Saphris.pdf,Schizophrenia,Do not list,Complete,"Dec 12, 2011","Jun 14, 2012",SR0262-000
prasugrel,Effient,Prasugrel,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Effient-Resubmission_June-18-12.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Effient_Resub-1.pdf,Acute coronary syndrome,Do not list,Complete,"Dec 12, 2011","Jun 14, 2012",SR0263-000
apixaban,Eliquis,Apixaban,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Eliquis_June-18-12_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Eliquis.pdf,"Venous thromboembolic events, prevention",List with clinical criteria and/or conditions,Complete,"Dec 20, 2011","Jun 14, 2012",SR0264-000
asenapine,Saphris,Asenapine,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Saphris-001-June%2018_2012.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Saphris.pdf,Bipolar I disorder,List with clinical criteria and/or conditions,Complete,"Dec 12, 2011","Jun 14, 2012",SR0262-001
zelboraf advanced melanoma,Zelboraf,Vemurafenib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zelboraf-adv-mel-coi-mnc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zelboraf-adv-mel-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zelboraf-adv-mel-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zelboraf-in-fdk-roche.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zelboraf-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zelboraf-pag-fdk-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zelboraf-unredact-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-zelborafadmel-in-fdk-mnc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_vemurafenib_zelboraf-advmel.pdf,Metastatic Melanoma,Reimburse with clinical criteria and/or conditions,Complete,"Dec 6, 2011","Jun 1, 2012",PC0006-000
oxybutynin chloride gel,Gelnique,Oxybutynin Chloride Gel,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Gelnique_May%2028-2012.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Gelnique.pdf,Overactive bladder,Do not list,Complete,"Oct 25, 2011","May 24, 2012",SR0260-000
mometasone furoate,ASMANEX,Mometasone furoate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Asmanex_%20May-16-12.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Asmanex.pdf,Asthma,List,Complete,"Nov 10, 2011","May 16, 2012",SR0258-000
sutent pancreatic neuroendocrine tumours,Sutent,Sunitinib malate,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_sutent-pnets.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-sutent-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-sutent-pnet-coi-cnets.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-sutent-pnet-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-sutent-pnet-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-sutent-pnet-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-sutent-pnet-pag-fd-irec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-sutentpnet-in-fdk-pzr.pdf,Pancreatic Neuroendocrine Tumour,Reimburse with clinical criteria and/or conditions,Complete,"Nov 7, 2011","May 3, 2012",PC0004-000
dexamethasone intravitreal implant,Ozurdex,Dexamethasone intravitreal implant,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Ozurdex_April-27-1_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Ozurdex.pdf,"Macular edema, central retinal vein occlusion",Do not list,Complete,"Sep 1, 2011","Apr 25, 2012",SR0247-000
belimumab,Benlysta,Belimumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Benlysta_April-27-12_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Benlysta.pdf,Systemic lupus erythematosus,Do not list,Complete,"Sep 19, 2011","Apr 25, 2012",SR0251-000
silodosin,RAPAFLO,Silodosin,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Rapaflo_April-20-12.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Rapaflo.pdf,Benign prostatic hyperplasia,Do not list,Complete,"Oct 25, 2011","Apr 19, 2012",SR0261-000
rivaroxaban,Xarelto,Rivaroxaban,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Xarelto-SPAF_April-20-12.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Xarelto-SPAF_2.pdf,"Atrial fibrillation, stroke prevention",List with clinical criteria and/or conditions,Complete,"Oct 21, 2011","Apr 19, 2012",SR0257-000
dienogest,Visanne,Dienogest,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Visanne_April-20-12.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Visanne.pdf,"Pain, pelvic pain associated with endometriosis",List with clinical criteria and/or conditions,Complete,"Oct 18, 2011","Apr 19, 2012",SR0255-000
emtricitabine rilpivirine tenofovir disoproxil fumarate,COMPLERA,Emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Complera_April-20-12.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Complera.pdf,HIV infection,List,Complete,"Oct 19, 2011","Apr 19, 2012",SR0256-000
yervoy advanced melanoma,Yervoy,Ipilimumab,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_yervoy-advmel.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-yervoy-adv-mel-coi-mnc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-yervoy-adv-mel-coi-sys.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-yervoy-adv-mel-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-yervoy-adv-mel-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-yervoy-adv-mel-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-yervoy-in-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-yervoyadvmel-in-fdk-bms.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-yervoyadvmel-in-fdk-mnc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-yervoyadvmel-pag-fd-irec.pdf,Advanced Melanoma,Reimburse with clinical criteria and/or conditions,Complete,"Dec 1, 2011","Apr 18, 2012",PC0003-000
ranibizumab,Lucentis,Ranibizumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr-complete_Lucentis_DME_March-21-12.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Lucentis.pdf,"Macular edema, diabetic",List with clinical criteria and/or conditions,Complete,"Sep 14, 2011","Mar 19, 2012",SR0253-000
rufinamide,Banzel,Rufinamide,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Banzel_March-19-12_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Banzel.pdf,Lennox-Gastaut syndrome,List with clinical criteria and/or conditions,Complete,"Sep 20, 2011","Mar 15, 2012",SR0252-000
rilpivirine,Edurant,Rilpivirine,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Edurant_Feb-17-12_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_edurant.pdf,HIV infection,List,Complete,"Jul 29, 2011","Feb 15, 2012",SR0243-000
linagliptin,Trajenta,Linagliptin,https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf; https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Trajenta_February_18_2012.pdf; https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_tracking_Trajenta.pdf,"Diabetes mellitus, type 2",List with clinical criteria and/or conditions,Complete,"Aug 23, 2011","Feb 15, 2012",SR0244-000
telaprevir,Incivek,Telaprevir,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Incivek_Feb-17-12_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Incivek.pdf,"Hepatitis C, chronic",List with clinical criteria and/or conditions,Complete,"Aug 23, 2011","Feb 15, 2012",SR0249-000
fentanyl citrate,Onsolis,Fentanyl Citrate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Onsolis_Feb-17-12_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_onsolis-resub_plr_aug-13-12_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Onsolis_2.pdf,"Pain, breakthrough cancer pain",Do not list,Complete,"Aug 22, 2011","Feb 15, 2012",SR0248-000
oxycodone hci naloxone hci,Targin,Oxycodone HCI / naloxone HCI,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Targin_2_Jan-27-12_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_targin_Resub1.pdf,"Pain, moderate to severe and relief of opioid-induced constipation",Do not list,Complete,"Jul 5, 2011","Jan 25, 2012",SR0241-000
votrient metastatic renal cell carcinoma,Votrient,Pazopanib hydrochloride,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-provfund_votrient-mrcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientmrcc-fn-cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientmrcc-fn-egr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientmrcc-fn-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientmrcc-in-fdk-gsk.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientmrcc-in-fdk-kcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientmrcc-initial-rec.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientmrcc-kcc-coi.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-votrientmrcc-pag-fd-irec.pdf,Metastatic Renal Cell Carcinoma,Reimburse,Complete,"Jul 14, 2011","Jan 5, 2012",PC0000-000
ticagrelor,Brilinta,Ticagrelor,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Brilinta_Dec-20-11.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Brilinta_plr_Aug-13-12_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_brilinta.pdf,Acute coronary syndromes,Do not list,Complete,"Jun 1, 2011","Dec 16, 2011",SR0234-000
fentanyl citrate,Abstral,Fentanyl citrate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Abstral_Dec-20-11.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Abstral_PLR_July-3-12.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_abstral.pdf,"Pain, breakthrough cancer pain",Do not list,Complete,"Jun 30, 2011","Dec 16, 2011",SR0240-000
telmisartan amlodipine,Twynsta,Telmisartan/ Amlodipine,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Twynsta_Dec-20-11.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Twynsta_plr_June-15-12.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Twynsta_2.pdf,Hypertension,List,Complete,"Aug 23, 2011","Dec 16, 2011",SR0245-000
fingolimod,Gilenya,Fingolimod,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Gilenya_Nov-18-11_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Gilenya_plr_Mar-1-12.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_gilenya.pdf,"Multiple Sclerosis, relapsing-remitting",List with clinical criteria and/or conditions,Complete,"May 10, 2011","Nov 16, 2011",SR0228-000
denosumab,XGEVA,Denosumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Xgeva_Nov-18-11_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Xgeva_plr_Mar-8-12.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_XGEVA-Pilot.pdf,Prevention of skeletal-related events due to bone metastases from solid tumours,List with clinical criteria and/or conditions,Complete,"Jun 6, 2011","Nov 16, 2011",SR0235-000
zoledronic acid,Aclasta,Zoledronic acid,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Aclasta-RFA_Nov-18-11_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Aclasta_RfA_PLR_April%204-2012.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_aclasta_request-advice.pdf,Osteoporosis,List with clinical criteria and/or conditions,Complete,"Jul 20, 2011","Nov 16, 2011",SF0242-000
boceprevir,Victrelis,Boceprevir,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Victrelis_Oct-26-11.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Victrelis_plain-lang-rec_Jan-6-12%20.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Victrelis_Pre-NOC.pdf,"Hepatitis C, chronic",List with clinical criteria and/or conditions,Complete,"May 3, 2011","Oct 24, 2011",SR0231-000
eltrombopag olamine,Revolade,Eltrombopag olamine,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Revolade_Oct-26-11_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Revolade_plain-lang-rec_Jan-6-12%20.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_revolade.pdf,Chronic immune thrombocytopenic purpura,Do not list,Complete,"Apr 26, 2011","Oct 24, 2011",SR0230-000
alitretinoin,Toctino,Alitretinoin,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Toctino_October_26_2011.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Toctino_plain-lang-rec__Jan-6-12%20.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_toctino.pdf,Eczema,List with clinical criteria and/or conditions,Complete,"May 6, 2011","Oct 24, 2011",SR0232-000
tapentadol,Nucynta CR,Tapentadol,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Nucynta_March-25-2014.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Nucynta_CR_PL_Nov-24-11.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Nucynta.pdf,"Pain, moderate to moderately severe",Do not list,Complete,"Feb 1, 2011","Sep 28, 2011",SR0224-000
mometasone furoate and formoterol,Zenhale (inhalation aerosol),Mometasone furoate and formoterol,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_zenhale_Oct-3-11_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Zenhale_plr_Dec-6-11.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Zenhale.pdf,Asthma,Do not list,Complete,"Feb 16, 2011","Sep 28, 2011",SR0225-000
buprenorphine transdermal patch,BuTrans,Buprenorphine transdermal patch,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Butrans-September-30-2011.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Butrans_PL_Nov-24-11.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_BuTrans_2.pdf,"Pain, moderate intensity persistent pain",Do not list,Complete,"May 9, 2011","Sep 28, 2011",SR0233-000
liraglutide,Victoza,Liraglutide,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete-Victoza-September-30-2011.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Victoza_plr_Dec_6-11.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_victoza.pdf,"Diabetes mellitus, Type 2",Do not list,Complete,"Nov 29, 2010","Sep 28, 2011",SR0217-000
roflumilast,Daxas,Roflumilast,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Daxas_August-3-2011_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Daxas_pl-Rec_Sept-16-11_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Daxas.pdf,Chronic obstructive pulmonary disease,Do not list,Complete,"Nov 30, 2010","Jul 27, 2011",SR0218-000
cyclosporine,Restasis ophthalmic emulsion,Cyclosporine,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Restatis_Final_July-20-2011_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Restasis_plr_Sept-2-11_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Restasis.pdf,Dry eye disease,Do not list,Complete,"Dec 17, 2010","Jul 18, 2011",SR0222-000
maraviroc,Celsentri,Maraviroc,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Celsentri_Final_July-20-2011_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Celsentri_pl-rec_Sept-13-11.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Celsentri_TNaive.pdf,HIV infection,Do not list,Complete,"Dec 8, 2010","Jul 18, 2011",SR0221-000
aripiprazole,Abilify,Aripiprazole,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Abilify_July-20-2011_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Abilify_plr_Sept-2-11_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Abilify_request-advice.pdf,Schizophrenia and related psychotic disorders,List with clinical criteria and/or conditions,Complete,"Mar 29, 2011","Jul 18, 2011",SF0226-000
aztreonam inhalation solution,Cayston,Aztreonam for inhalation solution,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Cayston_July-20-2011_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Cayston_plr_Sept-2-11_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Cayston.pdf,"Cystic fibrosis, chronic pulmonary pseudomonas aeruginosa infections",List with clinical criteria and/or conditions,Complete,"Dec 2, 2010","Jul 18, 2011",SR0220-000
dabigatran etexilate,Pradaxa,Dabigatran etexilate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Pradax_June-27-11.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Pradax_Plain_Lang_Rec_August-19-11_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Pradax_AF2.pdf,Atrial fibrillation prevention of stroke and systemic embolism,List with clinical criteria and/or conditions,Complete,"Oct 28, 2010","Jun 22, 2011",SR0214-000
paliperidone palmitate,Invega Sustenna,Paliperidone palmitate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Invega-Sustenna_April-29-11.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Invega-Sustenna_pl-recSept-13-11.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Invega%20Sustenna.pdf,Schizophrenia,Do not list,Complete,"Jul 9, 2010","Apr 25, 2011",SR0206-000
febuxostat,Uloric,Febuxostat,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Uloric_April-29-11.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Uloric_plr_June-10-11.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Uloric.pdf,Gout,List with clinical criteria and/or conditions,Complete,"Oct 27, 2010","Apr 25, 2011",SR0213-000
lacosamide,Vimpat,Lacosamide,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Vimpat_April-29-11.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Vimpat_plr_June-10-11.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Vimpat.pdf,"Epilepsy, partial onset seizures",List with clinical criteria and/or conditions,Complete,"Oct 25, 2010","Apr 25, 2011",SR0212-000
velaglucerase alfa,VPRIV,Velaglucerase alfa,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Vpriv_April-29-11.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_VPRIV_plain-l-r_July-12-011_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Vpriv.pdf,Gaucher Disease,List with clinical criteria and/or conditions,Complete,"Oct 28, 2010","Apr 25, 2011",SR0215-000
denosumab,Prolia,Denosumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Prolia_April-1-11.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/Prolia_Plain_Language_May-17-11_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Prolia.pdf,"Osteoporosis, postmenopausal women",List with clinical criteria and/or conditions,Complete,"Aug 26, 2010","Mar 30, 2011",SR0208-000
prasugrel hydrochloride,Effient,Prasugrel hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Effient-Feb-18-2011.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Effient.pdf,Acute Coronary Syndrome,Do not list,Complete,"May 5, 2010","Feb 16, 2011",SR0200-000
azelaic acid,Finacea,Azelaic acid,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Finacea_Feb-18-2011.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_finacea_plain-language_rec_april_5%2C_2011_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Finacea.pdf,Rosacea,List,Complete,"Aug 31, 2010","Feb 16, 2011",SR0209-000
canakinumab,Ilaris,Canakinumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Ilaris_Jan-28-2011.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/ilaris_plain_language_rec_march-15-2011_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Ilaris.pdf,Cryopyrin-Associated Periodic Syndrome,Do not list,Complete,"Jul 7, 2010","Jan 26, 2011",SR0204-000
sapropterin dihydrochloride,Kuvan,Sapropterin dihydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Kuvan_Jan-28-2011.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/kuvan_plain-language_rec_march-15-2011_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Kuvan.pdf,Phenylketonuria (PKU),Do not list,Complete,"Jul 8, 2010","Jan 26, 2011",SR0205-000
tocilizumab,Actemra,Tocilizumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Actemra-Nov-19-2010.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_actemra_plainl-r-r_jan11_2011_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Actemra.pdf,"Arthritis, Rheumatoid",List with clinical criteria and/or conditions,Complete,"May 27, 2010","Nov 17, 2010",SR0201-000
calcitriol,Silkis,Calcitriol,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Silkis_recommendation_Sept_23_2010.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Silkis.pdf,"Psoriasis, mild to moderate plaque",Do not list,Complete,"Mar 15, 2010","Sep 22, 2010",SR0199-000
tadalafil,Adcirca,Tadalafil,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Adcirca_July-19-2010.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Adcirca.pdf,Pulmonary arterial hypertension,List with clinical criteria and/or conditions,Complete,"Feb 5, 2010","Jul 15, 2010",SR0197-000
sitagliptin phosphate,Januvia,Sitagliptin phosphate,https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf; https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Januvia%20Resubmission_June-29-2010.pdf; https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_tracking_Januvia_Resubmission-1.pdf,Diabetes mellitus (Type 2),List with clinical criteria and/or conditions,Complete,"Oct 29, 2009","Jun 23, 2010",SR0181-000
sitagliptin phosphate monohydrate metformin hydrochloride,Janumet,Sitagliptin phosphate monohydrate / metformin hydrochloride,https://www.cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf; https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Janumet_June-29-2010.pdf; https://www.cadth.ca/sites/default/files/cdr/tracking/cdr_tracking_Janumet.pdf,Diabetes mellitus (Type 2),List with clinical criteria and/or conditions,Complete,"Nov 4, 2009","Jun 23, 2010",SR0182-000
raltegravir,Isentress,Raltegravir,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Isentress-HIV_June-29-2010.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Isentress_New-Indication.pdf,HIV (treatment naïve),Do not list,Complete,"Dec 4, 2009","Jun 23, 2010",SR0191-000
saxagliptin,Onglyza,Saxagliptin,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Onglyza_June-18-2010.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Onglyza.pdf,Diabetes mellitus (Type 2),Do not list,Complete,"Nov 9, 2009","Jun 17, 2010",SR0185-000
abatacept,Orencia,Abatacept,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Orencia-Resubmission_June-17-2010.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Orencia_Resubmission-1.pdf,"Arthritis, Rheumatoid",List in a similar manner,Complete,"Dec 2, 2009","Jun 17, 2010",SR0187-000
darunavir,Prezista,Darunavir,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Prezista_Pediatric_HIV_June-17-2010.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Prezista_New_Indication.pdf,HIV infection (Pediatric),List with clinical criteria and/or conditions,Complete,"Dec 22, 2009","Jun 17, 2010",SR0194-000
certolizumab pegol,Cimzia,Certolizumab pegol,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Cimzia_May-28-2010.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Cimzia.pdf,"Arthritis, rheumatoid",Do not list,Complete,"Sep 3, 2009","May 27, 2010",SR0175-000
dronedarone hydrochloride,Multaq,Dronedarone hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Multaq_May-31-2010.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Multaq.pdf,Atrial fibrillation,Do not list,Complete,"Sep 18, 2009","May 27, 2010",SR0177-000
romiplostim,Nplate,Romiplostim,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Nplate_May-27-2010.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Nplate.pdf,Chronic immune (idiopathic) thrombocytopenic purpura (ITP),Do not list,Complete,"Sep 29, 2009","May 27, 2010",SR0179-000
loteprednol etabonate,Lotemax,Loteprednol etabonate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Lotemax_May-19-2010.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Lotemax.pdf,Post-operative inflammation following cataract surgery,Do not list,Complete,"Dec 2, 2009","May 19, 2010",SR0186-000
hydromorphone hydrochloride,Jurnista,Hydromorphone hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Jurnista_May-19-2010.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Jurnista.pdf,"Pain, Chronic (moderate to severe)",Do not list,Complete,"Dec 4, 2009","May 19, 2010",SR0190-000
aripiprazole,Abilify,Aripiprazole,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Abilify_April-30-2010_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Abilify.pdf,Schizophrenia,Do not list,Complete,"Nov 6, 2009","Apr 27, 2010",SR0183-000
golimumab,Simponi,Golimumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Simponi-RA_March-17-2010_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Simponi_RA.pdf,"Arthritis, Rheumatoid",List in a similar manner,Complete,"Sep 3, 2009","Mar 17, 2010",SR0174-000
teriparatide rdna origin injection,Forteo,Teriparatide (rDNA origin) injection,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Forteo-ACP_March-17-2010.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Forteo_ACP_Submission.pdf,"Osteoporosis (in women), Severe",Do not list,Complete,"Oct 23, 2009","Mar 17, 2010",SR0180-000
golimumab,Simponi,Golimumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Simponi-PsA_March-17-2010_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Simponi_PsA.pdf,"Arthritis, psoriatic",List in a similar manner,Complete,"Sep 3, 2009","Mar 17, 2010",SR0195-000
golimumab,Simponi,Golimumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Simponi-AS_March-17-2010_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Simponi_AS.pdf,Ankylosing spondylitis,List in a similar manner,Complete,"Sep 3, 2009","Mar 17, 2010",SR0196-000
brinzolamide and timolol maleate suspension,Azarga,Brinzolamide and timolol maleate suspension,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Azarga_February_18_2010.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Azarga.pdf,Glaucoma and ocular hypertension,List in a similar manner to other drugs in class,Complete,"Aug 28, 2009","Feb 18, 2010",SR0173-000
eculizumab,Soliris,Eculizumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Soliris_February_18_2010.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SR0176_Soliris.pdf,Paroxysmal nocturnal hemoglobinuria (PNH),Do not list,Complete,"Sep 18, 2009","Feb 18, 2010",SR0176-000
lisdexamfetamine dimesylate,Vyvanse,Lisdexamfetamine dimesylate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Vyvanse-December-18-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Vyvanse.pdf,Attention deficit hyperactivity disorder,Do not list,Complete,"Jul 10, 2009","Dec 18, 2009",SR0171-000
clostridium botulinum neurotoxin type free complexing proteins,Xeomin,"Clostridium botulinum neurotoxin type A, free from complexing proteins",https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Xeomin_Blepharospasm-December-18-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Xeomin_Blepharospasm.pdf,Blepharospasm,List in a similar manner,Complete,"Jun 12, 2009","Dec 16, 2009",SR0168-000
clostridium botulinum neurotoxin type free complexing proteins,Xeomin,"Clostridium botulinum neurotoxin type A, free from complexing proteins",https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Xeomin_Cervical_Dystonia-December-18-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Xeomin_Cervical_Dystonia.pdf,Cervical Dystonia,List in a similar manner,Complete,"Jun 12, 2009","Dec 16, 2009",SR0192-000
clostridium botulinum neurotoxin type free complexing proteins,Xeomin,"Clostridium botulinum neurotoxin type A, free from complexing proteins",https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Xeomin_Post-Stroke_Spasticity-December-18-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Xeomin_Post-Stroke_Spasticity.pdf,"Spasticity, Post-stroke",Do not list,Complete,"Jun 12, 2009","Dec 16, 2009",SR0193-000
glatiramer acetate,Copaxone,Glatiramer acetate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_comoplete_Copaxone_November-27-2009%20.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Copaxone.pdf,"Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis",Do not list,Complete,"Apr 29, 2009","Nov 25, 2009",SR0164-000
eplerenone,Inspra,Eplerenone,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Inspra_November-27-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Inspra.pdf,Post myocardial infarction,Do not list,Complete,"May 6, 2009","Nov 25, 2009",SR0165-000
darunavir,Prezista,Darunavir,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Prezista_HIV_October-14-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Prezista_New_Indication-naive.pdf,HIV (treatment naive),List with clinical criteria and/or conditions,Complete,"Mar 27, 2009","Oct 14, 2009",SR0163-000
desvenlafaxine succinate,Pristiq,Desvenlafaxine succinate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Pristiq_September-25-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Pristiq.pdf,"Depressive, Major Disorder (MDD)",Do not list,Complete,"Mar 5, 2009","Sep 23, 2009",SR0159-000
pregabalin,Lyrica,Pregabalin,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Lyrica%20Resubmission_September_25-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Lyrica_Resubmission_1.pdf,diabetic peripheral neuropathy,Do not list,Complete,"Mar 20, 2009","Sep 23, 2009",SR0162-000
insulin detemir,Levemir,Insulin detemir,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Levemir_Resubmission_Adults_August_20-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Levemir_Resubmission_2.pdf,Diabetes mellitus,Do not list,Complete,"Mar 10, 2009","Aug 20, 2009",SR0160-000
insulin detemir,Levemir,Insulin detemir,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Levemir_Pediatrics_August_20_2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Levemir_new_indication.pdf,"Diabetes mellitus Type1, Pediatrics",Do not list,Complete,"Mar 10, 2009","Aug 20, 2009",SR0172-000
levodopa carbidopa,Duodopa,Levodopa / carbidopa,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Duodopa_July_24_2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Duodopa.pdf,Parkinson's disease,Do not list,Complete,"Dec 19, 2008","Jul 22, 2009",SR0154-000
teriparatide rdna origin injection,Forteo,Teriparatide (rDNA origin) injection,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Forteo_SIO_July%2023_2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_Forteo_New-Indication.pdf,"Osteoporosis, glucocorticoid induced",Do not list,Complete,"Dec 18, 2008","Jul 22, 2009",SR0152-000
alendronate sodium cholecalciferol,Fosavance 70/5600,Alendronate sodium / cholecalciferol,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Fosavance-70_5600_June-17-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Fosavance-5600.pdf,Osteoporosis,List in a similar manner to other drugs in class,Complete,"Dec 18, 2008","Jun 17, 2009",SR0153-000
ustekinumab,Stelara,Ustekinumab,https://www.cda-amc.ca/sites/default/files/attachments/2023-11/TS0001-PsO-Updated-Streamlined-Rec.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Stelara_June-17-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Stelara.pdf,Psoriasis,List with clinical criteria and/or conditions,Complete,"Jan 7, 2009","Jun 17, 2009",SR0156-000
solifenacin succinate,Vesicare,Solifenacin succinate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Vesicare-Resubmisson_1_June-17-2009.pdf,"Bladder, overactive",List with clinical criteria and/or conditions,Complete,"Jan 5, 2009","Jun 17, 2009",SR0155-000
olmesartan medoxomil hydrochlorothiazide,Olmetec Plus,Olmesartan medoxomil + hydrochlorothiazide,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Olmetec-Plus_May-27-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Olmetec-Olmetec_Plus.pdf,Hypertension,List in a similar manner to other drugs in class,Complete,"Nov 28, 2008","May 27, 2009",SR0151-000
olmesartan medoxomil,Olmetec,Olmesartan medoxomil,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Olmetec_May-27-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Olmetec.pdf,Hypertension,List in a similar manner to other drugs in class,Complete,"Nov 28, 2008","May 27, 2009",SR0150-000
abatacept,Orencia,Abatacept,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Orencia_Final_April%2024_2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_Orencia_New_Indication.pdf,"Arthritis, Juvenile Idiopathic & Juvenile Rheumatoid",List with clinical criteria and/or conditions,Complete,"Aug 29, 2008","Apr 22, 2009",SR0145-000
infliximab,Remicade,Infliximab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Remicade_Final_April_24_2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Remicade.pdf,Ulcerative Colitis,Do not list,Complete,"Sep 29, 2008","Apr 22, 2009",SR0146-000
darifenacin hydrobromide,Enablex,Darifenacin hydrobromide,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Enablex%20Resubmission-1_April-17-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdt_update_Enablex_Resubmission-1.pdf,"Bladder, overactive",List with clinical criteria and/or conditions,Complete,"Oct 1, 2008","Apr 16, 2009",SR0147-000
tenofovir disoproxil fumarate,Viread,Tenofovir disoproxil fumarate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Viread-HBV_March-18-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Viread-HBV.pdf,Hepatitis B (chronic),List with clinical criteria and/or conditions,Complete,"Oct 2, 2008","Mar 18, 2009",SR0148-000
natalizumab,Tysabri,Natalizumab,https://www.cda-amc.ca/sites/default/files/attachments/2025-03/TS0004-Cladribine-Natalizumab_Updated_Recommendations_1.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Tysabri-Resubmission_February-25-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Tysabri-Resubmission_1.pdf,"Multiple Sclerosis, relapsing-remitting",List with clinical criteria and/or conditions,Complete,"May 6, 2008","Feb 25, 2009",SR0133-000
insulin glulisine,Apidra,Insulin glulisine,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Apidra_February-19-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Apidra.pdf,"Diabetes, Mellitus (Type 1 & 2)",List in a similar manner to other drugs in class,Complete,"Aug 29, 2008","Feb 19, 2009",SR0144-000
dabigatran etexilate,Pradaxa,Dabigatran etexilate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Pradax_March-3-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Pradax.pdf,"Thromboembolism (venous), prevention",Do not list,Complete,"Jul 8, 2008","Jan 28, 2009",SR0140-000
sodium oxybate,Xyrem,Sodium oxybate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Xyrem%20Resubmission_January-28-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Xyrem_Resubmission_1.pdf,Narcolepsy,Do not list,Complete,"Jul 9, 2008","Jan 28, 2009",SR0141-000
sitaxsentan sodium,Thelin,Sitaxsentan sodium,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Thelin%20Resubmission_January-28-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/CDR_tracking_Thelin-Resubmission_1.pdf,Pulmonary arterial hypertension (WHO class II and III),Do not list,Complete,"May 5, 2008","Jan 28, 2009",SR0132-000
methylnaltrexone bromide,Relistor,Methylnaltrexone bromide,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Relistor_January-30-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Relistor.pdf,"Constipation, Opioid-induced",Do not list,Complete,"May 7, 2008","Jan 28, 2009",SR0135-000
ambrisentan,Volibris,Ambrisentan,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_volibris_complete-dec17-08.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Volibris.pdf,Pulmonary arterial hypertension (WHO class II and III),List with clinical criteria and/or conditions,Complete,"Jul 9, 2008","Dec 17, 2008",SR0142-000
emtricitabinetenofovir disoproxil fumarate,Truvada,Emtricitabine/tenofovir disoproxil fumarate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_truvada_rfa_complete-dec17-08.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_request-advice_Truvada.pdf,HIV infection,List with clinical criteria and/or conditions,Complete,"Jul 7, 2008","Dec 17, 2008",SF0138-000
rivaroxaban,Xarelto,Rivaroxaban,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_xarelto_complete-dec17-08.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Xarelto.pdf,"Thromboembolism (venous), prevention",List with clinical criteria and/or conditions,Complete,"May 7, 2008","Dec 17, 2008",SR0134-000
maraviroc,Celsentri,Maraviroc,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Celsentri_Final_Nov-12-08.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Celsentri-Resubmission_1.pdf,HIV,List with clinical criteria and/or conditions,Complete,"May 7, 2008","Nov 12, 2008",SR0136-000
ciclesonide nasal spray,Omnaris,Ciclesonide nasal spray,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Omnaris_Nov-12-08.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Omnaris.pdf,Allergic Rhinitis (seasonal and perennial),Do not list,Complete,"May 7, 2008","Nov 12, 2008",SR0137-000
adalimumab,Humira,Adalimumab,https://www.cda-amc.ca/sites/default/files/attachments/2023-11/TS0001-PsO-Updated-Streamlined-Rec.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Humira-Psoriasis_October_2008.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_Humira_New_Indication.pdf,Psoriasis,List with clinical criteria and/or conditions,Complete,"Apr 15, 2008","Oct 16, 2008",SR0130-000
carbidopa levodopa and entacapone,Stalevo,"Carbidopa, levodopa and entacapone",https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Stalevo_October-2008.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Stalevo.pdf,Parkinsons Disease,List in a similar manner,Complete,"Apr 15, 2008","Oct 16, 2008",SR0131-000
daptomycin,Cubicin,Daptomycin,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Cubicin_%20September-24-2008.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Cubicin.pdf,Skin and skin structure infections & bacteremia,Do not list,Complete,"Mar 6, 2008","Sep 24, 2008",SR0127-000
buprenorphinenaloxone,Suboxone,Buprenorphine/naloxone,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Suboxone_September-24-2008.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Suboxone.pdf,Opioid drug dependence (Substitution treatment),List with clinical criteria and/or conditions,Complete,"Mar 6, 2008","Sep 24, 2008",SR0128-000
ziprasidone hydrochloride,Zeldox,Ziprasidone hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Zeldox_August-14-2008.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Zeldox.pdf,Schizophrenia and related psychotic disorders,List with clinical criteria and/or conditions,Complete,"Jan 10, 2008","Aug 14, 2008",SR0124-000
duloxetine hydrochloride,Cymbalta,Duloxetine hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Cymbalta-DPN_August-14-2008.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_update_Cymbalta-DPN.pdf,"Pain, Neuropathic, Diabetic",List with clinical criteria and/or conditions,Complete,"Feb 8, 2008","Aug 14, 2008",SR0126-000
duloxetine hydrochloride,Cymbalta,Duloxetine hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Cymbalta-MDD_August-14-2008.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_update_Cymbalta-MDD.pdf,"Depressive, Major Disorder (MDD)",Do not list,Complete,"Feb 8, 2008","Aug 14, 2008",SR0125-000
etravirine,Intelence,Etravirine,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Intelence_August-14-2008.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Intelence.pdf,HIV,List with clinical criteria and/or conditions,Complete,"Apr 2, 2008","Aug 14, 2008",SR0129-000
rivastigmine,Exelon Patch,Rivastigmine,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Exelon-Patch_%20July-23-2008_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Exelon.pdf,Dementia (Alzheimer's type),Do not list,Complete,"Dec 21, 2007","Jul 23, 2008",SR0123-000
tramadol hydrochloride,Ralivia,Tramadol hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Ralivia_June_25_2008.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Ralivia.pdf,Pain,Do not list,Complete,"Oct 29, 2007","Jun 25, 2008",SR0110-000
zoledronic acid,Aclasta,Zoledronic acid,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Aclasta_FINAL_Nov-16-11_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Aclasta.pdf,"Osteoporosis, postmenopausal women",Do not list,Complete,"Nov 29, 2007","Jun 25, 2008",SR0114-000
mixed amphetamine salts,Adderall XR,Mixed amphetamine salts,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Adderall_June-25-2008.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Adderall%20XR_Resub2_OVW_Aug-12-09.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Adderall%20XR_Resub2_PLR_Aug-12-09.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Adderall%20XR_Resub2_SOD_Aug-12-09.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Adderall-XR_new-indication.pdf,"Attention deficit hyperactivity disorder, Adult",Do not list,Complete,"Nov 29, 2007","Jun 25, 2008",SR0116-000
aliskiren,Rasilez,Aliskiren,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Rasilez_June-25-2008_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Rasilez.pdf,Hypertension,Do not list,Complete,"Nov 30, 2007","Jun 25, 2008",SR0118-000
sitagliptin phosphate,Januvia,Sitagliptin phosphate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Januvia_June-18-2008_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_januvia_cedac-discuss_Sep-16-08_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_januvia_overview_Sep-16-08_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_januvia_plain-lang_Sep-16-08_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_update_Januvia.pdf,Diabetes mellitus (Type 2),Do not list,Complete,"Dec 20, 2007","Jun 18, 2008",SR0122-000
paliperidone,Invega,Paliperidone,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Invega_May_05_28.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Invega.pdf,Schizophrenia,Do not list,Complete,"Nov 1, 2007","May 28, 2008",SR0112-000
raltegravir,Isentress,Raltegravir,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Isentress_May-14-2008.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Isentress_discussion_Jul-10-08.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Isentress_overview_Jul-10-08.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Isentress_plainl-r-r_Posting_Jul-10-08.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Isentress.pdf,HIV,List with clinical criteria and/or conditions,Complete,"Nov 29, 2007","May 14, 2008",SR0115-000
efavirenz emtricitabine tenofovir disoproxil fumarate,Atripla,"Efavirenz, emtricitabine, tenofovir disoproxil fumarate",https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Atripla_April-17-2008.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Atripla.pdf,HIV,List with clinical criteria and/or conditions,Complete,"Oct 30, 2007","Apr 17, 2008",SR0111-000
tramadol hydrochloride,Tridural,Tramadol hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Tridural_April-17-2008.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Tridural.pdf,Pain,Do not list,Complete,"Nov 29, 2007","Apr 17, 2008",SR0117-000
ranibizumab,Lucentis,Ranibizumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Lucentis_March-27-2008.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Lucentis_overview_Jul-30-08_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Lucentis_plain-language_Jul-30-08_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_Lucentis_summary_Oct%2006-08.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Lucentis1.pdf,"Macular degeneration, age-related",List with clinical criteria and/or conditions,Complete,"Jul 12, 2007","Mar 27, 2008",SR0098-000
acamprosate calcium,Campral,Acamprosate calcium,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Campral_March-2008.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_campral_discussion_Jul-29-08.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_campral_overview_Jul-29-08.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_campral_plainl-r-r_Jul-29-08.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Campral.pdf,Alcohol Abstinence,List with clinical criteria and/or conditions,Complete,"Aug 29, 2007","Mar 27, 2008",SR0108-000
delta 9 tetrahydrocannabinolcannabidiol,Sativex,Delta-9-tetrahydrocannabinol/cannabidiol,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Sativex-Resubmission_February-20-2008.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Sativex_resubmission.pdf,"Pain, cancer (adjunctive analgesia to maximum tolerated strong opioids)",Do not list,Complete,"Aug 7, 2007","Feb 20, 2008",SR0106-000
aprepitant,Emend,Aprepitant,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Emend_February-20-2008.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_emend_cedac-discussion_May_28-08.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_emend_overview_May-28-08.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_emend_plainl-r-r_May-28-08.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Emend.pdf,"Nausea and Vomiting, Chemotherapy induced",List with clinical criteria and/or conditions,Complete,"Aug 29, 2007","Feb 20, 2008",SR0109-000
posaconazole,Spriafil,Posaconazole,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Spriafil_January-30-2008.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Spriafil.pdf,Aspergillus and Candida infections,Do not list,Complete,"May 24, 2007","Jan 30, 2008",SR0097-000
sitaxsentan sodium,Thelin,Sitaxsentan sodium,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Thelin_January-30-2008.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Thelin.pdf,Pulmonary arterial hypertension (WHO class II and III),Do not list,Complete,"Jun 22, 2007","Jan 30, 2008",SR0099-000
lanthanum carbonate hydrate,Fosrenol,Lanthanum carbonate hydrate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Fosrenol_February-29-2008.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Fosrenol.pdf,"Hyperphosphatemia, end-stage renal disease",Do not list,Complete,"Jun 28, 2007","Jan 30, 2008",SR0100-000
idursulfase,Elaprase,Idursulfase,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Elaprase_Dec-19-2007.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Elaprase.pdf,"Mucopolysarccharidosis II (MPS II), Hunter Syndrome",Do not list,Complete,"Jul 13, 2007","Dec 19, 2007",SR0104-000
adalimumab,Humira,Adalimumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Humira-Resubmission-Crohns_Dec-19-2007.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_humira-resub3-crohns_%20plainl-r-r_Mar-05-08_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_humira-resub3-crohns_cedac-discussion-Mar-26-08.pdf; https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/cdr_trans_humira-resub3-crohns_overview_Mar-07-08_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Humira_Resubmission_3.pdf,Crohn's disease,List with clinical criteria and/or conditions,Complete,"Jul 12, 2007","Dec 19, 2007",SR0105-000
entecavir,Baraclude,Entecavir,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Baracude_November-28-2007.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Baraclude.pdf,Hepatitis B (chronic),List with clinical criteria and/or conditions,Complete,"Dec 12, 2006","Nov 28, 2007",SR0089-000
ciprofloxacin hydrochloride dexamethasone otic suspension,Ciprodex,Ciprofloxacin hydrochloride & dexamethasone otic suspension,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Ciprodex_October-18-2007.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Ciprodex-Request-advice.pdf,"Otitis media with otorrhea & otitis externa, acute",List with clinical criteria and/or conditions,Complete,"Jun 15, 2007","Oct 18, 2007",SF0101-000
adefovir dipivoxil,Hepsera,Adefovir dipivoxil,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Hepsera_October-18-2007.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_request_advice_Hepsera.pdf,Hepatitis B,List with clinical criteria and/or conditions,Complete,"Jun 29, 2007","Oct 18, 2007",SF0103-000
telbivudine,Sebivo,Telbivudine,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Sebivo_September-26-2007.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Sebivo.pdf,Hepatitis B (chronic),Do not list,Complete,"Dec 4, 2006","Sep 26, 2007",SR0088-000
delta 9 tetrahydrocannabinolcannabidiol,Sativex,Delta-9-tetrahydrocannabinol/cannabidiol,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Sativex_September-26-2007.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Sativex.pdf,"Pain, Neuropathic (adjunctive) in MS.",Do not list,Complete,"Feb 27, 2007","Sep 26, 2007",SR0092-000
tramadol hydrochloride,Zytram XL,Tramadol hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_ZytramXL_September-26-2007.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Zytram_Resubmission.pdf,"Pain, acute",Do not list,Complete,"Mar 15, 2007","Sep 26, 2007",SR0093-000
varenicline tartrate,Champix,Varenicline tartrate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Champix_August-16-07.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Champix.pdf,Smoking-cessation,List with clinical criteria and/or conditions,Complete,"Mar 21, 2007","Aug 16, 2007",SR0094-000
lumiracoxib,Prexige,Lumiracoxib,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Prexige_July25-2007.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Prexige.pdf,Osteoarthritis (Knee),Do not list,Complete,"Dec 15, 2006","Jul 25, 2007",SR0090-000
lanreotide acetate,Somatuline Autogel,Lanreotide acetate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Somatuline-Autogel_July-19_2007.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Somatuline.pdf,Acromegaly,List in a similar manner to other drugs in class,Complete,"Feb 20, 2007","Jul 19, 2007",SR0091-000
abatacept,Orencia,Abatacept,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Orencia_June-27-2007.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Orencia.pdf,"Arthritis, Rheumatoid",List with clinical criteria and/or conditions,Complete,"Oct 26, 2006","Jun 27, 2007",SR0084-000
adalimumab,Humira,Adalimumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Humira_Resubmission_June-27-2007.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Humira%20Resubmission_02.pdf,Ankylosing spondylitis (AS),List with clinical criteria and/or conditions,Complete,"Nov 17, 2006","Jun 27, 2007",SR0087-000
alglucosidase,Myozyme,Alglucosidase,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Myozyme_June-14-2007_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Myozyme.pdf,Pompe's disease,List with clinical criteria and/or conditions,Complete,"Oct 10, 2006","Jun 14, 2007",SR0080-000
ramiprilhydrochlorothiazide,Altace HCT,Ramipril/hydrochlorothiazide,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Altace-HCT_June-14-2007_e.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Altace-HCR_Resubmission.pdf,Hypertension,List,Complete,"Mar 26, 2007","Jun 14, 2007",SR0095-000
tramadol hydrochloride acetaminophen,Tramacet,Tramadol hydrochloride /acetaminophen,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Tramacet_May17-07.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Tramacet.pdf,Acute pain,Do not list,Complete,"Oct 2, 2006","May 17, 2007",SR0079-000
penciclovir,Denavir,Penciclovir,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Denavir_e_April-26-2007.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Denavir.pdf,Herpes labialis (cold sores),Do not list,Complete,"Sep 20, 2006","Apr 26, 2007",SR0075-000
sunitinib malate,Sutent,Sunitinib malate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Sutent_e_April-26-2007%20.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Sutent_resubmission_01.pdf,"Cancer, Metastatic renal cell carcinoma",Do not list,Complete,"Sep 20, 2006","Apr 26, 2007",SR0077-000
histrelin acetate,Vantas,Histrelin acetate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Vantas_e_April-26-2007%20.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Vantas.pdf,"Cancer, prostate",Do not list,Complete,"Sep 20, 2006","Apr 26, 2007",SR0078-000
natalizumab,Tysabri,Natalizumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Tysabri_e_April-26-2007.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Tysabri.pdf,"Multiple Sclerosis, relapsing-remitting",Do not list,Complete,"Oct 26, 2006","Apr 26, 2007",SR0082-000
deferasirox,Exjade,Deferasirox,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Exjade_2007April19.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Exjade.pdf,Iron overload,List with clinical criteria and/or conditions,Complete,"Oct 26, 2006","Apr 19, 2007",SR0081-000
sunitinib,Sutent,Sunitinib,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Sutent_March-28-07.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Sutent.pdf,Gastrointestinal stromal tumour (GIST),List with clinical criteria and/or conditions,Complete,"Jul 20, 2006","Mar 28, 2007",SR0069-000
rasagiline mesylate,Azilect,Rasagiline mesylate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Azilect_March-28-07.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Azilect.pdf,Parkinson's disease,Do not list,Complete,"Sep 1, 2006","Mar 28, 2007",SR0073-000
sorafenib tablets,Nexavar,Sorafenib tablets,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Nexavar_Fe-28-07.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Nexavar.pdf,"Cancer, Renal cell carcinoma",Do not list,Complete,"Jul 31, 2006","Feb 28, 2007",SR0071-000
rituximab,Rituxan,Rituximab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Rituxan_Feb14-2007.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Rituxan.pdf,"Arthritis, Rheumatoid",List with clinical criteria and/or conditions,Complete,"Jun 26, 2006","Feb 14, 2007",SR0068-000
darunavir,Prezista,Darunavir,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Prezista_Feb14-2007.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Prezista.pdf,HIV infection,List with clinical criteria and/or conditions,Complete,"Aug 29, 2006","Feb 14, 2007",SR0072-000
sildenafil citrate,Revatio,Sildenafil citrate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Revatio_Feb14-2007.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Revatio.pdf,Pulmonary arterial hypertension (WHO class II and III),List in a similar manner,Complete,"Sep 20, 2006","Feb 14, 2007",SR0076-000
escitalopram oxalate,Cipralex,Escitalopram oxalate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Cipralex_Resubmission_Jan-24-2007.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Cipralex_resubmission.pdf,"Depression, Major Depressive Disorder (MDD)",Do not list,Complete,"Jun 8, 2006","Jan 24, 2007",SR0064-000
solifenacin succinate,Vesicare,Solifenacin succinate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Vesicare_Jan-24-2007.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Vesicare.pdf,"Bladder, overactive",Do not list,Complete,"Jul 24, 2006","Jan 24, 2007",SR0070-000
ciclesonide,Alvesco,Ciclesonide,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Alvesco_Dec-20-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Alvesco.pdf,asthma,List,Complete,"Jul 24, 2006","Dec 20, 2006",SR0074-000
adefovir dipivoxil,Hepsera,Adefovir dipivoxil,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Hepsera_Nov29-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Hepsera.pdf,Hepatitis B,Do not list,Complete,"Apr 24, 2006","Nov 29, 2006",SR0060-000
etonogestrelethinyl estradiol,NuvaRing,Etonogestrel/ethinyl estradiol,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_NuvaRing_Nov29-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_NuvaRing.pdf,"Contraceptive, ring",List with clinical criteria and/or conditions,Complete,"May 5, 2006","Nov 29, 2006",SR0062-000
adalimumab,Humira,Adalimumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Humira_Resubmission_Nov29-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Humira_Resubmission.pdf,"Arthritis, Psoriatic",List with clinical criteria and/or conditions,Complete,"Jun 21, 2006","Nov 29, 2006",SR0066-000
ramiprilfelodipine extended release,Altace Plus Felodipine,Ramipril/felodipine extended release,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_AltacePlus_Felodipine_Nov_15-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Altace_Plus_Felodipine.pdf,Hypertension,Do not list,Complete,"Jun 22, 2006","Nov 15, 2006",SR0067-000
insulin glargine rdna origin,Lantus,Insulin glargine (rDNA origin),https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Lantus_Oct25-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Lantus%20Resubmission.pdf,"Diabetes mellitus, Type 1 & 2",Do not list,Complete,"Mar 27, 2006","Oct 25, 2006",SR0058-000
voriconazole,VFEND,Voriconazole,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Vfend_Resubmission_oct25-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Vfend_Resubmission_2.pdf,Candidemia,List with clinical criteria and/or conditions,Complete,"Mar 24, 2006","Oct 25, 2006",SR0056-000
emtricitabinetenofovir disoproxil fumarate,Truvada,Emtricitabine/tenofovir disoproxil fumarate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Truvada_oct25-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_truvada_rfa_complete-dec17-08.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Truvada.pdf,HIV infection,List with clinical criteria and/or conditions,Complete,"May 29, 2006","Oct 25, 2006",SR0063-000
darifenacin hydrobromide,Enablex,Darifenacin hydrobromide,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Enablex_Oct-19-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Enablex.pdf,"Bladder, overactive",Do not list,Complete,"Apr 26, 2006","Oct 19, 2006",SR0061-000
alefacept,Amevive,Alefacept,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Amevive_Resubmission_Sept-27-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Amevive_Resubmission.pdf,"Psoriasis, moderate to severe chronic plaque",Do not list,Complete,"Feb 28, 2006","Sep 27, 2006",SR0053-000
alendronate sodiumcholecalciferol,Fosavance,Alendronate sodium/cholecalciferol,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Fosavance_Sept-27-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Fosavance.pdf,Osteoporosis,Do not list,Complete,"Mar 27, 2006","Sep 27, 2006",SR0059-000
efalizumab,Raptiva,Efalizumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Raptiva_August24-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Raptiva.pdf,"Psoriasis, moderate to severe chronic plaque",List with clinical criteria and/or conditions,Complete,"Oct 25, 2005","Aug 24, 2006",SR0043-000
travoprost and timolol maleate,DuoTrav,Travoprost and timolol maleate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_DuoTrav_August24-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_DuoTrav.pdf,Glaucoma,List with clinical criteria and/or conditions,Complete,"Mar 24, 2006","Aug 24, 2006",SR0057-000
trospium chloride,Trosec,Trospium chloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Trosec_August24-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Trosec.pdf,"Bladder, overactive",List with clinical criteria and/or conditions,Complete,"Mar 24, 2006","Aug 24, 2006",SR0055-000
insulin detemir,Levemir,Insulin detemir,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Levemir_August2_2006.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Levemir.pdf,Diabetes mellitus,Do not list,Complete,"Dec 19, 2005","Aug 2, 2006",SR0049-000
pegvisomant,Somavert,Pegvisomant,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Somavert_%20August2_2006.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Somavert.pdf,acromegaly,Do not list,Complete,"Jan 25, 2006","Aug 2, 2006",SR0050-000
pantoprazole magnesium,Pantoloc M,Pantoprazole magnesium,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Pantoloc%20M_July20_2006.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_PantolocM.pdf,"Gastric acid secretion, reduction of",List in a similar manner to other drugs in class,Complete,"Mar 17, 2006","Jul 20, 2006",SR0054-000
triptorelin pamoate,Trelstar,Triptorelin pamoate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Trelstar_July20_2006.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Trelstar.pdf,"Cancer, prostate",List in a similar manner to other drugs in class,Complete,"Feb 27, 2006","Jul 20, 2006",SR0051-000
treprostinil sodium,Remodulin,Treprostinil sodium,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Remodulin_July20_2006.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Remodulin_Resubmission_July21_2006.pdf,Pulmonary arterial hypertension (NYHA Class III and IV patients),List with clinical criteria and/or conditions,Complete,"Feb 24, 2006","Jul 20, 2006",SR0052-000
pegaptanib sodium,Macugen,Pegaptanib sodium,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Macugen_May25-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Macugen.pdf,"Macular degeneration, age-related",Do not list,Complete,"Oct 20, 2005","May 25, 2006",SR0044-000
quinagolide hydrochloride,Norprolac,Quinagolide hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Norprolac_Resubmission_May-17-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Norprolac%20Resubmission.pdf,Hyperprolactinemia,List with clinical criteria and/or conditions,Complete,"Nov 23, 2005","May 17, 2006",SR0046-000
tipranavir,Aptivus,Tipranavir,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Aptivus_May-17-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Aptivus.pdf,HIV infection,List with clinical criteria and/or conditions,Complete,"Dec 15, 2005","May 17, 2006",SR0047-000
amlodipine besylate atorvastatin calcium,Caduet,Amlodipine besylate/ atorvastatin calcium,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Caduet_May17-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Caduet.pdf,Hypertension/ Dyslipidemia,List with clinical criteria and/or conditions,Complete,"Dec 15, 2005","May 17, 2006",SR0048-000
insulin aspartinsulin aspart protamine,NovoMix 30,Insulin aspart/insulin aspart protamine,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_NovoMix30_April-26-06.pdf,Diabetes mellitus,Do not list,Complete,"Oct 13, 2005","Apr 26, 2006",SR0041-000
niacinlovastatin,Advicor,Niacin/lovastatin,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Advicor_April-26-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Advicor.pdf,Hypercholesterolemia and mixed dyslipidemia,List,Complete,"Oct 18, 2005","Apr 26, 2006",SR0042-000
tenofovir disoproxil fumarate,Viread,Tenofovir disoproxil fumarate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Viread_Resubmission_march2006.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Viread_Resubmission.pdf,HIV infection,List with clinical criteria and/or conditions,Complete,"Aug 11, 2005","Mar 15, 2006",SR0040-000
omalizumab,Xolair,Omalizumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Xolair_March7-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Xolair_Resubmission.pdf,"Asthma, severe persistent",Do not list,Complete,"Oct 13, 2005","Mar 7, 2006",SR0045-000
pregabalin,Lyrica,Pregabalin,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Lyrica_Jan26-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Lyrica.pdf,"Pain, Neuropathic",Do not list,Complete,"Jun 27, 2005","Jan 25, 2006",SR0036-000
erlotinib,Tarceva,Erlotinib,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Tarceva_Dec605.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Tarceva.pdf,"Cancer, Lung , non-small cell",List with clinical criteria and/or conditions,Complete,"Jul 19, 2005","Dec 7, 2005",SR0037-000
abacavirlamivudine,Kivexa,Abacavir/lamivudine,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Kivexa_Dec605.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Kivexa.pdf,HIV infection,List in a similar manner to other drugs in class,Complete,"Jul 26, 2005","Dec 7, 2005",SR0038-000
memantine hydrochloride,Ebixa,Memantine hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Ebixa_2005nov23.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Ebixa.pdf,"Dementia (Alzheimer type), moderate to severe",Do not list,Complete,"Dec 21, 2004","Nov 23, 2005",SR0025-000
quinagolide hydrochloride,Norprolac,Quinagolide hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Norprolac_2005Sept28.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Norprolac.pdf,Hyperprolactinemia,Do not list,Complete,"Dec 16, 2004","Sep 28, 2005",SR0026-000
atomoxetine hydrochloride,Strattera,Atomoxetine hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Strattera_2005Sept28.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Strattera.pdf,Attention deficit hyperactivity disorder,Do not list,Complete,"Jan 25, 2005","Sep 28, 2005",SR0031-000
insulin glargine rdna origin,Lantus,Insulin glargine (rDNA origin),https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Lantus_2005Sept28.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Lantus.pdf,"Diabetes mellitus, Type 1 & 2",Do not list,Complete,"Feb 11, 2005","Sep 28, 2005",SR0033-000
laronidase,Aldurazyme,Laronidase,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Aldurazyme_2005July14.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Aldurazyme.pdf,"Mucopolysarccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie",Do not list,Complete,"Feb 3, 2005","Jul 14, 2005",SR0032-000
mycophenolate sodium,Myfortic,Mycophenolate sodium,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Myfortic_2005July8.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Myfortic.pdf,"Organ rejection in allogeneic renal transplants, Prophylaxis",List in a similar manner to other drugs in class,Complete,"Mar 3, 2005","Jul 8, 2005",SR0034-000
drospirenone ethinyl estradiol,Yasmin,Drospirenone /ethinyl estradiol,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Yasmin_June162005.pdf,"Contraceptive, oral",List,Complete,"Jan 20, 2005","Jun 16, 2005",SR0029-000
fosamprenavir calcium,Telzir,Fosamprenavir calcium,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Telzir_June162005.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Telzir.pdf,HIV infection,List in a similar manner to other drugs in class,Complete,"Jan 24, 2005","Jun 16, 2005",SR0030-000
alefacept,Amevive,Alefacept,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Amevive_2005May26.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Amevive.pdf,"Psoriasis, moderate to severe chronic plaque",Do not list,Complete,"Nov 16, 2004","May 26, 2005",SR0024-000
agalsidase beta,Fabrazyme,Agalsidase beta,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Fabrazyme_Resubmission_may2005.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Fabrazyme_Resubmission.pdf,Fabry Disease,Do not list,Complete,"Dec 10, 2004","May 18, 2005",SR0028-000
voriconazole,VFEND,Voriconazole,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Voriconazole%28Vfend%29_April%2014-05.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Vfend_Resubmission.pdf,"Aspergillosis, Invasive",List with clinical criteria and/or conditions,Complete,"Oct 25, 2004","Apr 14, 2005",SR0023-000
cinacalcet hydrochloride,Sensipar,Cinacalcet hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Cinacalcet%28Sensipar%29_mar23-05.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Sensipar.pdf,Secondary hyper-parathyroidism in chronic kidney disease,Do not list,Complete,"Aug 20, 2004","Mar 23, 2005",SR0018-000
eletriptan hydrobromide,Relpax,Eletriptan hydrobromide,https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Relpax.pdf,Migraine,Do not list,Complete,"Sep 21, 2004","Mar 23, 2005",SR0021-000
adalimumab,Humira,Adalimumab,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Humira%28adalimumab%29Feb11-05.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Humira.pdf,"Arthritis, Rheumatoid",List with clinical criteria and/or conditions,Complete,"Sep 24, 2004","Feb 11, 2005",SR0022-000
ciprofloxacin hydrochloride and dexamethasone otic suspension,Ciprodex,Ciprofloxacin hydrochloride and dexamethasone otic suspension,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Ciprodex_feb24-06.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Ciprodex.pdf,"Otitis media with otorrhea & otitis externa, acute",Do not list,Complete,"Jun 11, 2004","Jan 26, 2005",SR0014-000
butoconazole nitrate,Gynazole.1,Butoconazole nitrate,https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Gynazole.1.pdf,Vaginal infection,Do not list,Complete,"Jun 30, 2004","Jan 26, 2005",SR0017-000
dutasteride,Avodart,Dutasteride,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Avodart_2005Jan24.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Avodart.pdf,"Prostatic hyperplasia, benign",List in a similar manner to other drugs in class,Complete,"Aug 24, 2004","Jan 20, 2005",SR0019-000
teriparatide rdna origin injection,Forteo,Teriparatide (rDNA origin) injection,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Forteo_2004Dec22.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Forteo.pdf,Osteoporosis,Do not list,Complete,"Jun 8, 2004","Dec 22, 2004",SR0015-000
eprosartan mesylate hydrochlorothiazide,Teveten Plus,Eprosartan mesylate/ hydrochlorothiazide,N/A,"Hypertension, Essential",List in a similar manner to other drugs in class,Complete,"Jul 8, 2004","Dec 15, 2004",SR0016-000
agalsidase alfa,Replagal,Agalsidase alfa,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Replagal_2004Nov24.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_replagal.pdf,Fabry Disease,Do not list,Complete,"Feb 19, 2004","Nov 24, 2004",SR0006-000
agalsidase beta,Fabrazyme,Agalsidase beta,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Fabrazyme_2004Nov24.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Fabrazyme.pdf,Fabry Disease,Do not list,Complete,"Feb 24, 2004","Nov 24, 2004",SR0007-000
mixed amphetamine salts,Adderall XR,Mixed amphetamine salts,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_AdderallXR_2004Nov24.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Adderall.pdf,Attention deficit hyperactivity disorder,Do not list,Complete,"Apr 13, 2004","Nov 24, 2004",SR0010-000
miglustat,Zavesca,Miglustat,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Zavesca_2004Nov24.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Zavesca.pdf,Gaucher disease,Do not list,Complete,"May 13, 2004","Nov 24, 2004",SR0012-000
treprostinil sodium,Remodulin,Treprostinil sodium,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Remodulin%20%28treprostinil%29_Nov17_04.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Remodulin.pdf,Pulmonary arterial hypertension (NYHA Class III and IV patients),Do not list,Complete,"Jul 14, 2004","Nov 17, 2004",SR0011-000
pegfilgrastim,Neulasta,Pegfilgrastim,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_neulasta_10-27-04.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_neulasta.pdf,Neutropenia,List with clinical criteria and/or conditions,Complete,"Mar 29, 2004","Oct 27, 2004",SR0009-000
peginterferon alfa 2a and ribavirin,Pegasys RBV,Peginterferon alfa-2a and Ribavirin,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Pegasys_10_14_04.pdf,"Hepatitis C, chronic",List in a similar manner to other drugs in class,Complete,"May 14, 2004","Oct 14, 2004",SR0013-000
tenofovir disoproxil fumarate,Viread,Tenofovir disoproxil fumarate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_viread_08-25-04.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Viread.pdf,HIV infection,Do not list,Complete,"Feb 23, 2004","Aug 25, 2004",SR0008-000
gefitinib,Iressa,Gefitinib,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_iressa_06-23-04.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Iressa.pdf,"Cancer, Lung , non-small cell",Do not list,Complete,"Dec 22, 2003","Jun 23, 2004",SR0003-000
norgelestrominethinyl estradiol,Evra,Norgelestromin/ethinyl estradiol,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Evra_06-23-04.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_EVRA.pdf,"Contraceptive, patch",Do not list,Complete,"Dec 19, 2003","Jun 23, 2004",SR0004-000
brimonidine tartratetimolol maleate,Combigan Ophthalmic Solution,Brimonidine tartrate/timolol maleate,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Combigan_05-27-04.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Combigan.pdf,Glaucoma,List with clinical criteria and/or conditions,Complete,"Dec 15, 2003","May 27, 2004",SR0001-000
atazanavir,Reyataz,Atazanavir,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Reyataz_05-27-04.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Reyataz.pdf,HIV infection,List in a similar manner to other drugs in class,Complete,"Dec 16, 2003","May 27, 2004",SR0002-000
almotriptan,Axert,Almotriptan,https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_Axert_05-27-04.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Axert.pdf,Migraine,List in a similar manner to other drugs in class,Complete,"Dec 24, 2003","May 27, 2004",SR0005-000
nab paclitaxel,N/A,nab-paclitaxel,https://cda-amc.ca/sites/default/files/DRR/2024/PX0360-Nab-Paclitaxel-DPI-Table.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/PX0360_Clinical_and_Pharmacoeconomic_Combined_Report.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/PX0360_Stakeholder_Feedback.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/PX0360_consolidated_FDR.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2024/PX0360-Nab-paclitaxel_FINAL.pdf,Gastrointestinal cancer,Reimburse with clinical criteria and/or conditions,Complete,"Feb 12, 2024",N/A,PX0360-000
biologics plaque psoriasis,N/A,N/A,https://cadth.ca/sites/default/files/DRR/2023/TS0001-000-Biologics-In-Plaque-Psoriasis.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/TSDrugClas/TS0001/TS0001-DPI-Table.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/TSDrugClas/TS0001/TS0001-PsO-Streamlined-Rec.pdf; https://www.cadth.ca/sites/default/files/DRR/2023/TSDrugClas/TS0001/TS0001-PsO-Updated-Streamlined-Rec.pdf,N/A,N/A,Complete,N/A,N/A,TS0001-000
acalabrutinib,Calquence,Acalabrutinib,N/A,Chronic Lymphocytic Leukemia (CLL),Reimburse with clinical criteria and/or conditions,Complete,"Apr 7, 2020",N/A,PC0211-000
nivolumab ipilimumab,Opdivo-Yervoy,Nivolumab-Ipilimumab,N/A,NSCLC,Reimburse with clinical criteria and/or conditions,Complete,"Jun 23, 2020",N/A,PC0218-000
eculizumab,Soliris,Eculizumab,https://www.cda-amc.ca/sites/default/files/cdr/advice/SF0416_Soliris_aHUS_RfA_Report.pdf; https://www.cda-amc.ca/sites/default/files/cdr/advice/cdr-advice-Soliris-aHUS-June-2-2015.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SF0416_Soliris.pdf,Atypical hemolytic uremic syndrome,N/A,Complete,"Feb 9, 2015",N/A,SF0416-000
sodium glucose cotransporter 2 inhibitors type 2 diabetes mellitus,N/A,Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes Mellitus,https://cadth.ca/sites/default/files/DRR/2024/TS0002%20Streamlined%20Drug%20Class%20Review%20-%20Final%20Recommendation%20and%20Reasons.pdf; https://cadth.ca/sites/default/files/DRR/2024/TS0002%20Updated%20CADTH%20Reimbursement%20Recommendations%20.pdf; https://cadth.ca/sites/default/files/DRR/2024/TS0002-000-SGLT2-Inhibitors-in-Type2-Diabetes-Supplemental-Material.pdf; https://cadth.ca/sites/default/files/DRR/2024/TS0002-SGLT2-Inhibitors-in-Type2-Diabetes-Report.pdf,N/A,N/A,Complete,N/A,N/A,TS0002-000
ingenol mebutate,Picato,Ingenol mebutate,https://www.cda-amc.ca/sites/default/files/cdr/advice/SF0382_PicatoRfA_CDEC_Briefing_Doc.pdf; https://www.cda-amc.ca/sites/default/files/cdr/complete/cdr_complete_SF0382_Picato-RfA_Oct_29-14.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_SF0382_Picato%20RfA.pdf,Actinic keratosis,N/A,Complete,"May 26, 2014",N/A,SF0382-000
sapropterin dihydrochloride,Kuvan,Sapropterin dihydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Kuvan_request-advice.pdf,Phenylketonuria,N/A,Complete,"Jun 1, 2011",N/A,SF0236-000
rivaroxaban,Xarelto,Rivaroxaban,https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_xarelto_request-advice.pdf,"Venous thromboembolism, prevention",N/A,Complete,"Jun 24, 2011",N/A,SF0239-000
rivaroxaban,Xarelto,Rivaroxaban,https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Xarelto-DVT_request-advice.pdf,Deep-vein thrombosis without symptomatic pulmonary embolism,N/A,Complete,"Oct 10, 2012",N/A,SF0295-000
acamprosate calcium,Campral,Acamprosate calcium,https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_request-advice_Campral.pdf,Alcohol Abstinence,N/A,Complete,"Jul 22, 2008",N/A,SF0143-000
tenofovir disoproxil fumarate,Viread,Tenofovir disoproxil fumarate,https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_request-advice_Viread.pdf,HIV infection,N/A,Complete,"Jul 7, 2008",N/A,SF0139-000
rasagiline mesylate,Azilect,Rasagiline mesylate,https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_Azilect_Request_for_Advice.pdf,Parkinson's disease,N/A,Complete,"Mar 10, 2009",N/A,SF0161-000
insulin glargine,Lantus,Insulin glargine (rDNA origin),https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_Lantus_Request_for_Advice.pdf,"Diabetes mellitus, Type 1 & 2",N/A,Complete,"Jun 9, 2009",N/A,SF0166-000
somatropin rdna origin,Omnitrope,Somatropin (rDNA origin),https://www.cda-amc.ca/sites/default/files/cdr/advice/cdr_advice_Omnitrope-December-18-2009.pdf; https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_tracking_Omnitrope.pdf,Growth hormone deficiency in children and adults,N/A,Complete,"Jun 12, 2009",N/A,SR0167-000
atomoxetine hydrochloride,Strattera,Atomoxetine hydrochloride,https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_request_advice_Strattera_dec22-06.pdf,Attention deficit hyperactivity disorder,N/A,Complete,"Sep 25, 2006",N/A,SF0085-000
efalizumab,Raptiva,Efalizumab,https://www.cda-amc.ca/sites/default/files/cdr/tracking/cdr_request_advice_Raptiva.pdf,"Psoriasis, moderate to severe chronic plaque",N/A,Complete,"Jun 19, 2007",N/A,SF0102-000
rfa inlyta metastatic renal cell carcinoma,Inlyta (RFA),Axitinib,https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_rfa_axitinib_inlyta_mrcc_fdk_kcc.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_rfa_axitinib_inlyta_mrcc_fdk_pfizer.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_rfa_axitinib_inlyta_mrcc_rfa_cgr.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_rfa_axitinib_inlyta_mrcc_rfa_rec.pdf,Metastatic Renal Cell Carcinoma,N/A,Complete,"Apr 18, 2017",N/A,PA0001-000
rfa bosulif chronic myeloid leukemia,Bosulif (RFA),Bosutinib,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/RFA0002BosutinibCML_FnRec_2019-07-31_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/RFA0002BosutinibCML_PatientInput_CML_2019-04-24_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/RFA0002BosutinibCML_RFA-ClinicalReport_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/RFA0002BosutinibCML_RFA_Post_01Aug2019_final.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr-profund-rfa-0002-bosutinib.pdf,Chronic Myeloid Leukemia,N/A,Complete,"Apr 8, 2019",N/A,PA0002-000
pegfilgrastim,Fulphila,pegfilgrastim,https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/se0588-fulphila-biosimilar-dossier.pdf,Febrile neutropenia in non-myeloid malignancies,N/A,Complete,"Nov 14, 2018",N/A,SE0588-000
pegfilgrastim,Lapelga,Pegfilgrastim,https://www.cda-amc.ca/sites/default/files/cdr/relatedinfo/SE0555_lapelga_biosimilar_dossier.pdf,Febrile neutropenia,N/A,Complete,"Feb 23, 2018",N/A,SE0555-000
mvasi metastatic colorectal cancer non small cell lung cancer biosimilar,Mvasi,Bevacizumab,https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10158MVASI_CADTHBiosimilarSummaryDossier_FINAL_14Jan2019.pdf; https://www.cda-amc.ca/sites/default/files/pcodr/pcodr_provfund_10158_bevacizumab_mvasi_mcrc_nsclc.pdf,mCRC NSCLC Biosimilar,N/A,Complete,"Oct 3, 2018",N/A,PC0158-000
nab paclitaxel,N/A,Nab-paclitaxel,https://cadth.ca/sites/default/files/DRR/2024/PX0354-Nab-Paclitaxel-DPI_Table.pdf; https://cadth.ca/sites/default/files/DRR/2024/PX0354-Nab-Paclitaxel-in-Combo-Gemcitabine_combined.pdf; https://cadth.ca/sites/default/files/DRR/2024/PX0354-PX0354-Nab-Paclitaxel-in-Combo-Gemcitabine-Stakeholder-Feedback.pdf; https://cda-amc.ca/sites/default/files/DRR/2024/PX0354_consolidated_Feedback_DR.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/PX0354-Nab-paclitaxel-FINAL_REC.pdf,Gastrointestinal cancer,Do not reimburse,Complete,"Dec 21, 2023",N/A,PX0354-000
optimal pharmacotherapy transplant ineligible multiple myeloma,N/A,Optimal Pharmacotherapy for Transplant-Ineligible Multiple Myeloma,https://cadth.ca/sites/default/files/DRR/2024/TR0014%20Final%20Recommendation%20and%20Reasons.pdf; https://cadth.ca/sites/default/files/DRR/2024/TR0014-Updated%20Reimbursement%20Recommendations.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/TR0014-MM-ESHPM-Combined-Report.pdf; https://www.cadth.ca/sites/default/files/DRR/2024/TR0014-Stakeholder-Feedback.pdf; https://www.cadth.ca/sites/default/files/ou-tr/Myeloma%20Canada_Combined%20document.pdf; https://www.cadth.ca/sites/default/files/ou-tr/TR0014-multiple-myeloma-protocol-final.pdf,N/A,N/A,Complete,N/A,N/A,TR0014-000 - OP0547-000
multiple myeloma,N/A,N/A,https://cda-amc.ca/sites/default/files/DRR/2025/PH0068%20Consolidated%20Feedback.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PH0068%20Consolidated%20Input.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PH0068-Multiple_Myeloma.pdf,Multiple Myeloma,N/A,Complete,N/A,N/A,PH0068-000
dabrafenib trametinib,TBC,dabrafenib trametinib,https://cda-amc.ca/sites/default/files/DRR/2025/PX0375-DPI_Table.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PX0375-Dabrafenib-Trametinib_Final_Rec.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PX0375-Dabrafenib_Trametinib_Combined_Review.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PX0375-Dabrafenib_Trametinib_Stakeholder_Input.pdf; https://cda-amc.ca/sites/default/files/DRR/2025/PX0375-Dabrafenib_Trametinib_Supplemental_Material.pdf; https://www.cda-amc.ca/sites/default/files/DRR/2025/PX0375_consolidated_feedback.pdf,Pediatric low grade glioma (ped LGG),Reimburse with clinical criteria and/or conditions,Complete,"Oct 7, 2024",N/A,PX0375-000
